mitomycin has been researched along with Bladder Cancer in 923 studies
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Intravesical chemotherapy using mitomycin C in patients with superficial bladder cancer after transurethral resection (TUR) has proved to be highly effective in preventing tumor recurrences and/or progression." | 10.16 | Treatment schedule of intravesical chemotherapy with mitomycin C in superficial bladder cancer: short-term courses or maintenance therapy. ( DeBruyne, FM; van der Meijden, AP, 1988) |
| "This study aimed to assess long-term follow-up after chemoresection with mitomycin (MMC), a nonsurgical treatment modality for recurrent nonmuscle invasive bladder cancer (NMIBC)." | 9.69 | DaBlaCa-13 Study: Oncological Outcome of Short-Term, Intensive Chemoresection With Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial. ( Azawi, N; Dyrskjøt, L; Hansen, E; Jensen, JB; Lindgren, MS; Nielsen, AM, 2023) |
| "Intravesical mitomycin-C is recommended immediately after transurethral resection of bladder tumor for nonmuscle-invasive bladder cancer." | 9.69 | Clinical Efficacy of Neoadjuvant Intravesical Mitomycin-C Therapy Immediately Before Transurethral Resection of Bladder Tumor in Patients With Nonmuscle-invasive Bladder Cancer: Preliminary Results of a Prospective, Randomized Phase II Study. ( Chung, J; Joung, JY; Kim, SH; Lee, HH; Lee, HW; Park, EY; Park, WS; Seo, HK, 2023) |
| " The aim of this study was to assess the effect of immediate neoadjuvant electromotive instillation of mitomycin C before transurethral resection for patients with non-muscle-invasive urothelial bladder cancer." | 9.69 | The effect of immediate neoadjuvant electromotive instillation of mitomycin C with Bacillus Calmette-Guérin versus BCG alone in non-muscle-invasive bladder cancer: A randomized controlled trial. ( Abdelbary, A; Abdelrahman, I; Aboulkassem, H; El Azab, A; El Faqeh M Okasha, A; Mohamed Karkeet, R; Saad Zaghloul, A, 2023) |
| "Our goal was to evaluate long-term safety and durability of response to UGN-101, a mitomycin-containing reverse thermal gel, as primary chemoablative treatment for low-grade upper tract urothelial carcinoma." | 9.51 | Durability of Response to Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma Using UGN-101, a Mitomycin-Containing Reverse Thermal Gel: OLYMPUS Trial Final Report. ( Chamie, K; Coleman, J; Godoy, G; Gore, JL; Hakim, G; Hu, B; Hubosky, SG; Humphreys, MR; Kaimakliotis, H; Klein, I; Kleinmann, N; Knoedler, JJ; Konorty, M; Lerner, SP; Lifshitz, D; Linehan, J; Matin, SF; O'Donnell, M; Pak, R; Pierorazio, PM; Quek, M; Raman, JD; Rivera, M; Scherr, D; Schoenberg, M; Seltzer, E; Shabsigh, A; Smith, AB; Strauss-Ayali, D; Verni, M; Weight, C; Weizer, A; Woods, M, 2022) |
| "The purpose of the study was to compare the outcomes of high-risk non-muscle-invasive bladder cancer (HR-NMIBC) patients treated with BCG vs recirculating hyperthermic intravesical chemotherapy (HIVEC) with mitomycin C (MMC)." | 9.51 | Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial. ( de la Rosa-Kehrmann, F; González-Díaz, A; González-Padilla, DA; Guerrero-Ramos, F; Inman, BA; Rodríguez-Antolín, A; Villacampa-Aubá, F, 2022) |
| "To compare the urinary pH, recurrence-free survival (RFS), and safety of adjuvant intravesical therapy in patients with non-muscle-invasive bladder cancer (NMIBC) receiving mitomycin C (MMC) therapy and MMC + cytosine arabinoside (Ara-C) therapy." | 9.51 | Intravesical mitomycin C (MMC) and MMC + cytosine arabinoside for non-muscle-invasive bladder cancer: a randomised clinical trial. ( Aoki, D; Hayashida, Y; Imasato, Y; Matsuo, T; Mitsunari, K; Miyata, Y; Nishikido, M; Ohba, K; Sakai, H; Takehara, K; Taniguchi, K; Tsurusaki, T; Watanabe, J, 2022) |
| "We performed a meta-analysis to evaluate the effect of intravesical mitomycin compared with gemcitabine on the treatment of non-muscle invasive bladder cancer." | 9.41 | Effect of intravesical mitomycin compared with gemcitabine on the treatment non-muscle invasive bladder cancer: A meta-analysis. ( Cheng, W; Chu, X; Huang, S; Zheng, H; Zheng, X; Zhou, Y, 2023) |
| "To evaluate the activity of intravesical mitomycin-C (MMC) to ablate recurrent low-risk non-muscle-invasive bladder cancer (NMIBC) and assess whether it may enable patients to avoid surgical intervention for treatment of recurrence." | 9.34 | CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin-C vs surgical management in low-risk non-muscle-invasive bladder cancer. ( Campain, N; Catto, JWF; Cooke, P; Cresswell, J; Davenport, K; Feber, A; Griffiths, TRL; Hall, E; Kelly, JD; Knight, A; Knowles, MA; Lewis, R; Masood, S; McGrath, JS; Mostafid, AH; Penegar, SR; Porta, N, 2020) |
| "To assess the prophylactic efficacy of postoperative single intravesical instillation with pirarubicin (THP) and mitomycin C (MMC) for low-risk non-muscle-invasive bladder cancer (NMBC)." | 9.34 | Randomized Study of Postoperative Single Intravesical Instillation With Pirarubicin and Mitomycin C for Low-risk Bladder Cancer. ( Aizawa, T; Fujii, Y; Fukui, I; Kageyama, Y; Urakami, S; Yamamoto, S, 2020) |
| "To investigate whether the timing of an immediate instillation of mitomycin C (on the day of transurethral resection of bladder tumour [TURBT] or 1 day later) has an impact on time to recurrence of non-muscle-invasive bladder cancer (NMIBC)." | 9.27 | The effect of timing of an immediate instillation of mitomycin C after transurethral resection in 941 patients with non-muscle-invasive bladder cancer. ( Beckers, GMA; Bosschieter, J; Lissenberg-Witte, BI; Nieuwenhuijzen, JA; van Ginkel, T; van Moorselaar, RJA; Vis, AN, 2018) |
| "From those 11 studies, it is shown that intravesical chemotherapy using Epirubicin and Mitomycin-C following TURB showed significant decrease of recurrence rate of bladder cancer even to progression of the disease compared to TURB alone (p<0." | 9.22 | Comparison Between Intravesical Chemotherapy Epirubicin and Mitomycin-C after TURB vs TURB Alone With Recurrence Rate of Non-Muscle Invasive Bladder Cancer: Meta-Analysis. ( Budaya, TN; Daryanto, B; Purnomo, AF; Seputra, KP, 2022) |
| "This review and meta-analysis aimed to systematically evaluate the clinical efficacy and safety of equipment-assisted intravesical instillation of mitomycin C (MMC) in patients with nonmuscular invasive bladder cancer (NMIBC) after transurethral resection of bladder tumour (TURBT)." | 9.22 | The clinical efficacy and safety of equipment-assisted intravesical instillation of mitomycin C after transurethral resection of bladder tumour in patients with nonmuscular invasive bladder cancer: A meta-analysis. ( Gao, D; Hu, C; Liu, J; Mao, D; Zhou, W, 2022) |
| "The aim of this study was to compare the long-term efficacy of BCG monotherapy to alternating therapy of mitomycin C (MMC) and BCG in patients with carcinoma in situ (CIS)." | 9.22 | Seventeen-year follow-up of the prospective randomized Nordic CIS study: BCG monotherapy versus alternating therapy with mitomycin C and BCG in patients with carcinoma in situ of the urinary bladder. ( Jahnson, S; Kaasinen, E; Malmström, PU; Mestad, O; Rintala, E; Wijkström, H, 2016) |
| "We analyzed the outcomes of a randomized trial demonstrating that in intermediate- to high-risk non-muscle-invasive bladder cancer, mitomycin C and bacillus Calmette-Guérin (BCG) reduced disease relapse compared with BCG alone but was more toxic." | 9.20 | Sequential combination of mitomycin C plus bacillus Calmette-Guérin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomiz ( Alonso, JM; Astobieta, A; Beardo, P; Chantada, V; Fernandez, JM; Gomez, M; Madero, R; Martinez Piñeiro, JA; Martinez-Piñeiro, L; Montesinos, M; Muntañola, P; Ojea, A; Portillo, JA; Rabadan, M; Rodriguez-Molina, J; Solsona, E; Unda, M; Zabala, JA, 2015) |
| "This paper aims to evaluate the safety and heating efficiency of external deep pelvic hyperthermia combined with intravesical mitomycin C (MMC) as a novel therapy for non-muscle-invasive bladder cancer (NMIBC)." | 9.19 | A pilot clinical trial of intravesical mitomycin-C and external deep pelvic hyperthermia for non-muscle-invasive bladder cancer. ( Craciunescu, OA; Dewhirst, MW; Inman, BA; Maccarini, PF; Stauffer, PR; Vujaskovic, Z, 2014) |
| "Sequential bacillus Calmette-Guerin (BCG) and electromotive mitomycin (sequential therapy) have been shown in a randomized prospective trial to be superior to therapy with BCG alone in patients with high-risk non-muscle-invasive bladder cancer." | 9.19 | Contemporary cost-effectiveness analysis comparing sequential bacillus Calmette-Guerin and electromotive mitomycin versus bacillus Calmette-Guerin alone for patients with high-risk non-muscle-invasive bladder cancer. ( Aprikian, AG; Bachir, BG; Black, PC; Breau, RH; Dragomir, A; Fairey, A; Kassouf, W; Kulkarni, GS; Tanguay, S, 2014) |
| "The purpose of this study was to determine the effectiveness of a single early instillation of mitomycin C (MMC) after transurethral resection of bladder tumor (TURBT) together with urinary alkalinization in patients with low-risk non-muscle-invasive bladder cancer (NMIBC)." | 9.17 | Single early instillation of mitomycin C and urinary alkalinization in low-risk non-muscle-invasive bladder cancer: a preliminary study. ( Ersoy, H; Karakoyunlu, AN; Ozok, HU; Sagnak, L; Topaloglu, H; Yaytokgil, M, 2013) |
| "• To present long-term efficacy data of intravesical thermochemotherapy vs chemotherapy alone with mitomycin-C (MMC) randomly administered to patients with non-muscle-invasive bladder cancer (NMIBC) as an adjuvant treatment after complete transurethral resection." | 9.15 | Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC). ( Colombo, R; Engelstein, D; Leib, Z; Pavone-Macaluso, M; Salonia, A, 2011) |
| "Our aim was to assess if sequential mitomycin C (MMC) plus BCG after transurethral resection (TUR) is worthy of further study in non-muscle-invasive bladder cancer patients with CIS." | 9.15 | Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 trial ( ( Algaba, F; Bono, A; Busch, C; Collette, S; da Silva, FC; Kirkali, Z; Oosterlinck, W; Sylvester, R, 2011) |
| "To study the benefits of a single, early, intravesical instillation of mitomycin C(MMC) after transurethral bladder resection (TURB) in patients with low-risk non-muscle-invasive bladder cancer (NMIBC)." | 9.15 | Long-term experience with early single mitomycin C instillations in patients with low-risk non-muscle-invasive bladder cancer: prospective, single-centre randomised trial. ( Albisinni, S; Alpi, G; Cantiani, A; Carbone, A; De Nunzio, C; Iori, F; Liberti, M; Tubaro, A, 2011) |
| " Our aim was to compare TURBT alone with immediate post-TURBT intravesical passive diffusion (PD) of mitomycin and immediate pre-TURBT intravesical electromotive drug administration (EMDA) of mitomycin in non-muscle invasive bladder cancer." | 9.15 | Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial. ( Di Stasi, SM; Giurioli, A; Leprini, G; Liberati, E; Masedu, F; Micali, F; Ricci, AR; Valenti, M; Verri, C; Vespasiani, G, 2011) |
| "To evaluate the efficacy and safety of intravesical instillation with gemcitabine after first-line intravesical chemotherapy failure, including mitomycin (MMC), epirubicin (EPB) and camptothecin (CPT), in the treatment of non-muscle-invasive bladder cancer (NMIBC)." | 9.15 | [Evaluation of the efficacy and safety of intravesical instillation with gemcitabine after first-line intravesical chemotherapy failure in the treatment of non-muscle-invasive bladder cancer]. ( Cao, M; Chen, HG; Ma, CK; Ma, J; Xue, W, 2011) |
| "The present study compared the therapeutic activity of intravesical BCG with intravesical mitomycin C chemotherapy in patients with non-muscle invasive bladder cancer at intermediate risk of recurrence in a prospective randomised trial." | 9.13 | A randomized prospective study of intravesical prophylaxis in non-musle invasive bladder cancer at intermediate risk of recurrence: mitomycin chemotherapy vs BCG immunotherapy. ( Del Nero, A; Mangiarotti, B; Montanari, E; Trinchieri, A, 2008) |
| "Various bladder cancer cell lines were treated with HTI-286 and mitomycin C (MMC) in vitro." | 9.13 | Intravesical chemotherapy of high-grade bladder cancer with HTI-286, a synthetic analogue of the marine sponge product hemiasterlin. ( Adomat, H; Andersen, RJ; Fazli, L; Fradet, Y; Gleave, ME; Hadaschik, BA; So, AI, 2008) |
| "It remains unclear whether people with non-muscle invasive bladder cancer (NMIBC) benefit from intravesical gemcitabine compared to other agents in the primary or recurrent setting following transurethral resection of a bladder tumor." | 9.12 | Intravesical gemcitabine for non-muscle invasive bladder cancer. ( Cleves, A; Dahm, P; Han, MA; Hwang, EC; Hwang, JE; Jung, JH; Maisch, P; Narayan, V, 2021) |
| "We analyzed the impact of a single Mitomycin C instillation in patients with low risk superficial bladder cancer with short and long-term follow-up." | 9.12 | Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term follow-up. ( El-Ganzoury, HM; El-Ghobashy, S; El-Leithy, TR; Roshdy, MM, 2007) |
| "The rationale for combining anticancer drugs has not been applied consistently to use of intravesical agents for treatment of superficial bladder cancer, for which immunotherapeutic BCG and chemotherapeutic mitomycin seem to be a potentially effective combination." | 9.12 | Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. ( Attisani, F; Capelli, G; De Carolis, A; Di Stasi, SM; Giannantoni, A; Giurioli, A; Stephen, RL; Storti, L; Valenti, M; Vespasiani, G; Zampa, G, 2006) |
| "To report the 10-year follow-up of a study randomizing between instillations of bacillus Calmette-Guérin (BCG) and mitomycin-C (MMC) for treating high-risk and not muscle-invasive urinary bladder cancer to assess progression, the need for more aggressive treatment and survival (cancer-specific and overall), as many of the published studies comparing different treatments for disease that is not muscle-invasive have a short follow-up." | 9.12 | Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin-C and bacillus Calmette-Guérin in patients with high-risk bladder cancer. ( Gårdmark, T; Jahnson, S; Malmström, PU; Wahlquist, R; Wijkström, H, 2007) |
| "To evaluate whether, in patients with carcinoma in situ (CIS) of the urinary bladder, alternating instillation therapy with mitomycin C (MMC) and bacillus Calmette-Guerin (BCG) was more effective and less toxic than conventional BCG monotherapy." | 9.10 | Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a nordic study. ( Duchek, M; Hellsten, S; Kaasinen, E; Malmström, PU; Mestad, O; Rintala, E; Wijkström, H, 2003) |
| "We analyze the impact of a single mitomycin C instillation in patients with low risk superficial bladder cancer with short and long-term followup." | 9.09 | Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup. ( Casanova, J; Dumont, R; Iborra, I; Monrós, JL; Ricós, JV; Solsona, E, 1999) |
| "We evaluated the prophylactic efficacy of instillations of intravesical mitomycin C in 57 patients with primary superficial bladder cancer in a multicenter clinical trial." | 9.09 | The effect of intravesical mitomycin C on the recurrence of superficial (Ta-T1) bladder cancer. A Hungarian Multicenter Study. ( Bodrogi, I; Határ, A; Kiss, A; Kiss, L; Kondás, J; Lukács, T; Szeldeli, P; Törzsök, F, 1999) |
| "To elucidate the most efficient topical therapy for carcinoma in situ of the bladder, the efficacy of intravesical mitomycin C plus doxorubicin therapy was compared with bacillus Calmette-Guerin (BCG) therapy." | 9.09 | Equivalent efficacy of mitomycin C plus doxorubicin instillation to bacillus Calmette-Guerin therapy for carcinoma in situ of the bladder. ( Fukui, I; Igarashi, K; Kojima, SI; Ohya, K; Sekine, H, 2001) |
| "Of 68 carcinoma in situ patients randomly treated with instillations 40 received mitomycin C and 28 received mitomycin C and Pasteur bacillus Calmette-Guerin (BCG) in alternating courses." | 9.08 | Alternating mitomycin C and bacillus Calmette-Guerin instillation therapy for carcinoma in situ of the bladder. The Finnbladder Group. ( Alfthan, O; Jauhiainen, K; Kaasinen, E; Rajala, P; Rintala, E; Ruutu, M, 1995) |
| "Results of a randomized prospective study are reported in which mitomycin C, Tice bacillus Calmette-Guerin (BCG) and RIVM-BCG were compared in 437 patients with primary or recurrent pTa and pT1 bladder tumors, including carcinoma in situ." | 9.08 | A randomized study of intravesical mitomycin C, bacillus Calmette-Guerin Tice and bacillus Calmette-Guerin RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder. ( Debruyne, FM; Doesburg, WH; van der Meijden, AP; Vegt, PD; Witjes, JA; Witjes, WP, 1995) |
| "We determined the role, if any, of 1 and 5 instillations of intravesical mitomycin C in the treatment of newly diagnosed superficial bladder cancer." | 9.08 | The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. ( Benyon, LL; Fellows, J; Freedman, LS; Grigor, KM; Hall, RR; Hargreave, TB; Lallemand, G; Munson, K; Newling, DW; Parmar, MK; Richards, B; Robinson, MR; Rose, MB; Smith, PH; Tolley, DA; Whelan, P; Williams, JL, 1996) |
| "A randomized multicenter trial was done to compare transurethral resection only to transurethral resection plus adjuvant mitomycin C and bacillus Calmette Guerin (BCG) instillation for treatment of superficial bladder cancer (stage pTa/1 grades 1 to 3 except primary stage pTa grade 1)." | 9.08 | A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating Clinics. ( Giani, G; Krege, S; Meyer, R; Otto, T; Rübben, H, 1996) |
| "To determine long-term efficacy of intravesical mitomycin C (MMC) versus bacille Calmette-Guérin (BCG) in patients with superficial bladder cancer with regard to recurrences and progression." | 9.08 | Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille Calmette-Guérin-RIVM and mitomycin C in superficial bladder cancer. EORTC GU Group and the Dutch South East Cooperative Urological Group. European Organisation for ( Collette, L; Debruyne, FM; Sylvester, R; v d Meijden, AP; van Aubel, A; Witjes, JA; Witjes, WP, 1998) |
| "We study toxicity and efficacy of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin (BCG) in patients with intermediate or high risk superficial bladder cancer compared to the use of intravesical mitomycin C alone." | 9.08 | Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer. ( Caris, CT; Debruyne, FM; Mungan, NA; Witjes, JA; Witjes, WP, 1998) |
| "Two hundred eighty-seven patients with primary pTa G2, pT1 G1 to G2 superficial bladder cancer, following complete transurethral resection (TUR), were randomly allocated to receive intravesical treatment, either with IFN (50 x 10(6) IU) or mitomycin (MIT-C; 40 mg)." | 9.07 | Prophylaxis of superficial bladder cancer with mitomycin or interferon alfa-2b: results of a multicentric Italian study. ( Boccardo, F; Cannata, D; Canobbio, L; Curotto, A; Decensi, A; Guarneri, D; Martorana, G; Pegoraro, C; Rubagotti, A; Selvaggi, F, 1994) |
| "We compared intravesical instillations with mitomycin-C (MMC), Bacillus Calmette-Guerin (BCG) Tice, and BCG-RIVM in patients with pTa-pT1 papillary carcinoma and primary carcinoma in situ (CIS) of the bladder." | 9.07 | A randomised prospective study comparing intravesical instillations of mitomycin-C, BCG-Tice, and BCG-RIVM in pTa-pT1 tumours and primary carcinoma in situ of the urinary bladder. Dutch South-East Cooperative Urological Group. ( Debruyne, FM; Doesburg, W; Schaafsma, HE; vd Meijden, AP; Witjes, JA; Witjes, WP, 1993) |
| "Between November 1986 and April 1989, 101 patients with superficial bladder cancer were treated with intravesical instillations of mitomycin C on day 1 and doxorubicin on day 2 of each week for 5 consecutive weeks." | 9.07 | Intravesical combination chemotherapy with mitomycin C and doxorubicin for superficial bladder cancer: a randomized trial of maintenance versus no maintenance following a complete response. ( Fukui, I; Ishiwata, D; Kawai, T; Kihara, K; Oshima, H; Sekine, H; Tachibana, Y, 1992) |
| "Intravesical chemotherapy involving the sequential instillation of mitomycin C (MMC) and Adriamycin (ADM) was performed in 40 patients with superficial bladder cancer (pathological stages Ta and T1)." | 9.07 | Sequential instillation therapy with mitomycin C and adriamycin for superficial bladder cancer. ( Abe, K; Isaka, S; Okano, T; Shimazaki, J, 1992) |
| "Both intravesical mitomycin C (MMC) and bacillus Calmette-Guérin (BCG; Pasteur strain F) were effective in the present prospective randomized multicenter study consisting of 91 patients with frequently recurrent superficial (Ta-T1) bladder cancer." | 9.07 | Intravesical chemotherapy (mitomycin C) versus immunotherapy (bacillus Calmette-Guérin) in superficial bladder cancer. ( Alfthan, O; Hansson, E; Jauhiainen, K; Juusela, H; Kanerva, K; Korhonen, H; Permi, J; Rintala, E; Sotarauta, M; Vaalasti, T, 1991) |
| "Sixty patients with Ta and T1 bladder cancer were randomized between treatment with resection only and resection and instillations with either Adriamycin or Mitomycin C." | 9.07 | Prophylactic instillation therapy of superficial bladder cancer. A randomized study comparing mitomycin C and adriamycin with special reference to DNA ploidy. ( Borgström, E; Brolin, J; Gustafson, H; Nyman, C; Tribukait, B; Wijkström, H, 1991) |
| "Thirty patients with advanced bladder cancer received combination chemotherapy with cis-platinum, adriamycin and mitomycin C." | 9.06 | Combination chemotherapy with cis-platinum, adriamycin, mitomycin-C (PAM) in patients with advanced bladder cancer. ( Bacoyiannis, C; Hatzichristou, H; Kosmidis, PA, 1990) |
| "Intravesical instillation of adriamycin (ADM) or mitomycin C (MMC) was carried out for the purpose of preventing the recurrence of superficial bladder cancers (Ta and T1) after transurethral resection or transurethral coagulation." | 9.06 | Prophylactic intravesical instillation therapy with adriamycin and mitomycin C in patients with superficial bladder cancer. ( Matsumura, Y; Ohmori, H; Ozaki, Y; Tsushima, T; Yoshimoto, J, 1987) |
| " Mitomycin C (MMC) and Bacillus Calmette-Guérin (BCG) are commonly used, competing forms of intravesical therapy for intermediate- or high-risk non-muscle invasive (Ta and T1) urothelial bladder cancer but their relative merits are somewhat uncertain." | 9.05 | Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer. ( Coles, B; Dahm, P; Dersch, R; Draeger, DL; Jensen, K; Kilian, S; Krabbe, LM; Kunath, F; Meerpohl, JJ; Schmidt, S, 2020) |
| " The relatively new pyrimidine analog gemcitabine (GEM) has exhibited anticancer effect on various solid cancers, such as the advanced bladder cancer." | 9.05 | Intravesical gemcitabine versus mitomycin for non-muscle invasive bladder cancer: a systematic review and meta-analysis of randomized controlled trial. ( Chen, K; Ding, Y; Dong, Z; Gao, K; Li, R; Li, W; Li, Y; Ma, X; Song, J; Wang, Y; Wang, Z; Yang, X, 2020) |
| "In a prospective, randomized, stratified study with crossover design the effect of thiotepa was compared to that of mitomycin C when each was instilled intravesically immediately at the end of complete removal of superficial bladder cancer (stages Ta and Tis) and later on tumor recurrence." | 9.05 | Intravesical thiotepa and mitomycin C treatment immediately after transurethral resection and later for superficial (stages Ta and Tis) bladder cancer: a prospective, randomized, stratified study with crossover design. ( Benson, RC; Hilton, JF; Taylor, WF; Zincke, H, 1985) |
| "This systematic review and cumulative analysis aimed to explore the efficacy and safety of the combination of intravesical mitomycin C (MMC) plus bacillus Calmette-Guerin (BCG) for non-muscle-invasive bladder cancer (NMIBC) patients." | 8.95 | Systematic Review and Cumulative Analysis of the Combination of Mitomycin C plus Bacillus Calmette-Guérin (BCG) for Non-Muscle-Invasive Bladder Cancer. ( Cai, C; Deng, T; Duan, X; Liu, B; Zeng, G; Zhang, T, 2017) |
| "To evaluate the effectiveness and toxicity of intravesical gemcitabine in preventing tumour recurrence and progression in non-muscle invasive bladder cancer (NMIBC)." | 8.88 | Intravesical gemcitabine for non-muscle invasive bladder cancer. ( Cleves, A; Jones, G; Kynaston, HG; Mason, M; Shelley, M; Wilt, TJ, 2012) |
| "To undertake a systematic review and meta-analysis comparing intravesical mitomycin C and Bacillus Calmette-Guerin in terms of tumour recurrence, disease progression and overall survival in Ta and T1 bladder cancer." | 8.82 | Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer. ( Coles, B; Court, JB; Kynaston, H; Mason, M; Shelley, MD; Wilt, TJ, 2003) |
| "To assess, in a systematic review and meta-analysis, the relative effectiveness of intravesical mitomycin C and bacillus Calmette-Guérin (BCG) for tumour recurrence, disease progression and overall survival in patients with medium- to high-risk Ta and T1 bladder cancer." | 8.82 | Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. ( Coles, B; Court, J; Kynaston, H; Mason, MD; Shelley, MD; Wilt, TJ, 2004) |
| "Bladder retraction is a rare complication of contact chemotherapy with mitomycin C in the treatment of superficial bladder cancer." | 8.79 | [Bladder retraction, a complication of chemoprophylaxis of superficial bladder cancer using intravesical mitomycin C. Apropos of a case and review of the literature]. ( Hubert, J; Mangin, P; Punga-Maole, ML, 1995) |
| "Perioperative instillation of mitomycin-C (MMC) has shown effectiveness in reducing the recurrence of low-grade non-muscle invasive bladder cancer (NMIBC)." | 8.31 | Single-Dose Post-Office Fulguration Mitomycin C Instillation Appears to Improve Recurrence-Free Survival in Patients With Low-Grade Noninvasive Bladder Cancer. ( Baniel, J; Golan, S; Halstuch, D; Karchever, I; Kedar, D; Lotan, P; Rubinshtein, D, 2023) |
| "To compare recurrence rate and side effects with two different maintenance regimens of postoperative intravesical therapy with mitomycin and BCG in T1 bladder cancer." | 8.12 | Comparison of intravesical adjuvant therapy in bladder cancer with two different maintenance regimens of mitomycin and BCG. ( Dutta, A; Gupta, S; Pal, DK, 2022) |
| "Intravesical instillations of mitomycin C, epirubicin and BCG are considered as the standard treatment for most patients diagnosed with non-muscle invasive bladder cancer." | 8.12 | [Guidelines from the cancer committee of the French Association of Urology (CC-AFU) for adequate intravesical instillations of Mitomycin C, Epirubicin, and BCG for non-muscle invasive bladder cancer]. ( Allory, Y; Audenet, F; Leon, P; Loriot, Y; Masson-Lecomte, A; Neuzillet, Y; Pradère, B; Roumiguié, M; Roupret, M; Saint, F; Seisen, T; Traxer, O; Xylinas, E, 2022) |
| "Due to limited local efficacy of BCG and mitomycin C and the worldwide shortage of BCG, there is a clinical need to develop novel intravesical agents and application forms in order to improve the oncological outcomes in non-muscle invasive bladder cancer (NMIBC)." | 8.12 | [Adjuvant instillation therapy for non-muscle invasive bladder cancer - beyond BCG and mitomycin C]. ( Gakis, G, 2022) |
| "Mitomycin C (MMC) is one of the most frequently utilized intravesical chemotherapy drugs for the management of non-muscle-invasive bladder cancer (NMIBC)." | 8.12 | Mitomycin C allergy after passive and device-assisted hyperthermia for non-muscle invasive bladder cancer treatment: A retrospective cohort from a high-volume center. ( Aumatell, J; Burgos Revilla, J; García-Rojo, E; González-Díaz, A; González-Padilla, DA; Guerrero-Ramos, F; Hernández-Arroyo, M; Rodríguez-Antolín, A; Subiela, JD, 2022) |
| " Because EAU Guidelines awarded a level of evidence of 1a to mitomycin C, the drug is widely used to treat bladder cancer." | 7.96 | Mitomycin C-induced cell cycle arrest enhances 5-aminolevulinic acid-based photodynamic therapy for bladder cancer. ( Hanazaki, K; Inoue, K; Ishii, T; Ishizuka, M; Karashima, T; Kawada, C; Nakayama, T; Namikawa, T; Nozawa, N; Ogura, SI; Yamamoto, S, 2020) |
| "Chemoradiation (CRT) with mitomycin-C (MMC) and 5-fluorouracil (5-FU) has been shown to be superior to radiation alone in patients with muscle-invasive bladder cancer (MIBC)." | 7.96 | Radiation with concurrent radiosensitizing capecitabine tablets and single-dose mitomycin-C for muscle-invasive bladder cancer: A convenient alternative to 5-fluorouracil. ( Mertens, LS; Noordzij, A; Pos, F; Schaake, EE; Schuring, N; van de Kamp, MW; van der Heijden, MS; van Rhijn, BWG; Voskuilen, CS, 2020) |
| "Mitomycin-C (MMC) and thiotepa are intravesical agents effective in reducing the recurrence of low-grade noninvasive bladder cancer when instilled perioperatively." | 7.91 | Single-dose perioperative mitomycin-C versus thiotepa for low-grade noninvasive bladder cancer. ( Blodgett, G; Castle, EP; Chang, YH; Etzioni, DA; Faraj, K; Habermann, EB; Humphreys, MR; Rose, KM; Tyson Ii, MD, 2019) |
| " This study was performed to compare the efficacy of intravesical mitomycin C (MMC) instillation for the prophylaxis of Ta or T1 high-risk nonmuscle invasive bladder cancer (NMIBC) using different schedules." | 7.91 | Comparison of Different Treatment Schedules of Mitomycin C Intravesical Instillation in High-Risk Superficial Bladder Cancer Patients. ( Cha, TL; Chen, HR; En, M; Kao, CC; Sun, GH; Tang, SH; Tsao, CW; Wu, ST; Yu, DS, 2019) |
| "This study aimed to investigate whether lidocaine, alone or in combination with other chemotherapeutic agents, inhibits the growth of human bladder cancer cells in vitro and orthotopically transplanted bladder tumors in vivo." | 7.88 | Lidocaine enhances the effects of chemotherapeutic drugs against bladder cancer. ( Li, M; Mi, Z; Ren, L; Xu, J; Yan, L; Yang, X; Zhang, S; Zhao, L, 2018) |
| "Objectives To explore the effect of electromotive drug administration of mitomycin C (EMDA-MMC) using a single dose of intravesical mitomycin C (MMC) to avoid transurethral resection (TURBT) for small non-muscle-invasive bladder cancer." | 7.88 | Single ablative intravesical electromotive mitomycin C administration for small non-muscle-invasive bladder cancer: a prospective study. ( Decaestecker, K; Lumen, N; Oosterlinck, W; Van Camp, C, 2018) |
| "Mitomycin-c (MMC) is the most used intravesical adjuvant agent in non-muscle invasive bladder cancer to prevent recurrence." | 7.88 | Drug resistance restricts the efficacy of short term low dose Mitomycin-C treatment in UMUC-3 bladder cancer cells. ( Goktas, S; Gul, M; Kars, MD; Kaynar, M, 2018) |
| "To evaluate oncological outcomes after combination intravesical therapy with gemcitabine (GC) and mitomycin C (MMC) in the setting of recurrent non-muscle-invasive bladder cancer (NMIBC) after failure of previous intravesical therapy." | 7.83 | Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer. ( Cockerill, PA; Frank, I; Karnes, RJ; Knoedler, JJ; Tarrell, R, 2016) |
| "To evaluate the practice of immediate postoperative instillation (IPOP) using mitomycin C for non-muscle invasive bladder cancer (NMIBC) treatment by urologists members of the French Association of Urology (AFU)." | 7.83 | [Observational survey of the French Urological Association Oncology Committee (CCAFU) evaluating the practice of immediate postoperative instillation (IPOP) using mitomycin C for non-muscle invasive bladder cancer (NMIBC) treatment]. ( Colin, P; Comperat, E; Dubosq, F; Houede, N; Larre, S; Masson-Lecomte, A; Mejean, A; Neuzillet, Y; Pignot, G; Puech, P; Roumiguie, M; Roupret, M; Xylinas, E, 2016) |
| "Starting in 2009 bacillus Calmette-Guérin/electromotive drug administration of mitomycin C was introduced as the standard induction regime in patients with high risk, nonmuscle invasive bladder cancer undergoing bladder conservation." | 7.83 | Sequential bacillus Calmette-Guérin/Electromotive Drug Administration of Mitomycin C as the Standard Intravesical Regimen in High Risk Nonmuscle Invasive Bladder Cancer: 2-Year Outcomes. ( Amery, S; Chatterton, K; Gan, C; Khan, MS; O'Brien, T; Thomas, K, 2016) |
| "To know the dermatologic side effects of intravesical treatment with Mitomycin C in non muscle invasive bladder cancer." | 7.83 | Dermatological side effects of intravesical Mitomycin C: Delayed hypersensitivity. ( Castillo Pacheco, C; Colomer Gallardo, A; González Satue, C; Ibarz Servio, L; Martínez Rodríguez, R, 2016) |
| "Between 2009 and 2011, 20 patients with intermediate and high risk nonmuscle invasive bladder cancer were treated with intravesical mitomycin C (40 mg) combined with regional hyperthermia." | 7.81 | Combining Mitomycin C and Regional 70 MHz Hyperthermia in Patients with Nonmuscle Invasive Bladder Cancer: A Pilot Study. ( Crezee, J; de la Rosette, JJ; de Reijke, TM; Geijsen, ED; Koning, CC; Rasch, CR; van Os, RM; Zum Vörde Sive Vörding, PJ, 2015) |
| "This study sought to determine if the addition of perioperative mitomycin C (MMC) to treatment with bacillus Calmette-Guérin (BCG) after transurethral resection (TURBT) is superior to TURBT plus BCG alone in high grade non-muscle invasive bladder cancer (NMIBC)." | 7.81 | Single instillation of mitomycin C plus bacillus Calmette-Guérin (BCG) versus BCG alone in high grade non-muscle invasive bladder cancer. ( Guzzo, TJ; Malkowicz, SB; Pietzak, EJ; Wein, AJ; Weiss, BE, 2015) |
| "An in vitro model was developed to understand if celecoxib could synergize with Mitomycin C (MMC), commonly used for the prevention of non-muscle invasive bladder cancer recurrence, and eventually elucidate if the mechanism of interaction involves multi drug resistance (MDR) transporters." | 7.79 | The interaction of celecoxib with MDR transporters enhances the activity of mitomycin C in a bladder cancer cell line. ( Ancona, P; Azzariti, A; Colabufo, NA; Contino, M; Cormio, L; Niso, M; Pagliarulo, A; Pagliarulo, V, 2013) |
| "To identify whether integrinβ1 subunit is responsible for the resistance of bladder cancer cell to the therapeutic drug mitomycin-C (MMC), when grown on fibronectin (FN)." | 7.78 | Engagement of integrinβ1 induces resistance of bladder cancer cells to mitomycin-C. ( Li, T; Pan, CW; Shen, ZJ; Zhang, CJ; Zhang, MG; Zhong, S, 2012) |
| "Intravesical BCG immunotherapy and mitomycin C are considered as the standard treatment for non-muscle invasive bladder cancer." | 7.78 | [Guidelines for good practice of intravesical instillations of BCG and mitomycin C from the French national cancer committee (CC-AFU) for non-muscle invasive bladder cancer]. ( Chartier-Kastler, E; Coloby, P; Larré, S; Mongiat-Artus, P; Neuzillet, Y; Pfister, C; Pignot, G; Rébillard, X; Rouprêt, M; Soulié, M, 2012) |
| "• To examine, using in vitro and in vivo models, the largely unexamined effect of mitomycin C (MMC), an effective intravesical treatment for superficial bladder cancer and carcinoma in situ, on expression of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor-2 (VEGFR-2), which mediates many of the angiogenic properties of VEGF." | 7.77 | Effect of mitomycin C on concentrations of vascular endothelial growth factor and its receptors in bladder cancer cells and in bladders of rats intravesically instilled with mitomycin C. ( Degrado, J; Hittelman, AB; Kaimakliotis, HZ; Verma, A; Weiss, RM; Wheeler, MA, 2011) |
| "To analyze the prognostic values of p53 and Ki-67 expression in intermediate-risk patients with nonmuscle-invasive bladder cancer who were treated with adjuvant intravesical mitomycin C." | 7.76 | Prognostic value of p53 and Ki-67 expression in intermediate-risk patients with nonmuscle-invasive bladder cancer receiving adjuvant intravesical mitomycin C therapy. ( Cho, KS; Chung, J; Chung, MK; Joung, JY; Lee, KH; Park, WS; Seo, HK, 2010) |
| " EMDA of intravesical mitomycin-C (MMC) has been used for treatment of non-muscle invasive bladder cancer (NMIBC) for about a decade on the basis of laboratory studies that demonstrated an enhanced administration rate of MMC into all bladder wall layers after EMDA compared to standard instillation/passive diffusion (PD)." | 7.75 | Updates in intravesical electromotive drug administration of mitomycin-C for non-muscle invasive bladder cancer. ( Di Stasi, SM; Riedl, C, 2009) |
| "T24 cells (human bladder cancer cell lines) were pre-coated with fibronectin, and treated with mitomycin C (MMC) and the specific phosphoinositide-3 kinase (PI3-K) inhibitor LY294002." | 7.75 | Cell adhesion to fibronectin induces mitomycin C resistance in bladder cancer cells. ( Pan, CW; Shao, Y; Shen, ZJ; Sun, J; Tang, XY; Wang, M; Wu, TT, 2009) |
| "Three-dimensional histocultures of RT4 (American Type Culture Collection, Rockville, Maryland) xenograft tumors and tumors from patients with bladder cancer were treated with MMC with or without 20 microM suramin." | 7.73 | Low dose suramin as a chemosensitizer of bladder cancer to mitomycin C. ( Au, JL; Chen, D; Lyness, G; Song, S; Wientjes, MG; Xin, Y, 2005) |
| "The human bladder cancer cell lines EJ28 and 5637 were transiently transfected with 3 antiVEGF AS-ODNs, followed by incubation with 3 doses of mitomycin C, gemcitabine or cisplatin CT." | 7.73 | Vascular endothelial growth factor antisense pretreatment of bladder cancer cells significantly enhances the cytotoxicity of mitomycin C, gemcitabine and Cisplatin. ( Förster, Y; Fuessel, S; Kotzsch, M; Kraemer, K; Krause, S; Meye, A; Schmidt, U; Schwenzer, B; Wirth, MP, 2005) |
| "Bladder cancer is a relatively common tumor in the urinary system, in which mitomycin C (MMC)-based chemotherapy or combination chemotherapy has been mainly used to treat patients with advanced bladder cancer." | 7.73 | Enhanced sensitivity to mitomycin C by abating heat shock protein 70 expression in human bladder cancer cell line of BIU-87. ( Guan, KP; He, LF; Hou, SK; Ren, L; Xu, KX; Yan, Z; Ye, HY, 2005) |
| "Transurethral resection followed by instillation of chemotherapeutic agents such as mitomycin is considered as standard therapy in recurrent superficial bladder cancer." | 7.73 | Reducing recurrence and costs in superficial bladder cancer: preclinical evaluation of osmotic cytolysis by distilled water vs. mitomycin. ( Fechner, G; Müller, SC; Pocha, K; Schmidt, D, 2006) |
| "We studied prophylactic intravesical instillation of mitomycin C (MMC) and pirarubicin (THP) following transurethral resection of bladder tumor (TUR-Bt) for superficial bladder cancer." | 7.73 | [5 years intravesical instillation with mitomycin-C and pirarubicin as a prophylactic treatment for superficial bladder cancer]. ( Ishizaka, K; Kobayashi, S; Machida, T; Oka, K, 2006) |
| "To determine if Meglumine-Eicosapentaenoic Acid (MeEPA) acts synergistically with epirubicin and mitomycin to enhance cytotoxicity towards bladder cancer cell lines in vitro." | 7.73 | Meglumine Eicosapentaenoic acid (MeEPA) a new soluble omega-3 fatty acid formulation: in vitro bladder cancer cytotoxicity tests in combination with epirubicin and mitomycin. ( Cooper, AJ; Harris, NM; Lwaleed, BA; Mackie, SJ; Sharma, DM, 2006) |
| "The enhancing effects of Smac gene on the mitomycin C-induced apoptosis of the bladder cancer cell line T24 were investigated." | 7.73 | Smac/DIABLO promotes mitomycin C-induced apoptosis of bladder cancer T24 cells. ( Fuqing, Z; Tong, Q; Wang, L; Zheng, L, 2006) |
| "To investigate the efficacy of inducing apoptosis in human bladder cancer cells by adriamycin and mitomycin and relevant mechanism." | 7.73 | [Adriamycin and mitomycin dose-dependently downregulate X-kinked inhibitor of apoptosis protein in human bladder cancer cells]. ( Chen, L; Gan, L; Lai, YQ; Li, M; Liu, G; Na, YQ; Yin, ZF; Yuan, YM, 2006) |
| "To evaluate the effect of combined use of oncolytic virus and the chemotherapeutic agents mitomycin (MMC) in growth inhibition of human bladder cancer cell line T-24 in vitro." | 7.73 | [Cytotoxic effect of oncolytic virus combined with mitomycin against human bladder cancer cells in vitro and in vivo]. ( Tan, WL; Wu, YD; Xie, Y; Zhao, GZ; Zheng, SB; Zhu, WH, 2006) |
| "To investigate the hypothesis that sequential mitomycin C and 5-aminolaevulinic acid (ALA)-mediated photodynamic therapy (PDT) interact additively in both the J82 bladder cancer cell line and its mitomycin-C-resistant derivative, J82/MMC, and to assess the theoretical basis of this interaction by measuring the relative mitochondrial density of the respective cell lines, on the basis that the mitochondria are the intracellular site where ALA is metabolized to the active photosensitizer, protoporphyrin IX." | 7.72 | Investigation of sequential mitomycin C and photodynamic therapy in a mitomycin-resistant bladder cancer cell-line model. ( Allman, R; Datta, SN; French, AJ; Matthews, PN, 2004) |
| "To investigate whether the heat shock protein (HSP) 70 antisense oligomers can enhance the sensitivity of bladder cancer cell EJ to mitomycin C." | 7.72 | [The heat shock protein 70 antisense oligomers enhance the sensitivity of bladder cancer cell EJ to mitomycin C]. ( He, LF; Hou, SK; Ren, L; Wang, SW; Yan, Z, 2004) |
| "To compare the tumoricidal efficacy of meglumine gamma-linolenic acid (MeGLA), mitomycin C, epirubicin and water on two urothelial cell lines, and to establish the effect of serum protein levels derived from bladder cancer resection craters on the action of these agents." | 7.70 | Bladder cancer recurrence by implantation of exfoliated cells: is gamma-linolenic acid an effective tumoricidal agent? ( Birch, BR; Cooper, AJ; Foley, SJ; Jennings, AM; Solomon, LZ, 1998) |
| "From January 1984 to December 1991, 58 patients with carcinoma in situ of the bladder were treated initially with intravesical mitomycin C and doxorubicin sequential therapy." | 7.69 | Histological grading of carcinoma in situ of the bladder: its clinical significance in patients who underwent intravesical mitomycin C and doxorubicin sequential therapy. ( Fukui, I; Kojima, S; Ohshima, H; Sekine, H; Yamada, T, 1996) |
| "This study describes characteristics of a human bladder cancer cell line, SCaBER/R, selected for resistance to a mitomycin C (MMC) analogue BMY 25067." | 7.69 | Characterization of a human bladder cancer cell line selected for resistance to BMY 25067, a novel analogue of mitomycin C. ( Emerson, EO; Gupta, V; Jani, JP; Singh, SV; Xu, BH; Zaren, HA, 1995) |
| "This study was undertaken to elucidate the mechanism(s) of cross-resistance to cisplatin (CDDP) in a mitomycin C (MMC)-resistant human bladder cancer cell line, J82/MMC." | 7.69 | Mechanism of cross-resistance to cisplatin in a mitomycin C-resistant human bladder cancer cell line. ( Backes, MG; Blanock, K; Emerson, EO; Jani, JP; Rihn, C; Scalamogna, D; Singh, SV; Specht, S; Stemmler, N; Xu, BH, 1995) |
| "Mitomycin C (MMC) was given intravesically to 14 patients with transitional-cell carcinoma in situ of the bladder (CIS) between 1985 and 1989." | 7.69 | Treatment of bladder carcinoma in situ with mitomycin C: long-term follow-up. ( Cecchi, M; Felipetto, R; Minervini, R; Viganò, L, 1994) |
| "This study describes characteristics of a human bladder cancer cell line J82/MMC that is 6-fold more resistant to mitomycin C (MMC) than the parental cells." | 7.69 | Characterization of a human bladder cancer cell line selected for resistance to mitomycin C. ( Gupta, V; Singh, SV; Xu, BH, 1994) |
| "Mitomycin C (MMC) was given intravesically over a period of 36 months to 14 patients with transitional-cell carcinoma in situ of the bladder (CIS)." | 7.69 | Intravesical mitomycin C for the treatment of carcinoma in situ of the bladder: 36 months follow-up. ( Cecchi, M; Felipetto, R; Minervini, R; Pagni, G; Viganò, L, 1994) |
| "A total of 43 patients with carcinoma in situ of the bladder (primary in 26 and secondary in 17) who underwent intravesical mitomycin C and doxorubicin sequential therapy for 2 multicenter studies were followed for a median period of 45 months (range 10 to 84)." | 7.69 | Intravesical mitomycin C and doxorubicin sequential therapy for carcinoma in situ of the bladder: a longer followup result. ( Fukui, I; Ohshima, H; Ohwada, F; Sekine, H; Yamada, T; Yokokawa, M, 1994) |
| "This study was undertaken to elucidate the mechanism(s) of differential sensitivity of human bladder cancer cell lines J82 and SCaBER to mitomycin C (MMC) and its analogue, BMY 25067." | 7.69 | Mechanism of differential sensitivity of human bladder cancer cells to mitomycin C and its analogue. ( Gupta, V; Singh, SV; Xu, BH, 1994) |
| "In this study, we have examined the relationship between sensitivity to mitomycin C (MMC) and glutathione (GSH) and glutathione transferase (GST) levels using a panel of three unrelated human bladder cancer cell lines." | 7.69 | Mitomycin C sensitivity in human bladder cancer cells: possible role of glutathione and glutathione transferase in resistance. ( Gupta, V; Singh, SV; Xu, BH, 1994) |
| "This study describes characteristics of a mitomycin C (MMC)-resistant human bladder cancer cell line, J82/MMC-2, which was established by repeated in vitro exposures of a 6-fold MMC-resistant variant (J82/MMC) to 18 nM MMC." | 7.69 | Biochemical characterization of a mitomycin C-resistant human bladder cancer cell line. ( Emerson, EO; Gupta, V; O'Toole, S; Roy, D; Scalamogna, D; Singh, SV; Xia, H; Zaren, HA, 1996) |
| "This study was undertaken to determine the mechanism of resistance of a human bladder cancer cell line SCaBER to mitomycin C (MMC)." | 7.69 | [Mechanism of resistance to mitomycin C in a human bladder cancer cell line]. ( Singh, SV; Sun, Y; Xu, B, 1995) |
| "The mechanism of increased sensitivity to etoposide (VP-16) in a human bladder cancer cell line (J82/MMC-2), which is >9-fold more resistant to mitomycin C (MMC) compared with parental cells (J82/WT), was investigated." | 7.69 | Mechanism of increased sensitivity to etoposide in a mitomycin C-resistant human bladder cancer cell line. ( Bleicher, RJ; Gupta, V; Singh, SV; Xia, H; Zaren, HA, 1997) |
| " Cell survival of ALA-mediated photodynamic therapy was measured in the J82 bladder cancer cell line, along with its mitomycin C-resistant counterpart J82/MMC." | 7.69 | Effect of photodynamic therapy in combination with mitomycin C on a mitomycin-resistant bladder cancer cell line. ( Allman, R; Datta, SN; Loh, C; Mason, M; Matthews, PN, 1997) |
| "Bladder wall calcification is a rare complication of intravesical therapy of superficial bladder cancer with Mitomycin C." | 7.68 | Incrusted cystitis after intravesical mitomycin C treatment. ( Algado, M; Botella, R; Llopis, M; Moreno, J, 1993) |
| "Treatment of superficial bladder cancers by intravesical mitomycin C (MMC) chemotherapy gives a varying and incomplete response." | 7.68 | Use of pharmacologic data and computer simulations to design an efficacy trial of intravesical mitomycin C therapy for superficial bladder cancer. ( Au, JL; Badalament, RA; Wientjes, MG, 1993) |
| "The effect of intravesical instillation of 200,000 IU hyaluronidase in addition to mitomycin C as chemoprophylaxis of superficial bladder cancer was evaluated." | 7.68 | Topical chemoprophylaxis of superficial bladder cancer with mitomycin C and adjuvant hyaluronidase. ( Höbarth, K; Maier, U; Marberger, M, 1992) |
| "We analyzed 29 cases of eosinophilic cystitis in a group of 80 patients with lower urothelial carcinoma who had been treated with mitomycin-C." | 7.68 | [Eosinophilic cystitis as a special form of response to mitomycin C. Analysis and comments on our cases]. ( Arango Toro, O; Bielsa Galí, O; Corominas, J; Gelabert Mas, A; Lladó Carbonell, C; Vesa Llanes, J, 1991) |
| "Intravesical mitomycin C (MMC) therapy is used to treat superficial bladder cancer." | 7.68 | Pharmacokinetics of intravesical mitomycin C in superficial bladder cancer patients. ( Au, JL; Badalament, RA; Dalton, JT; Drago, JR; Wientjes, MG, 1991) |
| "A total of 20 patients received intravesical bacillus Calmette-Guerin (BCG) or mitomycin C for the treatment of carcinoma in situ following previous pelvic radiation therapy." | 7.68 | Intravesical bacillus Calmette-Guerin or mitomycin C in the treatment of carcinoma in situ of the bladder following prior pelvic radiation therapy. ( Pisters, LL; Tykochinsky, G; Wajsman, Z, 1991) |
| "We studied 15 patients with histologically proved multifocal carcinoma in situ of the bladder who were in remission at a mean followup of 21 months after induction intravesical chemotherapy with mitomycin C." | 7.68 | Topical mitomycin C therapy for carcinoma in situ of the bladder: a followup. ( Grant, AB; Hosken, BM; Stricker, PD; Taylor, JS, 1990) |
| "Mitomycin C was given intravesically over periods of 2-32 months to 34 patients with carcinoma in situ of the urinary bladder." | 7.68 | Intravesical mitomycin C for carcinoma in situ of the urinary bladder. ( Hellsten, S; Henrikson, H; Idwall, I; Lindholm, K; Månsson, W; Mårtensson, S; Mikulowski, P; Oldbring, J, 1990) |
| "Mitomycin C 40 mg in 40 ml water was administered intravesically every week for 8 consecutive weeks to 60 patients with superficial bladder cancer." | 7.67 | Mitomycin C intravesical therapy in noninvasive bladder cancer after failure on thiotepa. ( Block, NL; Brannen, G; Cummings, KB; Flanagan, M; Issell, BF; Levin, EA; Prout, GR; Soloway, MS; Summers, JL; Veenema, R, 1984) |
| "Calcification of the bladder wall associated with intravesical mitomycin C for the treatment of superficial bladder cancer is a rare complication." | 7.67 | Bladder wall calcification after intravesical mitomycin C treatment of superficial bladder cancer. ( Badalament, RA; Drago, JR; Drago, PC; Lucas, J, 1989) |
| "During long periods of buffered instillations of mitomycin C (MMC) and doxorubicin (adriamycin; ADM) on carcinoma in situ (TIS), the complete response was 82% for MMC and 80% for ADM." | 7.67 | Effect of mitomycin C and doxorubicin instillation on carcinoma in situ of the urinary bladder. A Finnish multicenter study. ( Alfthan, O; Jauhiainen, K; Permi, J; Sotarauta, M, 1986) |
| "Both Mitomycin C (MMC) and doxorubicin (Adriamycin) (ADM) prevent the recurrence of superficial papillary (Ta-T1) urinary bladder cancers and also reduce the rate of progression." | 7.67 | Instillation of mitomycin C and doxorubicin in the prevention of recurrent superficial (Ta-T1) bladder cancer. ( Alfthan, O; Jauhiainen, K, 1987) |
| "We have investigated the effect of verapamil on the cytotoxicity of adriamycin and mitomycin C with human bladder cancer cell lines T-24 and JTC-30." | 7.67 | [Effect of a calcium influx blocker, verapamil, on the sensitivity of human bladder cancer cells to adriamycin and mitomycin C]. ( Kageyama, Y; Kihara, K; Ohta, S; Yoshida, K, 1988) |
| "A limited course of intravesical mitomycin C was tested in 12 patients who had at least three, and an average of six, occurrences of superficial bladder cancer, and were at high risk for subsequent recurrences." | 7.67 | Study of intravesical mitomycin C in patients with multiple prior occurrences of superficial bladder cancer. ( Brown, J; Johanson, KE; Schwarzman, MI; Surya, B, 1988) |
| "A total of 70 patients received intravesical mitomycin C for treatment of superficial bladder cancer." | 7.67 | Treatment of superficial bladder cancer with intravesical mitomycin C: analysis of immediate and long-term response in 70 patients. ( Soloway, MS, 1985) |
| "Twenty-three patients who were given intravesical Mitomycin C for treatment of superficial bladder cancer have been followed up for a further 12 and 24 months after an initial assessment 5 weeks after completing therapy." | 7.67 | Mitomycin C in superficial bladder cancer: 24-month follow-up. ( Newling, DW; Richards, B; Robinson, MR; Smith, PH; Somerville, JJ, 1985) |
| "Twenty-three patients with histologically proven superficial bladder cancer (Tis, Ta, T1) were treated with intravesical instillations of Mitomycin C at a dose of 20 mg in 20 ml of water 3 times weekly for 21 instillations." | 7.66 | A phase II study of intravesical mitomycin C in the treatment of superficial bladder cancer. ( Green, DF; Harrison, GS; Newling, DW; Richards, B; Robinson, MR; Smith, PH, 1983) |
| "Recurrences in non-muscle-invasive bladder cancer are common, despite adjuvant therapies." | 6.82 | Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer. ( Arends, TJ; Canepa, G; de Cobelli, O; Maffezzini, M; Moskovitz, B; Nativ, O; van der Heijden, AG; Verweij, F; Witjes, JA, 2016) |
| "Postoperative EMDA with mitomycin is a safe procedure." | 6.80 | [Non-muscle invasive bladder cancer: safety of postoperative EMDA-assisted instillation of mitomycin]. ( Niedworok, C; Rehme, C; Rübben, H; Vom Dorp, F, 2015) |
| "Primary outcome measurement was recurrence-free survival (RFS)." | 6.77 | Intracutaneous and intravesical immunotherapy with keyhole limpet hemocyanin compared with intravesical mitomycin in patients with non-muscle-invasive bladder cancer: results from a prospective randomized phase III trial. ( Caris, CT; Janzing-Pastors, MH; Lammers, RJ; Witjes, JA; Witjes, WP, 2012) |
| "The long-term bladder cancer-specific mortality was unexpectedly low despite the relatively ineffective instillation therapy and the poor outcome of the patients after progression." | 6.77 | Long-term results of maintenance treatment of mitomycin C or alternating mitomycin C and bacillus Calmette-Guérin instillation therapy of patients with carcinoma in situ of the bladder: a subgroup analysis of the prospective FinnBladder 2 study with a 17- ( Group, TF; Järvinen, R; Kaasinen, E; Rintala, E, 2012) |
| "The mitomycin C-treated patients had 41% recurrence, 1." | 6.68 | [Prevention of superficial bladder cancer with mitomycin C or interferon: final results of a prospective study]. ( Alonso Rodrigo, A; Barros Rodríguez, M; Benavente Delgado, J; Domínguez Freire, F; Nogueira March, YJ; Ojea Calvo, A; Rodríguez Iglesias, B; Vérez Vivero, M, 1996) |
| "Bladder cancer is the second most common urological malignant disease." | 6.58 | [Thermochemotherapy with Mitomycin C: an update on alternative treatment strategies in non-muscleinvasive bladder cancer]. ( Blaschke, S; Christoph, F; König, F; Lebentrau, S; Liehr, UB; Schostak, M, 2018) |
| "The treatment of non muscle invasive bladder cancer (NMIBC) continues to be a challenge." | 6.58 | Analysis of tolerance and security of chemo hyperthermia with Mitomycin C for the treatment of non-muscle invasive bladder cancer. ( Alvarez Casal, M; Domínguez, JL; León-Mata, J; Piñeiro Vázquez, E; Redorta, JP; Sousa Escandón, A; Sousa González, D, 2018) |
| "Urinary bladder cancer is one of the most frequent cancers worldwide." | 6.53 | Comparison of the combination therapy of bacillus Calmette-Guérin and mitomycin C with the monotherapy for non-muscle-invasive bladder cancer: a meta-analysis. ( Lan, Y; Lin, M; Liu, D, 2016) |
| "Bladder cancer is a heterogeneous disease: approximately 75% of its forms are non muscle invasive neoplasms." | 6.46 | Mitomycin C for the treatment of bladder cancer. ( Bassi, PF; Cappa, E; D'Agostino, D; Filianoti, A; Racioppi, M; Volpe, A, 2010) |
| "Patients with non-muscle-invasive bladder cancer with an intermediate or high risk need adjuvant intravesical therapy after surgery." | 6.45 | An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. ( Crawford, DE; Di Stasi, SM; Friedrich, M; Krege, S; Malmström, PU; Rintala, E; Solsona, E; Sylvester, RJ; Witjes, JA, 2009) |
| "Intravesical chemotherapy using mitomycin C in patients with superficial bladder cancer after transurethral resection (TUR) has proved to be highly effective in preventing tumor recurrences and/or progression." | 6.16 | Treatment schedule of intravesical chemotherapy with mitomycin C in superficial bladder cancer: short-term courses or maintenance therapy. ( DeBruyne, FM; van der Meijden, AP, 1988) |
| "To assess the clinical and oncological outcomes of sequential treatment with Bacillus Calmette-Guerin (BCG) and Mitomycin C (MMC) administered with Electromotive Drug Administration (EMDA) in patients with high-risk NMIBC who fail BCG immunotherapy." | 5.91 | Sequential Treatment With Bacillus Calmette-Güerin (BCG) and Mitomycin C Administered With Electromotive Drug Administration (EMDA) in Patients With High-Risk Nonmuscle Invasive Bladder Cancer After BCG Failure. ( Bravo, A; Breda, A; Gaya, JM; Huguet, J; Palou, J; Robalino, J; Rodríguez Faba, Ó; Sanz Gómez, I; Territo, Á, 2023) |
| "In the rat bladder cancer model, IVI of chidamide plus mitomycin C reduced tumor burden (Ki67 index) to a greater extent than either drug alone." | 5.72 | Chidamide and mitomycin C exert synergistic cytotoxic effects against bladder cancer cells in vitro and suppress tumor growth in a rat bladder cancer model. ( Chang, YC; Chen, SL; Sung, WW; Wang, SC; Wu, YC; Yu, CY, 2022) |
| "This study aimed to assess long-term follow-up after chemoresection with mitomycin (MMC), a nonsurgical treatment modality for recurrent nonmuscle invasive bladder cancer (NMIBC)." | 5.69 | DaBlaCa-13 Study: Oncological Outcome of Short-Term, Intensive Chemoresection With Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial. ( Azawi, N; Dyrskjøt, L; Hansen, E; Jensen, JB; Lindgren, MS; Nielsen, AM, 2023) |
| "Intravesical mitomycin-C is recommended immediately after transurethral resection of bladder tumor for nonmuscle-invasive bladder cancer." | 5.69 | Clinical Efficacy of Neoadjuvant Intravesical Mitomycin-C Therapy Immediately Before Transurethral Resection of Bladder Tumor in Patients With Nonmuscle-invasive Bladder Cancer: Preliminary Results of a Prospective, Randomized Phase II Study. ( Chung, J; Joung, JY; Kim, SH; Lee, HH; Lee, HW; Park, EY; Park, WS; Seo, HK, 2023) |
| " The aim of this study was to assess the effect of immediate neoadjuvant electromotive instillation of mitomycin C before transurethral resection for patients with non-muscle-invasive urothelial bladder cancer." | 5.69 | The effect of immediate neoadjuvant electromotive instillation of mitomycin C with Bacillus Calmette-Guérin versus BCG alone in non-muscle-invasive bladder cancer: A randomized controlled trial. ( Abdelbary, A; Abdelrahman, I; Aboulkassem, H; El Azab, A; El Faqeh M Okasha, A; Mohamed Karkeet, R; Saad Zaghloul, A, 2023) |
| "To compare the therapeutic effects of locoregional deep hyperthermia combined with intravesical chemotherapy with those of intravesical chemotherapy alone in patients with intermediate-/high-risk non-muscle invasive bladder cancer (NMIBC)." | 5.62 | Loco-regional deep hyperthermia combined with intravesical Mitomycin instillation reduces the recurrence of non-muscle invasive papillary bladder cancer. ( Fan, YC; Lai, BCH; Lee, HL; Lee, LM; Lin, KH; Lin, YW; Shih, HJ; Syu, SH; Wen, YC, 2021) |
| "Four patients (15." | 5.56 | Sequential administration of Bacillus Calmette-Guerin (BCG) and Electromotive Drug Administration (EMDA) of mitomycin C (MMC) for the treatment of high-grade nonmuscle invasive bladder cancer after BCG failure. ( Erlich, A; Fleshner, NE; Juvet, T; Krimus, L; Kuk, C; Kulkarni, GS; Lajkosz, K; Mari, A; Wallis, CJ; Zlotta, AR, 2020) |
| "Our goal was to evaluate long-term safety and durability of response to UGN-101, a mitomycin-containing reverse thermal gel, as primary chemoablative treatment for low-grade upper tract urothelial carcinoma." | 5.51 | Durability of Response to Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma Using UGN-101, a Mitomycin-Containing Reverse Thermal Gel: OLYMPUS Trial Final Report. ( Chamie, K; Coleman, J; Godoy, G; Gore, JL; Hakim, G; Hu, B; Hubosky, SG; Humphreys, MR; Kaimakliotis, H; Klein, I; Kleinmann, N; Knoedler, JJ; Konorty, M; Lerner, SP; Lifshitz, D; Linehan, J; Matin, SF; O'Donnell, M; Pak, R; Pierorazio, PM; Quek, M; Raman, JD; Rivera, M; Scherr, D; Schoenberg, M; Seltzer, E; Shabsigh, A; Smith, AB; Strauss-Ayali, D; Verni, M; Weight, C; Weizer, A; Woods, M, 2022) |
| "The purpose of the study was to compare the outcomes of high-risk non-muscle-invasive bladder cancer (HR-NMIBC) patients treated with BCG vs recirculating hyperthermic intravesical chemotherapy (HIVEC) with mitomycin C (MMC)." | 5.51 | Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial. ( de la Rosa-Kehrmann, F; González-Díaz, A; González-Padilla, DA; Guerrero-Ramos, F; Inman, BA; Rodríguez-Antolín, A; Villacampa-Aubá, F, 2022) |
| "BC2001, the largest randomised trial of bladder-sparing treatment for muscle-invasive bladder cancer (MIBC), demonstrated improvement in locoregional control by adding fluorouracil and mitomycin C to radiotherapy (James ND, Hussain SA, Hall E, et al." | 5.51 | Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-yr Follow-up of the Phase 3 Randomised Controlled BC2001 Trial. ( Crundwell, M; Hall, E; Huddart, R; Hussain, SA; James, N; Jenkins, P; Lewis, R; Lydon, A; Porta, N; Rawlings, C; Sheehan, D; Sreenivasan, T; Syndikus, I; Tremlett, J; Wallace, J, 2022) |
| "Optima II ("OPTimized Instillation of Mitomycin for Bladder Cancer Treatment," clinicaltrials." | 5.51 | Minimal Patient-Reported Side Effects for a Chemoablative Gel (UGN-102) Used as Frontline Treatment in Adults with Nonmuscle-Invasive Bladder Cancer. ( Basak, R; Giannone, K; Hilton, A; Lipman, R; Mueller, D; Smith, AB; Stover, AM; Teal, R; Waheed, M, 2022) |
| "To compare the urinary pH, recurrence-free survival (RFS), and safety of adjuvant intravesical therapy in patients with non-muscle-invasive bladder cancer (NMIBC) receiving mitomycin C (MMC) therapy and MMC + cytosine arabinoside (Ara-C) therapy." | 5.51 | Intravesical mitomycin C (MMC) and MMC + cytosine arabinoside for non-muscle-invasive bladder cancer: a randomised clinical trial. ( Aoki, D; Hayashida, Y; Imasato, Y; Matsuo, T; Mitsunari, K; Miyata, Y; Nishikido, M; Ohba, K; Sakai, H; Takehara, K; Taniguchi, K; Tsurusaki, T; Watanabe, J, 2022) |
| "When treated with mitomycin-C (MMC), miR-31-expressing UBC cells displayed lower survival and higher apoptotic rates, and deactivated Akt and ERK." | 5.43 | MicroRNA-31 functions as a tumor suppressor and increases sensitivity to mitomycin-C in urothelial bladder cancer by targeting integrin α5. ( Fan, Y; Liu, Y; Qin, L; Shen, Z; Wang, X; Xia, L; Xu, C; Xu, T; Zhang, X; Zhong, S; Zhu, Z, 2016) |
| "Ellagic acid (EA) is a polyphenolic compound that can be found as a naturally occurring hydrolysis product of ellagitannins in pomegranates, berries, grapes, green tea and nuts." | 5.43 | Ellagic Acid Inhibits Bladder Cancer Invasiveness and In Vivo Tumor Growth. ( Atzori, MG; Bonanno, E; Ceci, C; Cicconi, R; de Martino, MG; Graziani, G; Lacal, PM; Mattei, M; Miano, R; Scimeca, M; Tentori, L; Vespasiani, G, 2016) |
| " The clinical evidence on the beneficial effects of additional hyperthermia in combination with intravesical Mitomycin C for superficial non-muscle-invasive bladder cancer as well as for deep regional microwave hyperthermia techniques applied during an external beam radiotherapy or chemoradiation treatment for more advanced tumors are summarized." | 5.41 | The Emerging Evidence Supporting Integration of Deep Regional Hyperthermia With Chemoradiation in Bladder Cancer. ( Fietkau, R; Gaipl, US; Lamrani, A; Ott, OJ, 2023) |
| "We performed a meta-analysis to evaluate the effect of intravesical mitomycin compared with gemcitabine on the treatment of non-muscle invasive bladder cancer." | 5.41 | Effect of intravesical mitomycin compared with gemcitabine on the treatment non-muscle invasive bladder cancer: A meta-analysis. ( Cheng, W; Chu, X; Huang, S; Zheng, H; Zheng, X; Zhou, Y, 2023) |
| "Gemcitabine was administered first and retained for 90 minutes and then drained." | 5.40 | Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non-muscle invasive bladder cancer. ( Breyer, BN; Erickson, BA; Konety, BR; Lightfoot, AJ; O'Donnell, MA; Rosevear, HM, 2014) |
| "Bladder cancer is associated with high rates of recurrence making tertiary chemoprevention an attractive intervention strategy." | 5.40 | Anthocyans as tertiary chemopreventive agents in bladder cancer: anti-oxidant mechanisms and interaction with mitomycin C. ( Brown, K; Higgins, JA; Jones, GD; Zainol, M, 2014) |
| " The early absorption rate depends on TURBT extension." | 5.39 | Systemic absorption and pharmacokinetics of single-dose early intravesical mitomycin C after transurethral resection of non-muscle-invasive bladder cancer. ( Campodonico, F; Maffezzini, M; Manuputty, EE; Marini, V; Martelli, A; Mattioli, F; Puntoni, M; Tamagno, S, 2013) |
| "Non-muscle invasive bladder cancer is the most common type of bladder cancer in Western countries." | 5.38 | Chondroitin sulphate enhances the antitumor activity of gemcitabine and mitomycin-C in bladder cancer cells with different mechanisms. ( Abbruzzese, A; Altieri, V; Buonerba, C; Caraglia, M; Di Lorenzo, G; Facchini, G; Ferro, M; Giuberti, G; Perdonà, S; Porto, S; Sperlongano, P; Zappavigna, S, 2012) |
| "In two cell lines, T24 (bladder cancer cell line) and DC3F (Chinese hamster fibroblast), exposure to different concentrations of mitomycin (0." | 5.38 | Electroporation enhances mitomycin C cytotoxicity on T24 bladder cancer cell line: a potential improvement of intravesical chemotherapy in bladder cancer. ( Gehl, J; Hermann, GG; Vásquez, JL, 2012) |
| "Mitomycin C (MMC) is a widely used agent for the adjuvant treatment of bladder tumors." | 5.35 | Perivesical inflammation and necrosis due to mitomycin C instillation after transurethral resection of bladder tumor: we must be vigilant! ( Cek, M; Fazlioglu, A; Kurtulus, FO; Parlakkilic, O; Tandogdu, Z, 2009) |
| "To evaluate the activity of intravesical mitomycin-C (MMC) to ablate recurrent low-risk non-muscle-invasive bladder cancer (NMIBC) and assess whether it may enable patients to avoid surgical intervention for treatment of recurrence." | 5.34 | CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin-C vs surgical management in low-risk non-muscle-invasive bladder cancer. ( Campain, N; Catto, JWF; Cooke, P; Cresswell, J; Davenport, K; Feber, A; Griffiths, TRL; Hall, E; Kelly, JD; Knight, A; Knowles, MA; Lewis, R; Masood, S; McGrath, JS; Mostafid, AH; Penegar, SR; Porta, N, 2020) |
| "To assess the prophylactic efficacy of postoperative single intravesical instillation with pirarubicin (THP) and mitomycin C (MMC) for low-risk non-muscle-invasive bladder cancer (NMBC)." | 5.34 | Randomized Study of Postoperative Single Intravesical Instillation With Pirarubicin and Mitomycin C for Low-risk Bladder Cancer. ( Aizawa, T; Fujii, Y; Fukui, I; Kageyama, Y; Urakami, S; Yamamoto, S, 2020) |
| "In patients with superficial bladder cancer, the occurrence of primary carcinoma in situ was significantly greater in patients with the AA genotype compared with those with the GA or GG genotypes (P = 0." | 5.32 | Polymorphism within the cyclin D1 gene is associated with an increased risk of carcinoma in situ in patients with superficial bladder cancer. ( Habuchi, T; Higashi, S; Ito, M; Kamoto, T; Nishiyama, H; Ogawa, O; Tsuchiya, N; Wang, L; Watanabe, J, 2004) |
| "The RT112, RT4, 253J and T24 human bladder cancer cell lines were seeded in 96-well microtiter plates at 2." | 5.32 | The effect of hyperthermia on mitomycin-C induced cytotoxicity in four human bladder cancer cell lines. ( Jansen, CF; O'donnell, MA; Schalken, JA; van der Heijden, AG; Verhaegh, G; Witjes, JA, 2004) |
| "Patients were randomly assigned (1:1) to RITE (60min, 40mg mitomycin-C, 42±2°C) or control following stratification for carcinoma in situ (CIS) status (present/absent), therapy history (failure of previous induction/maintenance BCG), and treatment centre." | 5.30 | Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non-muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Th ( Bhatt, R; Billingham, LJ; Buckley, L; Cresswell, J; Datta, SN; Devall, AJ; Feneley, MR; Griffiths, TRL; Hodgson, D; Issa, R; Kelly, JD; Loubière, LS; Madaan, S; McGrath, J; Mostafid, H; Page, T; Panchal, A; Pope, AM; Sangar, V; Tan, WS, 2019) |
| "Celecoxib was not shown to reduce the risk of recurrence in intermediate- or high-risk non-muscle-invasive bladder cancer (NMIBC), although celecoxib was associated with delayed time to recurrence in pT1 NMIBC patients." | 5.30 | BOXIT-A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004). ( Andrews, S; Blazeby, J; Bogle, R; Brough, R; Burnett, S; Cresswell, J; Cruickshank, C; Hall, E; Huddart, R; Johnson, M; Kelly, JD; Madaan, S; Maynard, L; Mostafid, H; Palmer, A; Porta, N; Protheroe, A; Tan, WS, 2019) |
| "Eosinophilic cystitis is an unusual form of cystitis which is characterized by irritative voiding symptoms and haematuria." | 5.29 | Eosinophilic cystitis induced by mitomycin-C. ( Apaydin, E; Gürsan, A; Kandiloğlu, G; Ozyurt, C; Ulker, V, 1996) |
| " Combination with mitomycin C or interferon-alpha-2b potentiated the cytostatic effect." | 5.28 | Cytostatic effect of different strains of Bacillus Calmette-Guérin on human bladder cancer cells in vitro alone and in combination with mitomycin C and interferon-alpha. ( Alfthan, O; Jauhiainen, K; Kaasinen, E; Lähde, M; Nurmi, M; Rajala, P; Rintala, E, 1992) |
| "To investigate whether the timing of an immediate instillation of mitomycin C (on the day of transurethral resection of bladder tumour [TURBT] or 1 day later) has an impact on time to recurrence of non-muscle-invasive bladder cancer (NMIBC)." | 5.27 | The effect of timing of an immediate instillation of mitomycin C after transurethral resection in 941 patients with non-muscle-invasive bladder cancer. ( Beckers, GMA; Bosschieter, J; Lissenberg-Witte, BI; Nieuwenhuijzen, JA; van Ginkel, T; van Moorselaar, RJA; Vis, AN, 2018) |
| "From those 11 studies, it is shown that intravesical chemotherapy using Epirubicin and Mitomycin-C following TURB showed significant decrease of recurrence rate of bladder cancer even to progression of the disease compared to TURB alone (p<0." | 5.22 | Comparison Between Intravesical Chemotherapy Epirubicin and Mitomycin-C after TURB vs TURB Alone With Recurrence Rate of Non-Muscle Invasive Bladder Cancer: Meta-Analysis. ( Budaya, TN; Daryanto, B; Purnomo, AF; Seputra, KP, 2022) |
| "This review and meta-analysis aimed to systematically evaluate the clinical efficacy and safety of equipment-assisted intravesical instillation of mitomycin C (MMC) in patients with nonmuscular invasive bladder cancer (NMIBC) after transurethral resection of bladder tumour (TURBT)." | 5.22 | The clinical efficacy and safety of equipment-assisted intravesical instillation of mitomycin C after transurethral resection of bladder tumour in patients with nonmuscular invasive bladder cancer: A meta-analysis. ( Gao, D; Hu, C; Liu, J; Mao, D; Zhou, W, 2022) |
| "The aim of this study was to compare the long-term efficacy of BCG monotherapy to alternating therapy of mitomycin C (MMC) and BCG in patients with carcinoma in situ (CIS)." | 5.22 | Seventeen-year follow-up of the prospective randomized Nordic CIS study: BCG monotherapy versus alternating therapy with mitomycin C and BCG in patients with carcinoma in situ of the urinary bladder. ( Jahnson, S; Kaasinen, E; Malmström, PU; Mestad, O; Rintala, E; Wijkström, H, 2016) |
| "We analyzed the outcomes of a randomized trial demonstrating that in intermediate- to high-risk non-muscle-invasive bladder cancer, mitomycin C and bacillus Calmette-Guérin (BCG) reduced disease relapse compared with BCG alone but was more toxic." | 5.20 | Sequential combination of mitomycin C plus bacillus Calmette-Guérin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomiz ( Alonso, JM; Astobieta, A; Beardo, P; Chantada, V; Fernandez, JM; Gomez, M; Madero, R; Martinez Piñeiro, JA; Martinez-Piñeiro, L; Montesinos, M; Muntañola, P; Ojea, A; Portillo, JA; Rabadan, M; Rodriguez-Molina, J; Solsona, E; Unda, M; Zabala, JA, 2015) |
| "To determine the safety and toxicities of sequential MMC (mitomycin C) + BCG (bacillus Calmette-Guérin) in patients with non-muscle-invasive bladder cancer (NMIBC) and explore evidence for potentiation of BCG activity by MMC." | 5.20 | Sequential intravesical mitomycin plus Bacillus Calmette-Guérin for non-muscle-invasive urothelial bladder carcinoma: translational and phase I clinical trial. ( Curiel, TJ; Hernandez, J; Hugen, CM; Hurez, V; Jha, MK; Morales, EE; Svatek, RS; Tseng, TY; Zhao, XR, 2015) |
| "We demonstrated in non-muscle-invasive bladder cancer patients with exceptionally frequent recurrences that the risk of long-term recurrence was reduced from 78-80% to 43-45% if one perioperative plus four weekly mitomycin C instillations were followed by monthly bacillus Calmette-Guérin (BCG) instillations for 1 yr instead of alternating instillations of BCG and interferon-α2b." | 5.20 | Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Guérin (BCG) or alternating BCG and interferon ( Aaltomaa, S; Boström, PJ; Järvinen, R; Kaasinen, E; Kallio, J; Liukkonen, T; Marttila, T; Puolakka, VM; Rintala, E; Seppänen, M; Tuhkanen, K; Vaarala, M; Viitanen, J, 2015) |
| "This paper aims to evaluate the safety and heating efficiency of external deep pelvic hyperthermia combined with intravesical mitomycin C (MMC) as a novel therapy for non-muscle-invasive bladder cancer (NMIBC)." | 5.19 | A pilot clinical trial of intravesical mitomycin-C and external deep pelvic hyperthermia for non-muscle-invasive bladder cancer. ( Craciunescu, OA; Dewhirst, MW; Inman, BA; Maccarini, PF; Stauffer, PR; Vujaskovic, Z, 2014) |
| "Sequential bacillus Calmette-Guerin (BCG) and electromotive mitomycin (sequential therapy) have been shown in a randomized prospective trial to be superior to therapy with BCG alone in patients with high-risk non-muscle-invasive bladder cancer." | 5.19 | Contemporary cost-effectiveness analysis comparing sequential bacillus Calmette-Guerin and electromotive mitomycin versus bacillus Calmette-Guerin alone for patients with high-risk non-muscle-invasive bladder cancer. ( Aprikian, AG; Bachir, BG; Black, PC; Breau, RH; Dragomir, A; Fairey, A; Kassouf, W; Kulkarni, GS; Tanguay, S, 2014) |
| "The purpose of this study was to determine the effectiveness of a single early instillation of mitomycin C (MMC) after transurethral resection of bladder tumor (TURBT) together with urinary alkalinization in patients with low-risk non-muscle-invasive bladder cancer (NMIBC)." | 5.17 | Single early instillation of mitomycin C and urinary alkalinization in low-risk non-muscle-invasive bladder cancer: a preliminary study. ( Ersoy, H; Karakoyunlu, AN; Ozok, HU; Sagnak, L; Topaloglu, H; Yaytokgil, M, 2013) |
| "Synchronous chemotherapy with fluorouracil and mitomycin C combined with radiotherapy significantly improved locoregional control of bladder cancer, as compared with radiotherapy alone, with no significant increase in adverse events." | 5.16 | Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. ( Crundwell, M; Hall, E; Hendron, C; Huddart, RA; Hussain, SA; James, ND; Jenkins, P; Lewis, R; Rawlings, C; Sizer, B; Sreenivasan, T; Tremlett, J; Waters, R, 2012) |
| "• To present long-term efficacy data of intravesical thermochemotherapy vs chemotherapy alone with mitomycin-C (MMC) randomly administered to patients with non-muscle-invasive bladder cancer (NMIBC) as an adjuvant treatment after complete transurethral resection." | 5.15 | Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC). ( Colombo, R; Engelstein, D; Leib, Z; Pavone-Macaluso, M; Salonia, A, 2011) |
| "Our aim was to assess if sequential mitomycin C (MMC) plus BCG after transurethral resection (TUR) is worthy of further study in non-muscle-invasive bladder cancer patients with CIS." | 5.15 | Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 trial ( ( Algaba, F; Bono, A; Busch, C; Collette, S; da Silva, FC; Kirkali, Z; Oosterlinck, W; Sylvester, R, 2011) |
| "To study the benefits of a single, early, intravesical instillation of mitomycin C(MMC) after transurethral bladder resection (TURB) in patients with low-risk non-muscle-invasive bladder cancer (NMIBC)." | 5.15 | Long-term experience with early single mitomycin C instillations in patients with low-risk non-muscle-invasive bladder cancer: prospective, single-centre randomised trial. ( Albisinni, S; Alpi, G; Cantiani, A; Carbone, A; De Nunzio, C; Iori, F; Liberti, M; Tubaro, A, 2011) |
| " Our aim was to compare TURBT alone with immediate post-TURBT intravesical passive diffusion (PD) of mitomycin and immediate pre-TURBT intravesical electromotive drug administration (EMDA) of mitomycin in non-muscle invasive bladder cancer." | 5.15 | Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial. ( Di Stasi, SM; Giurioli, A; Leprini, G; Liberati, E; Masedu, F; Micali, F; Ricci, AR; Valenti, M; Verri, C; Vespasiani, G, 2011) |
| "To evaluate the efficacy and safety of intravesical instillation with gemcitabine after first-line intravesical chemotherapy failure, including mitomycin (MMC), epirubicin (EPB) and camptothecin (CPT), in the treatment of non-muscle-invasive bladder cancer (NMIBC)." | 5.15 | [Evaluation of the efficacy and safety of intravesical instillation with gemcitabine after first-line intravesical chemotherapy failure in the treatment of non-muscle-invasive bladder cancer]. ( Cao, M; Chen, HG; Ma, CK; Ma, J; Xue, W, 2011) |
| "The present study compared the therapeutic activity of intravesical BCG with intravesical mitomycin C chemotherapy in patients with non-muscle invasive bladder cancer at intermediate risk of recurrence in a prospective randomised trial." | 5.13 | A randomized prospective study of intravesical prophylaxis in non-musle invasive bladder cancer at intermediate risk of recurrence: mitomycin chemotherapy vs BCG immunotherapy. ( Del Nero, A; Mangiarotti, B; Montanari, E; Trinchieri, A, 2008) |
| "Various bladder cancer cell lines were treated with HTI-286 and mitomycin C (MMC) in vitro." | 5.13 | Intravesical chemotherapy of high-grade bladder cancer with HTI-286, a synthetic analogue of the marine sponge product hemiasterlin. ( Adomat, H; Andersen, RJ; Fazli, L; Fradet, Y; Gleave, ME; Hadaschik, BA; So, AI, 2008) |
| "It remains unclear whether people with non-muscle invasive bladder cancer (NMIBC) benefit from intravesical gemcitabine compared to other agents in the primary or recurrent setting following transurethral resection of a bladder tumor." | 5.12 | Intravesical gemcitabine for non-muscle invasive bladder cancer. ( Cleves, A; Dahm, P; Han, MA; Hwang, EC; Hwang, JE; Jung, JH; Maisch, P; Narayan, V, 2021) |
| "We analyzed the impact of a single Mitomycin C instillation in patients with low risk superficial bladder cancer with short and long-term follow-up." | 5.12 | Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term follow-up. ( El-Ganzoury, HM; El-Ghobashy, S; El-Leithy, TR; Roshdy, MM, 2007) |
| "The rationale for combining anticancer drugs has not been applied consistently to use of intravesical agents for treatment of superficial bladder cancer, for which immunotherapeutic BCG and chemotherapeutic mitomycin seem to be a potentially effective combination." | 5.12 | Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. ( Attisani, F; Capelli, G; De Carolis, A; Di Stasi, SM; Giannantoni, A; Giurioli, A; Stephen, RL; Storti, L; Valenti, M; Vespasiani, G; Zampa, G, 2006) |
| "To report the 10-year follow-up of a study randomizing between instillations of bacillus Calmette-Guérin (BCG) and mitomycin-C (MMC) for treating high-risk and not muscle-invasive urinary bladder cancer to assess progression, the need for more aggressive treatment and survival (cancer-specific and overall), as many of the published studies comparing different treatments for disease that is not muscle-invasive have a short follow-up." | 5.12 | Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin-C and bacillus Calmette-Guérin in patients with high-risk bladder cancer. ( Gårdmark, T; Jahnson, S; Malmström, PU; Wahlquist, R; Wijkström, H, 2007) |
| "We conducted a phase I/II study investigating synchronous chemoradiotherapy with mitomycin C and infusional 5-fluorouracil (5-FU) in muscle invasive bladder cancer." | 5.11 | Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer. ( Glaholm, JG; Hussain, SA; James, ND; Peake, DR; Stocken, DD; Wallace, DM; Zarkar, A, 2004) |
| "To report a phase-1 study of patients with recurrent superficial bladder cancer treated with photodynamic therapy (PDT) using sequential mitomycin C and 5-aminolaevulinic acid (ALA)." | 5.11 | A phase-1 study of sequential mitomycin C and 5-aminolaevulinic acid-mediated photodynamic therapy in recurrent superficial bladder carcinoma. ( Allman, R; Datta, SN; French, AJ; Mason, MD; Matthews, PN; Skyrme, RJ, 2005) |
| "To evaluate whether, in patients with carcinoma in situ (CIS) of the urinary bladder, alternating instillation therapy with mitomycin C (MMC) and bacillus Calmette-Guerin (BCG) was more effective and less toxic than conventional BCG monotherapy." | 5.10 | Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a nordic study. ( Duchek, M; Hellsten, S; Kaasinen, E; Malmström, PU; Mestad, O; Rintala, E; Wijkström, H, 2003) |
| " Results of our preclinical and clinical studies including a randomized prospective phase III trial have validated the concept that enhanced drug delivery can significantly improve the treatment efficacy of intravesical mitomycin C therapy of superficial bladder cancer." | 5.10 | Clinical aspects of drug delivery to tumors. ( Au, JL; Jang, SH; Wientjes, MG, 2002) |
| "Ablative therapy with interferon-alpha was less effective than mitomycin-C in patients with superficial bladder cancer." | 5.10 | A randomized comparative dose-ranging study of interferon-alpha and mitomycin-C as an internal control in primary or recurrent superficial transitional cell carcinoma of the bladder. ( Malmström, PU, 2002) |
| "We analyze the impact of a single mitomycin C instillation in patients with low risk superficial bladder cancer with short and long-term followup." | 5.09 | Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup. ( Casanova, J; Dumont, R; Iborra, I; Monrós, JL; Ricós, JV; Solsona, E, 1999) |
| "We evaluated the prophylactic efficacy of instillations of intravesical mitomycin C in 57 patients with primary superficial bladder cancer in a multicenter clinical trial." | 5.09 | The effect of intravesical mitomycin C on the recurrence of superficial (Ta-T1) bladder cancer. A Hungarian Multicenter Study. ( Bodrogi, I; Határ, A; Kiss, A; Kiss, L; Kondás, J; Lukács, T; Szeldeli, P; Törzsök, F, 1999) |
| ", placement of the drug directly in the bladder) with mitomycin C is beneficial for patients with superficial bladder cancer who are at high risk of recurrence, but standard therapy is empirically based and patient response rates have been variable, in part because of inadequate drug delivery." | 5.09 | Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. ( Au, JL; Badalament, RA; Chin, JL; Harbrecht, JD; Lerner, SP; Miles, BJ; Pollifrone, DL; Venema, PL; Warner, JA; Wientjes, MG; Young, DC, 2001) |
| "To elucidate the most efficient topical therapy for carcinoma in situ of the bladder, the efficacy of intravesical mitomycin C plus doxorubicin therapy was compared with bacillus Calmette-Guerin (BCG) therapy." | 5.09 | Equivalent efficacy of mitomycin C plus doxorubicin instillation to bacillus Calmette-Guerin therapy for carcinoma in situ of the bladder. ( Fukui, I; Igarashi, K; Kojima, SI; Ohya, K; Sekine, H, 2001) |
| "Of 68 carcinoma in situ patients randomly treated with instillations 40 received mitomycin C and 28 received mitomycin C and Pasteur bacillus Calmette-Guerin (BCG) in alternating courses." | 5.08 | Alternating mitomycin C and bacillus Calmette-Guerin instillation therapy for carcinoma in situ of the bladder. The Finnbladder Group. ( Alfthan, O; Jauhiainen, K; Kaasinen, E; Rajala, P; Rintala, E; Ruutu, M, 1995) |
| "Results of a randomized prospective study are reported in which mitomycin C, Tice bacillus Calmette-Guerin (BCG) and RIVM-BCG were compared in 437 patients with primary or recurrent pTa and pT1 bladder tumors, including carcinoma in situ." | 5.08 | A randomized study of intravesical mitomycin C, bacillus Calmette-Guerin Tice and bacillus Calmette-Guerin RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder. ( Debruyne, FM; Doesburg, WH; van der Meijden, AP; Vegt, PD; Witjes, JA; Witjes, WP, 1995) |
| "We determined the role, if any, of 1 and 5 instillations of intravesical mitomycin C in the treatment of newly diagnosed superficial bladder cancer." | 5.08 | The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. ( Benyon, LL; Fellows, J; Freedman, LS; Grigor, KM; Hall, RR; Hargreave, TB; Lallemand, G; Munson, K; Newling, DW; Parmar, MK; Richards, B; Robinson, MR; Rose, MB; Smith, PH; Tolley, DA; Whelan, P; Williams, JL, 1996) |
| "A randomized multicenter trial was done to compare transurethral resection only to transurethral resection plus adjuvant mitomycin C and bacillus Calmette Guerin (BCG) instillation for treatment of superficial bladder cancer (stage pTa/1 grades 1 to 3 except primary stage pTa grade 1)." | 5.08 | A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating Clinics. ( Giani, G; Krege, S; Meyer, R; Otto, T; Rübben, H, 1996) |
| "The authors present the results of two parallel phase II trials, instituted by the EORTC Genito-Urinary Group in 1986, whose aims were to assess the tolerability and ablative capacity of mitomycin C (study 30864) and epirubicin (study 30869) in patients with multiple primary or recurrent Ta-T1 bladder cancer." | 5.08 | Chemoresection in Ta-T1 bladder cancer. Members of the EORTC Genito-Urinary Group. ( Bono, AV; Denis, L; Hall, RR; Lovisolo, JA; Sylvester, R, 1996) |
| "To determine long-term efficacy of intravesical mitomycin C (MMC) versus bacille Calmette-Guérin (BCG) in patients with superficial bladder cancer with regard to recurrences and progression." | 5.08 | Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille Calmette-Guérin-RIVM and mitomycin C in superficial bladder cancer. EORTC GU Group and the Dutch South East Cooperative Urological Group. European Organisation for ( Collette, L; Debruyne, FM; Sylvester, R; v d Meijden, AP; van Aubel, A; Witjes, JA; Witjes, WP, 1998) |
| "We study toxicity and efficacy of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin (BCG) in patients with intermediate or high risk superficial bladder cancer compared to the use of intravesical mitomycin C alone." | 5.08 | Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer. ( Caris, CT; Debruyne, FM; Mungan, NA; Witjes, JA; Witjes, WP, 1998) |
| "A randomized and placedo-controlled trial on intravesical N-CWS instillation versus mitomycin-C(MMC) therapy for recurrence prevention in postopenative bladder cancer patients was carried out." | 5.08 | [Long-term results of intravesical N-CWS instillation to prevent recurrence after surgery for bladder cancer]. ( Chen, S; Lin, Z; Xu, E, 1997) |
| "Two hundred eighty-seven patients with primary pTa G2, pT1 G1 to G2 superficial bladder cancer, following complete transurethral resection (TUR), were randomly allocated to receive intravesical treatment, either with IFN (50 x 10(6) IU) or mitomycin (MIT-C; 40 mg)." | 5.07 | Prophylaxis of superficial bladder cancer with mitomycin or interferon alfa-2b: results of a multicentric Italian study. ( Boccardo, F; Cannata, D; Canobbio, L; Curotto, A; Decensi, A; Guarneri, D; Martorana, G; Pegoraro, C; Rubagotti, A; Selvaggi, F, 1994) |
| "We compared intravesical instillations with mitomycin-C (MMC), Bacillus Calmette-Guerin (BCG) Tice, and BCG-RIVM in patients with pTa-pT1 papillary carcinoma and primary carcinoma in situ (CIS) of the bladder." | 5.07 | A randomised prospective study comparing intravesical instillations of mitomycin-C, BCG-Tice, and BCG-RIVM in pTa-pT1 tumours and primary carcinoma in situ of the urinary bladder. Dutch South-East Cooperative Urological Group. ( Debruyne, FM; Doesburg, W; Schaafsma, HE; vd Meijden, AP; Witjes, JA; Witjes, WP, 1993) |
| "Between November 1986 and April 1989, 101 patients with superficial bladder cancer were treated with intravesical instillations of mitomycin C on day 1 and doxorubicin on day 2 of each week for 5 consecutive weeks." | 5.07 | Intravesical combination chemotherapy with mitomycin C and doxorubicin for superficial bladder cancer: a randomized trial of maintenance versus no maintenance following a complete response. ( Fukui, I; Ishiwata, D; Kawai, T; Kihara, K; Oshima, H; Sekine, H; Tachibana, Y, 1992) |
| "Intravesical chemotherapy involving the sequential instillation of mitomycin C (MMC) and Adriamycin (ADM) was performed in 40 patients with superficial bladder cancer (pathological stages Ta and T1)." | 5.07 | Sequential instillation therapy with mitomycin C and adriamycin for superficial bladder cancer. ( Abe, K; Isaka, S; Okano, T; Shimazaki, J, 1992) |
| "Both intravesical mitomycin C (MMC) and bacillus Calmette-Guérin (BCG; Pasteur strain F) were effective in the present prospective randomized multicenter study consisting of 91 patients with frequently recurrent superficial (Ta-T1) bladder cancer." | 5.07 | Intravesical chemotherapy (mitomycin C) versus immunotherapy (bacillus Calmette-Guérin) in superficial bladder cancer. ( Alfthan, O; Hansson, E; Jauhiainen, K; Juusela, H; Kanerva, K; Korhonen, H; Permi, J; Rintala, E; Sotarauta, M; Vaalasti, T, 1991) |
| "Sixty patients with Ta and T1 bladder cancer were randomized between treatment with resection only and resection and instillations with either Adriamycin or Mitomycin C." | 5.07 | Prophylactic instillation therapy of superficial bladder cancer. A randomized study comparing mitomycin C and adriamycin with special reference to DNA ploidy. ( Borgström, E; Brolin, J; Gustafson, H; Nyman, C; Tribukait, B; Wijkström, H, 1991) |
| "Thirty patients with advanced bladder cancer received combination chemotherapy with cis-platinum, adriamycin and mitomycin C." | 5.06 | Combination chemotherapy with cis-platinum, adriamycin, mitomycin-C (PAM) in patients with advanced bladder cancer. ( Bacoyiannis, C; Hatzichristou, H; Kosmidis, PA, 1990) |
| "Intravesical instillation of adriamycin (ADM) or mitomycin C (MMC) was carried out for the purpose of preventing the recurrence of superficial bladder cancers (Ta and T1) after transurethral resection or transurethral coagulation." | 5.06 | Prophylactic intravesical instillation therapy with adriamycin and mitomycin C in patients with superficial bladder cancer. ( Matsumura, Y; Ohmori, H; Ozaki, Y; Tsushima, T; Yoshimoto, J, 1987) |
| "A randomized, controlled study was begun in 1982 on the effect of keyhole-limpet hemocyanin and mitomycin C in the prevention of recurrent superficial bladder cancer (stages pTa to pT1, grades 0 to 3) in 44 patients." | 5.06 | Immunotherapy in bladder cancer with keyhole-limpet hemocyanin: a randomized study. ( Engelmann, U; Gasch, J; Jurincic, CD; Klippel, KF, 1988) |
| "A prospective randomized clinical trial was conducted by the National Bladder Cancer Group to compare thiotepa and mitomycin C in ablating residual Ta, T1 and TIS transitional cell carcinoma of the bladder." | 5.06 | Intravesical thiotepa versus mitomycin C in patients with Ta, T1 and TIS transitional cell carcinoma of the bladder: a phase III prospective randomized study. ( Barton, B; Hazra, T; Heney, NM; Koontz, WW; Soloway, M; Trump, DL; Weinstein, RS, 1988) |
| " Mitomycin C (MMC) and Bacillus Calmette-Guérin (BCG) are commonly used, competing forms of intravesical therapy for intermediate- or high-risk non-muscle invasive (Ta and T1) urothelial bladder cancer but their relative merits are somewhat uncertain." | 5.05 | Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer. ( Coles, B; Dahm, P; Dersch, R; Draeger, DL; Jensen, K; Kilian, S; Krabbe, LM; Kunath, F; Meerpohl, JJ; Schmidt, S, 2020) |
| " The relatively new pyrimidine analog gemcitabine (GEM) has exhibited anticancer effect on various solid cancers, such as the advanced bladder cancer." | 5.05 | Intravesical gemcitabine versus mitomycin for non-muscle invasive bladder cancer: a systematic review and meta-analysis of randomized controlled trial. ( Chen, K; Ding, Y; Dong, Z; Gao, K; Li, R; Li, W; Li, Y; Ma, X; Song, J; Wang, Y; Wang, Z; Yang, X, 2020) |
| "In a prospective, randomized, stratified study with crossover design the effect of thiotepa was compared to that of mitomycin C when each was instilled intravesically immediately at the end of complete removal of superficial bladder cancer (stages Ta and Tis) and later on tumor recurrence." | 5.05 | Intravesical thiotepa and mitomycin C treatment immediately after transurethral resection and later for superficial (stages Ta and Tis) bladder cancer: a prospective, randomized, stratified study with crossover design. ( Benson, RC; Hilton, JF; Taylor, WF; Zincke, H, 1985) |
| "In an effort to decrease recurrence and progression rates in non-muscle-invasive bladder cancer (NMIBC), transurethral resection of a bladder tumor is followed by intravesical instillations using Mitomycin-C (MMC) and Bacillus Calmette-Guérin (BCG)." | 4.98 | [Chemohyperthermia using MMC in non-muscle-invasive bladder cancer: Current status and future perspectives.] ( Arends, TJH; Coenen, JJMJH; van Valenberg, FJP; Witjes, JA, 2018) |
| "This systematic review and cumulative analysis aimed to explore the efficacy and safety of the combination of intravesical mitomycin C (MMC) plus bacillus Calmette-Guerin (BCG) for non-muscle-invasive bladder cancer (NMIBC) patients." | 4.95 | Systematic Review and Cumulative Analysis of the Combination of Mitomycin C plus Bacillus Calmette-Guérin (BCG) for Non-Muscle-Invasive Bladder Cancer. ( Cai, C; Deng, T; Duan, X; Liu, B; Zeng, G; Zhang, T, 2017) |
| "Mitomycin C (MMC) as an intravesical chemotherapeutic agent is a well-known option for treatment of nonmuscle invasive bladder cancer (NMIBC) recurrence; it is probably the most commonly used agent given its low rate of side effects and its efficacy." | 4.93 | Mitomycin C: new strategies to improve efficacy of a well-known therapy. ( Bassi, PF; Di Gianfrancesco, L; Filianoti, A; Lenci, N; Racioppi, M; Ragonese, M; Recupero, SM, 2016) |
| "To evaluate the effectiveness and toxicity of intravesical gemcitabine in preventing tumour recurrence and progression in non-muscle invasive bladder cancer (NMIBC)." | 4.88 | Intravesical gemcitabine for non-muscle invasive bladder cancer. ( Cleves, A; Jones, G; Kynaston, HG; Mason, M; Shelley, M; Wilt, TJ, 2012) |
| "To undertake a systematic review and meta-analysis comparing intravesical mitomycin C and Bacillus Calmette-Guerin in terms of tumour recurrence, disease progression and overall survival in Ta and T1 bladder cancer." | 4.82 | Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer. ( Coles, B; Court, JB; Kynaston, H; Mason, M; Shelley, MD; Wilt, TJ, 2003) |
| "To assess, in a systematic review and meta-analysis, the relative effectiveness of intravesical mitomycin C and bacillus Calmette-Guérin (BCG) for tumour recurrence, disease progression and overall survival in patients with medium- to high-risk Ta and T1 bladder cancer." | 4.82 | Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. ( Coles, B; Court, J; Kynaston, H; Mason, MD; Shelley, MD; Wilt, TJ, 2004) |
| "Intravesical therapy of superficial bladder cancer has been in routine use since the introduction of thiotepa in 1961." | 4.80 | Improved patient outcomes with BCG immunotherapy vs. chemotherapy - Swedish and worldwide experience. ( Malmström, P, 2000) |
| "Bladder retraction is a rare complication of contact chemotherapy with mitomycin C in the treatment of superficial bladder cancer." | 4.79 | [Bladder retraction, a complication of chemoprophylaxis of superficial bladder cancer using intravesical mitomycin C. Apropos of a case and review of the literature]. ( Hubert, J; Mangin, P; Punga-Maole, ML, 1995) |
| "Perioperative instillation of mitomycin-C (MMC) has shown effectiveness in reducing the recurrence of low-grade non-muscle invasive bladder cancer (NMIBC)." | 4.31 | Single-Dose Post-Office Fulguration Mitomycin C Instillation Appears to Improve Recurrence-Free Survival in Patients With Low-Grade Noninvasive Bladder Cancer. ( Baniel, J; Golan, S; Halstuch, D; Karchever, I; Kedar, D; Lotan, P; Rubinshtein, D, 2023) |
| "To compare recurrence rate and side effects with two different maintenance regimens of postoperative intravesical therapy with mitomycin and BCG in T1 bladder cancer." | 4.12 | Comparison of intravesical adjuvant therapy in bladder cancer with two different maintenance regimens of mitomycin and BCG. ( Dutta, A; Gupta, S; Pal, DK, 2022) |
| "Intravesical chemotherapy instillation by mitomycin - C (MMC) immediately after transurethral resection of bladder tumor (TURBT), although effective in reducing the incidence of non- muscle invasive bladder cancer (NMIBC) recurrence, can result in non desirable effects like bladder irritation and hematuria ." | 4.12 | Continuous Saline Bladder Irrigation in Reducing Recurrence and Progression When Compared to Immediate Mitomycin- C Instillation Post- Resection of Bladder Tumor: A Short Communication. ( Abdel Majid, A; Abuhamad, M; Al Demour, S; Al Zoubi, MS; Al-Zubi, MT; Alsmadi, J; Bani-Hani, M; Elayan, B; Santarisi, A; Taysir Eldos, B, 2022) |
| "Mitomycin C is the gold standard intravesical adjuvant therapy for intermediate-risk non-muscle-invasive bladder cancer (NMIBC)." | 4.12 | [Intravesical adjuvant regimen of epitubicin for intermediate risk NMIBC: Feasability study from CC-AFU vessie]. ( Audenet, F; Brunelle, S; Compérat, E; Houédé, N; Lanz, C; Larré, S; Masson-Lecomte, A; Méjean, A; Neuzillet, Y; Pignot, G; Rollin, P; Roumiguié, M; Rouprêt, M; Xylinas, E, 2022) |
| "Intravesical instillations of mitomycin C, epirubicin and BCG are considered as the standard treatment for most patients diagnosed with non-muscle invasive bladder cancer." | 4.12 | [Guidelines from the cancer committee of the French Association of Urology (CC-AFU) for adequate intravesical instillations of Mitomycin C, Epirubicin, and BCG for non-muscle invasive bladder cancer]. ( Allory, Y; Audenet, F; Leon, P; Loriot, Y; Masson-Lecomte, A; Neuzillet, Y; Pradère, B; Roumiguié, M; Roupret, M; Saint, F; Seisen, T; Traxer, O; Xylinas, E, 2022) |
| "Due to limited local efficacy of BCG and mitomycin C and the worldwide shortage of BCG, there is a clinical need to develop novel intravesical agents and application forms in order to improve the oncological outcomes in non-muscle invasive bladder cancer (NMIBC)." | 4.12 | [Adjuvant instillation therapy for non-muscle invasive bladder cancer - beyond BCG and mitomycin C]. ( Gakis, G, 2022) |
| "Mitomycin C (MMC) is one of the most frequently utilized intravesical chemotherapy drugs for the management of non-muscle-invasive bladder cancer (NMIBC)." | 4.12 | Mitomycin C allergy after passive and device-assisted hyperthermia for non-muscle invasive bladder cancer treatment: A retrospective cohort from a high-volume center. ( Aumatell, J; Burgos Revilla, J; García-Rojo, E; González-Díaz, A; González-Padilla, DA; Guerrero-Ramos, F; Hernández-Arroyo, M; Rodríguez-Antolín, A; Subiela, JD, 2022) |
| "UROMOL racial subtype distributions were similar with class 2a being most common with 10 genes commonly upregulated in AAs compared to EAs including EFEMP1, S100A16, and MCL1 which are associated with progression to muscle-invasive bladder cancer, mitomycin C resistance, and bacillus Calmette-Guérin durability, respectively." | 4.12 | Characterizing molecular subtypes of high-risk non-muscle-invasive bladder cancer in African American patients. ( Chan, KS; Choi, W; Choi-Kuaea, Y; De Hoedt, AM; Dyrskjøt, L; Eyzaguirre, EJ; Freedland, SJ; Galvan, GC; Kim, M; McConkey, DJ; Shan, Y; Theodorescu, D; Tyler, DS; Widen, S; Williams, SB; You, S; Yu, A, 2022) |
| "Patients newly diagnosed with low-risk non-muscle invasive bladder cancer and given a postoperative single instillation of mitomycin-C were retrospectively reviewed." | 4.12 | Impact of Urinary pH on the Efficacy of a Postoperative Single Instillation of Mitomycin-C. ( Asfuroglu, A; Aslan, Y; Aykanat, IC; Balci, M; Senel, C; Tuncel, A, 2022) |
| "Chemohyperthermia (CHT) with mitomycin C (MMC) is together with Bacillus Calmette-Guérin (BCG), and passive MMC, a treatment option for patients with non muscle-invasive bladder cancer." | 4.02 | Quality of life and adverse events in patients with nonmuscle invasive bladder cancer receiving adjuvant treatment with BCG, MMC, or chemohyperthermia. ( Corona-laPuerta, M; García-Jarabo, E; González-Díaz, A; González-Padilla, DA; Guerrero-Ramos, F; Rodríguez-Antolín, A; Rodríguez-Serrano, A; Villacampa-Aubá, F, 2021) |
| " Because EAU Guidelines awarded a level of evidence of 1a to mitomycin C, the drug is widely used to treat bladder cancer." | 3.96 | Mitomycin C-induced cell cycle arrest enhances 5-aminolevulinic acid-based photodynamic therapy for bladder cancer. ( Hanazaki, K; Inoue, K; Ishii, T; Ishizuka, M; Karashima, T; Kawada, C; Nakayama, T; Namikawa, T; Nozawa, N; Ogura, SI; Yamamoto, S, 2020) |
| "To evaluate the tissue penetration and safety of convective hyperthermia combined with intravesical mitomycin C (MMC) pharmacokinetics in live porcine bladder models using the Combat bladder recirculation system (BRS)." | 3.96 | Safety and efficacy of intravesical chemotherapy and hyperthermia in the bladder: results of a porcine study. ( Brousell, SC; Chang, A; Etienne, W; Fantony, JJ; Grimberg, DC; Inman, BA; Longo, TA; Maccarini, P; Spasojevic, I; Tan, WP, 2020) |
| "Chemoradiation (CRT) with mitomycin-C (MMC) and 5-fluorouracil (5-FU) has been shown to be superior to radiation alone in patients with muscle-invasive bladder cancer (MIBC)." | 3.96 | Radiation with concurrent radiosensitizing capecitabine tablets and single-dose mitomycin-C for muscle-invasive bladder cancer: A convenient alternative to 5-fluorouracil. ( Mertens, LS; Noordzij, A; Pos, F; Schaake, EE; Schuring, N; van de Kamp, MW; van der Heijden, MS; van Rhijn, BWG; Voskuilen, CS, 2020) |
| "Mitomycin-C (MMC) and thiotepa are intravesical agents effective in reducing the recurrence of low-grade noninvasive bladder cancer when instilled perioperatively." | 3.91 | Single-dose perioperative mitomycin-C versus thiotepa for low-grade noninvasive bladder cancer. ( Blodgett, G; Castle, EP; Chang, YH; Etzioni, DA; Faraj, K; Habermann, EB; Humphreys, MR; Rose, KM; Tyson Ii, MD, 2019) |
| " This study was performed to compare the efficacy of intravesical mitomycin C (MMC) instillation for the prophylaxis of Ta or T1 high-risk nonmuscle invasive bladder cancer (NMIBC) using different schedules." | 3.91 | Comparison of Different Treatment Schedules of Mitomycin C Intravesical Instillation in High-Risk Superficial Bladder Cancer Patients. ( Cha, TL; Chen, HR; En, M; Kao, CC; Sun, GH; Tang, SH; Tsao, CW; Wu, ST; Yu, DS, 2019) |
| " The growth inhibitory effect of pro-GA, a novel GGCT inhibitor, in the presence or absence of mitomycin C (MMC) was assessed in three distinct bladder cancer cell lines." | 3.91 | Pro-GA, a Novel Inhibitor of γ-Glutamylcyclotransferase, Suppresses Human Bladder Cancer Cell Growth. ( Chano, T; Hanada, E; Ii, H; Kageyama, S; Kawauchi, A; Kita, H; Kubota, S; Murai, R; Nakata, S, 2019) |
| "Non-muscle invasive bladder cancer (NMIBC) is a highly recurrent disease with potential progression to muscle invasive disease despite the standard bladder instillations with mitomycin C (MMC) or Bacille Calmette-Guérin immunotherapy." | 3.88 | Intravesical radiofrequency induced hyperthermia enhances mitomycin C accumulation in tumour tissue. ( Arends, TJH; Falke, J; Lammers, RJM; Oosterwijk, E; van der Heijden, AG; van Valenberg, FJP; Witjes, JA, 2018) |
| "This study aimed to investigate whether lidocaine, alone or in combination with other chemotherapeutic agents, inhibits the growth of human bladder cancer cells in vitro and orthotopically transplanted bladder tumors in vivo." | 3.88 | Lidocaine enhances the effects of chemotherapeutic drugs against bladder cancer. ( Li, M; Mi, Z; Ren, L; Xu, J; Yan, L; Yang, X; Zhang, S; Zhao, L, 2018) |
| "Objectives To explore the effect of electromotive drug administration of mitomycin C (EMDA-MMC) using a single dose of intravesical mitomycin C (MMC) to avoid transurethral resection (TURBT) for small non-muscle-invasive bladder cancer." | 3.88 | Single ablative intravesical electromotive mitomycin C administration for small non-muscle-invasive bladder cancer: a prospective study. ( Decaestecker, K; Lumen, N; Oosterlinck, W; Van Camp, C, 2018) |
| "Loco-regional hyperthermia combined with mitomycin C is used for treatment of nonmuscle invasive bladder cancer (NMIBC)." | 3.88 | The effect of air pockets in the urinary bladder on the temperature distribution during loco-regional hyperthermia treatment of bladder cancer patients. ( Bakker, A; Crezee, J; Geijsen, ED; Hulshof, MCCM; Kok, HP; Reijke, TM; Schooneveldt, G, 2018) |
| "Mitomycin-c (MMC) is the most used intravesical adjuvant agent in non-muscle invasive bladder cancer to prevent recurrence." | 3.88 | Drug resistance restricts the efficacy of short term low dose Mitomycin-C treatment in UMUC-3 bladder cancer cells. ( Goktas, S; Gul, M; Kars, MD; Kaynar, M, 2018) |
| "To evaluate oncological outcomes after combination intravesical therapy with gemcitabine (GC) and mitomycin C (MMC) in the setting of recurrent non-muscle-invasive bladder cancer (NMIBC) after failure of previous intravesical therapy." | 3.83 | Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer. ( Cockerill, PA; Frank, I; Karnes, RJ; Knoedler, JJ; Tarrell, R, 2016) |
| "Hyperthermic mitomycin (HM) is a novel treatment modality for selected patients with high-risk non-muscle invasive bladder cancer (NMIBC)." | 3.83 | Predictive Factors for Time to Progression after Hyperthermic Mitomycin C Treatment for High-Risk Non-Muscle Invasive Urothelial Carcinoma of the Bladder: An Observational Cohort Study of 97 Patients. ( Ayres, BE; Bailey, M; Chiocchia, V; Dutton, S; Issa, R; Le Roux, P; Pai, A; Perry, MJ; Sooriakumaran, P; Swinn, M, 2016) |
| "SFN was compared with several commonly used chemotherapy drugs, including mitomycin (MMC) and pirarubicin (THP) for anticancer effects on the bladder cancer cell lines T24, BTT, and BIU-87 and SFN half inhibitory concentrations (IC50) were determined after 48 hours of treatment." | 3.83 | Evaluation of Su Fu'ning Lotion's Inhibitory Effects on Bladder Cancer Cells In Vitro and In Vivo by Intravesical Instillation. ( Ren, L; Wang, J; Yang, X; Zhang, H; Zhao, L, 2016) |
| "To evaluate the practice of immediate postoperative instillation (IPOP) using mitomycin C for non-muscle invasive bladder cancer (NMIBC) treatment by urologists members of the French Association of Urology (AFU)." | 3.83 | [Observational survey of the French Urological Association Oncology Committee (CCAFU) evaluating the practice of immediate postoperative instillation (IPOP) using mitomycin C for non-muscle invasive bladder cancer (NMIBC) treatment]. ( Colin, P; Comperat, E; Dubosq, F; Houede, N; Larre, S; Masson-Lecomte, A; Mejean, A; Neuzillet, Y; Pignot, G; Puech, P; Roumiguie, M; Roupret, M; Xylinas, E, 2016) |
| "Starting in 2009 bacillus Calmette-Guérin/electromotive drug administration of mitomycin C was introduced as the standard induction regime in patients with high risk, nonmuscle invasive bladder cancer undergoing bladder conservation." | 3.83 | Sequential bacillus Calmette-Guérin/Electromotive Drug Administration of Mitomycin C as the Standard Intravesical Regimen in High Risk Nonmuscle Invasive Bladder Cancer: 2-Year Outcomes. ( Amery, S; Chatterton, K; Gan, C; Khan, MS; O'Brien, T; Thomas, K, 2016) |
| "Purpose To examine the effectiveness of hyperthermic intravesical chemotherapy (HIVEC™) with mitomycin-C (MMC) for patients with intermediate-high-risk non-muscle invasive bladder cancer (NMIBC)." | 3.83 | Recirculant hyperthermic IntraVEsical chemotherapy (HIVEC) in intermediate-high-risk non-muscle-invasive bladder cancer. ( Aparici, V; Carro, E; Monserrat, V; Murias, C; Neira, P; Piñeiro, I; Rodríguez, S; Sousa, A; Uribarri, C, 2016) |
| "To know the dermatologic side effects of intravesical treatment with Mitomycin C in non muscle invasive bladder cancer." | 3.83 | Dermatological side effects of intravesical Mitomycin C: Delayed hypersensitivity. ( Castillo Pacheco, C; Colomer Gallardo, A; González Satue, C; Ibarz Servio, L; Martínez Rodríguez, R, 2016) |
| "In vivo electrochemotherapy with mitomycin C or cisplatin was more effective than chemotherapy alone in a bladder cancer tumor model, opening new perspectives in bladder cancer therapy." | 3.81 | In vitro and in vivo experiments on electrochemotherapy for bladder cancer. ( Gehl, J; Ibsen, P; Lindberg, H; Vásquez, JL, 2015) |
| "To prospectively evaluate the outcome of combined microwave-induced bladder wall hyperthermia and intravesical mitomycin C instillation (thermochemotherapy) in patients with recurrent non-muscle-invasive bladder cancer." | 3.81 | Is thermochemotherapy with the Synergo system a viable treatment option in patients with recurrent non-muscle-invasive bladder cancer? ( Kiss, B; Roth, B; Schneider, S; Thalmann, GN, 2015) |
| "To examine the effectiveness of mitomycin-C and chemo-hyperthermia in combination for patients with high-risk non-muscle-invasive bladder cancer." | 3.81 | Results of Intravesical Chemo-Hyperthermia in High-risk Non-muscle Invasive Bladder Cancer. ( Akarken, I; Cakmak, O; Celik, O; Divrik, RT; Ekin, RG; Ilbey, YO; Tarhan, H; Zorlu, F, 2015) |
| "Between 2009 and 2011, 20 patients with intermediate and high risk nonmuscle invasive bladder cancer were treated with intravesical mitomycin C (40 mg) combined with regional hyperthermia." | 3.81 | Combining Mitomycin C and Regional 70 MHz Hyperthermia in Patients with Nonmuscle Invasive Bladder Cancer: A Pilot Study. ( Crezee, J; de la Rosette, JJ; de Reijke, TM; Geijsen, ED; Koning, CC; Rasch, CR; van Os, RM; Zum Vörde Sive Vörding, PJ, 2015) |
| "This study sought to determine if the addition of perioperative mitomycin C (MMC) to treatment with bacillus Calmette-Guérin (BCG) after transurethral resection (TURBT) is superior to TURBT plus BCG alone in high grade non-muscle invasive bladder cancer (NMIBC)." | 3.81 | Single instillation of mitomycin C plus bacillus Calmette-Guérin (BCG) versus BCG alone in high grade non-muscle invasive bladder cancer. ( Guzzo, TJ; Malkowicz, SB; Pietzak, EJ; Wein, AJ; Weiss, BE, 2015) |
| " We evaluated the predictive value of these polymorphisms on the sensitivity of bladder cancer patients to epirubicin and mitomycin chemotherapy instillation as well as their toxicities." | 3.81 | GSTP1 and GSTO1 single nucleotide polymorphisms and the response of bladder cancer patients to intravesical chemotherapy. ( Cheng, Y; Deng, X; Li, X; Liu, X; Lu, Q; Qin, C; Yang, X; Yin, C; Zhao, R, 2015) |
| "To better understand the risk of short-term complications associated with perioperative intravesical mitomycin-C (MMC) therapy for patients undergoing endoscopic management of non-muscle invasive bladder cancer." | 3.80 | Complications associated with single-dose, perioperative mitomycin-C for patients undergoing bladder tumor resection. ( Crossley, HS; Dailey, SM; Filson, CP; He, C; Lentz, H; Montgomery, JS; Tallman, CT; Weizer, AZ, 2014) |
| "The aim of this study was to determine the efficacy of epigallocatechin-3-gallate (EGCG) (Polyphenon E®) in comparison with mitomycin C (MMC) to prevent tumor cell implantation/growth in an animal model of superficial bladder cancer and search for possible mechanism(s) of action." | 3.80 | Epigallocatechin-3-gallate prevents tumor cell implantation/growth in an experimental rat bladder tumor model. ( Jankun, J; Keck, RW; Selman, SH, 2014) |
| " The secondary objective was to observe recurrence-free survival differences in 1) the epirubicin group vs the mitomycin group and 2) the highly recurrent (greater than 2 recurrences in 24 months) nonmuscle invasive bladder cancer group vs the other groups." | 3.80 | Combined chemohyperthermia: 10-year single center experience in 160 patients with nonmuscle invasive bladder cancer. ( Arends, TJ; van der Heijden, AG; Witjes, JA, 2014) |
| " This study evaluated the growth inhibition of GFW using normal human urothelial cells and bladder cancer cells; the efficacy of GFW treatment was further compared with mitomycin C, epirubicin, and cisplatin." | 3.79 | The investigation of a traditional Chinese medicine, Guizhi Fuling Wan (GFW) as an intravesical therapeutic agent for urothelial carcinoma of the bladder. ( Chan, MW; Chen, LG; Chen, SY; Hsieh, HY; Hsu, CD; Lin, MY; Lu, CC; Shen, CH, 2013) |
| "An in vitro model was developed to understand if celecoxib could synergize with Mitomycin C (MMC), commonly used for the prevention of non-muscle invasive bladder cancer recurrence, and eventually elucidate if the mechanism of interaction involves multi drug resistance (MDR) transporters." | 3.79 | The interaction of celecoxib with MDR transporters enhances the activity of mitomycin C in a bladder cancer cell line. ( Ancona, P; Azzariti, A; Colabufo, NA; Contino, M; Cormio, L; Niso, M; Pagliarulo, A; Pagliarulo, V, 2013) |
| "The effectiveness of locoregional hyperthermia combined with intravesical instillation of mitomycin C to reduce the risk of recurrence and progression of intermediate- and high-risk nonmuscle-invasive bladder cancer is currently investigated in clinical trials." | 3.79 | Novel multisensor probe for monitoring bladder temperature during locoregional chemohyperthermia for nonmuscle-invasive bladder cancer: technical feasibility study. ( Cordeiro, ER; Crezee, H; de la Rosette, J; de Reijke, TM; Geijsen, DE; Hulshof, MC; Schooneveldt, G; Sijbrands, J; Zum Vörde Sive Vörding, PJ, 2013) |
| "To identify whether integrinβ1 subunit is responsible for the resistance of bladder cancer cell to the therapeutic drug mitomycin-C (MMC), when grown on fibronectin (FN)." | 3.78 | Engagement of integrinβ1 induces resistance of bladder cancer cells to mitomycin-C. ( Li, T; Pan, CW; Shen, ZJ; Zhang, CJ; Zhang, MG; Zhong, S, 2012) |
| "To compare the efficacy of bacillus Calmette-Guerin (BCG) and mitomycin-C (MMC) intravesical instillation for primary T1G3 bladder cancer (BC)." | 3.78 | Adjuvant intravesical instillation for primary T1G3 bladder cancer: BCG versus MMC in Korea. ( Cho, IC; Chung, J; Joung, JY; Kim, EK; Lee, KH; Park, WS; Seo, HK, 2012) |
| "Intravesical BCG immunotherapy and mitomycin C are considered as the standard treatment for non-muscle invasive bladder cancer." | 3.78 | [Guidelines for good practice of intravesical instillations of BCG and mitomycin C from the French national cancer committee (CC-AFU) for non-muscle invasive bladder cancer]. ( Chartier-Kastler, E; Coloby, P; Larré, S; Mongiat-Artus, P; Neuzillet, Y; Pfister, C; Pignot, G; Rébillard, X; Rouprêt, M; Soulié, M, 2012) |
| "• To examine, using in vitro and in vivo models, the largely unexamined effect of mitomycin C (MMC), an effective intravesical treatment for superficial bladder cancer and carcinoma in situ, on expression of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor-2 (VEGFR-2), which mediates many of the angiogenic properties of VEGF." | 3.77 | Effect of mitomycin C on concentrations of vascular endothelial growth factor and its receptors in bladder cancer cells and in bladders of rats intravesically instilled with mitomycin C. ( Degrado, J; Hittelman, AB; Kaimakliotis, HZ; Verma, A; Weiss, RM; Wheeler, MA, 2011) |
| "5 is associated with a decreased risk of tumor recurrence in patients treated with intravesical mitomycin C for nonmuscle invasive bladder cancer." | 3.77 | Urinary pH is highly associated with tumor recurrence during intravesical mitomycin C therapy for nonmuscle invasive bladder tumor. ( Kikuchi, E; Maeda, T; Matsumoto, K; Miyajima, A; Oya, M, 2011) |
| "Treatment of HTB5 and HTB9 bladder cancer cells for 24 to 72 hours with valproic acid and mitomycin C resulted in concentration and time dependent decreases in viability and proliferation." | 3.77 | Potentiation of mitomycin C tumoricidal activity for transitional cell carcinoma by histone deacetylase inhibitors in vitro. ( Deb, AA; Koul, HK; Koul, S; Kumar, B; Lim, DD; Meacham, RB; Rove, KO; Wilson, SS, 2011) |
| "To study the differential effects of bacillus Calmette-Guérin (BCG) and mitomycin C (MMC) intravesical therapy on the false-positive rate of PDD of bladder cancer." | 3.76 | Photodynamic diagnosis (5-aminolevulinic acid) of transitional cell carcinoma after bacillus Calmette-Guérin immunotherapy and mitomycin C intravesical therapy. ( Bosch, JL; Draga, RO; Grimbergen, MC; Jonges, TN; Kok, ET; van Swol, CF, 2010) |
| "Although recommended management strategy for nonmuscle-invasive bladder cancer (NMIBC) involves a single postoperative intravesical therapy with mitomycin C (MMC), it is uncommonly used among urologists, in part because of potential increased costs." | 3.76 | Contemporary cost analysis of single instillation of mitomycin after transurethral resection of bladder tumor in a universal health care system. ( Brophy, JM; Feifer, A; Kassouf, W; Segal, R; Xie, X, 2010) |
| "To analyze the prognostic values of p53 and Ki-67 expression in intermediate-risk patients with nonmuscle-invasive bladder cancer who were treated with adjuvant intravesical mitomycin C." | 3.76 | Prognostic value of p53 and Ki-67 expression in intermediate-risk patients with nonmuscle-invasive bladder cancer receiving adjuvant intravesical mitomycin C therapy. ( Cho, KS; Chung, J; Chung, MK; Joung, JY; Lee, KH; Park, WS; Seo, HK, 2010) |
| " EMDA of intravesical mitomycin-C (MMC) has been used for treatment of non-muscle invasive bladder cancer (NMIBC) for about a decade on the basis of laboratory studies that demonstrated an enhanced administration rate of MMC into all bladder wall layers after EMDA compared to standard instillation/passive diffusion (PD)." | 3.75 | Updates in intravesical electromotive drug administration of mitomycin-C for non-muscle invasive bladder cancer. ( Di Stasi, SM; Riedl, C, 2009) |
| "T24 cells (human bladder cancer cell lines) were pre-coated with fibronectin, and treated with mitomycin C (MMC) and the specific phosphoinositide-3 kinase (PI3-K) inhibitor LY294002." | 3.75 | Cell adhesion to fibronectin induces mitomycin C resistance in bladder cancer cells. ( Pan, CW; Shao, Y; Shen, ZJ; Sun, J; Tang, XY; Wang, M; Wu, TT, 2009) |
| "To report a prospective controlled study to compare the acceptance of two different ways of administering intravesical mitomycin C, as the immediate intravesical administration of chemotherapy after surgery decreases the risk of recurrence in patients with superficial bladder cancer, but response rates are variable, partly because of inadequate drug delivery and thus an adequate administration time is important for optimum oncological efficacy." | 3.74 | Increasing patient comfort by optimized postoperative administration of intravesical mitomycin C. ( Granig, T; Mueller, T; Steiner, H; Stoehr, B; Zangerl, F, 2008) |
| "The recurrence rate of superficial bladder cancer is still high even the patients received postoperative intravesical infusion of chemotherapeutic drugs, such as mitomycin C (MMC)." | 3.74 | [Establishment and application of an orthotopic murine bladder cancer model]. ( Cen, JN; Chen, JH; He, J; Hou, JQ; Wen, DG; Yang, SM, 2007) |
| "The inhibitory effects of NaB on human bladder cancer cell lines in vitro and the synergetic effect of NaB with mitomycin c, cisplatin (CDDP) and adriamycin were detected by the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide assay." | 3.74 | Two hour exposure to sodium butyrate sensitizes bladder cancer to anticancer drugs. ( Li, S; Li, X; Tian, B; Tian, Y; Wang, D; Wang, Z, 2008) |
| "Three-dimensional histocultures of RT4 (American Type Culture Collection, Rockville, Maryland) xenograft tumors and tumors from patients with bladder cancer were treated with MMC with or without 20 microM suramin." | 3.73 | Low dose suramin as a chemosensitizer of bladder cancer to mitomycin C. ( Au, JL; Chen, D; Lyness, G; Song, S; Wientjes, MG; Xin, Y, 2005) |
| "The human bladder cancer cell lines EJ28 and 5637 were transiently transfected with 3 antiVEGF AS-ODNs, followed by incubation with 3 doses of mitomycin C, gemcitabine or cisplatin CT." | 3.73 | Vascular endothelial growth factor antisense pretreatment of bladder cancer cells significantly enhances the cytotoxicity of mitomycin C, gemcitabine and Cisplatin. ( Förster, Y; Fuessel, S; Kotzsch, M; Kraemer, K; Krause, S; Meye, A; Schmidt, U; Schwenzer, B; Wirth, MP, 2005) |
| "Bladder cancer is a relatively common tumor in the urinary system, in which mitomycin C (MMC)-based chemotherapy or combination chemotherapy has been mainly used to treat patients with advanced bladder cancer." | 3.73 | Enhanced sensitivity to mitomycin C by abating heat shock protein 70 expression in human bladder cancer cell line of BIU-87. ( Guan, KP; He, LF; Hou, SK; Ren, L; Xu, KX; Yan, Z; Ye, HY, 2005) |
| "Transurethral resection followed by instillation of chemotherapeutic agents such as mitomycin is considered as standard therapy in recurrent superficial bladder cancer." | 3.73 | Reducing recurrence and costs in superficial bladder cancer: preclinical evaluation of osmotic cytolysis by distilled water vs. mitomycin. ( Fechner, G; Müller, SC; Pocha, K; Schmidt, D, 2006) |
| "We studied prophylactic intravesical instillation of mitomycin C (MMC) and pirarubicin (THP) following transurethral resection of bladder tumor (TUR-Bt) for superficial bladder cancer." | 3.73 | [5 years intravesical instillation with mitomycin-C and pirarubicin as a prophylactic treatment for superficial bladder cancer]. ( Ishizaka, K; Kobayashi, S; Machida, T; Oka, K, 2006) |
| "To determine if Meglumine-Eicosapentaenoic Acid (MeEPA) acts synergistically with epirubicin and mitomycin to enhance cytotoxicity towards bladder cancer cell lines in vitro." | 3.73 | Meglumine Eicosapentaenoic acid (MeEPA) a new soluble omega-3 fatty acid formulation: in vitro bladder cancer cytotoxicity tests in combination with epirubicin and mitomycin. ( Cooper, AJ; Harris, NM; Lwaleed, BA; Mackie, SJ; Sharma, DM, 2006) |
| "The enhancing effects of Smac gene on the mitomycin C-induced apoptosis of the bladder cancer cell line T24 were investigated." | 3.73 | Smac/DIABLO promotes mitomycin C-induced apoptosis of bladder cancer T24 cells. ( Fuqing, Z; Tong, Q; Wang, L; Zheng, L, 2006) |
| "To investigate the efficacy of inducing apoptosis in human bladder cancer cells by adriamycin and mitomycin and relevant mechanism." | 3.73 | [Adriamycin and mitomycin dose-dependently downregulate X-kinked inhibitor of apoptosis protein in human bladder cancer cells]. ( Chen, L; Gan, L; Lai, YQ; Li, M; Liu, G; Na, YQ; Yin, ZF; Yuan, YM, 2006) |
| "To evaluate the effect of combined use of oncolytic virus and the chemotherapeutic agents mitomycin (MMC) in growth inhibition of human bladder cancer cell line T-24 in vitro." | 3.73 | [Cytotoxic effect of oncolytic virus combined with mitomycin against human bladder cancer cells in vitro and in vivo]. ( Tan, WL; Wu, YD; Xie, Y; Zhao, GZ; Zheng, SB; Zhu, WH, 2006) |
| "Immediate adjuvant Mitomycin C (MMC) instillation is routine practice in the treatment of superficial bladder cancer." | 3.72 | Unusual complication after immediate postoperative intravesical mitomycin C instillation. ( Bex, A; Horenblas, S; Nieuwenhuijzen, JA, 2003) |
| " A reduction in urinary IL-8 levels after treatment with bacille Calmette-Guérin or mitomycin C may reflect a decrease in bladder cancer cells and/or in other cells that produce IL-8." | 3.72 | Urinary interleukin-8 levels are elevated in subjects with transitional cell carcinoma. ( Hausladen, DA; Sheryka, E; Weiss, RM; Wheeler, MA, 2003) |
| "To investigate the hypothesis that sequential mitomycin C and 5-aminolaevulinic acid (ALA)-mediated photodynamic therapy (PDT) interact additively in both the J82 bladder cancer cell line and its mitomycin-C-resistant derivative, J82/MMC, and to assess the theoretical basis of this interaction by measuring the relative mitochondrial density of the respective cell lines, on the basis that the mitochondria are the intracellular site where ALA is metabolized to the active photosensitizer, protoporphyrin IX." | 3.72 | Investigation of sequential mitomycin C and photodynamic therapy in a mitomycin-resistant bladder cancer cell-line model. ( Allman, R; Datta, SN; French, AJ; Matthews, PN, 2004) |
| "To investigate whether the heat shock protein (HSP) 70 antisense oligomers can enhance the sensitivity of bladder cancer cell EJ to mitomycin C." | 3.72 | [The heat shock protein 70 antisense oligomers enhance the sensitivity of bladder cancer cell EJ to mitomycin C]. ( He, LF; Hou, SK; Ren, L; Wang, SW; Yan, Z, 2004) |
| "The design of an ongoing Phase III study of intravesical mitomycin C therapy to treat bladder cancer is partly based on the assumption that drug penetration into bladder tissue is linearly related to drug concentration." | 3.70 | Bladder tissue uptake of mitomycin C during intravesical therapy is linear with drug concentration in urine. ( Au, JL; Badalament, RA; Gao, X; Wientjes, MG, 1998) |
| "Treatment of the T24 human bladder cancer cell line with anti-Fas mAb in combination with 5-fluorouracil, mitomycin C or methotrexate did not overcome resistance to these agents." | 3.70 | Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II). ( Bonavida, B; Mizutani, Y; Yoshida, O, 1998) |
| "To compare the tumoricidal efficacy of meglumine gamma-linolenic acid (MeGLA), mitomycin C, epirubicin and water on two urothelial cell lines, and to establish the effect of serum protein levels derived from bladder cancer resection craters on the action of these agents." | 3.70 | Bladder cancer recurrence by implantation of exfoliated cells: is gamma-linolenic acid an effective tumoricidal agent? ( Birch, BR; Cooper, AJ; Foley, SJ; Jennings, AM; Solomon, LZ, 1998) |
| "A 71-year-old man developed an exfoliative dermatitis of the palms of the hands and soles of the feet, and a generalized itch, during treatment with intravesical instillations of mitomycin C for an undifferentiated carcinoma of the bladder." | 3.70 | Type III and type IV hypersensitivity reactions due to mitomycin C. ( Bruynzeel, DP; Kunkeler, L; Nieboer, C, 2000) |
| "From January 1984 to December 1991, 58 patients with carcinoma in situ of the bladder were treated initially with intravesical mitomycin C and doxorubicin sequential therapy." | 3.69 | Histological grading of carcinoma in situ of the bladder: its clinical significance in patients who underwent intravesical mitomycin C and doxorubicin sequential therapy. ( Fukui, I; Kojima, S; Ohshima, H; Sekine, H; Yamada, T, 1996) |
| "This study describes characteristics of a human bladder cancer cell line, SCaBER/R, selected for resistance to a mitomycin C (MMC) analogue BMY 25067." | 3.69 | Characterization of a human bladder cancer cell line selected for resistance to BMY 25067, a novel analogue of mitomycin C. ( Emerson, EO; Gupta, V; Jani, JP; Singh, SV; Xu, BH; Zaren, HA, 1995) |
| "This study was undertaken to elucidate the mechanism(s) of cross-resistance to cisplatin (CDDP) in a mitomycin C (MMC)-resistant human bladder cancer cell line, J82/MMC." | 3.69 | Mechanism of cross-resistance to cisplatin in a mitomycin C-resistant human bladder cancer cell line. ( Backes, MG; Blanock, K; Emerson, EO; Jani, JP; Rihn, C; Scalamogna, D; Singh, SV; Specht, S; Stemmler, N; Xu, BH, 1995) |
| "Mitomycin C (MMC) was given intravesically to 14 patients with transitional-cell carcinoma in situ of the bladder (CIS) between 1985 and 1989." | 3.69 | Treatment of bladder carcinoma in situ with mitomycin C: long-term follow-up. ( Cecchi, M; Felipetto, R; Minervini, R; Viganò, L, 1994) |
| "This study describes characteristics of a human bladder cancer cell line J82/MMC that is 6-fold more resistant to mitomycin C (MMC) than the parental cells." | 3.69 | Characterization of a human bladder cancer cell line selected for resistance to mitomycin C. ( Gupta, V; Singh, SV; Xu, BH, 1994) |
| "Presentation of one study on the incidence of fibrino-necrotic ulcers in patients undergoing endovesical chemoprophylaxis with mitomycin C." | 3.69 | [Fibrino-necrotic ulcers in endovesical chemoprophylaxis in superficial bladder carcinoma: our case histories]. ( Arnáiz Esteban, F; Espuela Orgaz, R; Fernández Rosáenz, J; Guinda Sevillano, C; Martínez Pérez, E; Nogueras Gimeno, MA; Pérez Arbej, JA, 1994) |
| "Mitomycin C (MMC) was given intravesically over a period of 36 months to 14 patients with transitional-cell carcinoma in situ of the bladder (CIS)." | 3.69 | Intravesical mitomycin C for the treatment of carcinoma in situ of the bladder: 36 months follow-up. ( Cecchi, M; Felipetto, R; Minervini, R; Pagni, G; Viganò, L, 1994) |
| "A total of 43 patients with carcinoma in situ of the bladder (primary in 26 and secondary in 17) who underwent intravesical mitomycin C and doxorubicin sequential therapy for 2 multicenter studies were followed for a median period of 45 months (range 10 to 84)." | 3.69 | Intravesical mitomycin C and doxorubicin sequential therapy for carcinoma in situ of the bladder: a longer followup result. ( Fukui, I; Ohshima, H; Ohwada, F; Sekine, H; Yamada, T; Yokokawa, M, 1994) |
| "This study was undertaken to elucidate the mechanism(s) of differential sensitivity of human bladder cancer cell lines J82 and SCaBER to mitomycin C (MMC) and its analogue, BMY 25067." | 3.69 | Mechanism of differential sensitivity of human bladder cancer cells to mitomycin C and its analogue. ( Gupta, V; Singh, SV; Xu, BH, 1994) |
| "In this study, we have examined the relationship between sensitivity to mitomycin C (MMC) and glutathione (GSH) and glutathione transferase (GST) levels using a panel of three unrelated human bladder cancer cell lines." | 3.69 | Mitomycin C sensitivity in human bladder cancer cells: possible role of glutathione and glutathione transferase in resistance. ( Gupta, V; Singh, SV; Xu, BH, 1994) |
| "This study describes characteristics of a mitomycin C (MMC)-resistant human bladder cancer cell line, J82/MMC-2, which was established by repeated in vitro exposures of a 6-fold MMC-resistant variant (J82/MMC) to 18 nM MMC." | 3.69 | Biochemical characterization of a mitomycin C-resistant human bladder cancer cell line. ( Emerson, EO; Gupta, V; O'Toole, S; Roy, D; Scalamogna, D; Singh, SV; Xia, H; Zaren, HA, 1996) |
| "This study was undertaken to determine the mechanism of resistance of a human bladder cancer cell line SCaBER to mitomycin C (MMC)." | 3.69 | [Mechanism of resistance to mitomycin C in a human bladder cancer cell line]. ( Singh, SV; Sun, Y; Xu, B, 1995) |
| "We evaluated the DNA cytophotometry in 446 bladder washing samples from 64 patients under mitomycin C after superficial bladder cancer during an observation period of up to 5 years." | 3.69 | Cytophotometry in the monitoring of bladder cancer under intravesical chemotherapy. ( Foeger, A; Maier, U; Marberger, M; Simak, R; Susani, M; Wiener, H; Zhang, ZF, 1996) |
| "Cultures of three human tumour cell lines, including two bladder carcinomas and one renal adenocarcinoma, and two mouse cell lines were treated with mitomycin C (concentration range 320 pM-50 microM) at a range of pH (5." | 3.69 | Sensitivity of cell lines to mitomycin C. ( Courtney, JM; Plumb, JA; Scott, R; Watts, PL, 1996) |
| "The mechanism of increased sensitivity to etoposide (VP-16) in a human bladder cancer cell line (J82/MMC-2), which is >9-fold more resistant to mitomycin C (MMC) compared with parental cells (J82/WT), was investigated." | 3.69 | Mechanism of increased sensitivity to etoposide in a mitomycin C-resistant human bladder cancer cell line. ( Bleicher, RJ; Gupta, V; Singh, SV; Xia, H; Zaren, HA, 1997) |
| " Cell survival of ALA-mediated photodynamic therapy was measured in the J82 bladder cancer cell line, along with its mitomycin C-resistant counterpart J82/MMC." | 3.69 | Effect of photodynamic therapy in combination with mitomycin C on a mitomycin-resistant bladder cancer cell line. ( Allman, R; Datta, SN; Loh, C; Mason, M; Matthews, PN, 1997) |
| "This study was undertaken to elucidate the mechanism of cellular resistance to BMS-181174, a novel analogue of mitomycin C (MMC), in a human bladder cancer cell line." | 3.69 | Characterization of a BMS-181174-resistant human bladder cancer cell line. ( Bleicher, RJ; Gupta, V; Hu, X; Singh, SV; Srivastava, SK; Xia, H; Zaren, HA, 1997) |
| "Bladder wall calcification is a rare complication of intravesical therapy of superficial bladder cancer with Mitomycin C." | 3.68 | Incrusted cystitis after intravesical mitomycin C treatment. ( Algado, M; Botella, R; Llopis, M; Moreno, J, 1993) |
| "Treatment of superficial bladder cancers by intravesical mitomycin C (MMC) chemotherapy gives a varying and incomplete response." | 3.68 | Use of pharmacologic data and computer simulations to design an efficacy trial of intravesical mitomycin C therapy for superficial bladder cancer. ( Au, JL; Badalament, RA; Wientjes, MG, 1993) |
| "The effect of intravesical instillation of 200,000 IU hyaluronidase in addition to mitomycin C as chemoprophylaxis of superficial bladder cancer was evaluated." | 3.68 | Topical chemoprophylaxis of superficial bladder cancer with mitomycin C and adjuvant hyaluronidase. ( Höbarth, K; Maier, U; Marberger, M, 1992) |
| "At the Institute of Urology, University of Padova, 125 patients with multifocal superficial bladder cancer underwent treatment with intravesical Mitomycin C (MMC; 1 weekly instillation of 40 mg for 8 consecutive weeks) between January 1982 and December 1988." | 3.68 | Mitomycin C in multiple superficial bladder tumors: short-term therapy, long-term results. ( Bassi, P; Drago-Ferrante, GL; Garbeglio, A; Maruzzi, D; Meneghini, A; Milani, C; Pagano, F; Piazza, N; Zattoni, F, 1992) |
| "We analyzed 29 cases of eosinophilic cystitis in a group of 80 patients with lower urothelial carcinoma who had been treated with mitomycin-C." | 3.68 | [Eosinophilic cystitis as a special form of response to mitomycin C. Analysis and comments on our cases]. ( Arango Toro, O; Bielsa Galí, O; Corominas, J; Gelabert Mas, A; Lladó Carbonell, C; Vesa Llanes, J, 1991) |
| "A chemosensitivity test was carried out on superficial bladder cancers using the trypan blue dye exclusion assay for the purpose of screening chemosensitive drugs for intravesical chemotherapy." | 3.68 | [Chemosensitivity test on superficial urinary bladder cancer using the dye exclusion assay--model of intravesical chemotherapy]. ( Irisawa, C; Koseki, K; Shiraiwa, Y, 1991) |
| "Intravesical mitomycin C (MMC) therapy is used to treat superficial bladder cancer." | 3.68 | Pharmacokinetics of intravesical mitomycin C in superficial bladder cancer patients. ( Au, JL; Badalament, RA; Dalton, JT; Drago, JR; Wientjes, MG, 1991) |
| "A total of 20 patients received intravesical bacillus Calmette-Guerin (BCG) or mitomycin C for the treatment of carcinoma in situ following previous pelvic radiation therapy." | 3.68 | Intravesical bacillus Calmette-Guerin or mitomycin C in the treatment of carcinoma in situ of the bladder following prior pelvic radiation therapy. ( Pisters, LL; Tykochinsky, G; Wajsman, Z, 1991) |
| "Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C." | 3.68 | Secondary hematologic neoplasm after intravesical chemotherapy for superficial bladder carcinoma. ( Abels, J; Hagemeyer, A; Kurth, KH; Sonneveld, P, 1990) |
| "We studied 15 patients with histologically proved multifocal carcinoma in situ of the bladder who were in remission at a mean followup of 21 months after induction intravesical chemotherapy with mitomycin C." | 3.68 | Topical mitomycin C therapy for carcinoma in situ of the bladder: a followup. ( Grant, AB; Hosken, BM; Stricker, PD; Taylor, JS, 1990) |
| "Mitomycin C was given intravesically over periods of 2-32 months to 34 patients with carcinoma in situ of the urinary bladder." | 3.68 | Intravesical mitomycin C for carcinoma in situ of the urinary bladder. ( Hellsten, S; Henrikson, H; Idwall, I; Lindholm, K; Månsson, W; Mårtensson, S; Mikulowski, P; Oldbring, J, 1990) |
| "Mitomycin C 40 mg in 40 ml water was administered intravesically every week for 8 consecutive weeks to 60 patients with superficial bladder cancer." | 3.67 | Mitomycin C intravesical therapy in noninvasive bladder cancer after failure on thiotepa. ( Block, NL; Brannen, G; Cummings, KB; Flanagan, M; Issell, BF; Levin, EA; Prout, GR; Soloway, MS; Summers, JL; Veenema, R, 1984) |
| "Although intravesical mitomycin C (MMC) is effective in the treatment of superficial bladder cancer, its expense is a major factor limiting its use." | 3.67 | The stability and antitumor activity of recycled (intravesical) mitomycin C. ( Buice, RG; Hopkins, SC; Matheny, R; Soloway, MS, 1984) |
| "Mitomycin C is an active drug in the treatment of superficial bladder cancer." | 3.67 | Studies of mitomycin C absorption after intravesical treatment of superficial bladder tumors. ( Block, A; Dhafir, RA; Dragone, N; MacDonald, S; Pfeffer, M; Pontes, JE; Wajsman, Z, 1984) |
| "The use of mitomycin C, an effective agent in the intravesical treatment of superficial bladder cancer, is limited by its high cost." | 3.67 | Mitomycin C reused: an in vitro cost-effectiveness study. ( Carroll, PR; Dombrovskis, S; Kim, MJ; Williams, RD, 1984) |
| "We present a series of 13 patients with diffuse carcinoma in situ (CIS) of the bladder who failed an initial induction course of intravesical therapy with Mitomycin C, thiotepa, doxorubicin or Bacillus Calmette Guérin (BCG)." | 3.67 | Conservative treatment of diffuse carcinoma in situ of the bladder with repeated courses of intravesical therapy. ( deKernion, JB; Mukamel, E, 1989) |
| "Calcification of the bladder wall associated with intravesical mitomycin C for the treatment of superficial bladder cancer is a rare complication." | 3.67 | Bladder wall calcification after intravesical mitomycin C treatment of superficial bladder cancer. ( Badalament, RA; Drago, JR; Drago, PC; Lucas, J, 1989) |
| "The authors studied the effect of bladder instillation of mitomycin C (MMC), a potential carcinogen, on the duration and severity of the hyperplasia induced by transurethral fulguration." | 3.67 | Mutual neoplastic promotion by instillation of mitomycin C and cauterization on rat bladder urothelium. ( Akaza, H; Koseki, K; Niijima, T, 1986) |
| "During long periods of buffered instillations of mitomycin C (MMC) and doxorubicin (adriamycin; ADM) on carcinoma in situ (TIS), the complete response was 82% for MMC and 80% for ADM." | 3.67 | Effect of mitomycin C and doxorubicin instillation on carcinoma in situ of the urinary bladder. A Finnish multicenter study. ( Alfthan, O; Jauhiainen, K; Permi, J; Sotarauta, M, 1986) |
| " A human bladder cancer cell line was exposed to a range of concentrations of the four drugs commonly used to treat superficial bladder cancer (adriamycin, epodyl, mitomycin-c, thiotepa) for periods of 30, 60 and 120 min." | 3.67 | Intravesical chemotherapy: in vitro studies on the relationship between dose and cytotoxicity. ( English, PJ; Hepburn, PJ; Masters, JR; Parris, CN; Walker, MC, 1986) |
| "Of 299 patients who presented with superficial bladder cancer (Ta, T1), 60 were treated by intravesical chemotherapy (Epodyl, methotrexate or mitomycin C)." | 3.67 | Superficial bladder cancer: intravesical chemotherapy and tumour progression to muscle invasion or metastases. ( Chisholm, GD; Elton, RA; Hargreave, TB; Newsam, JE; Smith, G, 1986) |
| "Tween 80 was shown to enhance significantly the cytotoxic activities of the four drugs (adriamycin, epodyl, mitomycin-c, thiotepa) most frequently administered intravesically to treat superficial bladder cancer." | 3.67 | Intravesical chemotherapy: combination with Tween 80 increases cytotoxicity in vitro. ( English, P; Masters, JR; Newman, B; Parris, CN; Riddle, P; Walker, MC, 1987) |
| "Both Mitomycin C (MMC) and doxorubicin (Adriamycin) (ADM) prevent the recurrence of superficial papillary (Ta-T1) urinary bladder cancers and also reduce the rate of progression." | 3.67 | Instillation of mitomycin C and doxorubicin in the prevention of recurrent superficial (Ta-T1) bladder cancer. ( Alfthan, O; Jauhiainen, K, 1987) |
| "Three cases are presented in which eosinophilic cystitis developed when patients who were known to have superficial bladder cancer were treated with instillations of the alkylating agent Mitomycin C." | 3.67 | Allergy to mitomycin C complicating topical administration for urothelial cancer. ( Grigor, KM; Inglis, JA; Tolley, DA, 1987) |
| "We have investigated the effect of verapamil on the cytotoxicity of adriamycin and mitomycin C with human bladder cancer cell lines T-24 and JTC-30." | 3.67 | [Effect of a calcium influx blocker, verapamil, on the sensitivity of human bladder cancer cells to adriamycin and mitomycin C]. ( Kageyama, Y; Kihara, K; Ohta, S; Yoshida, K, 1988) |
| "We report 5 cases of invasive squamous cell bladder cancer treated with preoperative mitomycin C and 5-fluorouracil in combination with preoperative external beam radiation therapy (the Nigro regimen), and the subsequent apparent cure of 3 of the 5 patients." | 3.67 | A new treatment for invasive squamous cell bladder cancer: the Nigro regimen: preoperative chemotherapy and radiation therapy. ( Gee, WF; Medina, WD; Mendiondo, OA; Patterson, JM; Ray, EH, 1988) |
| "A limited course of intravesical mitomycin C was tested in 12 patients who had at least three, and an average of six, occurrences of superficial bladder cancer, and were at high risk for subsequent recurrences." | 3.67 | Study of intravesical mitomycin C in patients with multiple prior occurrences of superficial bladder cancer. ( Brown, J; Johanson, KE; Schwarzman, MI; Surya, B, 1988) |
| "Intravesical chemotherapy with sequential instillation of mitomycin C and adriamycin was carried out on 19 patients with superficial bladder cancer (Ta, T1 and Tis)." | 3.67 | [Sequential intravesical chemotherapy with mitomycin C and adriamycin for superficial bladder tumor (preliminary report)]. ( Fukui, I; Kihara, K; Sekine, H; Yamada, T, 1985) |
| "A total of 70 patients received intravesical mitomycin C for treatment of superficial bladder cancer." | 3.67 | Treatment of superficial bladder cancer with intravesical mitomycin C: analysis of immediate and long-term response in 70 patients. ( Soloway, MS, 1985) |
| "Pharmacokinetics of anti-neoplastic agents (Cis-platinum: CDDP, Mitomycin C: MMC and Doxorubicin hydrochloride: ADM) in intra-arterial infusion chemotherapy with direct hemoperfusion (DHP) for bladder cancer were compared using dogs." | 3.67 | [Fundamental study on intra-arterial chemotherapy with direct hemoperfusion]. ( Nakano, Y, 1985) |
| "Twenty-three patients who were given intravesical Mitomycin C for treatment of superficial bladder cancer have been followed up for a further 12 and 24 months after an initial assessment 5 weeks after completing therapy." | 3.67 | Mitomycin C in superficial bladder cancer: 24-month follow-up. ( Newling, DW; Richards, B; Robinson, MR; Smith, PH; Somerville, JJ, 1985) |
| " The technique of cauterization and implantation of tumor cells was performed in C3H/He mice to simulate the early stage of bladder cancer to evaluate a regimen of intravesical mitomycin C followed by the systemic immunopotentiator, levamisole." | 3.66 | Chemoimmunotherapy of implanted murine bladder cancer. ( Akaza, H; Crabtree, WN; Matheny, RB; Soloway, MS, 1983) |
| "Twenty-three patients with histologically proven superficial bladder cancer (Tis, Ta, T1) were treated with intravesical instillations of Mitomycin C at a dose of 20 mg in 20 ml of water 3 times weekly for 21 instillations." | 3.66 | A phase II study of intravesical mitomycin C in the treatment of superficial bladder cancer. ( Green, DF; Harrison, GS; Newling, DW; Richards, B; Robinson, MR; Smith, PH, 1983) |
| "We investigated the effectiveness of intravesically administered drugs on the tumor incidence and tumor size in a FANFT-induced animal model for bladder cancer." | 3.66 | Single and sequential combination intravesical chemotherapy of murine bladder cancer. ( McCallum, LW; Murphy, WM; Nissenkorn, I; Soloway, MS, 1982) |
| " Acute toxicity was assessed (Common Terminology Criteria for Adverse Events) weekly during radiotherapy and at 10 weeks after the start of treatment." | 3.30 | Acute Toxicity of Hypofractionated and Conventionally Fractionated (Chemo)Radiotherapy Regimens for Bladder Cancer: An Exploratory Analysis from the RAIDER Trial. ( Alonzi, R; Birtle, A; Cheung, KC; Choudhury, A; Foroudi, F; Gribble, H; Griffin, C; Hafeez, S; Hall, E; Henry, A; Hilman, S; Hindson, B; Huddart, R; Lewis, R; McLaren, DB; McNair, H; Muthukumar, D; Nikapota, A; Olorunfemi, A; Omar, A; Parikh, O; Philipps, L; Rimmer, Y; Syndikus, I; Tolentino, A; Varughese, M; Vassallo-Bonner, C; Webster, A, 2023) |
| "Muscle-invasive bladder cancer (MIBC) has a poor prognosis." | 3.11 | Phase 1 Study of Chemoradiotherapy Combined with Nivolumab ± Ipilimumab for the Curative Treatment of Muscle-invasive Bladder Cancer. ( Bins, AD; de Reijke, TM; de Ruiter, BM; Donker, M; Hulshof, MCCM; Lipman, D; Maartje Piet, AH; Oddens, JR; van der Hulle, T; van Gennep, EJ; van Hattum, JW; van Moorselaar, RJA; Voortman, J, 2022) |
| "Non-muscle invasive bladder cancer (NMIBC) is characterized by a high rate of recurrence and progression, despite surgery and adjuvant therapies." | 3.01 | A systematic review of the efficacy of intravesical electromotive drug administration therapy for non-muscle invasive bladder cancer. ( Arrabal-Polo, MÁ; Gómez-Lechuga, P; Jiménez-Moleón, JJ; Martín, MA; Melgarejo-Segura, MT; Morales-Martínez, A; Pareja-Vílchez, M; Yáñez-Castillo, Y, 2023) |
| "Mitomycin C (MMC) was the chemotherapeutic agent." | 2.90 | Development of a high-precision bladder hyperthermic intracavitary chemotherapy device for bladder cancer and pharmacokinetic study. ( Ba, M; Cui, S; Gong, Y; Lin, K; Long, H; Tu, Y; Wu, W; Wu, Y; Zhang, B, 2019) |
| " The primary endpoint was recurrence-free survival, and secondary endpoints were progression-free survival and adverse events." | 2.84 | Randomized controlled study of the efficacy and safety of continuous saline bladder irrigation after transurethral resection for the treatment of non-muscle-invasive bladder cancer. ( Masui, S; Onishi, T; Sasaki, T; Shibahara, T; Sugino, Y; Yabana, T, 2017) |
| "In patients with muscle invasive bladder cancer (MIBC), necrosis is prognostic for survival following surgery or radiotherapy and predicts benefit from hypoxia modification of radiotherapy." | 2.84 | The predictive and prognostic value of tumour necrosis in muscle invasive bladder cancer patients receiving radiotherapy with or without chemotherapy in the BC2001 trial (CRUK/01/004). ( Choudhury, A; Denley, H; Hall, E; Hendron, C; Huddart, R; Hussain, SA; James, N; Lewis, R; Porta, N; West, CM, 2017) |
| "Non-muscle-invasive bladder cancer (NMIBC) represents a significant global therapeutic challenge, particularly in the era of Bacillus Calmette-Guérin (BCG) shortage." | 2.82 | Adjuvant therapies for non-muscle-invasive bladder cancer: advances during BCG shortage. ( Balasubramanian, A; Bolton, D; Gunjur, A; Lawrentschuk, N; Papa, N; Perera, M; Weickhardt, A, 2022) |
| "Recurrences in non-muscle-invasive bladder cancer are common, despite adjuvant therapies." | 2.82 | Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer. ( Arends, TJ; Canepa, G; de Cobelli, O; Maffezzini, M; Moskovitz, B; Nativ, O; van der Heijden, AG; Verweij, F; Witjes, JA, 2016) |
| "Postoperative EMDA with mitomycin is a safe procedure." | 2.80 | [Non-muscle invasive bladder cancer: safety of postoperative EMDA-assisted instillation of mitomycin]. ( Niedworok, C; Rehme, C; Rübben, H; Vom Dorp, F, 2015) |
| "Patients with a history of bladder cancer were excluded." | 2.78 | Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasi ( Chandra, A; Chatterton, K; Khan, MS; O'Brien, T; Ray, E; Thomas, K, 2013) |
| "Primary outcome measurement was recurrence-free survival (RFS)." | 2.77 | Intracutaneous and intravesical immunotherapy with keyhole limpet hemocyanin compared with intravesical mitomycin in patients with non-muscle-invasive bladder cancer: results from a prospective randomized phase III trial. ( Caris, CT; Janzing-Pastors, MH; Lammers, RJ; Witjes, JA; Witjes, WP, 2012) |
| "The long-term bladder cancer-specific mortality was unexpectedly low despite the relatively ineffective instillation therapy and the poor outcome of the patients after progression." | 2.77 | Long-term results of maintenance treatment of mitomycin C or alternating mitomycin C and bacillus Calmette-Guérin instillation therapy of patients with carcinoma in situ of the bladder: a subgroup analysis of the prospective FinnBladder 2 study with a 17- ( Group, TF; Järvinen, R; Kaasinen, E; Rintala, E, 2012) |
| "Bladder cancer is a disease with a high prevalence due to its recurrence rate." | 2.73 | [Therapeutic effect of mitomycin C in the immediate postoperatory in patients with low-risk non-muscle-invasive bladder tumours]. ( Alvarez Múgica, M; Escaf Bramada, S; Fernández Gómez, JM; García Rodríguez, J; Jalón Monzón, A; Regadera Sejas, FJ, 2008) |
| "Bladder cancer is mostly superficial at first diagnosis." | 2.72 | Intravesical adjuvant therapy using mitomycin C. ( Bhuiyan, ZH; Islam, MA; Shameem, IA, 2006) |
| "Of 148 newly diagnosed patients with T1 bladder cancer 142 were prospectively randomized in 2 groups between January 2001 and January 2005." | 2.72 | The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. ( Divrik, RT; Ozen, H; Yildirim, U; Zorlu, F, 2006) |
| "Patients with G3 bladder tumors (Stage Ta or T1) were treated with combined intravesical chemotherapy with mitomycin-C and local radiofrequency hyperthermia of the bladder wall." | 2.71 | Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer. ( Colombo, R; Gofrit, ON; Leib, Z; Naspro, R; Nativ, O; Pode, D; Shapiro, A; Sidi, A; van der Heijden, AG; Witjes, JA, 2004) |
| "A recurrence of bladder tumors following surgery for transitional cell carcinoma of the upper urinary tract is not rarely observed." | 2.70 | Prophylactic intravesical instillation of mitomycin C and cytosine arabinoside for prevention of recurrent bladder tumors following surgery for upper urinary tract tumors: a prospective randomized study. ( Ariyoshi, A; Fujisawa, Y; Kumazawa, J; Morita, I; Naito, S; Omoto, T; Osada, Y; Sakamoto, N; Yamashita, H, 2001) |
| "The management of locally advanced bladder cancer remains controversial with poor local control with radiotherapy alone." | 2.70 | A phase I-II study of synchronous chemoradiotherapy for poor prognosis locally advanced bladder cancer. ( Glaholm, JG; Hussain, SA; James, ND; Moffitt, DD; Peake, D; Wallace, DM, 2001) |
| "The mitomycin C-treated patients had 41% recurrence, 1." | 2.68 | [Prevention of superficial bladder cancer with mitomycin C or interferon: final results of a prospective study]. ( Alonso Rodrigo, A; Barros Rodríguez, M; Benavente Delgado, J; Domínguez Freire, F; Nogueira March, YJ; Ojea Calvo, A; Rodríguez Iglesias, B; Vérez Vivero, M, 1996) |
| "mitomycin C (MMC), is a particularly important question." | 2.67 | Pharmacodynamics and pharmacokinetics of intravesical mitomycin C upon different dwelling times. ( De Bruijn, EA; Maes, RA; Sleeboom, HP; Tjaden, UR; van Helsdingen, PJ; van Oosterom, AT, 1992) |
| "Non-muscle-invasive bladder cancer can be a challenging disease to manage." | 2.66 | Heated Intravesical Chemotherapy: Biology and Clinical Utility. ( Inman, BA; Longo, TA; Tan, WP, 2020) |
| "The treatment of bladder cancer is one of the most active areas of clinical cancer research." | 2.66 | Approaches to the treatment of bladder cancer at Stanford. ( Torti, FM, 1987) |
| "Bladder cancer is the second most common urological malignant disease." | 2.58 | [Thermochemotherapy with Mitomycin C: an update on alternative treatment strategies in non-muscleinvasive bladder cancer]. ( Blaschke, S; Christoph, F; König, F; Lebentrau, S; Liehr, UB; Schostak, M, 2018) |
| "Mitomycin C is an antitumor alkylating antibiotic agent that inhibits DNA synthesis extensively used as intravesical chemotherapy agent in the adjuvant treatment of urothelial carcinoma." | 2.58 | [Immediate post TURBT MMC instillation.] ( Domínguez-Escrig, JL, 2018) |
| "The treatment of non muscle invasive bladder cancer (NMIBC) continues to be a challenge." | 2.58 | Analysis of tolerance and security of chemo hyperthermia with Mitomycin C for the treatment of non-muscle invasive bladder cancer. ( Alvarez Casal, M; Domínguez, JL; León-Mata, J; Piñeiro Vázquez, E; Redorta, JP; Sousa Escandón, A; Sousa González, D, 2018) |
| "As our molecular understanding of bladder cancer continues to advance, more and more novel agents are entering clinical trials across the spectrum of bladder cancer stages." | 2.58 | Current Clinical Trials in Non-muscle Invasive Bladder Cancer. ( Batista da Costa, J; Black, PC; Mannas, M; Nykopp, TK, 2018) |
| "There was no disease progression in either treatment arm at three months' follow-up." | 2.55 | Intravesical electromotive drug administration for non-muscle invasive bladder cancer. ( Dahm, P; Gudeloglu, A; Jung, JH; Kiziloz, H; Konety, BR; Kuntz, GM; Miller, A, 2017) |
| "Non-muscle invasive bladder cancer (NMIBC) has a high tendency for recurrence and progression." | 2.53 | The role of hyperthermia as a treatment for non-muscle invasive bladder cancer. ( Bahouth, Z; Halachmi, S; Moskovitz, B; Nativ, O, 2016) |
| "Bladder cancer is the second commonest urinary tract malignancy with 70-80 % being non-muscle invasive (NMIBC) at diagnosis." | 2.53 | High-Risk Non-Muscle-Invasive Bladder Cancer-Therapy Options During Intravesical BCG Shortage. ( Bach, C; Heer, R; Johnson, MI; Persad, R; Veeratterapillay, R, 2016) |
| "Urinary bladder cancer is one of the most frequent cancers worldwide." | 2.53 | Comparison of the combination therapy of bacillus Calmette-Guérin and mitomycin C with the monotherapy for non-muscle-invasive bladder cancer: a meta-analysis. ( Lan, Y; Lin, M; Liu, D, 2016) |
| "Bladder cancer is very common and most cases are diagnosed as nonmuscle invasive disease, which is characterized by its propensity to recur and progress." | 2.53 | Intravesical electro-osmotic administration of mitomycin C. ( Celestino, F; De Carlo, F; Di Stasi, SM; Pagliarulo, V; Verri, C, 2016) |
| "The drugs used in the treatment of bladder cancer are represented by the products referred to diagnosis (hexyl aminolevulinate), the intravesical instillations for the treatment of tumors not infiltrating the muscle and the infiltrating tumor chemotherapy (neo-adjuvant treatment or metastatic tumors)." | 2.49 | [Medical treatment of bladder carcinoma]. ( Bastide, C; Bay, JO; Bruyere, F; Guy, L; Karsenty, G; Mahammedi, H, 2013) |
| "Non-muscle-invasive bladder cancer is characterized by frequent recurrences requiring repeated transurethral resections and carries a risk of progression to muscle-invasive disease." | 2.49 | Adjuvant methods to improve results of local bladder irrigations by chemotherapy for NMIBC. ( Dekel, Y; Freifeld, Y; Stein, A, 2013) |
| "Bladder cancer is a heterogeneous disease: approximately 75% of its forms are non muscle invasive neoplasms." | 2.46 | Mitomycin C for the treatment of bladder cancer. ( Bassi, PF; Cappa, E; D'Agostino, D; Filianoti, A; Racioppi, M; Volpe, A, 2010) |
| "Non-muscle-invasive bladder cancers form a heterogeneous group of tumours with varying recurrence and progression rates." | 2.45 | Therapeutic options in the management of intermediate-risk nonmuscle-invasive bladder cancer. ( Horvath, A; Mostafid, H, 2009) |
| "Patients with non-muscle-invasive bladder cancer with an intermediate or high risk need adjuvant intravesical therapy after surgery." | 2.45 | An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. ( Crawford, DE; Di Stasi, SM; Friedrich, M; Krege, S; Malmström, PU; Rintala, E; Solsona, E; Sylvester, RJ; Witjes, JA, 2009) |
| "Superficial bladder cancer can be treated surgically, but patients are at high risk for recurrence." | 2.43 | Bladder cancer: current optimal intravesical treatment. ( Hale, K; Lamm, DL; McGee, WR, 2005) |
| "Mitomycin C has emerged as a major agent for an immediate post-resection intravesical instillation." | 2.43 | Risk of post-operative intravesical mitomycin C instillation following transurethral bladder tumor resection. ( Haas, GP; Jones, K; Landas, S; Shapiro, O; Wang, C, 2006) |
| " On the other hand, bacillus Calmette-Guerin (BCG) currently appears to be the most effective agent for intravesical use, especially in patients with high grade and stage neoplasms but the optimum strain, dosage and duration schedule have not been determined." | 2.41 | Intravesical therapy of superficial bladder cancer. ( Melekos, MD; Moutzouris, GD, 2000) |
| "Superficial bladder cancer accounts for approximately 70% to 80% of all newly diagnosed bladder cancers." | 2.41 | An overview of the treatment of superficial bladder cancer. Intravesical chemotherapy. ( Duque, JL; Loughlin, KR, 2000) |
| "Close to 75% of all bladder tumors are confined to the urothelium (stage Ta, or carcinoma in situ), and nearly 30% of papillary tumors invade the lamina propria (stage T1)." | 2.41 | Intravesical therapy for superficial bladder cancer. ( Baselli, EC; Greenberg, RE, 2000) |
| " Pharmacokinetic models of drug absorption from the bladder have been developed, both in animals and humans." | 2.40 | Intravesical drug delivery. Pharmacokinetic and clinical considerations. ( De Bruijn, EA; Highley, MS; Maes, RA; van Oosterom, AT, 1999) |
| "The management of superficial bladder cancer has advanced significantly in recent years." | 2.39 | BCG in perspective: advances in the treatment of superficial bladder cancer. ( Lamm, DL, 1995) |
| "More than 90 percent of bladder cancers are transitional cell carcinoma (TCC)." | 2.38 | Managing superficial bladder cancer: an overview. ( Soloway, MS, 1992) |
| " Different dosage schedules and methods require further study." | 2.38 | Intravesical chemotherapy. Treatment selection, techniques, and results. ( Richie, JP, 1992) |
| "7." | 2.38 | Rationale for intravesical chemotherapy in the treatment and prophylaxis of superficial transitional cell carcinoma. ( Jordan, AM; Murphy, WM; Soloway, MS, 1989) |
| "Management of the superficial bladder cancer patient consists of two complementary but separate therapeutic goals: treatment of the existing tumor(s) and prevention of tumor recurrence." | 2.37 | The biology and treatment of superficial bladder cancer. ( Lum, BL; Torti, FM, 1984) |
| " Ureteral stenosis and other adverse events were abstracted from the medical records." | 1.91 | Efficacy and Safety of Mitomycin Gel (UGN-101) as an Adjuvant Therapy After Complete Endoscopic Management of Upper Tract Urothelial Carcinoma. ( Bjurlin, M; Dickstein, R; Eisner, B; Feldman, A; Ghodoussipour, S; Humphreys, M; Jacob, J; Kaimakliotis, H; Labbate, C; Linehan, J; Lotan, Y; Matin, SF; Murray, K; Nieder, A; O'Donnell, M; Quek, M; Rose, K; Sexton, W; Tachibana, I; Woldu, S, 2023) |
| "In nonmuscle invasive bladder cancer (NMIBC) patients who fail standard intravesical treatment and are unfit or unwilling to undergo a radical cystectomy, radiofrequency (RF)-induced hyperthermia combined with intravesical chemotherapy (RF-CHT) has shown promising results." | 1.91 | Evaluation of thermal dose effect in radiofrequency-induced hyperthermia with intravesical chemotherapy for nonmuscle invasive bladder cancer. ( Brummelhuis, ISG; Crezee, J; Witjes, JA, 2023) |
| "7 mM of alpha-oleate combined with Epirubicin or Mitomycin C." | 1.91 | Long-term prevention of bladder cancer progression by alpha1-oleate alone or in combination with chemotherapy. ( Ambite, I; Babjuk, M; Cavalera, M; Chaudhuri, A; Esmaeili, P; Hien, TT; Sabari, S; Svanborg, C; Wan, MLY, 2023) |
| "For females without known risk factors, bladder cancer can be regarded as a sentinel environmental cancer." | 1.91 | Complete Remission of BCG-Refractory High-grade Bladder CIS with Pharmacologic Ascorbate and Mistletoe. ( Armstrong, J; Davis, D; Kogan, M; Lowe, P; Meng, M; Morash, C; Seely, D, 2023) |
| "During the BCG drug shortage, eligible bladder cancer patients were less likely to receive gold standard intravesical BCG with a large variation in treatment patterns between US states." | 1.91 | Variation in Statewide Intravesical Treatment Rates for Non-Muscle Invasive Bladder Cancer During the Bacillus Calmette-Guerin Drug Shortage. ( Chun, B; Davies, BJ; Gabriel, N; He, M; Hernandez, I; Jacobs, BL; Jones, C; Vasan, R, 2023) |
| "To assess the clinical and oncological outcomes of sequential treatment with Bacillus Calmette-Guerin (BCG) and Mitomycin C (MMC) administered with Electromotive Drug Administration (EMDA) in patients with high-risk NMIBC who fail BCG immunotherapy." | 1.91 | Sequential Treatment With Bacillus Calmette-Güerin (BCG) and Mitomycin C Administered With Electromotive Drug Administration (EMDA) in Patients With High-Risk Nonmuscle Invasive Bladder Cancer After BCG Failure. ( Bravo, A; Breda, A; Gaya, JM; Huguet, J; Palou, J; Robalino, J; Rodríguez Faba, Ó; Sanz Gómez, I; Territo, Á, 2023) |
| "Urinary bladder cancer is a common cancer worldwide." | 1.72 | In vitro assessment of intra-operative and post-operative environment in reducing bladder cancer recurrence. ( Chan, RC; Kong, AW; Ng, CF; Teoh, JY; To, KF; Tse, RT; Wong, CY; Zhao, H, 2022) |
| "In the rat bladder cancer model, IVI of chidamide plus mitomycin C reduced tumor burden (Ki67 index) to a greater extent than either drug alone." | 1.72 | Chidamide and mitomycin C exert synergistic cytotoxic effects against bladder cancer cells in vitro and suppress tumor growth in a rat bladder cancer model. ( Chang, YC; Chen, SL; Sung, WW; Wang, SC; Wu, YC; Yu, CY, 2022) |
| "Mitomycin C was released from the IPN-balloons into the urinary bladder of live pigs in concentrations adequate to inhibit carcinoma cell growth." | 1.72 | A new catheter-integrated drug-delivery system for controlled intravesical mitomycin C release. ( Alm, M; Andersen, TE; Hjelmager, JS; Stærk, K; Thomsen, P, 2022) |
| "Although bladder cancer (BLCA) is the 10th most common tumor worldwide, particularly practical markers and prognostic models that might guide therapy are needed." | 1.72 | In silico development and experimental validation of a novel 7-gene signature based on PI3K pathway-related genes in bladder cancer. ( Bi, J; Wang, L; Wang, Y, 2022) |
| "A group of patients with urothelial bladder cancer, presenting for the first time for definitive treatment, were prospectively enrolled from 2013 to 2017." | 1.72 | Demographics, pathological characteristics and survival in urothelial bladder cancer in a cohort of Sri Lankan patients. ( Abeygunasekara, A; Dissanayake, V; Ediriweera, D; Goonewardena, S; Jayasekara, R; Lokuhetty, D; Malalasekera, AP; Perera, N; Wettasinghe, K, 2022) |
| "To compare the therapeutic effects of locoregional deep hyperthermia combined with intravesical chemotherapy with those of intravesical chemotherapy alone in patients with intermediate-/high-risk non-muscle invasive bladder cancer (NMIBC)." | 1.62 | Loco-regional deep hyperthermia combined with intravesical Mitomycin instillation reduces the recurrence of non-muscle invasive papillary bladder cancer. ( Fan, YC; Lai, BCH; Lee, HL; Lee, LM; Lin, KH; Lin, YW; Shih, HJ; Syu, SH; Wen, YC, 2021) |
| "Patients with large bladder tumors were evaluated for this study." | 1.62 | Treatment of Large Non-Muscle-Invasive Bladder Cancer: The Potential Role of Neoadjuvant Intravesical Chemotherapy. ( Buchholz, N; Di Paola, G; Gazzano, G; Hasan, IM; Hendawi, NA; Inneo, V; Raber, M; Tessa, L; Vercesi, A; Viglio, A, 2021) |
| "Inverted papilloma is a rare entity in the spectrum of urological diseases." | 1.62 | [Intravesical Gemcitabine instillations following BCG failure and allergy to Mitomycin: A unique case of a patient with an inverted papilloma of the bladder]. ( Hupe, MC; Kramer, M; Matzen, M; Merseburger, AS; Offermann, A; Perner, S; Tharun, L, 2021) |
| "Hyperthermic Mitomycin using the HIVEC® device is a rather safe and well tolerated treatment." | 1.56 | [Safety of Hyperthermic IntraVEsical Chemotherapy (HIVEC) for BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients]. ( Branger, N; Dermeche, S; Fakhfakh, S; Gravis, G; Marquette, T; Maubon, T; Pignot, G; Rybikowski, S; Verde, KL; Walz, J, 2020) |
| "Evaluating over 4000 new bladder cancer patients, we found that the QPI programme was associated with low recurrence and accurate staging following the initial transurethral resection of bladder tumour." | 1.56 | Enhanced Quality and Effectiveness of Transurethral Resection of Bladder Tumour in Non-muscle-invasive Bladder Cancer: A Multicentre Real-world Experience from Scotland's Quality Performance Indicators Programme. ( Ahmad, I; Bhatt, J; Clark, E; Hamid, S; Hasan, R; Hendry, D; Hollins, G; Johnston, A; Mariappan, P; Mitchell, IDC; Nandwani, GM; Padovani, L; Simpson, H; Thomas, BG; Trail, M, 2020) |
| "Four patients (15." | 1.56 | Sequential administration of Bacillus Calmette-Guerin (BCG) and Electromotive Drug Administration (EMDA) of mitomycin C (MMC) for the treatment of high-grade nonmuscle invasive bladder cancer after BCG failure. ( Erlich, A; Fleshner, NE; Juvet, T; Krimus, L; Kuk, C; Kulkarni, GS; Lajkosz, K; Mari, A; Wallis, CJ; Zlotta, AR, 2020) |
| "Bovine ocular squamous cell carcinoma (BOSCC) also called cancer eye, represents the most economically important neoplasm in large animals." | 1.56 | Efficacy of BCG vaccine and Mitomycin C for the treatment of ocular squamous cell carcinoma in bovines. ( Devalam, RP; Podarala, V; Prasanna Lakshmi, M; Venkata, SKR, 2020) |
| "In gene expression analysis of bladder cancer patients, the survival of patients with high RAD54L expression was shorter with cancer progression than in patients with low RAD54L expression." | 1.56 | E2F1 Promotes Progression of Bladder Cancer by Modulating RAD54L Involved in Homologous Recombination Repair. ( Baek, SW; Choi, YH; Chu, IS; Chung, JW; Jeong, MS; Kim, SK; Kim, WT; Lee, JH; Leem, SH; Mun, JY; Park, WY; Roh, YG; Yang, GE, 2020) |
| "Topical therapy of nonmuscle-invasive bladder cancer (NMIBC) is based on immunotherapy with Bacillus Calmette-Guerin and chemotherapy administered by passive instillation, but an active drug administration achieves a better concentration of the drugs in the bladder." | 1.51 | Intravesical Treatment with Electro-Mediated Administration of Mytomicin C as Prophylaxis for Intermediate and High-Risk Nonmuscle-Invasive Bladder Cancer: A Retrospective Multicenter Study. ( Carando, R; Cotrufo, S; Ludovico, GM; Zazzara, M, 2019) |
| "Thirty‑six C57BL/6J mice bearing bladder cancer were randomly divided into six treatment groups as follows: control, BCG, MMC, ADM, MMC‑BCG and ADM‑BCG." | 1.51 | Intravesical treatment of chemotherapeutic agents sensitizes bacillus Calmette‑Guerin by the modulation of the tumor immune environment. ( Fujimoto, K; Gotoh, D; Hori, S; Iida, K; Itami, Y; Miyake, M; Morizawa, Y; Nakai, Y; Onishi, K; Onishi, S; Tanaka, N; Tatsumi, Y, 2019) |
| "Ninety mice bearing orthotopic bladder cancer induced by BBN were randomly divided into six groups and treated with chemotherapeutic agents once a week for four weeks." | 1.46 | Topical and systemic immunoreaction triggered by intravesical chemotherapy in an N-butyl-N-(4-hydroxybutyl) nitorosamine induced bladder cancer mouse model. ( Fujimoto, K; Hori, S; Miyake, M; Morizawa, Y; Nakai, Y; Onishi, S; Tanaka, N; Tatsumi, Y, 2017) |
| "The treatment of non muscle-invasive bladder cancer (NMIBC) encompasses a range of different procedures." | 1.46 | Cytological and histological changes in the urothelium produced by electromotive drug administration (EMDA) and by the combination of intravescical hyperthermia and chemotherapy (thermochemotherapy). ( Bassi, PF; De Pascalis, I; Emilio, S; Larocca, LM; Lopez-Beltran, A; Marques, RC; Pierconti, F; Straccia, P; Volavsek, M, 2017) |
| "Appendicovesical fistula is a rare entity, with only 116 cases reported to date." | 1.43 | Appendicovesical Fistula Following Transurethral Resection of Bladder Tumor With Mitomycin C. ( Feng, TS; Fleshner, P; Kaminski, J; Rusnack, S, 2016) |
| "When treated with mitomycin-C (MMC), miR-31-expressing UBC cells displayed lower survival and higher apoptotic rates, and deactivated Akt and ERK." | 1.43 | MicroRNA-31 functions as a tumor suppressor and increases sensitivity to mitomycin-C in urothelial bladder cancer by targeting integrin α5. ( Fan, Y; Liu, Y; Qin, L; Shen, Z; Wang, X; Xia, L; Xu, C; Xu, T; Zhang, X; Zhong, S; Zhu, Z, 2016) |
| "The current intravesical treatment of bladder cancer (BC) is limited to a few chemotherapeutics that show imperfect effectiveness and are associated with some serious complications." | 1.43 | Clostridium perfringens enterotoxin as a potential drug for intravesical treatment of bladder cancer. ( Gabig, TG; Romanov, V; Waltzer, WC; Whyard, T, 2016) |
| "Ellagic acid (EA) is a polyphenolic compound that can be found as a naturally occurring hydrolysis product of ellagitannins in pomegranates, berries, grapes, green tea and nuts." | 1.43 | Ellagic Acid Inhibits Bladder Cancer Invasiveness and In Vivo Tumor Growth. ( Atzori, MG; Bonanno, E; Ceci, C; Cicconi, R; de Martino, MG; Graziani, G; Lacal, PM; Mattei, M; Miano, R; Scimeca, M; Tentori, L; Vespasiani, G, 2016) |
| "Non-muscle invasive bladder cancer is treated with intravesical chemotherapy (IVC) after transurethral resection (TUR) to reduce the probability of recurrence." | 1.42 | High-dose chemotherapeutics of intravesical chemotherapy rapidly induce mitochondrial dysfunction in bladder cancer-derived spheroids. ( Endo, H; Inoue, M; Nakayama, M; Nishimura, K; Nonomura, N; Okuyama, H; Yoshida, T, 2015) |
| "Gemcitabine was administered first and retained for 90 minutes and then drained." | 1.40 | Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non-muscle invasive bladder cancer. ( Breyer, BN; Erickson, BA; Konety, BR; Lightfoot, AJ; O'Donnell, MA; Rosevear, HM, 2014) |
| "We estimate the annual incidence of bladder cancer in Spain and describe the clinical profile of patients with bladder cancer enrolled in a population based study." | 1.40 | Bladder cancer in Spain 2011: population based study. ( Amón Sesmero, JH; Bohorquez Barrientos, A; Castiñeiras Fernández, J; Chantada-Abal, V; Concepción Masip, T; Cózar, JM; de la Rosa-Kehrmann, F; Gómez Rodríguez, A; Gomez-Pascual, JA; Hevia, M; Hidalgo Zabala, E; Lozano, F; Martínez-Ballesteros, C; Medina-Lopez, RA; Miñana, B; Moreno-Sierra, J; Palou, J; Parra Escobar, JL; Pizá Reus, P; Ramos, M; Requena-Tapia, MJ; Ribal, MJ; Rioja Sanz, C; Rodríguez Fernández, E; Serrano, O; Subirá Ríos, J; Unda Urzaiz, M, 2014) |
| "Bladder cancer is associated with high rates of recurrence making tertiary chemoprevention an attractive intervention strategy." | 1.40 | Anthocyans as tertiary chemopreventive agents in bladder cancer: anti-oxidant mechanisms and interaction with mitomycin C. ( Brown, K; Higgins, JA; Jones, GD; Zainol, M, 2014) |
| "Mitomycin C (MMC) has shown potent efficacy against a wide spectrum of cancers and is clinical first choice in superficial bladder tumors." | 1.40 | Cationic core-shell nanoparticles for intravesical chemotherapy in tumor-induced rat model: safety and efficacy. ( Bilensoy, E; Erdogar, N; Eroglu, H; İskit, AB; Mungan, NA; Sargon, MF, 2014) |
| " At the start of treatments, temperature rise measurements were performed with 3 different antenna settings optimized for each patient, from which the absorbed power (specific absorption rate [SAR]) was derived." | 1.40 | Toward online adaptive hyperthermia treatment planning: correlation between measured and simulated specific absorption rate changes caused by phase steering in patients. ( Bardati, F; Bel, A; Ciampa, S; Crezee, J; de Kroon-Oldenhof, R; Geijsen, ED; Kok, HP; Stalpers, LJ; Steggerda-Carvalho, EJ; van Stam, G; Zum Vörde Sive Vörding, PJ, 2014) |
| "Recurrence rates of nonmuscle invasive bladder cancer were obtained from a randomized clinical trial comparing transurethral resection of bladder tumor with or without perioperative mitomycin C." | 1.40 | Commentary on "economic and humanistic consequences of preventable bladder tumor recurrences in nonmuscle invasive bladder cancer cases." Lee CT, Barocas D, Globe DR, Oefelein MG, Colayco DC, Bruno A, O׳Day K, Bramley T, Department of Urology, University ( Hollenbeck, BK, 2014) |
| " The early absorption rate depends on TURBT extension." | 1.39 | Systemic absorption and pharmacokinetics of single-dose early intravesical mitomycin C after transurethral resection of non-muscle-invasive bladder cancer. ( Campodonico, F; Maffezzini, M; Manuputty, EE; Marini, V; Martelli, A; Mattioli, F; Puntoni, M; Tamagno, S, 2013) |
| "Non-muscle invasive bladder cancer is the most common type of bladder cancer in Western countries." | 1.38 | Chondroitin sulphate enhances the antitumor activity of gemcitabine and mitomycin-C in bladder cancer cells with different mechanisms. ( Abbruzzese, A; Altieri, V; Buonerba, C; Caraglia, M; Di Lorenzo, G; Facchini, G; Ferro, M; Giuberti, G; Perdonà, S; Porto, S; Sperlongano, P; Zappavigna, S, 2012) |
| "Ectopic expression of FAVL in bladder cancer cells as well as normal human cells confer an impaired FA pathway and hypersensitivity to Mitomycin C, similar to those found in FA cells, indicating that FAVL elevation may possess the same tumor promotion potential as an impaired FA pathway harbored in FA cells." | 1.38 | FAVL impairment of the Fanconi anemia pathway promotes the development of human bladder cancer. ( Dudimah, FD; Fei, P; Panneerselvam, J; Park, HK; Wang, H; Zhang, J; Zhang, P, 2012) |
| "All of the recurrences in this group had stage Ta grade 1 tumors." | 1.38 | 10-year single-center experience of combined intravesical chemohyperthermia for nonmuscle invasive bladder cancer. ( Halachmi, S; Moskovitz, B; Moskovitz, M; Nativ, O, 2012) |
| "In two cell lines, T24 (bladder cancer cell line) and DC3F (Chinese hamster fibroblast), exposure to different concentrations of mitomycin (0." | 1.38 | Electroporation enhances mitomycin C cytotoxicity on T24 bladder cancer cell line: a potential improvement of intravesical chemotherapy in bladder cancer. ( Gehl, J; Hermann, GG; Vásquez, JL, 2012) |
| "Recurrence rates of nonmuscle invasive bladder cancer were obtained from a randomized clinical trial comparing transurethral resection of bladder tumor with or without perioperative mitomycin C." | 1.38 | Economic and humanistic consequences of preventable bladder tumor recurrences in nonmuscle invasive bladder cancer cases. ( Barocas, D; Bramley, T; Bruno, A; Colayco, DC; Globe, DR; Lee, CT; O'Day, K; Oefelein, MG, 2012) |
| "Mitomycin C and EGCG were studied for their in vitro and in vivo effects." | 1.37 | A comparative study of the inhibiting effects of mitomycin C and polyphenolic catechins on tumor cell implantation/growth in a rat bladder tumor model. ( Keck, RW; Selman, SH, 2011) |
| "The charts of patients with superficial bladder cancer treated with induction or maintenance intravesical therapy (IVT) were reviewed retrospectively." | 1.35 | A multicolour fluorescence in situ hybridization test predicts recurrence in patients with high-risk superficial bladder tumours undergoing intravesical therapy. ( Berry, A; Carroll, P; Konety, B; Whitson, J, 2009) |
| "However, drug eruptions after the second instillation of epirubicin and the first instillation of mitomycin C might have been due to allergic reactions to the drugs." | 1.35 | Drug eruption due to intravesical instillations of both epirubicin and mitomycin C. ( Fuse, H; Imamura, T; Kaji, K; Oishi, N; Okumura, A, 2009) |
| "RT112 bladder cancer cells (Catalog No." | 1.35 | Multidrug resistance in a urothelial cancer cell line after 1-hour mitomycin C exposure. ( Birare, N; Cooper, AJ; Lwaleed, BA, 2009) |
| "Mitomycin C treatment after 1 h and 7 d prolonged survival to more than 300 d in 40% and 50%, respectively; however, treatment turned out to be nephrotoxic." | 1.35 | Intravesical alpha-radioimmunotherapy with 213Bi-anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude mice. ( Autenrieth, M; Bruchertseifer, F; Morgenstern, A; Pfost, B; Saur, D; Schwaiger, M; Seidl, C; Senekowitsch-Schmidtke, R, 2009) |
| "Mitomycin C (MMC) is a widely used agent for the adjuvant treatment of bladder tumors." | 1.35 | Perivesical inflammation and necrosis due to mitomycin C instillation after transurethral resection of bladder tumor: we must be vigilant! ( Cek, M; Fazlioglu, A; Kurtulus, FO; Parlakkilic, O; Tandogdu, Z, 2009) |
| "The XIAP gene was transfected into bladder cancer cell line T24 by liposome and the positive clone was screened by G418." | 1.34 | Expression of X-linked inhibitor of apoptosis protein and its effect on chemotherapeutic sensitivity of bladder carcinoma. ( Bi, Y; Tong, Q; Wang, L; Zeng, F; Zheng, L, 2007) |
| "T739 mice were randomly divided into 8 groups after subcutaneous inoculation of bladder carcinoma cells, the control group (A); two mitomycin C (MMC) group, treated with MMC of routine dosage (B) and low-dosage (C) respectively; three SJZD groups, treated with SJZD of high (D), medium (E) and low-dosage (F) respectively; and two combined treatment groups, treated with SJZD of high-dosage + MMC of routine dosage(G) and SJZD of high-dosage + MMC of low-dosage(H)." | 1.33 | [Toxicity attenuation and efficacy potentiation effects of sijunzi decoction on bladder carcinoma treated by chemotherapy in mice]. ( Li, CG; Li, ML; Shu, XH, 2005) |
| "To study the therapeutic effect and synergistic inhibition effect of high intensity focused ultrasound in combination with mitomycin on T739 mice bladder tumor." | 1.32 | [An experimental study on high intensity focused ultrasound combined with mitomycin treatment of bladder tumor]. ( Sun, LA; Wang, GM; Xu, YQ; Xu, ZB; Yang, YF, 2003) |
| "In patients with superficial bladder cancer, the occurrence of primary carcinoma in situ was significantly greater in patients with the AA genotype compared with those with the GA or GG genotypes (P = 0." | 1.32 | Polymorphism within the cyclin D1 gene is associated with an increased risk of carcinoma in situ in patients with superficial bladder cancer. ( Habuchi, T; Higashi, S; Ito, M; Kamoto, T; Nishiyama, H; Ogawa, O; Tsuchiya, N; Wang, L; Watanabe, J, 2004) |
| "The RT112, RT4, 253J and T24 human bladder cancer cell lines were seeded in 96-well microtiter plates at 2." | 1.32 | The effect of hyperthermia on mitomycin-C induced cytotoxicity in four human bladder cancer cell lines. ( Jansen, CF; O'donnell, MA; Schalken, JA; van der Heijden, AG; Verhaegh, G; Witjes, JA, 2004) |
| " In this study, an alternative approach was proposed and pharmaco-therapeutic agent delivery systems which will supply the suitable dosage of the agent for a certain time period were designed to solve those problems." | 1.32 | Bioadhesive drug carriers for postoperative chemotherapy in bladder cancer. ( Denkbaş, EB; Eroğlu, M; Ozdemir, N; Oztürk, E, 2004) |
| "In phase II trials in superficial bladder cancer, marker lesions have been used to test the ablative activity of intravesical chemo- or immunotherapy." | 1.31 | Frequency of positive biopsies after visual disappearance of superficial bladder cancer marker lesions. ( Bono, AV; Brausi, M; de Balincourt, C; Hall, R; Mack, D; Oosterlinck, W; Sylvester, R, 2001) |
| " An alternative approach can be proposed as to design a pharmacotherapeutic agent delivery system, which will supply the suitable dosage of the agent for a certain time period to solve those problems." | 1.31 | Design and evaluation of a mucoadhesive therapeutic agent delivery system for postoperative chemotherapy in superficial bladder cancer. ( Acar, A; Denkbaş, EB; Eroğlu, M; Irmak, S, 2002) |
| "Nine patients with locally invasive bladder cancer received 1 to 4 courses of neoadjuvant intra-arterial chemotherapy, followed by radical cystectomy." | 1.30 | [Neoadjuvant intra-arterial chemotherapy based on chemosensitivity tests for locally invasive bladder cancer]. ( Aikawa, K; Ishibashi, K; Koseki, K; Ogihara, M; Shiraiwa, Y; Yamaguchi, O, 1997) |
| "We reviewed our series of stage Ta bladder cancer patients with a long-term follow-up in order to clarify the prognosis of these patients, especially those who have repeated recurrences." | 1.30 | [The results of a long-term follow-up for patients with stage Ta bladder cancer, especially regarding those with multiple recurrences]. ( Fujioka, T; Mori, Y; Nagakubo, I; Tsukamoto, T; Yamauchi, T, 1998) |
| "Human solid tumor histocultures represent a clinically relevant experimental system for pharmacodynamic study." | 1.30 | Regional heterogeneity and pharmacodynamics in human solid tumor histoculture. ( Au, JL; Weaver, JR; Wientjes, MG, 1999) |
| "Mitomycin C was administered initially and mitoxantrone was administered following the same schedule if disease recurred during followup." | 1.29 | Up-front intravesical chemotherapy for low stage, low grade recurrent bladder cancer. ( Carmignani, G; Maffezzini, M; Raber, M; Simonato, A; Zanon, M, 1996) |
| "7% tumor growth inhibition, and these conditions for hyperthermia were subsequently used as a criterion for evaluating the effects of its combination with various anticancer agents." | 1.29 | Studies of effects of anticancer agents in combination with/without hyperthermia on metastasized human bladder cancer cells in chick embryos using the polymerase chain reaction technique. ( Endo, Y; Kunimi, K; Lee, SW; Noguchi, M; Ohkawa, M; Sasaki, T; Uchibayashi, T, 1994) |
| "A human bladder cancer cell line resistant to adriamycin (ADM), T24/ADM9 has been established in vitro by exposing T24 parent cells to progressively higher concentrations of the drug over a period of 12 months." | 1.29 | Non-P-glycoprotein-mediated atypical multidrug resistance in a human bladder cancer cell line. ( Hasegawa, S; Koga, H; Kotoh, S; Kumazawa, J; Kuwano, M; Naito, S; Yokomizo, A, 1995) |
| " The dosing solution (40 mg/20 ml) was instilled just prior to the start of surgery and maintained for 60-115 min until just prior to bladder excision." | 1.29 | Penetration of intravesical doxorubicin in human bladders. ( Au, JL; Badalament, RA; Wientjes, MG, 1996) |
| "Trans-urethral resection of the bladder cancer was performed in 8 patients, supported in two cases by immunotherapy with B." | 1.29 | [pT1G3 bladder carcinoma: our experience]. ( Bernardini, P; D'Addezio, F; Del Nero, A; Dell'Orto, P; Mangiarotti, B; Pisani, E; Trinchieri, A, 1996) |
| "Twenty of 22 cases, including 11 of 13 bladder cancer cases, 1 of 3 renal cancer cases, 2 of 3 testicular cancer cases and 1 of 1 adrenal cortical cancer cases, were evaluable in the clinical study of the CGM assay." | 1.29 | [Efficacy of the chemosensitivity test using collagen gel matrix-supported culture system for urogenital tumors]. ( Aikawa, K; Irisawa, C; Ishibashi, K; Ishiwata, H; Koseki, K; Ogihara, M; Shiraiwa, Y, 1996) |
| "mitomycin C after pretreatment with interferon alpha showed a dramatic decrease in cell proliferation (from 98." | 1.29 | Interferons modify in vitro proliferation of human bladder transitional cell carcinoma in the presence of doxorubicin and mitomycin C. ( Kinne, RK; Okamoto, E; Sökeland, J, 1996) |
| " The goal of the present study was to determine if the efficacy of intravesical MMC therapy in patients treated for superficial bladder cancer can be enhanced by using acidified dosing solutions." | 1.29 | Different pH dependency of mitomycin C activity in monolayer and three-dimensional cultures. ( Au, JL; Schmittgen, T; Yen, WC, 1996) |
| "Eosinophilic cystitis is an unusual form of cystitis which is characterized by irritative voiding symptoms and haematuria." | 1.29 | Eosinophilic cystitis induced by mitomycin-C. ( Apaydin, E; Gürsan, A; Kandiloğlu, G; Ozyurt, C; Ulker, V, 1996) |
| " The success of treatment seems out of question on dosage but with the continuation of the instillation program." | 1.28 | Endovesical instillation of mitomycin-C in preventing recurrence of superficial bladder carcinoma. ( Wu, JJ; Yin, ZL; Zhu, JN, 1992) |
| " PDT combined with either adriamycin, MMC or BCG, produced a greater retardation in the growth of the MBT-2 tumor than monotherapy with adriamycin, MMC, BCG or PDT." | 1.28 | Effects of photodynamic therapy in combination with intravesical drugs in a murine bladder tumor model. ( Cho, YH; Smith, JA; Straight, RC, 1992) |
| " Combination with mitomycin C or interferon-alpha-2b potentiated the cytostatic effect." | 1.28 | Cytostatic effect of different strains of Bacillus Calmette-Guérin on human bladder cancer cells in vitro alone and in combination with mitomycin C and interferon-alpha. ( Alfthan, O; Jauhiainen, K; Kaasinen, E; Lähde, M; Nurmi, M; Rajala, P; Rintala, E, 1992) |
| "Superficial bladder cancer has a good prognosis compared with invasive bladder cancer." | 1.28 | [Superficial bladder cancer: prophylaxis of recurrence and progression]. ( Akaza, H; Koiso, K; Miyanaga, N, 1991) |
| " To determine the minimum concentration and exposure time necessary to reduce tumor LI by 90%, the data for 6 tumors were computer fitted to the pharmacodynamic relationship Cn x T = k." | 1.28 | Pharmacodynamics of mitomycin C in cultured human bladder tumors. ( Au, JL; Badalament, RA; Schmittgen, TD; Wientjes, MG, 1991) |
| "One hundred three patients with bladder cancer underwent balloon-occluded arterial infusion." | 1.28 | [Balloon-occluded arterial infusion as chemotherapy in bladder cancer--long-term results]. ( Kawabata, M; Mitsuzane, K; Nomura, S; Sato, M; Terada, M; Yamada, R, 1990) |
| " The results of long-term treatment (2 years) suggest that reduced bladder capacity correlates with the cumulative dosage of mitomycin C." | 1.28 | Reduced bladder capacity in patients receiving intravesical chemoprophylaxis with mitomycin C. ( Brütsch, HP; Eijsten, A; Hauri, D; Hotz, E; Knönagel, H, 1990) |
| "Mitomycin C is an alkylating agent, used by intravesical instillation to treat carcinoma of the bladder." | 1.28 | Dermatitis due to intravesical mitomycin C: a delayed-type hypersensitivity reaction? ( Colver, GB; Hunter, JA; Inglis, JA; McVittie, E; Spencer, MJ; Tolley, DA, 1990) |
| "Treatment with mitomycin C of target cells did not change their NK sensitivity." | 1.28 | Enhancement by X-ray irradiation of target cell susceptibility to natural killer cells. ( Fujimoto, T; Ikenaga, M; Mizutani, Y; Uchida, A; Yoshida, O, 1989) |
| " The retinoids given in combination with MMC produced additive effects." | 1.27 | [Inhibitory effects of aromatic retinoic acid analog, administered alone or in combination with mitomycin C, on the in vitro growth of rat bladder carcinoma cells]. ( Fujita, J; Yoshida, O, 1984) |
| "Moreover, malignant bladder tumors in rabbits were successfully treated with this method." | 1.27 | Intravesical chemotherapy of urinary bladder tumor in rabbit by ferromagnetic mitomycin C. ( Abe, R; Kato, T; Mori, H; Nemoto, R; Shindo, M, 1983) |
| "Mitomycin C has proved to be useful as prophylaxis against superficial bladder tumor recurrences." | 1.27 | Prostatic recurrences in the management of superficial bladder tumors. ( Bondhus, MJ; Chaikin, L; Lockhart, JL; Politano, VA, 1983) |
| "Most superficial bladder tumors are best treated by transurethral resection." | 1.27 | Severely contracted bladder following intravesical mitomycin C therapy. ( Englander, L; Huben, RP; McGill, W; Pontes, JE; Wajsman, Z, 1983) |
| "Mitomycin C was administered in one course of 10 daily doses of 40 mg, starting 24 to 48 hours after TUR." | 1.27 | Intravesical instillation of mitomycin C in the prophylactic treatment of recurring superficial transitional cell carcinoma of the bladder. ( Bendimerad, O; Bouvier, R; Devonec, M; Dubernard, JM; Gelet, A; Sarkissian, J, 1983) |
| "Mitomycin C of 1 mg/kg was administered via a catheter placed into the regional artery." | 1.27 | [Combination of intra-arterial administration of anticancer agent and hemocarboperfusion in treatment of advanced cancer]. ( Agishi, T; Hata, H; Ishigami, J; Kamidono, S; Nagata, T; Ota, K; Shibayama, K; Shida, K; Yamagata, J; Yamanaka, E, 1983) |
| "Although experimental induction of bladder cancer with powerful carcinogens may completely overwhelm host defenses and result in more and higher grade neoplasms, similar tumors may occur after exposure to substances not generally considered to be carcinogenic." | 1.27 | Bladder cancer induced by noncarcinogenic substances. ( Akaza, H; Murphy, WM; Soloway, MS, 1984) |
| " The difference between the effect of MMC alone and that of MMC given in combination with Ro 10-9359 was not statistically significant." | 1.27 | Therapeutic effect of a retinoid (Ro 10-9359) on rats with bladder tumours induced by N-butyl-N-(4-hydroxybutyl)-nitrosamine upon administration alone or in combination with mitomycin C. ( Fujita, J; Ito, Y; Tokuda, H; Yoshida, O, 1983) |
| "The rate of recurring bladder tumors decreased after instillation therapy." | 1.27 | [Experimental and clinical studies on intravesical instillation therapy for bladder cancer]. ( Imai, K; Kaburagi, Y; Miki, M; Yamanaka, H, 1983) |
| "The anti-tumor effect of twice a week instillation of 30 mg mitomycin C combined with 200 mg cytosine arabinoside dissolved in 30 ml saline was studied in 37 bladder tumor patients." | 1.27 | [Anti-tumor effect of intravesical instillation of mitomycin C combined with cytosine arabinoside]. ( Fujioka, H; Matsuda, M; Matsumiya, K; Nakano, E; Osafune, M; Sonoda, T; Tada, Y; Takaha, M, 1984) |
| " Both preparations provided a sustained-release property and a sensitive response to conventional magnetic force, although certain differences in the release rate of drug, magnetic responsiveness, and particle size were found between the two dosage forms." | 1.27 | Magnetic microcapsules for targeted delivery of anticancer drugs. ( Abe, R; Goto, A; Harada, M; Homma, M; Kato, T; Mori, H; Murota, H; Nemoto, R; Unno, K, 1984) |
| "The effects of interferon alone and in combination with either adriamycin, mitomycin C or thiotepa were evaluated for antiproliferative activity for the mouse bladder tumor, MBT-2." | 1.27 | Effects of interferon in combination with cytotoxic drugs on mouse bladder tumor (MBT-2) growth in vitro and in vivo. ( Bahnson, R; Ratliff, TL, 1988) |
| "Mitomycin C was associated with hyaluronidase, 200." | 1.27 | Mitomycin C plasma levels after intravesical instillation with and without hyaluronidase. ( Baumgartner, G; Maier, U, 1986) |
| "Urine from patients with bladder cancer before treatment had osmolalities in the range 187 to 852 mOsm." | 1.27 | Intravesical chemotherapy: studies on the relationship between osmolality and cytotoxicity. ( Groos, E; Masters, JR, 1986) |
| "We report a case of invasive squamous cell carcinoma of the urinary bladder, which was perforated intraperitoneally after intra-arterial chemotherapy." | 1.27 | [A case of invasive squamous carcinoma of the urinary bladder perforated intraperitoneally after intra-arterial chemotherapy]. ( Sakurai, T; Sugao, H; Takatera, H; Takiuchi, H; Yokokawa, K, 1987) |
| "Patients with multiple bladder tumors, bladder tumors inaccessible to endoscopic resection, or lesions too extensive to completely resect, or with medial contraindications for endoscopic resection procedures, were included in these studies." | 1.27 | Combined thiotepa and mitomycin C instillation therapy for low-grade superficial bladder tumor. ( Gonder, M; Hu, KN; Khan, AS; Kim, A; Soroff, H, 1985) |
| "Neither doxorubicin (ADM) nor mitomycin C (MMC) were well absorbed through the intact or damaged rabbit bladder wall into the blood stream." | 1.27 | The absorption of doxorubicin and mitomycin C in perioperative instillation. An experimental and clinical study. ( Alfthan, O; Eksborg, S; Jauhiainen, K; Kangas, L; Perilä, M, 1985) |
| "An aromatic retinoic acid analog (Ro 10-9359) was given orally in combination with intraperitoneal administration of mitomycin C (MMC), in an attempt to reduce the toxicity and enhance the therapeutic effect." | 1.26 | Therapeutic effect of an aromatic retinoic acid analog on rats with bladder carcinoma upon administration alone or in combination with mitomycin C. ( Fujita, J; Miyakawa, M; Tokuda, H; Yoshida, O, 1982) |
| "The effect of CDDP was studied on rat bladder tumors induced by N-butyl-N-(4-hydroxybutyl)-nitrosamine (BBN)." | 1.26 | [Effect of cis-diamminedichloroplatinum (II) (CDDP) on bladder cancer on rats induced by N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN)]. ( Miyakawa, M; Yoshida, O, 1982) |
| "Chemotherapy of advanced bladder cancer aims to destroy all the cancer cells in the host." | 1.26 | [Bladder cancer: chemotherapy of advanced bladder cancer]. ( Koiso, K, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 204 (22.10) | 18.7374 |
| 1990's | 183 (19.83) | 18.2507 |
| 2000's | 179 (19.39) | 29.6817 |
| 2010's | 236 (25.57) | 24.3611 |
| 2020's | 121 (13.11) | 2.80 |
| Authors | Studies |
|---|---|
| Gordon, NS | 1 |
| Baxter, LA | 1 |
| Goel, A | 3 |
| Arnold, R | 1 |
| Kaur, B | 1 |
| Liu, W | 2 |
| Pirrie, SJ | 1 |
| Hussain, S | 1 |
| Viney, R | 1 |
| Ford, D | 1 |
| Zarkar, A | 2 |
| Wood, MA | 1 |
| Mitin, T | 1 |
| Thompson, RF | 1 |
| James, ND | 5 |
| Ward, DG | 1 |
| Bryan, RT | 3 |
| Gupta, S | 1 |
| Dutta, A | 1 |
| Pal, DK | 1 |
| Lewicki, P | 1 |
| Arenas-Gallo, C | 1 |
| Qiu, Y | 1 |
| Venkat, S | 1 |
| Basourakos, SP | 1 |
| Scherr, D | 3 |
| Shoag, JE | 1 |
| Carrión, DM | 1 |
| Gómez Rivas, J | 1 |
| Aguilera Bazán, A | 1 |
| Ballesteros Ruiz, C | 1 |
| Álvarez-Maestro, M | 1 |
| Ríos González, E | 1 |
| Martínez-Piñeiro, L | 3 |
| Unsworth-White, SR | 1 |
| Kitchen, MO | 1 |
| Wen, YC | 1 |
| Lee, LM | 1 |
| Lin, YW | 1 |
| Syu, SH | 1 |
| Lin, KH | 1 |
| Fan, YC | 1 |
| Lee, HL | 1 |
| Lai, BCH | 1 |
| Shih, HJ | 1 |
| Matin, SF | 8 |
| Pierorazio, PM | 1 |
| Kleinmann, N | 1 |
| Gore, JL | 1 |
| Shabsigh, A | 1 |
| Hu, B | 5 |
| Chamie, K | 4 |
| Godoy, G | 1 |
| Hubosky, SG | 1 |
| Rivera, M | 1 |
| O'Donnell, M | 6 |
| Quek, M | 3 |
| Raman, JD | 4 |
| Knoedler, JJ | 2 |
| Weight, C | 1 |
| Weizer, A | 1 |
| Woods, M | 1 |
| Kaimakliotis, H | 6 |
| Smith, AB | 4 |
| Linehan, J | 8 |
| Coleman, J | 1 |
| Humphreys, MR | 4 |
| Pak, R | 1 |
| Lifshitz, D | 2 |
| Verni, M | 2 |
| Klein, I | 1 |
| Konorty, M | 1 |
| Strauss-Ayali, D | 2 |
| Hakim, G | 1 |
| Seltzer, E | 2 |
| Schoenberg, M | 3 |
| Lerner, SP | 3 |
| Zazzara, M | 2 |
| Nazaraj, A | 1 |
| Scarcia, M | 1 |
| Cardo, G | 1 |
| Carando, R | 2 |
| Ludovico, GM | 2 |
| Tse, RT | 1 |
| Zhao, H | 1 |
| Wong, CY | 1 |
| Kong, AW | 1 |
| Chan, RC | 1 |
| To, KF | 1 |
| Ng, CF | 2 |
| Teoh, JY | 4 |
| Wang, SC | 2 |
| Yu, CY | 1 |
| Wu, YC | 1 |
| Chang, YC | 1 |
| Chen, SL | 2 |
| Sung, WW | 2 |
| Guerrero-Ramos, F | 4 |
| González-Padilla, DA | 3 |
| González-Díaz, A | 3 |
| de la Rosa-Kehrmann, F | 3 |
| Rodríguez-Antolín, A | 3 |
| Inman, BA | 7 |
| Villacampa-Aubá, F | 3 |
| Balasubramanian, A | 1 |
| Gunjur, A | 1 |
| Weickhardt, A | 1 |
| Papa, N | 1 |
| Bolton, D | 1 |
| Lawrentschuk, N | 1 |
| Perera, M | 1 |
| Bani-Hani, M | 1 |
| Abdel Majid, A | 1 |
| Al-Zubi, MT | 1 |
| Al Demour, S | 1 |
| Al Zoubi, MS | 1 |
| Abuhamad, M | 1 |
| Santarisi, A | 1 |
| Taysir Eldos, B | 1 |
| Alsmadi, J | 1 |
| Elayan, B | 1 |
| Babjuk, M | 4 |
| Rosen, GH | 1 |
| Nallani, A | 1 |
| Muzzey, C | 1 |
| Murray, KS | 6 |
| Rollin, P | 1 |
| Xylinas, E | 5 |
| Lanz, C | 1 |
| Audenet, F | 2 |
| Brunelle, S | 1 |
| Compérat, E | 3 |
| Houédé, N | 2 |
| Larré, S | 4 |
| Masson-Lecomte, A | 3 |
| Pignot, G | 4 |
| Roumiguié, M | 3 |
| Méjean, A | 2 |
| Rouprêt, M | 10 |
| Neuzillet, Y | 5 |
| Leon, P | 2 |
| Saint, F | 2 |
| Allory, Y | 1 |
| Loriot, Y | 1 |
| Pradère, B | 4 |
| Seisen, T | 2 |
| Traxer, O | 2 |
| Gakis, G | 1 |
| Song, Y | 1 |
| Du, Y | 1 |
| Qin, C | 3 |
| Xu, T | 2 |
| Subiela, JD | 1 |
| Hernández-Arroyo, M | 1 |
| García-Rojo, E | 2 |
| Aumatell, J | 1 |
| Burgos Revilla, J | 1 |
| Hall, E | 7 |
| Hussain, SA | 7 |
| Porta, N | 4 |
| Lewis, R | 6 |
| Crundwell, M | 3 |
| Jenkins, P | 3 |
| Rawlings, C | 3 |
| Tremlett, J | 3 |
| Sreenivasan, T | 2 |
| Wallace, J | 1 |
| Syndikus, I | 3 |
| Sheehan, D | 2 |
| Lydon, A | 1 |
| Huddart, R | 4 |
| James, N | 3 |
| You, S | 1 |
| Kim, M | 1 |
| Widen, S | 1 |
| Yu, A | 2 |
| Galvan, GC | 1 |
| Choi-Kuaea, Y | 1 |
| Eyzaguirre, EJ | 1 |
| Dyrskjøt, L | 3 |
| McConkey, DJ | 1 |
| Choi, W | 1 |
| Theodorescu, D | 1 |
| Chan, KS | 1 |
| Shan, Y | 1 |
| Tyler, DS | 1 |
| De Hoedt, AM | 1 |
| Freedland, SJ | 1 |
| Williams, SB | 1 |
| Stover, AM | 1 |
| Basak, R | 1 |
| Mueller, D | 1 |
| Lipman, R | 1 |
| Teal, R | 1 |
| Hilton, A | 1 |
| Giannone, K | 1 |
| Waheed, M | 1 |
| Senel, C | 1 |
| Asfuroglu, A | 1 |
| Aykanat, IC | 1 |
| Balci, M | 1 |
| Aslan, Y | 1 |
| Tuncel, A | 1 |
| Stærk, K | 1 |
| Hjelmager, JS | 1 |
| Alm, M | 1 |
| Thomsen, P | 1 |
| Andersen, TE | 1 |
| Kim, SH | 2 |
| Wang, L | 4 |
| Wang, Y | 3 |
| Bi, J | 1 |
| de Ruiter, BM | 1 |
| van Hattum, JW | 1 |
| Lipman, D | 1 |
| de Reijke, TM | 4 |
| van Moorselaar, RJA | 4 |
| van Gennep, EJ | 1 |
| Maartje Piet, AH | 1 |
| Donker, M | 1 |
| van der Hulle, T | 1 |
| Voortman, J | 1 |
| Oddens, JR | 3 |
| Hulshof, MCCM | 2 |
| Bins, AD | 1 |
| Tan, WS | 7 |
| Prendergast, A | 1 |
| Ackerman, C | 1 |
| Yogeswaran, Y | 1 |
| Cresswell, J | 4 |
| Mariappan, P | 2 |
| Phull, J | 1 |
| Hunter-Campbell, P | 1 |
| Lazarowicz, H | 1 |
| Mishra, V | 1 |
| Rane, A | 1 |
| Davies, M | 1 |
| Warburton, H | 1 |
| Cooke, P | 2 |
| Mostafid, H | 7 |
| Wilby, D | 1 |
| Mills, R | 1 |
| Issa, R | 4 |
| Kelly, JD | 10 |
| Daryanto, B | 1 |
| Purnomo, AF | 1 |
| Seputra, KP | 1 |
| Budaya, TN | 1 |
| Lindgren, MS | 4 |
| Hansen, E | 1 |
| Azawi, N | 2 |
| Nielsen, AM | 1 |
| Jensen, JB | 4 |
| Lee, HW | 1 |
| Lee, HH | 1 |
| Park, EY | 1 |
| Park, WS | 3 |
| Joung, JY | 3 |
| Chung, J | 3 |
| Seo, HK | 3 |
| Zhou, W | 1 |
| Liu, J | 3 |
| Mao, D | 1 |
| Hu, C | 1 |
| Gao, D | 1 |
| Hegmann, L | 1 |
| Sturm, S | 1 |
| Niegisch, G | 1 |
| Windolf, J | 1 |
| Suschek, CV | 1 |
| Rose, KM | 3 |
| Narang, G | 1 |
| Rosen, G | 1 |
| Labatte, C | 1 |
| Dumitrascu, CI | 1 |
| Campagna, J | 1 |
| Manley, BJ | 1 |
| Spiess, PE | 1 |
| Li, R | 2 |
| Adibi, M | 1 |
| Sexton, WJ | 3 |
| Melgarejo-Segura, MT | 1 |
| Morales-Martínez, A | 1 |
| Yáñez-Castillo, Y | 1 |
| Arrabal-Polo, MÁ | 1 |
| Gómez-Lechuga, P | 1 |
| Pareja-Vílchez, M | 1 |
| Jiménez-Moleón, JJ | 1 |
| Martín, MA | 1 |
| Campodonico, F | 3 |
| Mattioli, F | 2 |
| Introini, C | 1 |
| Melgarejo Segura, MT | 4 |
| Morales Martínez, A | 4 |
| Yáñez Castillo, Y | 4 |
| Arrabal Polo, MÁ | 4 |
| Gómez Lechuga, P | 3 |
| Pareja Vílchez, M | 4 |
| Arrabal Martín, M | 4 |
| Sahoo, S | 3 |
| Pandey, A | 3 |
| Mandal, S | 3 |
| Kumar Das, M | 3 |
| Nayak, P | 3 |
| Woldu, SL | 3 |
| Labbate, C | 6 |
| Rose, K | 5 |
| Sexton, W | 5 |
| Tachibana, I | 5 |
| Jacob, J | 6 |
| Dickstein, R | 6 |
| Nieder, A | 5 |
| Bjurlin, MA | 3 |
| Humphreys, M | 5 |
| Ghodoussipour, S | 5 |
| Quek, ML | 3 |
| Eisner, BH | 4 |
| Feldman, AS | 4 |
| Lotan, Y | 11 |
| Angulo, JC | 3 |
| Álvarez-Ossorio, JL | 3 |
| Domínguez-Escrig, JL | 4 |
| Moyano, JL | 3 |
| Sousa, A | 4 |
| Fernández, JM | 4 |
| Gómez-Veiga, F | 3 |
| Unda, M | 4 |
| Carballido, J | 4 |
| Carrero, V | 3 |
| Fernandez-Aparicio, T | 3 |
| García de Jalón, Á | 3 |
| Solsona, E | 11 |
| Inman, B | 3 |
| Palou, J | 11 |
| Mustard, C | 3 |
| Ott, OJ | 2 |
| Gaipl, US | 2 |
| Lamrani, A | 2 |
| Fietkau, R | 2 |
| Yanagisawa, T | 2 |
| Quhal, F | 2 |
| Kawada, T | 2 |
| Mostafaei, H | 2 |
| Motlagh, RS | 2 |
| Laukhtina, E | 3 |
| Rajwa, P | 2 |
| Deimling, MV | 2 |
| Bianchi, A | 2 |
| Pallauf, M | 2 |
| Majdoub, M | 2 |
| Moschini, M | 5 |
| Karakiewicz, PI | 5 |
| Miki, J | 2 |
| Kimura, T | 2 |
| Shariat, SF | 8 |
| Muilwijk, T | 1 |
| Akand, M | 1 |
| Raskin, Y | 1 |
| Jorissen, C | 1 |
| Vander Eeckt, K | 1 |
| Van Bruwaene, S | 1 |
| Van Cleynenbreugel, B | 2 |
| Joniau, S | 1 |
| Van Der Aa, F | 1 |
| Cheng, W | 1 |
| Zhou, Y | 1 |
| Chu, X | 1 |
| Huang, S | 1 |
| Zheng, X | 1 |
| Zheng, H | 1 |
| Chen, CC | 2 |
| Fa, YC | 1 |
| Kuo, YY | 1 |
| Liu, YC | 1 |
| Lin, CY | 1 |
| Wang, XH | 1 |
| Lu, YH | 1 |
| Chiang, YH | 1 |
| Yang, CM | 1 |
| Wu, LC | 1 |
| Ho, JA | 1 |
| Woldu, S | 4 |
| Murray, K | 2 |
| Bjurlin, M | 3 |
| Eisner, B | 1 |
| Feldman, A | 2 |
| Paolo, G | 1 |
| Francesco, S | 1 |
| Chen, W | 2 |
| Tan, M | 1 |
| Yu, C | 1 |
| Liao, G | 1 |
| Kong, D | 1 |
| Bai, J | 1 |
| Yang, B | 1 |
| Gong, H | 1 |
| Basile, G | 1 |
| Brummelhuis, ISG | 1 |
| Crezee, J | 4 |
| Witjes, JA | 22 |
| van Wijngaarden, C | 1 |
| Bus, MTJ | 1 |
| Ruiter, AEC | 1 |
| Lagerveld, BW | 1 |
| Hien, TT | 1 |
| Ambite, I | 1 |
| Wan, MLY | 1 |
| Cavalera, M | 1 |
| Esmaeili, P | 1 |
| Chaudhuri, A | 1 |
| Sabari, S | 1 |
| Svanborg, C | 1 |
| Peng, CK | 1 |
| Davis, D | 1 |
| Seely, D | 1 |
| Morash, C | 1 |
| Armstrong, J | 1 |
| Meng, M | 1 |
| Lowe, P | 1 |
| Kogan, M | 1 |
| Cerrato, C | 1 |
| Mir, MC | 1 |
| Salonia, A | 7 |
| Briganti, A | 4 |
| Montorsi, F | 6 |
| Busetto, GM | 1 |
| Finati, M | 1 |
| Chirico, M | 1 |
| Cinelli, F | 1 |
| D'Altilia, N | 1 |
| Falagario, UG | 1 |
| Sanguedolce, F | 1 |
| Del Giudice, F | 2 |
| De Berardinis, E | 2 |
| Ferro, M | 2 |
| Crocetto, F | 1 |
| Porreca, A | 2 |
| Di Gianfrancesco, L | 4 |
| Calo', B | 1 |
| Mancini, V | 1 |
| Bettocchi, C | 1 |
| Carrieri, G | 1 |
| Cormio, L | 2 |
| Chun, B | 1 |
| He, M | 1 |
| Jones, C | 1 |
| Vasan, R | 1 |
| Gabriel, N | 1 |
| Jacobs, BL | 1 |
| Hernandez, I | 1 |
| Davies, BJ | 1 |
| Soria, F | 2 |
| Delacruz, JE | 1 |
| Aznar-Cervantes, SD | 1 |
| Aranda, J | 1 |
| Martínez-Pla, L | 1 |
| Cepeda, M | 1 |
| Pérez-Lanzac, A | 1 |
| Bueno, G | 1 |
| Sánchez-Margallo, FM | 1 |
| Sanz Gómez, I | 1 |
| Huguet, J | 2 |
| Bravo, A | 1 |
| Robalino, J | 1 |
| Rodríguez Faba, Ó | 1 |
| Territo, Á | 1 |
| Gaya, JM | 1 |
| Breda, A | 2 |
| Halstuch, D | 1 |
| Lotan, P | 1 |
| Karchever, I | 1 |
| Rubinshtein, D | 1 |
| Kedar, D | 3 |
| Baniel, J | 3 |
| Golan, S | 1 |
| Seiler, R | 1 |
| Egger, M | 1 |
| De Menna, M | 1 |
| Wehrli, S | 1 |
| Minoli, M | 1 |
| Radić, M | 1 |
| Lyatoshinsky, P | 1 |
| Hösli, R | 1 |
| Blarer, J | 1 |
| Abt, D | 1 |
| Kruithof-de Julio, M | 1 |
| Song, S | 2 |
| Smith, A | 1 |
| Asero, V | 1 |
| Scornajenghi, CM | 1 |
| Krajewski, W | 1 |
| Szydełko, T | 1 |
| Malkiewicz, B | 1 |
| Nowak, Ł | 1 |
| Gallioli, A | 1 |
| Basran, S | 1 |
| Chung, BI | 1 |
| Hafeez, S | 1 |
| Omar, A | 1 |
| Alonzi, R | 1 |
| Birtle, A | 2 |
| Cheung, KC | 1 |
| Choudhury, A | 2 |
| Foroudi, F | 1 |
| Gribble, H | 1 |
| Henry, A | 1 |
| Hilman, S | 1 |
| Hindson, B | 1 |
| Muthukumar, D | 1 |
| McLaren, DB | 1 |
| McNair, H | 1 |
| Nikapota, A | 1 |
| Olorunfemi, A | 1 |
| Parikh, O | 1 |
| Philipps, L | 1 |
| Rimmer, Y | 1 |
| Tolentino, A | 1 |
| Varughese, M | 1 |
| Vassallo-Bonner, C | 1 |
| Webster, A | 1 |
| Griffin, C | 1 |
| Kaimakliotis, HZ | 2 |
| Akbulut, F | 1 |
| Pazir, Y | 1 |
| Esmeray, A | 1 |
| Erbin, A | 1 |
| Ozgor, F | 1 |
| Sarilar, O | 1 |
| Prasad, SM | 2 |
| Huang, WC | 2 |
| Shore, ND | 2 |
| Brown, G | 1 |
| Genov, P | 1 |
| Shishkov, D | 1 |
| Khuskivadze, A | 1 |
| Ganev, T | 1 |
| Marchev, D | 1 |
| Orlov, I | 1 |
| Kopyltsov, E | 1 |
| Zubarev, V | 1 |
| Nosov, A | 1 |
| Komlev, D | 1 |
| Burger, B | 1 |
| Raju, S | 2 |
| Meads, A | 2 |
| Yu, QX | 1 |
| Wang, JC | 1 |
| Liu, JF | 1 |
| Ye, LX | 1 |
| Guo, YQ | 1 |
| Zheng, HH | 1 |
| Murthy, PB | 1 |
| Malalasekera, AP | 1 |
| Ediriweera, D | 1 |
| Goonewardena, S | 1 |
| Perera, N | 1 |
| Abeygunasekara, A | 1 |
| Jayasekara, R | 1 |
| Wettasinghe, K | 1 |
| Dissanayake, V | 1 |
| Lokuhetty, D | 1 |
| El Azab, A | 1 |
| Abdelbary, A | 1 |
| El Faqeh M Okasha, A | 1 |
| Aboulkassem, H | 1 |
| Saad Zaghloul, A | 1 |
| Mohamed Karkeet, R | 1 |
| Abdelrahman, I | 1 |
| Racioppi, M | 6 |
| Ragonese, M | 3 |
| Palermo, G | 2 |
| Sacco, E | 4 |
| Bassi, P | 4 |
| Cotrufo, S | 1 |
| Faraj, K | 1 |
| Chang, YH | 1 |
| Habermann, EB | 1 |
| Etzioni, DA | 1 |
| Blodgett, G | 1 |
| Castle, EP | 1 |
| Tyson Ii, MD | 1 |
| Tan, WP | 2 |
| Longo, TA | 2 |
| Marquette, T | 1 |
| Walz, J | 1 |
| Rybikowski, S | 1 |
| Maubon, T | 1 |
| Branger, N | 1 |
| Fakhfakh, S | 1 |
| Verde, KL | 1 |
| Dermeche, S | 1 |
| Gravis, G | 1 |
| Ba, M | 2 |
| Cui, S | 2 |
| Long, H | 2 |
| Gong, Y | 2 |
| Wu, Y | 2 |
| Lin, K | 1 |
| Tu, Y | 1 |
| Zhang, B | 1 |
| Wu, W | 1 |
| Jeglinschi, S | 1 |
| Schirmann, A | 1 |
| Durand, M | 1 |
| Sanchez, S | 1 |
| Schmidt, S | 2 |
| Kunath, F | 2 |
| Coles, B | 5 |
| Draeger, DL | 2 |
| Krabbe, LM | 2 |
| Dersch, R | 2 |
| Kilian, S | 2 |
| Jensen, K | 2 |
| Dahm, P | 4 |
| Meerpohl, JJ | 2 |
| Khan, W | 1 |
| Zugail, AS | 1 |
| Blanc, E | 1 |
| Neuziller, Y | 1 |
| Lebret, T | 3 |
| Liu, X | 3 |
| Li, S | 3 |
| Mostafid, AH | 2 |
| Griffiths, TRL | 2 |
| Penegar, SR | 1 |
| Davenport, K | 1 |
| McGrath, JS | 1 |
| Campain, N | 1 |
| Masood, S | 1 |
| Knowles, MA | 1 |
| Feber, A | 1 |
| Knight, A | 1 |
| Catto, JWF | 1 |
| Fankhauser, CD | 1 |
| Alsyouf, M | 1 |
| Pierorazio, P | 1 |
| Groegler, J | 1 |
| Nakayama, T | 1 |
| Nozawa, N | 1 |
| Kawada, C | 1 |
| Yamamoto, S | 2 |
| Ishii, T | 1 |
| Ishizuka, M | 1 |
| Namikawa, T | 1 |
| Ogura, SI | 1 |
| Hanazaki, K | 1 |
| Inoue, K | 5 |
| Karashima, T | 1 |
| Freifeld, Y | 2 |
| Ghandour, R | 1 |
| Singla, N | 1 |
| Bagrodia, A | 1 |
| Rapoport, LM | 1 |
| Gazimiev, M | 1 |
| Delafuente, K | 1 |
| Kulangara, R | 1 |
| Robyak, H | 1 |
| Petros, FG | 1 |
| Margulis, V | 1 |
| Li, Y | 2 |
| Song, J | 1 |
| Gao, K | 1 |
| Chen, K | 1 |
| Yang, X | 5 |
| Ding, Y | 2 |
| Ma, X | 1 |
| Li, W | 1 |
| Wang, Z | 2 |
| Dong, Z | 1 |
| Chang, A | 1 |
| Brousell, SC | 1 |
| Grimberg, DC | 2 |
| Fantony, JJ | 1 |
| Etienne, W | 1 |
| Spasojevic, I | 1 |
| Maccarini, P | 1 |
| Johnston, A | 1 |
| Padovani, L | 1 |
| Clark, E | 1 |
| Trail, M | 1 |
| Hamid, S | 1 |
| Hollins, G | 1 |
| Simpson, H | 1 |
| Thomas, BG | 1 |
| Hasan, R | 1 |
| Bhatt, J | 1 |
| Ahmad, I | 1 |
| Nandwani, GM | 1 |
| Mitchell, IDC | 1 |
| Hendry, D | 1 |
| Juvet, T | 1 |
| Mari, A | 1 |
| Lajkosz, K | 1 |
| Wallis, CJ | 1 |
| Kuk, C | 1 |
| Erlich, A | 1 |
| Krimus, L | 1 |
| Fleshner, NE | 1 |
| Kulkarni, GS | 2 |
| Zlotta, AR | 1 |
| Bue, P | 1 |
| Blichert-Refsgaard, L | 1 |
| Sundelin, MO | 1 |
| Rodríguez-Serrano, A | 1 |
| García-Jarabo, E | 1 |
| Corona-laPuerta, M | 1 |
| Voskuilen, CS | 1 |
| van de Kamp, MW | 1 |
| Schuring, N | 1 |
| Mertens, LS | 1 |
| Noordzij, A | 1 |
| Pos, F | 1 |
| van Rhijn, BWG | 1 |
| van der Heijden, MS | 1 |
| Schaake, EE | 1 |
| Pierconti, F | 2 |
| Martini, M | 1 |
| Fiorentino, V | 1 |
| Cenci, T | 1 |
| Capodimonti, S | 1 |
| Straccia, P | 2 |
| Pugliese, D | 1 |
| Cindolo, L | 1 |
| Larocca, LM | 2 |
| Bassi, PF | 6 |
| Necchi, A | 1 |
| Chang, SS | 6 |
| Kageyama, Y | 2 |
| Fujii, Y | 2 |
| Aizawa, T | 1 |
| Urakami, S | 1 |
| Fukui, I | 9 |
| Breton, J | 1 |
| Bernardeau, S | 1 |
| Vallée, M | 1 |
| Pillot, P | 1 |
| Lebacle, C | 1 |
| Delpech, PO | 1 |
| Charles, T | 1 |
| Biscans, C | 1 |
| Vallat, A | 1 |
| Pfister, C | 2 |
| Irani, J | 5 |
| Podarala, V | 1 |
| Prasanna Lakshmi, M | 1 |
| Venkata, SKR | 1 |
| Devalam, RP | 1 |
| Sri, D | 1 |
| Lee, HJ | 1 |
| El-Gemmal, S | 1 |
| Backhouse, C | 1 |
| Tay, A | 1 |
| John, B | 1 |
| Perry, MJ | 2 |
| Ayres, BE | 2 |
| Mun, JY | 1 |
| Baek, SW | 1 |
| Park, WY | 1 |
| Kim, WT | 1 |
| Kim, SK | 1 |
| Roh, YG | 1 |
| Jeong, MS | 1 |
| Yang, GE | 1 |
| Lee, JH | 1 |
| Chung, JW | 1 |
| Choi, YH | 1 |
| Chu, IS | 1 |
| Leem, SH | 1 |
| Raber, M | 2 |
| Buchholz, N | 1 |
| Vercesi, A | 1 |
| Hendawi, NA | 1 |
| Inneo, V | 1 |
| Di Paola, G | 1 |
| Tessa, L | 1 |
| Gazzano, G | 1 |
| Viglio, A | 1 |
| Hasan, IM | 1 |
| Pyrgidis, N | 1 |
| Lackner, J | 1 |
| Schneidewind, L | 1 |
| Sokolakis, I | 1 |
| Dudinec, J | 1 |
| Shah, A | 1 |
| Matzen, M | 1 |
| Offermann, A | 1 |
| Tharun, L | 1 |
| Perner, S | 1 |
| Merseburger, AS | 1 |
| Kramer, M | 1 |
| Hupe, MC | 1 |
| Signorini, C | 1 |
| Maffezzini, M | 5 |
| Jou, YC | 1 |
| Dia, YC | 1 |
| Wang, ST | 1 |
| Yu, MH | 1 |
| Yang, HY | 1 |
| Chen, LC | 1 |
| Shen, CH | 2 |
| Liu, YW | 1 |
| Gierth, M | 1 |
| Breyer, J | 2 |
| Zeman, F | 1 |
| Fritsche, HM | 1 |
| Cordes, J | 1 |
| Karl, A | 1 |
| Zaak, D | 1 |
| Stenzl, A | 2 |
| von Schmeling, IK | 1 |
| Sommerhuber, A | 1 |
| Zierer, T | 1 |
| Burger, M | 3 |
| Mayr, R | 1 |
| Han, MA | 1 |
| Maisch, P | 1 |
| Jung, JH | 2 |
| Hwang, JE | 1 |
| Narayan, V | 1 |
| Cleves, A | 2 |
| Hwang, EC | 1 |
| Ourfali, S | 1 |
| Matillon, X | 1 |
| Ricci, E | 1 |
| Fassi-Fehri, H | 1 |
| Benoit-Janin, M | 1 |
| Badet, L | 1 |
| Colombel, M | 2 |
| Çilesiz, NC | 1 |
| Özkan, A | 1 |
| Kalkanlı, A | 1 |
| Gezmiş, CT | 1 |
| Yazıcı, G | 1 |
| Onuk, Ö | 1 |
| Nuhoğlu, B | 2 |
| Taylor, CA | 1 |
| Tobert, CM | 1 |
| Kahnoski, RJ | 1 |
| Humphrey, JE | 1 |
| Lane, BR | 1 |
| Miyata, Y | 1 |
| Tsurusaki, T | 1 |
| Hayashida, Y | 1 |
| Imasato, Y | 1 |
| Takehara, K | 1 |
| Aoki, D | 1 |
| Nishikido, M | 1 |
| Watanabe, J | 2 |
| Mitsunari, K | 1 |
| Matsuo, T | 1 |
| Ohba, K | 1 |
| Taniguchi, K | 1 |
| Sakai, H | 1 |
| Chevli, KK | 1 |
| Trainer, A | 1 |
| Saltzstein, D | 1 |
| Ehrlich, Y | 1 |
| Friedman, B | 1 |
| D'Anna, R | 1 |
| Morris, D | 1 |
| Tyson, M | 1 |
| Sankin, A | 1 |
| Kates, M | 1 |
| Kester, S | 1 |
| Karsh, L | 1 |
| Cinman, A | 1 |
| Lahiri, S | 1 |
| Malinowski, M | 1 |
| Gabai, N | 1 |
| Hayne, D | 3 |
| Stockler, M | 3 |
| McCombie, SP | 2 |
| Lawrence, N | 1 |
| Martin, A | 2 |
| Sengupta, S | 2 |
| Davis, ID | 2 |
| Wang, B | 1 |
| Yan, Z | 3 |
| Wang, S | 1 |
| Hori, S | 2 |
| Miyake, M | 2 |
| Tatsumi, Y | 2 |
| Onishi, S | 2 |
| Morizawa, Y | 2 |
| Nakai, Y | 2 |
| Tanaka, N | 2 |
| Fujimoto, K | 2 |
| Kim, TS | 1 |
| Chung, JI | 1 |
| Noh, GH | 1 |
| Hwang, H | 1 |
| Deng, T | 1 |
| Liu, B | 1 |
| Duan, X | 1 |
| Zhang, T | 1 |
| Cai, C | 1 |
| Zeng, G | 1 |
| Gözen, AS | 1 |
| Umari, P | 1 |
| Scheitlin, W | 1 |
| Su, FE | 1 |
| Akin, Y | 1 |
| Rassweiler, J | 1 |
| Bosschieter, J | 3 |
| Nieuwenhuijzen, JA | 4 |
| van Ginkel, T | 3 |
| Vis, AN | 3 |
| Witte, B | 1 |
| Newling, D | 1 |
| Beckers, GMA | 3 |
| Hodgkinson, L | 1 |
| Emilio, S | 1 |
| De Pascalis, I | 1 |
| Marques, RC | 1 |
| Volavsek, M | 1 |
| Lopez-Beltran, A | 1 |
| Ringuette Goulet, C | 1 |
| Bernard, G | 2 |
| Chabaud, S | 2 |
| Couture, A | 1 |
| Langlois, A | 1 |
| Neveu, B | 1 |
| Pouliot, F | 2 |
| Bolduc, S | 2 |
| Gudeloglu, A | 1 |
| Kiziloz, H | 1 |
| Kuntz, GM | 1 |
| Miller, A | 1 |
| Konety, BR | 2 |
| Christoph, F | 1 |
| König, F | 1 |
| Lebentrau, S | 1 |
| Blaschke, S | 1 |
| Liehr, UB | 1 |
| Schostak, M | 2 |
| Wilson, SS | 2 |
| Crawford, ED | 2 |
| Unda-Urzaiz, M | 1 |
| Fernandez-Gomez, JM | 1 |
| Cozar-Olmo, JM | 1 |
| Juárez, A | 1 |
| van Valenberg, FJP | 2 |
| van der Heijden, AG | 8 |
| Lammers, RJM | 1 |
| Falke, J | 3 |
| Arends, TJH | 3 |
| Oosterwijk, E | 3 |
| Kent, M | 1 |
| Dabi, Y | 1 |
| Rieken, M | 2 |
| Kluth, LA | 1 |
| Al Hussein Al Awamlh, B | 1 |
| Ouzaid, I | 1 |
| Pycha, A | 2 |
| Comploj, E | 1 |
| Svatek, RS | 3 |
| Holmang, S | 2 |
| Huang, SY | 1 |
| Chien, CC | 2 |
| Hseu, RS | 1 |
| Huang, VYJ | 1 |
| Chiang, SY | 1 |
| Huang, CJ | 2 |
| Chen, SK | 2 |
| Tsai, RY | 1 |
| Lin, HT | 1 |
| Cheng, YC | 2 |
| Lissenberg-Witte, BI | 2 |
| Zhao, L | 2 |
| Li, M | 3 |
| Yan, L | 1 |
| Zhang, S | 1 |
| Mi, Z | 1 |
| Ren, L | 4 |
| Xu, J | 1 |
| Bhandari, P | 1 |
| Novikova, G | 1 |
| Goergen, CJ | 1 |
| Irudayaraj, J | 1 |
| Decaestecker, K | 3 |
| Lumen, N | 2 |
| Van Camp, C | 1 |
| Oosterlinck, W | 9 |
| Böhm, WU | 1 |
| Koch, R | 1 |
| Wenzel, S | 1 |
| Wirth, MP | 4 |
| Toma, M | 1 |
| Wang, C | 2 |
| Li, A | 1 |
| Yang, S | 1 |
| Qiao, R | 1 |
| Zhu, X | 1 |
| Zhang, J | 3 |
| Batura, D | 1 |
| Hashemzehi, T | 1 |
| Colemeadow, J | 1 |
| Faba, OR | 1 |
| Tselis, N | 1 |
| Prott, FJ | 1 |
| Ott, O | 1 |
| Weiss, C | 1 |
| Rödel, C | 2 |
| Crijnen, J | 1 |
| Coenen, JJMJH | 1 |
| Castellano-Gauna, D | 1 |
| Duarte-Ojeda, JM | 1 |
| Sousa Escandón, A | 2 |
| León Mata, J | 1 |
| Sousa González, D | 2 |
| Alvarez Casal, M | 2 |
| Rodríguez, S | 2 |
| Piñeiro Vazquez, S | 1 |
| León-Mata, J | 1 |
| Domínguez, JL | 1 |
| Redorta, JP | 1 |
| Piñeiro Vázquez, E | 1 |
| Chantada-Abal, V | 2 |
| Chantada-Tirado, C | 1 |
| Lamas-Díaz, L | 1 |
| Caramés-Masana, F | 1 |
| Villegas-Piguave, AD | 1 |
| Villar-Vázquez, N | 1 |
| Tapiero, S | 1 |
| Helfand, A | 1 |
| Yossepowitch, O | 1 |
| Nadu, A | 1 |
| Margel, D | 1 |
| Miernik, A | 1 |
| Gupte, A | 1 |
| Matcha, A | 1 |
| Lauzardo, M | 1 |
| Wirtz, RM | 1 |
| Erben, P | 1 |
| Rinaldetti, S | 1 |
| Worst, TS | 1 |
| Stoehr, R | 1 |
| Eckstein, M | 1 |
| Sikic, D | 1 |
| Denzinger, S | 1 |
| Hartmann, A | 1 |
| Otto, W | 1 |
| Garg, H | 1 |
| Nayak, B | 1 |
| Singh, P | 1 |
| Soloway, MS | 27 |
| Panchal, A | 1 |
| Buckley, L | 1 |
| Devall, AJ | 1 |
| Loubière, LS | 1 |
| Pope, AM | 1 |
| Feneley, MR | 2 |
| Madaan, S | 2 |
| Bhatt, R | 1 |
| McGrath, J | 1 |
| Sangar, V | 1 |
| Page, T | 1 |
| Hodgson, D | 1 |
| Datta, SN | 4 |
| Billingham, LJ | 1 |
| Protheroe, A | 1 |
| Bogle, R | 1 |
| Blazeby, J | 1 |
| Palmer, A | 1 |
| Johnson, M | 1 |
| Brough, R | 1 |
| Andrews, S | 1 |
| Cruickshank, C | 1 |
| Burnett, S | 1 |
| Maynard, L | 1 |
| Siracusano, S | 1 |
| Silvestri, T | 1 |
| Bassi, S | 1 |
| Porcaro, AB | 1 |
| Cerruto, MA | 1 |
| Talamini, R | 1 |
| Artibani, W | 1 |
| Schooneveldt, G | 2 |
| Kok, HP | 2 |
| Bakker, A | 1 |
| Geijsen, ED | 3 |
| Reijke, TM | 1 |
| Chen, HR | 1 |
| Kao, CC | 1 |
| Tsao, CW | 2 |
| Tang, SH | 1 |
| En, M | 1 |
| Cha, TL | 1 |
| Sun, GH | 1 |
| Wu, ST | 1 |
| Yu, DS | 1 |
| Lenis, AT | 2 |
| Asanad, K | 1 |
| Blaibel, M | 1 |
| Donin, NM | 2 |
| Nykopp, TK | 1 |
| Batista da Costa, J | 1 |
| Mannas, M | 1 |
| Black, PC | 2 |
| Gul, M | 1 |
| Goktas, S | 1 |
| Kars, MD | 1 |
| Kaynar, M | 1 |
| Mathes, J | 1 |
| Todenhöfer, T | 1 |
| van den Tempel, N | 1 |
| Naipal, KAT | 1 |
| Raams, A | 1 |
| van Gent, DC | 1 |
| Franckena, M | 1 |
| Boormans, JL | 1 |
| Kanaar, R | 1 |
| Onishi, K | 1 |
| Iida, K | 1 |
| Gotoh, D | 1 |
| Itami, Y | 1 |
| Goulet, CR | 1 |
| Champagne, A | 1 |
| Vandal, D | 1 |
| Hanada, E | 1 |
| Kageyama, S | 1 |
| Murai, R | 1 |
| Kubota, S | 1 |
| Ii, H | 1 |
| Nakata, S | 1 |
| Kita, H | 1 |
| Kawauchi, A | 1 |
| Chano, T | 1 |
| Huang, Y | 1 |
| Cen, J | 1 |
| Liu, Z | 1 |
| Wei, J | 1 |
| Chen, Z | 2 |
| Feng, Z | 1 |
| Lu, J | 2 |
| Fang, Y | 1 |
| Zhou, F | 1 |
| Luo, J | 1 |
| Mo, C | 1 |
| Arshad, Z | 1 |
| Zaidi, SZ | 1 |
| Huang, CP | 1 |
| Chen, J | 1 |
| Liu, G | 2 |
| Zhang, Y | 1 |
| Messing, E | 1 |
| Yeh, S | 1 |
| Chang, C | 1 |
| Lu, CC | 1 |
| Lin, MY | 1 |
| Chen, SY | 1 |
| Chen, LG | 1 |
| Hsieh, HY | 1 |
| Chan, MW | 1 |
| Hsu, CD | 1 |
| Lightfoot, AJ | 1 |
| Breyer, BN | 1 |
| Rosevear, HM | 1 |
| Erickson, BA | 1 |
| O'Donnell, MA | 2 |
| Neutsch, L | 1 |
| Wambacher, M | 1 |
| Wirth, EM | 1 |
| Spijker, S | 1 |
| Kählig, H | 1 |
| Wirth, M | 1 |
| Gabor, F | 1 |
| Pagliarulo, V | 2 |
| Ancona, P | 1 |
| Niso, M | 1 |
| Colabufo, NA | 1 |
| Contino, M | 1 |
| Azzariti, A | 1 |
| Pagliarulo, A | 1 |
| Filson, CP | 1 |
| Montgomery, JS | 1 |
| Dailey, SM | 1 |
| Crossley, HS | 1 |
| Lentz, H | 1 |
| Tallman, CT | 1 |
| He, C | 1 |
| Weizer, AZ | 1 |
| Manuputty, EE | 2 |
| Puntoni, M | 2 |
| Martelli, A | 1 |
| Marini, V | 1 |
| Tamagno, S | 2 |
| Aagaard, MF | 1 |
| Mogensen, K | 1 |
| Hermann, GG | 2 |
| Huddart, RA | 2 |
| Adab, FA | 1 |
| Hendron, C | 3 |
| Waters, R | 2 |
| Bowman, KJ | 1 |
| Al-Moneef, MM | 1 |
| Sherwood, BT | 1 |
| Colquhoun, AJ | 1 |
| Goddard, JC | 1 |
| Griffiths, TR | 1 |
| Payne, D | 1 |
| Singh, S | 2 |
| Butterworth, PC | 1 |
| Khan, MA | 1 |
| Summerton, DJ | 1 |
| Steward, WP | 1 |
| McKelvey-Martin, VJ | 1 |
| McKeown, SR | 1 |
| Kockelbergh, RC | 1 |
| Mellon, JK | 1 |
| Symonds, RP | 1 |
| Jones, GD | 2 |
| Miñana, B | 1 |
| Cózar, JM | 2 |
| Unda Urzaiz, M | 1 |
| Medina-Lopez, RA | 1 |
| Subirá Ríos, J | 1 |
| Lozano, F | 1 |
| Ribal, MJ | 1 |
| Rodríguez Fernández, E | 1 |
| Castiñeiras Fernández, J | 1 |
| Concepción Masip, T | 1 |
| Requena-Tapia, MJ | 1 |
| Moreno-Sierra, J | 1 |
| Hevia, M | 1 |
| Gómez Rodríguez, A | 1 |
| Martínez-Ballesteros, C | 1 |
| Ramos, M | 1 |
| Amón Sesmero, JH | 1 |
| Pizá Reus, P | 1 |
| Bohorquez Barrientos, A | 1 |
| Rioja Sanz, C | 1 |
| Gomez-Pascual, JA | 1 |
| Hidalgo Zabala, E | 1 |
| Parra Escobar, JL | 1 |
| Serrano, O | 1 |
| O'Brien, T | 3 |
| Ray, E | 2 |
| Chatterton, K | 2 |
| Khan, MS | 2 |
| Chandra, A | 1 |
| Thomas, K | 2 |
| Elmamoun, MH | 1 |
| Christmas, TJ | 1 |
| Woodhouse, CR | 1 |
| Cordeiro, ER | 1 |
| Geijsen, DE | 1 |
| Zum Vörde Sive Vörding, PJ | 3 |
| Sijbrands, J | 1 |
| Hulshof, MC | 1 |
| de la Rosette, J | 1 |
| Crezee, H | 1 |
| Arentsen, HC | 2 |
| Høgset, A | 1 |
| Alfred Witjes, J | 3 |
| Delto, JC | 1 |
| Kacker, R | 1 |
| Bubley, G | 1 |
| DeWolf, WC | 1 |
| Guy, L | 1 |
| Mahammedi, H | 1 |
| Bastide, C | 1 |
| Bruyere, F | 1 |
| Karsenty, G | 1 |
| Bay, JO | 1 |
| Jankun, J | 1 |
| Keck, RW | 2 |
| Selman, SH | 2 |
| Milla, P | 1 |
| Fiorito, C | 1 |
| Arpicco, S | 1 |
| Cattel, L | 1 |
| Gontero, P | 2 |
| Stauffer, PR | 1 |
| Craciunescu, OA | 1 |
| Maccarini, PF | 1 |
| Dewhirst, MW | 1 |
| Vujaskovic, Z | 1 |
| Canepa, G | 2 |
| Zargar, H | 1 |
| Aning, J | 1 |
| Ischia, J | 1 |
| So, A | 1 |
| Black, P | 1 |
| Chung, CA | 1 |
| Chen, WY | 1 |
| Ruaan, RC | 1 |
| Li, C | 1 |
| Hu, WW | 1 |
| Arends, TJ | 4 |
| Higgins, JA | 1 |
| Zainol, M | 1 |
| Brown, K | 1 |
| Bachir, BG | 1 |
| Dragomir, A | 1 |
| Aprikian, AG | 1 |
| Tanguay, S | 1 |
| Fairey, A | 1 |
| Breau, RH | 1 |
| Kassouf, W | 2 |
| Erdogar, N | 2 |
| İskit, AB | 2 |
| Eroglu, H | 1 |
| Sargon, MF | 1 |
| Mungan, NA | 4 |
| Bilensoy, E | 3 |
| Molina Escudero, R | 1 |
| Alvarez Ardura, M | 1 |
| Ripalda Ferretti, E | 1 |
| Crespo Martínez, L | 1 |
| González Avila, N | 1 |
| Dorado Valentín, M | 1 |
| Páez Borda, A | 1 |
| Ciampa, S | 1 |
| de Kroon-Oldenhof, R | 1 |
| Steggerda-Carvalho, EJ | 1 |
| van Stam, G | 1 |
| Stalpers, LJ | 1 |
| Bardati, F | 1 |
| Bel, A | 1 |
| Ohsugi, H | 1 |
| Kitamura, Y | 1 |
| Manabe, Y | 1 |
| Masuda, N | 1 |
| Ito, H | 2 |
| Mishina, M | 1 |
| Okuno, H | 1 |
| Vásquez, JL | 2 |
| Ibsen, P | 1 |
| Lindberg, H | 1 |
| Gehl, J | 2 |
| Madero, R | 2 |
| Chantada, V | 2 |
| Zabala, JA | 1 |
| Portillo, JA | 1 |
| Alonso, JM | 1 |
| Astobieta, A | 1 |
| Rabadan, M | 1 |
| Ojea, A | 2 |
| Rodriguez-Molina, J | 1 |
| Beardo, P | 1 |
| Muntañola, P | 1 |
| Gomez, M | 1 |
| Montesinos, M | 1 |
| Martinez Piñeiro, JA | 1 |
| Rehme, C | 1 |
| Niedworok, C | 1 |
| Rübben, H | 4 |
| Vom Dorp, F | 1 |
| Kiss, B | 1 |
| Schneider, S | 1 |
| Thalmann, GN | 1 |
| Roth, B | 1 |
| Yoshida, T | 1 |
| Okuyama, H | 1 |
| Nakayama, M | 1 |
| Endo, H | 1 |
| Nonomura, N | 1 |
| Nishimura, K | 1 |
| Inoue, M | 1 |
| Zhao, XR | 1 |
| Morales, EE | 1 |
| Jha, MK | 1 |
| Tseng, TY | 1 |
| Hugen, CM | 1 |
| Hurez, V | 1 |
| Hernandez, J | 1 |
| Curiel, TJ | 1 |
| Hollenbeck, BK | 1 |
| Lammers, RJ | 3 |
| Somford, DM | 1 |
| Hendriks, JC | 1 |
| de Weijert, MC | 1 |
| Deng, X | 2 |
| Zhang, X | 3 |
| Cheng, Y | 2 |
| Zhao, R | 2 |
| Li, X | 5 |
| Lu, Q | 2 |
| Yin, C | 2 |
| Rivière, A | 1 |
| Ploussard, G | 1 |
| Desgranchamps, F | 1 |
| Cockerill, PA | 1 |
| Frank, I | 1 |
| Tarrell, R | 1 |
| Karnes, RJ | 1 |
| Lykke, MR | 1 |
| Nielsen, TK | 1 |
| Ebbensgaard, NA | 1 |
| Zieger, K | 1 |
| Järvinen, R | 4 |
| Marttila, T | 3 |
| Kaasinen, E | 13 |
| Rintala, E | 15 |
| Aaltomaa, S | 1 |
| Kallio, J | 2 |
| Liukkonen, T | 3 |
| Puolakka, VM | 2 |
| Seppänen, M | 1 |
| Tuhkanen, K | 2 |
| Vaarala, M | 1 |
| Viitanen, J | 2 |
| Boström, PJ | 1 |
| Ringoir, A | 1 |
| Ekin, RG | 1 |
| Akarken, I | 1 |
| Cakmak, O | 1 |
| Tarhan, H | 1 |
| Celik, O | 1 |
| Ilbey, YO | 1 |
| Divrik, RT | 2 |
| Zorlu, F | 2 |
| Boström, P | 1 |
| Chalasani, V | 1 |
| Long, A | 1 |
| Sylvester, RJ | 5 |
| Sydes, MR | 1 |
| Gudjonsson, S | 1 |
| De Nunzio, C | 2 |
| Okamura, K | 1 |
| Ali-El-Dein, B | 1 |
| Tatar, CA | 1 |
| N'Dow, J | 1 |
| Koning, CC | 1 |
| de la Rosette, JJ | 1 |
| Rasch, CR | 1 |
| van Os, RM | 1 |
| Zigeuner, R | 1 |
| Cowan, NC | 1 |
| Böhle, A | 6 |
| Van Rhijn, BW | 1 |
| Taylor, JA | 1 |
| Weiss, BE | 1 |
| Pietzak, EJ | 1 |
| Wein, AJ | 1 |
| Malkowicz, SB | 1 |
| Guzzo, TJ | 2 |
| Sooriakumaran, P | 1 |
| Chiocchia, V | 1 |
| Dutton, S | 1 |
| Pai, A | 1 |
| Le Roux, P | 1 |
| Swinn, M | 1 |
| Bailey, M | 1 |
| Zhang, H | 2 |
| Wang, J | 2 |
| Shibing, Y | 1 |
| Qiang, W | 1 |
| Shelley, M | 2 |
| Court, JB | 2 |
| Kynaston, HG | 2 |
| Wilt, TJ | 4 |
| Mason, M | 4 |
| Bahouth, Z | 1 |
| Halachmi, S | 2 |
| Moskovitz, B | 6 |
| Nativ, O | 9 |
| Lailler, G | 1 |
| Rouanne, M | 1 |
| Ojha, R | 1 |
| Jha, V | 1 |
| Singh, SK | 1 |
| Feng, TS | 1 |
| Rusnack, S | 1 |
| Kaminski, J | 1 |
| Fleshner, P | 1 |
| Colin, P | 1 |
| Dubosq, F | 1 |
| Puech, P | 1 |
| de Cobelli, O | 1 |
| Verweij, F | 1 |
| Gan, C | 1 |
| Amery, S | 1 |
| Piñeiro, I | 1 |
| Aparici, V | 1 |
| Monserrat, V | 1 |
| Neira, P | 1 |
| Carro, E | 1 |
| Murias, C | 1 |
| Uribarri, C | 1 |
| Colomer Gallardo, A | 1 |
| Martínez Rodríguez, R | 1 |
| Castillo Pacheco, C | 1 |
| González Satue, C | 1 |
| Ibarz Servio, L | 1 |
| Qin, L | 1 |
| Zhu, Z | 1 |
| Wang, X | 4 |
| Liu, Y | 1 |
| Fan, Y | 1 |
| Zhong, S | 2 |
| Xia, L | 1 |
| Xu, C | 1 |
| Shen, Z | 1 |
| Hassan, M | 1 |
| Qureshi, A | 1 |
| Nasir, H | 1 |
| Amantini, C | 1 |
| Morelli, MB | 1 |
| Nabissi, M | 1 |
| Cardinali, C | 1 |
| Santoni, M | 1 |
| Gismondi, A | 1 |
| Santoni, G | 1 |
| Poletajew, S | 1 |
| Radziszewski, P | 1 |
| Onishi, T | 2 |
| Sugino, Y | 1 |
| Shibahara, T | 1 |
| Masui, S | 1 |
| Yabana, T | 2 |
| Sasaki, T | 3 |
| Veeratterapillay, R | 1 |
| Heer, R | 1 |
| Johnson, MI | 1 |
| Persad, R | 2 |
| Bach, C | 1 |
| Gabig, TG | 1 |
| Waltzer, WC | 1 |
| Whyard, T | 1 |
| Romanov, V | 1 |
| Lan, Y | 1 |
| Liu, D | 1 |
| Lin, M | 1 |
| Wijkström, H | 6 |
| Mestad, O | 2 |
| Jahnson, S | 3 |
| Malmström, PU | 7 |
| Esuvaranathan, K | 1 |
| Mbeutcha, A | 1 |
| Rink, M | 1 |
| Seitz, C | 1 |
| Lucca, I | 1 |
| Mathieu, R | 1 |
| Klatte, T | 1 |
| Lenci, N | 1 |
| Filianoti, A | 2 |
| Recupero, SM | 1 |
| Serretta, V | 2 |
| Scalici Gesolfo, C | 1 |
| Alonge, V | 1 |
| Di Maida, F | 1 |
| Caruana, G | 1 |
| Di Stasi, SM | 7 |
| Verri, C | 3 |
| Celestino, F | 1 |
| De Carlo, F | 1 |
| Duarte, S | 1 |
| Caliliw, R | 1 |
| Torres, C | 1 |
| Smithson, A | 1 |
| Agmon-Gerstein, Y | 1 |
| Malchi, N | 1 |
| Said, J | 1 |
| Raman, SS | 1 |
| Holden, S | 1 |
| Pantuck, A | 1 |
| Belldegrun, AS | 1 |
| Colombo, R | 13 |
| van Valenberg, H | 1 |
| Zhuo, C | 1 |
| Zhuang, H | 1 |
| Tian, S | 1 |
| Cui, H | 1 |
| Jiang, R | 1 |
| Liu, C | 1 |
| Tao, R | 1 |
| Lin, X | 1 |
| Ceci, C | 1 |
| Tentori, L | 1 |
| Atzori, MG | 1 |
| Lacal, PM | 1 |
| Bonanno, E | 1 |
| Scimeca, M | 1 |
| Cicconi, R | 1 |
| Mattei, M | 1 |
| de Martino, MG | 1 |
| Vespasiani, G | 4 |
| Miano, R | 1 |
| Graziani, G | 1 |
| Lu, DD | 1 |
| Boorjian, SA | 2 |
| Shenoy, SP | 1 |
| Marla, PK | 1 |
| Sharma, P | 1 |
| Batchu, CK | 1 |
| Reddy, VR | 1 |
| Pai, VM | 1 |
| West, CM | 1 |
| Denley, H | 1 |
| Wu, C | 1 |
| Zhou, X | 1 |
| Miao, C | 1 |
| Tang, Q | 1 |
| Chang, X | 1 |
| Ni, H | 1 |
| Prasad, NN | 1 |
| Muddukrishna, SN | 1 |
| Rischmann, P | 1 |
| Stoehr, B | 1 |
| Mueller, T | 1 |
| Granig, T | 1 |
| Zangerl, F | 1 |
| Steiner, H | 1 |
| Erhan Eroğlu, H | 1 |
| Ozkul, Y | 1 |
| Tatlisen, A | 1 |
| Silici, S | 1 |
| Dangle, PP | 1 |
| Wang, WP | 1 |
| Pohar, KS | 1 |
| Mazerolles, C | 1 |
| Horvath, A | 1 |
| Jalón Monzón, A | 2 |
| Fernández Gómez, JM | 2 |
| Escaf Bramada, S | 1 |
| Alvarez Múgica, M | 2 |
| García Rodríguez, J | 1 |
| Regadera Sejas, FJ | 2 |
| El-Ghobashy, S | 1 |
| El-Leithy, TR | 1 |
| Roshdy, MM | 1 |
| El-Ganzoury, HM | 1 |
| Escaf Barmadah, S | 1 |
| Martín Benito, JL | 1 |
| Sarisozen, C | 1 |
| Esendağli, G | 1 |
| Doğan, AL | 1 |
| Aktaş, Y | 1 |
| Sen, M | 1 |
| Whitson, J | 1 |
| Berry, A | 1 |
| Carroll, P | 1 |
| Konety, B | 1 |
| Riedl, C | 1 |
| Hendricksen, K | 2 |
| Gofrit, O | 1 |
| Risi, O | 1 |
| Liberati, E | 2 |
| Dutto, L | 1 |
| Mangiarotti, B | 2 |
| Trinchieri, A | 3 |
| Del Nero, A | 2 |
| Montanari, E | 1 |
| Mevcha, A | 1 |
| Calleary, J | 1 |
| Gillatt, DA | 1 |
| Sankila, A | 1 |
| Liang, ZK | 1 |
| Zhang, L | 1 |
| Hu, ZM | 1 |
| Huang, X | 1 |
| Shi, XH | 1 |
| Tan, WL | 2 |
| Gao, JM | 1 |
| Crawford, DE | 1 |
| Friedrich, M | 1 |
| Krege, S | 3 |
| Dalbagni, G | 2 |
| Donaldson, AM | 1 |
| Gonzalez, JG | 1 |
| Parmar, MK | 5 |
| Donaldson, N | 1 |
| Okumura, A | 1 |
| Oishi, N | 1 |
| Kaji, K | 1 |
| Imamura, T | 1 |
| Fuse, H | 2 |
| Pan, CW | 2 |
| Shen, ZJ | 2 |
| Wu, TT | 1 |
| Tang, XY | 1 |
| Wang, M | 1 |
| Sun, J | 1 |
| Shao, Y | 1 |
| Lingnau, A | 1 |
| Miller, K | 1 |
| Steiner, U | 1 |
| Jentzmik, F | 1 |
| Weikert, S | 1 |
| Cohen, M | 1 |
| Sidi, A | 2 |
| Leibovitch, I | 2 |
| Cameo, MI | 1 |
| Lezcano, MA | 1 |
| Gil, D | 1 |
| Blas, M | 2 |
| Birare, N | 1 |
| Lwaleed, BA | 3 |
| Cooper, AJ | 4 |
| Pfost, B | 1 |
| Seidl, C | 1 |
| Autenrieth, M | 1 |
| Saur, D | 1 |
| Bruchertseifer, F | 1 |
| Morgenstern, A | 1 |
| Schwaiger, M | 1 |
| Senekowitsch-Schmidtke, R | 1 |
| Descazeaud, A | 1 |
| Mignard, JP | 1 |
| Davin, JL | 1 |
| Draga, RO | 1 |
| Grimbergen, MC | 1 |
| Kok, ET | 1 |
| Jonges, TN | 1 |
| van Swol, CF | 1 |
| Bosch, JL | 1 |
| Fernandez, DG | 1 |
| Fernández, AF | 1 |
| Vallejo, MS | 1 |
| Osorio, JL | 1 |
| Anguita, MJ | 1 |
| Jimenez, AL | 1 |
| Fazlioglu, A | 1 |
| Tandogdu, Z | 1 |
| Kurtulus, FO | 1 |
| Parlakkilic, O | 1 |
| Cek, M | 1 |
| Addeo, R | 1 |
| Caraglia, M | 2 |
| Bellini, S | 1 |
| Abbruzzese, A | 2 |
| Vincenzi, B | 1 |
| Montella, L | 1 |
| Miragliuolo, A | 1 |
| Guarrasi, R | 1 |
| Lanna, M | 1 |
| Cennamo, G | 1 |
| Faiola, V | 1 |
| Del Prete, S | 1 |
| Lamm, D | 1 |
| Brausi, M | 5 |
| Akaza, H | 8 |
| Buckley, R | 1 |
| Shelley, MD | 3 |
| Mason, MD | 3 |
| Kynaston, H | 3 |
| Wada, H | 1 |
| Nakano, Y | 3 |
| Yamada, H | 1 |
| Saiga, T | 1 |
| Yamanaka, A | 1 |
| Sakai, N | 1 |
| Yates, DR | 1 |
| Feifer, A | 1 |
| Xie, X | 1 |
| Brophy, JM | 1 |
| Segal, R | 1 |
| Vandepitte, J | 1 |
| Maes, J | 1 |
| Van Poppel, H | 1 |
| Lerut, E | 1 |
| Agostinis, P | 1 |
| de Witte, PA | 1 |
| Guillotreau, J | 1 |
| Zerbib, M | 2 |
| Haifler, M | 1 |
| Lang, E | 1 |
| Sabler, I | 1 |
| Gutman, Y | 1 |
| Lindner, A | 1 |
| Zisman, A | 1 |
| Volpe, A | 2 |
| Cappa, E | 2 |
| D'Agostino, D | 2 |
| Pinto, F | 1 |
| D'Addessi, A | 2 |
| Aldemir, M | 1 |
| Canda, AE | 1 |
| Balbay, MD | 1 |
| Cho, KS | 1 |
| Chung, MK | 1 |
| Lee, KH | 2 |
| Chade, DC | 1 |
| Scherr, DS | 1 |
| Verma, A | 1 |
| Degrado, J | 1 |
| Hittelman, AB | 1 |
| Wheeler, MA | 3 |
| Weiss, RM | 3 |
| Carretero, R | 1 |
| Cabrera, T | 1 |
| Gil, H | 1 |
| Saenz-Lopez, P | 1 |
| Maleno, I | 1 |
| Aptsiauri, N | 1 |
| Garrido, F | 1 |
| Leib, Z | 3 |
| Pavone-Macaluso, M | 2 |
| Engelstein, D | 1 |
| Calistru, AM | 1 |
| Baudrier, T | 1 |
| Mota, A | 1 |
| Alexandrescu, D | 1 |
| Cunha, AL | 1 |
| Silva, J | 1 |
| Azevedo, F | 1 |
| Au, JL | 16 |
| Wientjes, MG | 14 |
| Corcoran, AT | 1 |
| Gingrich, JR | 1 |
| Kirkali, Z | 1 |
| Sylvester, R | 9 |
| da Silva, FC | 2 |
| Busch, C | 2 |
| Algaba, F | 1 |
| Collette, S | 1 |
| Bono, A | 2 |
| Maeda, T | 1 |
| Kikuchi, E | 2 |
| Matsumoto, K | 1 |
| Miyajima, A | 1 |
| Oya, M | 1 |
| Mansoor, M | 1 |
| Ali, S | 1 |
| Fasihuddin, Q | 1 |
| Baloch, MU | 1 |
| Ooi, WL | 1 |
| Hou, JC | 1 |
| Landas, S | 2 |
| Wang, CY | 1 |
| Shapiro, O | 2 |
| Hoshina, A | 1 |
| Neulander, EZ | 2 |
| Kaneti, J | 2 |
| Laufer, M | 1 |
| Carbone, A | 1 |
| Albisinni, S | 1 |
| Alpi, G | 1 |
| Cantiani, A | 1 |
| Liberti, M | 2 |
| Tubaro, A | 1 |
| Iori, F | 1 |
| Singh, R | 2 |
| Coker, B | 1 |
| Beard, R | 1 |
| Grossman, HB | 1 |
| Valenti, M | 2 |
| Giurioli, A | 2 |
| Leprini, G | 1 |
| Masedu, F | 1 |
| Ricci, AR | 1 |
| Micali, F | 1 |
| Cao, M | 1 |
| Ma, CK | 1 |
| Ma, J | 1 |
| Chen, HG | 1 |
| Xue, W | 1 |
| Bhattacharyya, M | 1 |
| Powles, T | 1 |
| Mutsvangwa, K | 1 |
| Wilson, P | 1 |
| Oliver, T | 1 |
| Shamash, J | 1 |
| Zhang, HH | 1 |
| Qi, F | 1 |
| Shi, YR | 1 |
| Miao, JG | 1 |
| Zhou, M | 1 |
| He, W | 1 |
| Chen, MF | 1 |
| Zu, XB | 1 |
| Qi, L | 1 |
| Badalato, GM | 1 |
| Hruby, G | 1 |
| Razmjoo, M | 1 |
| McKiernan, JM | 1 |
| Deb, AA | 1 |
| Rove, KO | 1 |
| Kumar, B | 1 |
| Koul, S | 1 |
| Lim, DD | 1 |
| Meacham, RB | 1 |
| Koul, HK | 1 |
| Giuberti, G | 1 |
| Zappavigna, S | 1 |
| Perdonà, S | 1 |
| Facchini, G | 1 |
| Sperlongano, P | 1 |
| Porto, S | 1 |
| Di Lorenzo, G | 1 |
| Buonerba, C | 1 |
| Altieri, V | 2 |
| Watson, CJ | 1 |
| O'Kane, H | 1 |
| Maxwell, P | 2 |
| Sharaf, O | 1 |
| Petak, I | 1 |
| Hyland, PL | 1 |
| O'Rouke, D | 1 |
| McKnight, J | 1 |
| Canning, P | 2 |
| Williamson, K | 1 |
| Ho, CC | 1 |
| Paul, S | 1 |
| Jones, G | 1 |
| Krane, LS | 1 |
| Kader, AK | 1 |
| Levine, EA | 1 |
| Zhang, CJ | 1 |
| Li, T | 1 |
| Zhang, MG | 1 |
| Fradet, Y | 2 |
| Nielsen, ME | 1 |
| Pruthi, RS | 1 |
| Amiel, G | 1 |
| Shore, N | 1 |
| Cho, IC | 1 |
| Kim, EK | 1 |
| Sizer, B | 1 |
| Witjes, WP | 6 |
| Janzing-Pastors, MH | 1 |
| Caris, CT | 2 |
| Rocchini, L | 2 |
| Suardi, N | 2 |
| Benigni, F | 2 |
| Colciago, G | 2 |
| Bettiga, A | 2 |
| Pellucchi, F | 2 |
| Maccagnano, C | 2 |
| Rigatti, P | 8 |
| Castillo, OA | 1 |
| Landerer, E | 1 |
| Feria-Flores, M | 1 |
| Vidal-Mora, I | 1 |
| Franco, C | 1 |
| Li, L | 1 |
| Li, B | 1 |
| Shao, J | 1 |
| Group, TF | 1 |
| Panneerselvam, J | 1 |
| Park, HK | 1 |
| Dudimah, FD | 1 |
| Zhang, P | 1 |
| Wang, H | 3 |
| Fei, P | 1 |
| Moskovitz, M | 1 |
| Andreu-Barasoain, M | 1 |
| Gómez de la Fuente, E | 1 |
| Pinedo, F | 1 |
| Nuño, A | 1 |
| López-Estebaranz, JL | 1 |
| Garg, M | 1 |
| Prakash, J | 1 |
| Kunze, D | 1 |
| Erdmann, K | 1 |
| Froehner, M | 2 |
| Fuessel, S | 2 |
| Lee, CT | 1 |
| Barocas, D | 1 |
| Globe, DR | 1 |
| Oefelein, MG | 1 |
| Colayco, DC | 1 |
| Bruno, A | 1 |
| O'Day, K | 1 |
| Bramley, T | 1 |
| Coloby, P | 1 |
| Rébillard, X | 1 |
| Mongiat-Artus, P | 1 |
| Chartier-Kastler, E | 1 |
| Soulié, M | 1 |
| Ersoy, H | 1 |
| Yaytokgil, M | 1 |
| Karakoyunlu, AN | 1 |
| Topaloglu, H | 1 |
| Sagnak, L | 1 |
| Ozok, HU | 1 |
| Dekel, Y | 2 |
| Stein, A | 1 |
| Barlow, LJ | 1 |
| Benson, MC | 1 |
| Hellström, P | 2 |
| Juusela, H | 2 |
| Rajala, P | 3 |
| Korhonen, H | 3 |
| Shackley, DC | 1 |
| Haylett, A | 1 |
| Whitehurst, C | 1 |
| Betts, CD | 1 |
| O'Flynn, K | 1 |
| Clarke, NW | 1 |
| Moore, JV | 1 |
| Jocham, D | 2 |
| Bock, PR | 2 |
| Hara, I | 1 |
| Miyake, H | 1 |
| Takechi, Y | 1 |
| Eto, H | 1 |
| Gotoh, A | 1 |
| Fujisawa, M | 1 |
| Okada, H | 1 |
| Arakawa, S | 1 |
| Kamidono, S | 4 |
| Lynn, NN | 1 |
| Howe, MC | 1 |
| Hale, RJ | 1 |
| Collins, GN | 1 |
| O'Reilly, PH | 1 |
| Oehlschläger, S | 1 |
| Loessnitzer, A | 1 |
| Hakenberg, OW | 1 |
| Manseck, A | 1 |
| Wang, Q | 1 |
| Sun, Y | 2 |
| Chen, XY | 1 |
| Kong, Q | 1 |
| Zhang, KL | 1 |
| Li, H | 2 |
| Hellsten, S | 2 |
| Duchek, M | 1 |
| Bex, A | 1 |
| Horenblas, S | 1 |
| Hausladen, DA | 2 |
| Altieri, DC | 1 |
| Colberg, JW | 1 |
| Tong, M | 1 |
| Yu, LZ | 1 |
| Liu, LB | 1 |
| Pan, BN | 1 |
| Na, YQ | 2 |
| Sheryka, E | 1 |
| Zang, M | 1 |
| Xu, F | 1 |
| Giannantoni, A | 2 |
| Stephen, RL | 3 |
| Capelli, G | 2 |
| Navarra, P | 1 |
| Massoud, R | 1 |
| Server Pastor, G | 1 |
| Rigabert Montiel, M | 1 |
| Bañón Pérez, V | 1 |
| Valdelvira Nadal, P | 1 |
| Cao Avellaneda, E | 1 |
| García Hernández, JA | 1 |
| Pérez Albacete, M | 1 |
| Thiruchelvam, N | 1 |
| Rath-Wolfson, L | 1 |
| Kugel, V | 1 |
| Koren, R | 1 |
| MYHRE, K | 1 |
| FJAERLI, J | 1 |
| Kijima, T | 1 |
| Masuda, H | 1 |
| Suzuki, M | 1 |
| Okada, Y | 2 |
| Yano, M | 1 |
| Hyochi, N | 1 |
| Kawakami, S | 1 |
| Hayashi, T | 2 |
| Kobayashi, T | 3 |
| Kihara, K | 7 |
| Da Pozzo, LF | 3 |
| Caldarera, E | 1 |
| Lamm, DL | 5 |
| Giannopoulos, A | 1 |
| Constantinides, C | 1 |
| Fokaeas, E | 1 |
| Stravodimos, C | 1 |
| Giannopoulou, M | 1 |
| Kyroudi, A | 1 |
| Gounaris, A | 1 |
| Peyromaure, M | 1 |
| French, AJ | 2 |
| Allman, R | 3 |
| Matthews, PN | 3 |
| Wang, GM | 1 |
| Yang, YF | 1 |
| Sun, LA | 1 |
| Xu, ZB | 1 |
| Xu, YQ | 1 |
| Williams-Cox, D | 1 |
| Basu, S | 3 |
| Brown, JE | 2 |
| Flannigan, GM | 2 |
| Gill, JH | 2 |
| Loadman, PM | 2 |
| Martin, SW | 2 |
| Naylor, B | 2 |
| Scally, AJ | 2 |
| Seargent, JM | 2 |
| Shah, T | 2 |
| Puri, R | 3 |
| Phillips, RM | 2 |
| Court, J | 1 |
| Gofrit, ON | 1 |
| Shapiro, A | 2 |
| Pode, D | 1 |
| Naspro, R | 1 |
| Elmer, A | 1 |
| Bermes, U | 1 |
| Drath, L | 1 |
| Büscher, E | 1 |
| Viertel, A | 1 |
| Stocken, DD | 1 |
| Peake, DR | 1 |
| Glaholm, JG | 2 |
| Wallace, DM | 2 |
| Piovesan, LF | 1 |
| Salvador, J | 1 |
| Vicente, J | 1 |
| Villavicencio, H | 1 |
| Gattegno, B | 1 |
| Ito, M | 1 |
| Habuchi, T | 1 |
| Higashi, S | 1 |
| Nishiyama, H | 1 |
| Tsuchiya, N | 1 |
| Kamoto, T | 1 |
| Ogawa, O | 1 |
| Jansen, CF | 2 |
| Verhaegh, G | 2 |
| Schalken, JA | 2 |
| He, LF | 2 |
| Hou, SK | 2 |
| Wang, SW | 1 |
| Oztürk, E | 1 |
| Eroğlu, M | 2 |
| Ozdemir, N | 1 |
| Denkbaş, EB | 2 |
| Hurst, RE | 1 |
| Kamat, CD | 1 |
| Kyker, KD | 1 |
| Green, DE | 1 |
| Ihnat, MA | 1 |
| Fidalgo, A | 1 |
| Lobo, L | 1 |
| Meyer, G | 1 |
| Kravtzov, A | 1 |
| Gross, M | 1 |
| Kastin, A | 1 |
| Biton, K | 1 |
| Stewart, AB | 2 |
| Raviv, G | 1 |
| Pinthus, JH | 1 |
| Shefi, S | 1 |
| Mor, Y | 1 |
| Kaufman-Francis, K | 1 |
| Levron, J | 1 |
| Weissenberg, R | 1 |
| Ramon, J | 1 |
| Madgar, I | 1 |
| Li, CG | 1 |
| Li, ML | 1 |
| Shu, XH | 1 |
| Skyrme, RJ | 1 |
| Xin, Y | 1 |
| Lyness, G | 1 |
| Chen, D | 1 |
| Krause, S | 1 |
| Förster, Y | 1 |
| Kraemer, K | 1 |
| Kotzsch, M | 1 |
| Schmidt, U | 1 |
| Meye, A | 1 |
| Schwenzer, B | 1 |
| Mullerad, M | 1 |
| Bochner, BH | 2 |
| Adusumilli, PS | 1 |
| Bhargava, A | 1 |
| Hui-Ni, C | 1 |
| Kattan, MW | 1 |
| Chou, TC | 1 |
| Fong, Y | 1 |
| Senior, K | 1 |
| McGee, WR | 1 |
| Hale, K | 1 |
| Foschi, N | 1 |
| Delicato, G | 1 |
| Destito, A | 1 |
| Guan, KP | 1 |
| Ye, HY | 1 |
| Xu, KX | 1 |
| Harland, SJ | 2 |
| Zampa, G | 1 |
| Storti, L | 1 |
| Attisani, F | 1 |
| De Carolis, A | 1 |
| Bonacina, P | 1 |
| Butti, A | 1 |
| Cappoli, S | 1 |
| Esposito, N | 1 |
| Invernizzi, S | 1 |
| Librizzi, A | 1 |
| Locatelli, G | 1 |
| Islam, MA | 1 |
| Bhuiyan, ZH | 1 |
| Shameem, IA | 1 |
| Rajkumar, RG | 1 |
| Clarke, NS | 1 |
| Prescott, S | 2 |
| Yildirim, U | 1 |
| Ozen, H | 1 |
| Fechner, G | 1 |
| Pocha, K | 1 |
| Schmidt, D | 1 |
| Müller, SC | 1 |
| Kobayashi, S | 1 |
| Oka, K | 3 |
| Machida, T | 3 |
| Ishizaka, K | 1 |
| Besarani, D | 1 |
| Al-Akraa, M | 1 |
| Kureshi, F | 1 |
| Kalaaji, AN | 1 |
| Halvorson, L | 1 |
| Pittelkow, MR | 1 |
| Davis, MD | 1 |
| Bolenz, C | 1 |
| Cao, Y | 2 |
| Arancibia, MF | 1 |
| Trojan, L | 1 |
| Alken, P | 1 |
| Michel, MS | 1 |
| Mackie, SJ | 1 |
| Sharma, DM | 1 |
| Harris, NM | 1 |
| Fuqing, Z | 1 |
| Zheng, L | 2 |
| Tong, Q | 2 |
| Segawa, N | 1 |
| Kotake, Y | 1 |
| Hamada, S | 1 |
| Takahara, K | 1 |
| Azuma, H | 1 |
| Katsuoka, Y | 1 |
| Tsuji, M | 1 |
| Yin, ZF | 1 |
| Lai, YQ | 1 |
| Yuan, YM | 1 |
| Chen, L | 1 |
| Gan, L | 1 |
| Burgués, JP | 1 |
| Gómez, L | 1 |
| Pontones, JL | 1 |
| Vera, CD | 1 |
| Jiménez-Cruz, JF | 1 |
| Ozonas, M | 1 |
| Zhao, GZ | 1 |
| Zheng, SB | 1 |
| Wu, YD | 1 |
| Xie, Y | 1 |
| Zhu, WH | 1 |
| Jones, K | 1 |
| Haas, GP | 1 |
| Gårdmark, T | 1 |
| Wahlquist, R | 1 |
| Friedrich, MG | 2 |
| Pichlmeier, U | 3 |
| Schwaibold, H | 4 |
| Conrad, S | 2 |
| Huland, H | 9 |
| Evans, CP | 1 |
| Yang, SM | 1 |
| Wen, DG | 1 |
| Hou, JQ | 1 |
| He, J | 1 |
| Cen, JN | 1 |
| Chen, JH | 1 |
| Nogueira, JL | 1 |
| Flores, N | 1 |
| Gómez, JM | 1 |
| Molina, JR | 1 |
| Camacho, JE | 1 |
| Piñeiro, LM | 1 |
| Rodríguez, RH | 1 |
| Isorna, S | 1 |
| Martínez-Piñeiro, JA | 2 |
| Bartoletti, R | 1 |
| Cai, T | 1 |
| Mondaini, N | 1 |
| Farina, U | 1 |
| Melone, F | 1 |
| Mazzoli, S | 1 |
| Ayyildiz, A | 1 |
| Akgül, T | 1 |
| Chan, SY | 1 |
| Hulsbergen-Van de Kaa, CA | 1 |
| Bi, Y | 1 |
| Zeng, F | 1 |
| Lyakhovich, A | 1 |
| Surralles, J | 1 |
| Qiao, BM | 1 |
| Sun, G | 1 |
| Tang, Y | 1 |
| Chang, JW | 1 |
| Wang, WC | 1 |
| Ma, TX | 1 |
| Speers, AG | 1 |
| Featherstone, JM | 1 |
| Chen, F | 1 |
| Zhang, G | 1 |
| Payne, R | 1 |
| See, WA | 1 |
| Karam, JA | 1 |
| Ashfaq, R | 1 |
| Sagalowsky, AI | 1 |
| Soler-Martínez, J | 1 |
| Vozmediano-Chicharro, R | 1 |
| Morales-Jiménez, P | 1 |
| Hernández-Alcaraz, D | 1 |
| Vivas-Vargas, E | 1 |
| Santos García-Vaquero, I | 1 |
| Baena-González, V | 1 |
| Kalsi, J | 1 |
| Lemy, A | 1 |
| Wissing, KM | 1 |
| Rorive, S | 1 |
| Zlotta, A | 1 |
| Roumeguere, T | 1 |
| Muniz Martinez, MC | 1 |
| Decaestecker, C | 1 |
| Salmon, I | 1 |
| Abramowicz, D | 1 |
| Vanherweghem, JL | 1 |
| Nortier, J | 1 |
| Ost, MC | 1 |
| Patel, KP | 1 |
| Rastinehad, AR | 1 |
| Chu, PY | 1 |
| Anderson, AE | 1 |
| Smith, AD | 1 |
| Lee, BR | 1 |
| Hadaschik, BA | 1 |
| Adomat, H | 1 |
| Fazli, L | 1 |
| Andersen, RJ | 1 |
| Gleave, ME | 1 |
| So, AI | 1 |
| Isbarn, H | 1 |
| Budäus, L | 1 |
| Wang, D | 1 |
| Tian, B | 1 |
| Tian, Y | 1 |
| Beltrami, P | 1 |
| Ruggera, L | 1 |
| Cazzoletti, L | 1 |
| Schiavone, D | 1 |
| Zattoni, F | 3 |
| Weisenthal, LM | 1 |
| Lalude, AO | 1 |
| Miller, JB | 1 |
| Spaulding, JT | 1 |
| Fujii, A | 1 |
| Hamami, G | 2 |
| Umezu, K | 1 |
| Oda, Y | 1 |
| Ishigami, J | 3 |
| Edsmyr, F | 1 |
| Andersson, L | 1 |
| Esposti, PL | 1 |
| Fujihiro, S | 1 |
| Takeuchi, T | 1 |
| Fujimoto, Y | 1 |
| Okano, M | 2 |
| Horie, M | 1 |
| Kanematsu, M | 1 |
| Kuriyama, M | 1 |
| Ban, Y | 1 |
| Nishiura, T | 1 |
| Uchibayashi, T | 2 |
| Ohmori, H | 4 |
| Paulson, DF | 1 |
| Kato, T | 5 |
| Salem, PA | 1 |
| Yoshida, O | 10 |
| Miyakawa, M | 3 |
| Watanabe, H | 3 |
| Mishina, T | 2 |
| Nakagawa, K | 1 |
| Fukuyama, T | 1 |
| Ogura, K | 1 |
| Ueyama, H | 1 |
| Itoh, H | 1 |
| Neild, VS | 1 |
| Sanderson, KV | 1 |
| Riddle, PR | 1 |
| Fujita, J | 3 |
| Tokuda, H | 2 |
| Crabtree, WN | 1 |
| Matheny, RB | 1 |
| Nemoto, R | 3 |
| Shindo, M | 1 |
| Mori, H | 2 |
| Abe, R | 2 |
| Harker, WG | 1 |
| Torti, FM | 3 |
| Lum, BL | 2 |
| Jauhiainen, K | 11 |
| Kangas, L | 2 |
| Nieminen, AL | 1 |
| Käpylä, H | 1 |
| Alfthan, O | 11 |
| Lockhart, JL | 1 |
| Chaikin, L | 1 |
| Bondhus, MJ | 1 |
| Politano, VA | 1 |
| Wajsman, Z | 3 |
| McGill, W | 1 |
| Englander, L | 1 |
| Huben, RP | 2 |
| Pontes, JE | 2 |
| Murphy, WM | 7 |
| Devonec, M | 1 |
| Bouvier, R | 1 |
| Sarkissian, J | 1 |
| Bendimerad, O | 1 |
| Gelet, A | 1 |
| Dubernard, JM | 1 |
| Thomas, SD | 1 |
| Ogawa, H | 2 |
| Hiraoka, Y | 1 |
| Kawai, H | 1 |
| Yamagata, J | 1 |
| Agishi, T | 1 |
| Ota, K | 1 |
| Shida, K | 1 |
| Shibayama, K | 1 |
| Yamanaka, E | 1 |
| Hata, H | 1 |
| Nagata, T | 1 |
| Ikeuchi, T | 2 |
| Onodera, Y | 2 |
| Kai, Y | 2 |
| Friedell, GH | 1 |
| Smith, PH | 8 |
| Child, JA | 1 |
| Mulder, JH | 1 |
| Van Oosterom, AT | 4 |
| Richards, B | 5 |
| Stoter, G | 1 |
| Dalesio, O | 1 |
| De Pauw, M | 3 |
| Ohtani, M | 2 |
| Fukushima, S | 3 |
| Ito, N | 3 |
| Koiso, K | 7 |
| Niijima, T | 5 |
| Harrison, GS | 1 |
| Green, DF | 1 |
| Newling, DW | 6 |
| Robinson, MR | 5 |
| Ratliff, TL | 2 |
| Oakley, DM | 1 |
| Catalona, WJ | 1 |
| Farsund, T | 1 |
| Laerum, OD | 1 |
| Høstmark, J | 1 |
| Jordfald, G | 1 |
| Flüchter, SH | 6 |
| Hlobil, H | 2 |
| Harzmann, R | 5 |
| Rothe, KF | 1 |
| Bichler, KH | 6 |
| Ito, Y | 1 |
| Issell, BF | 1 |
| Prout, GR | 5 |
| Cummings, KB | 1 |
| Brannen, G | 1 |
| Veenema, R | 1 |
| Flanagan, M | 1 |
| Block, NL | 1 |
| Summers, JL | 1 |
| Levin, EA | 1 |
| Hopkins, SC | 2 |
| Buice, RG | 1 |
| Matheny, R | 2 |
| Tenaglia, R | 1 |
| Gentile, V | 1 |
| Koontz, WW | 2 |
| Otto, U | 3 |
| Droese, M | 1 |
| Klöppel, G | 3 |
| Dhafir, RA | 1 |
| Pfeffer, M | 1 |
| MacDonald, S | 1 |
| Block, A | 1 |
| Dragone, N | 1 |
| Yamanaka, H | 1 |
| Kaburagi, Y | 1 |
| Imai, K | 1 |
| Miki, M | 1 |
| Carroll, PR | 1 |
| Williams, RD | 1 |
| Kim, MJ | 1 |
| Dombrovskis, S | 1 |
| Okamura, T | 3 |
| Sakata, T | 1 |
| Erdmann, WD | 1 |
| Denis, L | 3 |
| Kopp, J | 1 |
| Jakse, G | 3 |
| Matsuda, M | 1 |
| Matsumiya, K | 1 |
| Tada, Y | 1 |
| Nakano, E | 1 |
| Fujioka, H | 1 |
| Osafune, M | 1 |
| Takaha, M | 1 |
| Sonoda, T | 1 |
| Unno, K | 1 |
| Goto, A | 1 |
| Murota, H | 1 |
| Harada, M | 1 |
| Homma, M | 1 |
| Whelan, P | 4 |
| Flynn, C | 1 |
| Ramsden, C | 1 |
| Nissenkorn, I | 2 |
| Herrod, H | 1 |
| DeFuria, MD | 2 |
| Crooke, S | 1 |
| Finebaum, P | 1 |
| Wallace, S | 1 |
| Chuang, VP | 1 |
| Samuels, M | 1 |
| Johnson, D | 1 |
| McCallum, LW | 1 |
| Erdmann, D | 2 |
| Erdmann, W | 1 |
| Griffin, PP | 1 |
| Nocks, BN | 1 |
| Daly, JJ | 1 |
| Jacobi, GH | 1 |
| Engelmann, U | 3 |
| Frohneberg, D | 1 |
| Thüroff, JW | 1 |
| Dahm, HH | 1 |
| Lutzeyer, W | 1 |
| Yoshimoto, J | 2 |
| Omoto, T | 2 |
| Kano, M | 1 |
| Ariyoshi, A | 2 |
| Momose, S | 1 |
| Masaki, Z | 1 |
| Morita, I | 2 |
| Ishisawa, N | 1 |
| Hofmann, W | 1 |
| Langkopf, B | 1 |
| Fujiwara, T | 1 |
| Maegawa, M | 1 |
| Nakao, M | 2 |
| Nakagawa, S | 2 |
| Pavlotsky, A | 2 |
| Eidelman, A | 2 |
| Barak, F | 2 |
| Walach, N | 1 |
| Horn, Y | 2 |
| Manyak, MJ | 1 |
| Sekine, H | 8 |
| Yamada, T | 7 |
| Kojima, S | 2 |
| Ohshima, H | 2 |
| Simonato, A | 1 |
| Zanon, M | 1 |
| Carmignani, G | 1 |
| Sengeløv, L | 1 |
| Nielsen, OS | 1 |
| Kamby, C | 1 |
| von der Maase, H | 1 |
| Ruutu, M | 2 |
| Punga-Maole, ML | 1 |
| Hubert, J | 1 |
| Mangin, P | 1 |
| Szemes, Z | 1 |
| Kovács, R | 1 |
| Singh, SV | 10 |
| Xu, BH | 5 |
| Gupta, V | 8 |
| Emerson, EO | 3 |
| Zaren, HA | 6 |
| Jani, JP | 2 |
| Backes, MG | 1 |
| Rihn, C | 1 |
| Scalamogna, D | 2 |
| Stemmler, N | 1 |
| Specht, S | 1 |
| Blanock, K | 1 |
| Moltó, L | 1 |
| Alvarez-Mon, M | 1 |
| Olivier, C | 1 |
| Gimeno, F | 1 |
| Manzano, L | 1 |
| Klingenberger, HJ | 2 |
| Huland, E | 3 |
| Klän, R | 1 |
| Moyano Calvo, JL | 2 |
| Herrero Torres, L | 2 |
| Melón Rey, FJ | 2 |
| Rabadán Ruiz, M | 2 |
| Pereira Sanz, I | 2 |
| Vegt, PD | 1 |
| Doesburg, WH | 2 |
| Debruyne, FM | 10 |
| van der Meijden, AP | 5 |
| Bouffioux, C | 2 |
| Kurth, KH | 4 |
| Kruger, CB | 1 |
| Mizutani, Y | 4 |
| Fukumoto, M | 1 |
| Bonavida, B | 2 |
| Schmittgen, TD | 3 |
| Weaver, JM | 1 |
| Badalament, RA | 10 |
| Klein, EA | 1 |
| Young, DC | 2 |
| Eickelmann, P | 2 |
| Schulz, WA | 2 |
| Rohde, D | 2 |
| Schmitz-Dräger, B | 1 |
| Sies, H | 2 |
| Fernández Arjona, M | 1 |
| Minguez Martínez, R | 1 |
| Lee, SW | 3 |
| Kunimi, K | 1 |
| Ohkawa, M | 1 |
| Endo, Y | 1 |
| Noguchi, M | 1 |
| Minervini, R | 3 |
| Felipetto, R | 3 |
| Viganò, L | 3 |
| Cecchi, M | 2 |
| Fiore, AA | 1 |
| Iorio, B | 1 |
| Vennarecci, G | 1 |
| Venditti, D | 1 |
| Cervelli, V | 1 |
| Giudiceandrea, F | 1 |
| Casciani, CU | 1 |
| Guinda Sevillano, C | 1 |
| Arnáiz Esteban, F | 1 |
| Fernández Rosáenz, J | 1 |
| Pérez Arbej, JA | 1 |
| Martínez Pérez, E | 1 |
| Nogueras Gimeno, MA | 1 |
| Espuela Orgaz, R | 1 |
| Yamada, Y | 2 |
| Washida, H | 1 |
| Tozawa, K | 1 |
| Honma, H | 1 |
| Kang, K | 1 |
| Pagni, G | 1 |
| Mulders, PF | 1 |
| Meyden, AP | 1 |
| Oosterhof, GO | 1 |
| Ohwada, F | 2 |
| Yokokawa, M | 2 |
| Llopis, M | 1 |
| Moreno, J | 1 |
| Botella, R | 1 |
| Algado, M | 1 |
| Boccardo, F | 1 |
| Cannata, D | 1 |
| Rubagotti, A | 1 |
| Guarneri, D | 1 |
| Decensi, A | 1 |
| Canobbio, L | 1 |
| Curotto, A | 1 |
| Martorana, G | 1 |
| Pegoraro, C | 1 |
| Selvaggi, F | 1 |
| Vecchioli Scaldazza, C | 2 |
| Wörle, K | 1 |
| Steinbach, P | 1 |
| Hofstädter, F | 1 |
| Wang, RC | 1 |
| Hassan, F | 1 |
| Regueiro López, JC | 1 |
| Alvarez-Cienfuegos, FR | 1 |
| Leva Vallejo, M | 1 |
| Prieto Castro, R | 1 |
| Merchan García, JA | 1 |
| Saceda López, JL | 1 |
| Requena Tapia, MJ | 1 |
| López-Pardo, RL | 1 |
| Gelabert-Mas, A | 1 |
| Arango Toro, O | 3 |
| Bielsa Gali, O | 3 |
| Lladó Carbonell, C | 2 |
| vd Meijden, AP | 1 |
| Doesburg, W | 3 |
| Schaafsma, HE | 1 |
| Wahlberg, JE | 1 |
| Lindelöf, B | 1 |
| Borgmann, V | 1 |
| al-Abadi, H | 1 |
| Friedrichs, R | 1 |
| Nagel, R | 1 |
| Hamdy, FC | 1 |
| Hastie, KJ | 1 |
| Kerry, R | 1 |
| Williams, JL | 3 |
| Naito, S | 2 |
| Hasegawa, S | 1 |
| Yokomizo, A | 1 |
| Koga, H | 1 |
| Kotoh, S | 1 |
| Kuwano, M | 1 |
| Kumazawa, J | 2 |
| Xia, H | 5 |
| O'Toole, S | 1 |
| Roy, D | 1 |
| Lev, A | 3 |
| Freschi, M | 1 |
| Gallus, G | 1 |
| Tolley, DA | 6 |
| Grigor, KM | 4 |
| Lallemand, G | 1 |
| Benyon, LL | 1 |
| Fellows, J | 1 |
| Freedman, LS | 3 |
| Hall, RR | 3 |
| Hargreave, TB | 6 |
| Munson, K | 1 |
| Rose, MB | 1 |
| Stanisic, TH | 1 |
| Macaluso, MP | 1 |
| Pawinsky, A | 1 |
| Van Glabbeke, M | 1 |
| Vicini, D | 1 |
| Bettaglio, G | 1 |
| Dallera, P | 1 |
| Ruggieri, M | 1 |
| Mirando, P | 1 |
| Franceschetti, GP | 1 |
| Sali, C | 1 |
| Picchio, GL | 1 |
| Dell'Orto, P | 1 |
| D'Addezio, F | 1 |
| Bernardini, P | 1 |
| Pisani, E | 1 |
| Lundholm, C | 2 |
| Norlén, BJ | 2 |
| Ekman, P | 1 |
| Lagerkvist, M | 1 |
| Lindeborg, T | 1 |
| Olsson, JL | 1 |
| Tveter, K | 1 |
| Westberg, R | 1 |
| Ogihara, M | 2 |
| Aikawa, K | 2 |
| Ishibashi, K | 2 |
| Irisawa, C | 2 |
| Shiraiwa, Y | 3 |
| Koseki, K | 5 |
| Ishiwata, H | 1 |
| Xu, B | 1 |
| Villaronga, A | 1 |
| Bellver, E | 1 |
| Perli, G | 1 |
| Pautaso, O | 1 |
| Bengochea, D | 1 |
| Roldán, RA | 1 |
| Podskubska, O | 1 |
| Belén, R | 1 |
| Delgado, G | 1 |
| Laberti, O | 1 |
| Lando, R | 1 |
| Rey, H | 1 |
| Bengio, R | 1 |
| Minuzzi, L | 1 |
| Goldman, E | 1 |
| Milman, A | 1 |
| Sanguinetti, O | 1 |
| Wernert, O | 1 |
| Giani, G | 1 |
| Meyer, R | 1 |
| Otto, T | 2 |
| Iavarone, C | 1 |
| Minocchi, L | 1 |
| Arecchi, S | 1 |
| Nicolucci, D | 1 |
| Porcelli, C | 1 |
| D'orazi, V | 1 |
| Greco, L | 1 |
| Stio, F | 1 |
| Martino, G | 1 |
| Messinetti, S | 1 |
| Pinto, T | 1 |
| Hu, X | 2 |
| Benson, PJ | 1 |
| Pampaloni, S | 1 |
| Fiorentini, L | 1 |
| Bono, AV | 2 |
| Lovisolo, JA | 1 |
| Simak, R | 1 |
| Wiener, H | 2 |
| Foeger, A | 1 |
| Susani, M | 2 |
| Zhang, ZF | 1 |
| Maier, U | 7 |
| Marberger, M | 3 |
| Okamoto, E | 1 |
| Kinne, RK | 1 |
| Sökeland, J | 1 |
| Watts, PL | 1 |
| Plumb, JA | 1 |
| Courtney, JM | 1 |
| Scott, R | 1 |
| Oberfield, RA | 1 |
| Zinman, LN | 1 |
| Leibenhaut, M | 1 |
| Girshovich, L | 1 |
| Silverman, ML | 1 |
| Kawasaki, T | 1 |
| Tomita, Y | 1 |
| Bilim, V | 1 |
| Takeda, M | 1 |
| Takahashi, K | 1 |
| Kumanishi, T | 1 |
| Yen, WC | 2 |
| Schmittgen, T | 1 |
| Kasahara, K | 2 |
| Inoue, Y | 1 |
| Yamashita, M | 1 |
| Morioka, M | 1 |
| Fujita, Y | 1 |
| Shuin, T | 2 |
| Nohales Taurines, G | 1 |
| Cortadellas Angel, R | 1 |
| Gelabert Mas, A | 2 |
| Bleicher, RJ | 3 |
| Ojea Calvo, A | 1 |
| Domínguez Freire, F | 1 |
| Vérez Vivero, M | 1 |
| Alonso Rodrigo, A | 1 |
| Rodríguez Iglesias, B | 1 |
| Benavente Delgado, J | 1 |
| Barros Rodríguez, M | 1 |
| Nogueira March, YJ | 1 |
| Ulker, V | 1 |
| Apaydin, E | 1 |
| Gürsan, A | 1 |
| Ozyurt, C | 1 |
| Kandiloğlu, G | 1 |
| Paroni, R | 2 |
| Arcelloni, C | 1 |
| De Vecchi, E | 1 |
| Fermo, I | 1 |
| Mauri, D | 1 |
| Gomez Torrijos, E | 1 |
| Borja, J | 1 |
| Galindo, PA | 1 |
| Feo, F | 1 |
| Cortina, P | 1 |
| Casanueva, T | 1 |
| Santos, O | 1 |
| Loh, C | 1 |
| Otto, B | 1 |
| Goepel, M | 1 |
| Srivastava, SK | 1 |
| Yamaguchi, O | 1 |
| Mian, C | 1 |
| Hofbauer, J | 1 |
| Haitel, A | 1 |
| Campo, B | 1 |
| Pizzocaro, G | 1 |
| Parma, A | 1 |
| Mazza, G | 1 |
| Vicini, A | 1 |
| Gao, X | 1 |
| Ayed, M | 1 |
| Ben Hassine, L | 1 |
| Ben Slama, R | 1 |
| Chelbi, N | 1 |
| Ghozzi, S | 1 |
| Drissi, H | 1 |
| Jemni, M | 1 |
| Chebil, M | 1 |
| Chopin, DK | 1 |
| Solomon, LZ | 1 |
| Jennings, AM | 1 |
| Foley, SJ | 1 |
| Birch, BR | 1 |
| v d Meijden, AP | 1 |
| Collette, L | 1 |
| van Aubel, A | 1 |
| Raffenberg, G | 1 |
| Kaviani, S | 1 |
| Wolff, J | 1 |
| Kurdistani, SK | 1 |
| Arizti, P | 1 |
| Reimer, CL | 1 |
| Sugrue, MM | 2 |
| Aaronson, SA | 2 |
| Tsukamoto, T | 1 |
| Fujioka, T | 1 |
| Yamauchi, T | 1 |
| Mori, Y | 1 |
| Nagakubo, I | 1 |
| Smits, G | 1 |
| Schaafsma, E | 1 |
| Kiemeney, L | 1 |
| Caris, C | 1 |
| Debruyne, F | 1 |
| Wass, AR | 1 |
| Lawson, TR | 1 |
| Urwin, GH | 1 |
| Iborra, I | 3 |
| Ricós, JV | 3 |
| Monrós, JL | 3 |
| Casanova, J | 3 |
| Dumont, R | 3 |
| Wester, K | 1 |
| Morales, A | 2 |
| Doherty, AP | 1 |
| Trendell-Smith, N | 1 |
| Stirling, R | 1 |
| Rogers, H | 1 |
| Bellringer, J | 1 |
| Mauroy, B | 3 |
| Bonnal, JL | 2 |
| Prevost, B | 2 |
| Chive, M | 2 |
| Lhotellier, V | 1 |
| Sozanski, JP | 2 |
| Vanseymortier, L | 1 |
| Stefaniak, X | 1 |
| Fang, L | 1 |
| Igarashi, M | 2 |
| Leung, J | 1 |
| Ferraris, V | 2 |
| Serao, A | 1 |
| Buffa, G | 1 |
| Weaver, JR | 1 |
| Highley, MS | 1 |
| Maes, RA | 2 |
| De Bruijn, EA | 2 |
| Malmström, P | 1 |
| Melekos, MD | 1 |
| Moutzouris, GD | 1 |
| Kondás, J | 1 |
| Kiss, L | 1 |
| Határ, A | 1 |
| Kiss, A | 1 |
| Lukács, T | 1 |
| Szeldeli, P | 1 |
| Törzsök, F | 1 |
| Bodrogi, I | 1 |
| Cliff, AM | 2 |
| Romaniuk, CS | 1 |
| Parr, NJ | 2 |
| Duque, JL | 1 |
| Loughlin, KR | 1 |
| Kunkeler, L | 1 |
| Nieboer, C | 1 |
| Bruynzeel, DP | 1 |
| Williamson, KE | 2 |
| Weir, HP | 1 |
| McManus, DT | 1 |
| Hamilton, PW | 1 |
| Keane, PF | 2 |
| Johnston, SR | 2 |
| Echarti, C | 1 |
| Jurincic-Winkler, CD | 1 |
| Klippel, KF | 2 |
| Pere, AK | 1 |
| Dietsch, A | 1 |
| Camart, JC | 1 |
| Baselli, EC | 2 |
| Greenberg, RE | 2 |
| Chen, S | 1 |
| Lin, Z | 1 |
| Xu, E | 1 |
| Li, Q | 1 |
| Xu, X | 1 |
| Lismer, L | 1 |
| Heatherwick, B | 1 |
| Scoble, J | 1 |
| Da Pozzo, L | 1 |
| Scattoni, V | 1 |
| Roscigno, M | 1 |
| Neykov, K | 1 |
| Donkov, I | 1 |
| Mirchov, R | 1 |
| Montie, JE | 1 |
| Warner, JA | 1 |
| Venema, PL | 1 |
| Pollifrone, DL | 1 |
| Harbrecht, JD | 1 |
| Chin, JL | 1 |
| Miles, BJ | 1 |
| Sakamoto, N | 1 |
| Osada, Y | 1 |
| Fujisawa, Y | 1 |
| Yamashita, H | 1 |
| Gan, Y | 1 |
| Mo, Y | 1 |
| Kalns, JE | 1 |
| Danenberg, K | 1 |
| Danenberg, P | 1 |
| Sun, HZ | 2 |
| Wu, SF | 2 |
| Tu, ZH | 2 |
| Duggan, BJ | 1 |
| Anderson, NH | 1 |
| Liu, CC | 1 |
| Chou, YH | 1 |
| Huang, CH | 1 |
| Tsai, KB | 1 |
| Moffitt, DD | 1 |
| Peake, D | 1 |
| Cighetti, G | 1 |
| Huncharek, M | 1 |
| Kupelnick, B | 1 |
| Masters, JR | 5 |
| Ohya, K | 1 |
| Kojima, SI | 1 |
| Igarashi, K | 1 |
| Raitanen, MP | 1 |
| Talja, M | 1 |
| Ervasti, J | 1 |
| Tammela, TL | 1 |
| Mack, D | 1 |
| Hall, R | 1 |
| de Balincourt, C | 1 |
| Jang, SH | 1 |
| Zang, Z | 1 |
| Xu, H | 1 |
| Yu, L | 1 |
| Yang, D | 2 |
| Xie, S | 1 |
| Shi, Y | 1 |
| Li, Z | 1 |
| Li, J | 1 |
| Guo, Y | 1 |
| Gu, F | 1 |
| Liu, S | 1 |
| Han, W | 1 |
| Hao, J | 1 |
| Dunst, J | 1 |
| Diestelhorst, A | 1 |
| Heynemann, H | 1 |
| Schrott, KM | 1 |
| Sauer, R | 1 |
| Cuervo Pinna, MA | 1 |
| Cuervo Pinna, C | 1 |
| Macías Castillo, S | 1 |
| Bureo Dacal, JC | 1 |
| Espada Alonso, MJ | 1 |
| Pimentel Leo, J | 1 |
| Mitsumori, K | 1 |
| Sato, K | 2 |
| Irmak, S | 1 |
| Acar, A | 1 |
| Clark, T | 1 |
| Cookson, MS | 1 |
| Morgia, G | 1 |
| Mauceri, G | 1 |
| Mazzone, G | 1 |
| Motta, M | 1 |
| Kakehi, Y | 1 |
| Nishio, Y | 1 |
| Tomoyoshi, T | 1 |
| Konami, T | 1 |
| Usui, T | 1 |
| Igawa, M | 1 |
| Takenaka, I | 1 |
| Fujita, K | 1 |
| Sakai, T | 1 |
| Kimura, H | 1 |
| Katayama, T | 1 |
| Wang, SH | 1 |
| van der Meijden, PM | 2 |
| Roos, EP | 1 |
| Steerenberg, PA | 3 |
| Nakamura, K | 2 |
| Hihara, T | 1 |
| Nishiumi, T | 1 |
| Yoneyama, T | 1 |
| Vidal, C | 1 |
| de la Fuente, R | 1 |
| González Quintela, A | 1 |
| Kotake, T | 2 |
| Matsumura, Y | 5 |
| Isaka, S | 4 |
| Obata, K | 2 |
| Ohashi, Y | 1 |
| Ohe, H | 2 |
| Ohi, Y | 1 |
| Tachibana, Y | 1 |
| Kawai, T | 4 |
| Ishiwata, D | 3 |
| Oshima, H | 1 |
| Okano, T | 2 |
| Abe, K | 1 |
| Shimazaki, J | 2 |
| Uekado, Y | 2 |
| Hirano, A | 2 |
| Shinka, T | 2 |
| Ohkawa, T | 2 |
| Pagano, F | 3 |
| Milani, C | 3 |
| Piazza, N | 2 |
| Meneghini, A | 3 |
| Garbeglio, A | 3 |
| Tsushima, T | 3 |
| Nasu, Y | 2 |
| Abeki, N | 1 |
| Noda, M | 1 |
| Saika, T | 1 |
| Kobashi, K | 1 |
| Ozaki, Y | 3 |
| Tanahashi, T | 1 |
| Busemann, E | 1 |
| Gerdes, J | 1 |
| Ulmer, AJ | 1 |
| Flad, HD | 1 |
| Uemura, M | 1 |
| Kasamatsu, Y | 1 |
| Sawada, M | 1 |
| Takemura, S | 1 |
| Sugino, S | 1 |
| Kondou, M | 1 |
| Droller, MJ | 3 |
| Flanigan, RC | 2 |
| Nseyo, UO | 1 |
| Yamada, S | 1 |
| Deguchi, T | 1 |
| Nezasa, S | 1 |
| Tamaki, M | 1 |
| Ehara, H | 1 |
| Kawada, Y | 1 |
| Höbarth, K | 2 |
| Wu, JJ | 1 |
| Yin, ZL | 1 |
| Zhu, JN | 1 |
| Cho, YH | 1 |
| Straight, RC | 1 |
| Smith, JA | 1 |
| Maruzzi, D | 1 |
| Drago-Ferrante, GL | 1 |
| Sleeboom, HP | 2 |
| van Helsdingen, PJ | 4 |
| Tjaden, UR | 3 |
| Ferrito, F | 1 |
| Brandão, T | 1 |
| Santos, A | 1 |
| Knopf, HJ | 1 |
| Graff, J | 1 |
| Nurmi, M | 1 |
| Lähde, M | 1 |
| Richie, JP | 1 |
| Thrasher, JB | 1 |
| Brosman, SA | 1 |
| Kinoshita, N | 1 |
| Tochigi, H | 1 |
| Yanagawa, M | 1 |
| Yamakawa, K | 1 |
| Sakurai, M | 1 |
| Hioki, T | 1 |
| Kawamura, J | 1 |
| Oliver, RT | 2 |
| Miyanaga, N | 1 |
| Nio, Y | 1 |
| Tarkington, M | 1 |
| Sommers, CL | 1 |
| Gelmann, EP | 1 |
| Tefft, MC | 1 |
| Lynch, JH | 1 |
| Hansson, E | 1 |
| Kanerva, K | 1 |
| Permi, J | 2 |
| Sotarauta, M | 2 |
| Vaalasti, T | 1 |
| Hörbarth, K | 1 |
| Jauhiainen, KE | 1 |
| Alfthan, OS | 1 |
| Gustafson, H | 1 |
| Nyman, C | 1 |
| Brolin, J | 1 |
| Borgström, E | 1 |
| Tribukait, B | 1 |
| Foo, KT | 1 |
| Tan, EC | 1 |
| Tung, KH | 1 |
| Tock, EP | 1 |
| Vesa Llanes, J | 1 |
| Corominas, J | 1 |
| Megias Garrigós, J | 1 |
| Pelluch Auladell, A | 1 |
| Romero Pérez, P | 1 |
| Fernandez García, J | 1 |
| Gassó Matoses, M | 1 |
| Sánchez Marcos, M | 1 |
| Mira Llinarés, A | 1 |
| Arregui, MA | 1 |
| Aguirre, A | 1 |
| Gil, N | 1 |
| Goday, J | 1 |
| Ratón, JA | 1 |
| Drago, JR | 3 |
| Seraphim, LA | 1 |
| Perrapato, SD | 1 |
| Slocum, HK | 1 |
| Rustum, YM | 1 |
| Calabuig, C | 2 |
| Dore, B | 1 |
| Aubert, J | 1 |
| Yabusaki, N | 1 |
| Komatsu, H | 1 |
| Tago, K | 1 |
| Ueno, A | 1 |
| Dalton, JT | 1 |
| Pisters, LL | 1 |
| Tykochinsky, G | 1 |
| Kosmidis, PA | 1 |
| Bacoyiannis, C | 1 |
| Hatzichristou, H | 1 |
| Sonneveld, P | 1 |
| Hagemeyer, A | 1 |
| Abels, J | 1 |
| Stricker, PD | 2 |
| Grant, AB | 2 |
| Hosken, BM | 2 |
| Taylor, JS | 2 |
| Månsson, W | 1 |
| Henrikson, H | 1 |
| Idwall, I | 1 |
| Lindholm, K | 1 |
| Mikulowski, P | 1 |
| Mårtensson, S | 1 |
| Oldbring, J | 1 |
| Feddersen, I | 2 |
| Brachmann, W | 2 |
| Hubmann, H | 2 |
| Kaufmann, J | 2 |
| Knipper, W | 2 |
| Lantzius-Beninga, F | 2 |
| Miura, K | 1 |
| Yuri, Y | 1 |
| Tsukada, T | 1 |
| Yasumoto, R | 1 |
| Asakawa, M | 1 |
| Yoshihara, H | 1 |
| Sakamoto, W | 1 |
| Iseki, T | 1 |
| Nakatani, T | 1 |
| Wada, S | 1 |
| Kishimoto, T | 1 |
| Maekawa, M | 1 |
| Nishio, S | 1 |
| Schneider, A | 1 |
| Arndt, R | 1 |
| Mitsuzane, K | 1 |
| Kawabata, M | 1 |
| Terada, M | 1 |
| Nomura, S | 2 |
| Sato, M | 1 |
| Yamada, R | 1 |
| Eijsten, A | 1 |
| Knönagel, H | 1 |
| Hotz, E | 1 |
| Brütsch, HP | 1 |
| Hauri, D | 1 |
| James, K | 1 |
| Chisholm, GD | 3 |
| Smyth, JF | 1 |
| Colver, GB | 1 |
| Inglis, JA | 2 |
| McVittie, E | 1 |
| Spencer, MJ | 1 |
| Hunter, JA | 1 |
| Honda, K | 1 |
| Satomura, K | 1 |
| Hashida, M | 1 |
| Sezaki, H | 1 |
| Gohji, K | 1 |
| Murao, S | 1 |
| Aogauchi, R | 1 |
| Maeda, S | 1 |
| Sugiyama, T | 1 |
| Uchida, T | 1 |
| Kobayashi, K | 1 |
| Honda, N | 1 |
| Arakawa, T | 1 |
| Omata, T | 1 |
| Endo, T | 1 |
| Ishibashi, A | 1 |
| Koshiba, K | 1 |
| Trybula, M | 1 |
| King, M | 1 |
| Hadjissotiriou, GG | 1 |
| Green, DK | 1 |
| McIntyre, MA | 1 |
| Bahnson, R | 1 |
| Takashi, M | 1 |
| Murase, T | 1 |
| Aota, Y | 1 |
| Nagai, T | 1 |
| Kinjo, T | 1 |
| Sabashi, M | 1 |
| Shimoji, T | 1 |
| Miyake, K | 1 |
| Hamajma, N | 1 |
| Mizuno, S | 1 |
| Russell, KJ | 1 |
| Koh, WJ | 1 |
| Russell, AH | 1 |
| Griffin, BR | 1 |
| Markette, KL | 1 |
| Tong, DY | 1 |
| Griffin, TW | 1 |
| Baumgartner, G | 2 |
| Takeuchi, S | 1 |
| Hosoda, K | 3 |
| Suzuki, S | 1 |
| Giesbers, AA | 1 |
| Kramer, AE | 1 |
| Alon, H | 1 |
| Kim, HH | 1 |
| Lee, C | 1 |
| Irwin, R | 1 |
| Zincke, H | 2 |
| Kubota, Y | 1 |
| Kakizaki, H | 1 |
| Numasawa, K | 1 |
| Suzuki, K | 1 |
| Kato, H | 1 |
| Steimann, J | 1 |
| Strohmaier, WL | 1 |
| Mukamel, E | 1 |
| deKernion, JB | 1 |
| Jordan, AM | 1 |
| de Jong, WH | 2 |
| Steg, A | 1 |
| Boccon-Gibod, L | 1 |
| Hanna, MG | 1 |
| Brosman, S | 1 |
| Fisher, HA | 1 |
| Biserte, J | 1 |
| Rigot, JM | 1 |
| Mazeman, E | 1 |
| Franssen, MP | 2 |
| Taki, Y | 1 |
| Hiura, M | 1 |
| Ryoji, O | 1 |
| Takenawa, J | 1 |
| Kiriyama, T | 1 |
| Drago, PC | 1 |
| Lucas, J | 1 |
| Farha, AJ | 1 |
| Krauss, DJ | 1 |
| Saito, K | 1 |
| Takahashi, T | 1 |
| Uchida, A | 1 |
| Fujimoto, T | 1 |
| Ikenaga, M | 1 |
| Giunta, A | 1 |
| Tejerizo, JC | 1 |
| dal Bianco, M | 1 |
| Zhou, CL | 1 |
| Niell, HB | 1 |
| Wood, CA | 1 |
| Ozono, S | 2 |
| Okajima, E | 2 |
| Hirao, Y | 2 |
| Babaya, K | 1 |
| Komada, S | 1 |
| Matsuki, H | 1 |
| Takahashi, S | 1 |
| Ohishi, H | 1 |
| Yoshioka, T | 1 |
| Tolley, D | 1 |
| Hetherington, JW | 2 |
| Sala, F | 1 |
| Crosti, C | 1 |
| Bencini, PL | 1 |
| Perotta, E | 1 |
| Mansi, M | 1 |
| Weaver, DJ | 2 |
| Barrett, BA | 2 |
| Ross, G | 2 |
| Adelstein, EH | 2 |
| Eifer, K | 1 |
| Frentz, G | 1 |
| Blatnik, AF | 2 |
| Shelton, TB | 1 |
| Mobley, WC | 1 |
| Loening, SA | 1 |
| Narayana, AS | 1 |
| Culp, DA | 1 |
| Cant, JD | 1 |
| Ellison, MF | 1 |
| Butler, KM | 1 |
| Gomella, LG | 1 |
| McRoberts, JW | 1 |
| Zein, TA | 1 |
| Friedberg, N | 1 |
| Kim, H | 1 |
| Groos, E | 2 |
| Rikken, CH | 2 |
| Walker, L | 1 |
| Walker, MC | 2 |
| Parris, CN | 2 |
| Hepburn, PJ | 1 |
| English, PJ | 1 |
| Wilhelms, E | 2 |
| Criée, CP | 2 |
| Neubauer, H | 2 |
| Neuhaus, KL | 2 |
| Ohtaguro, K | 1 |
| Smith, G | 1 |
| Elton, RA | 1 |
| Newsam, JE | 1 |
| Akagi, T | 1 |
| Obama, T | 1 |
| Levin, DR | 1 |
| Araki, S | 1 |
| Numa, H | 1 |
| Okada, K | 1 |
| Erlichman, C | 1 |
| Vidgen, D | 1 |
| Wu, A | 1 |
| Newman, B | 1 |
| Riddle, P | 1 |
| English, P | 1 |
| Adib, RS | 1 |
| Perry, A | 2 |
| Blech, M | 1 |
| Truss, F | 1 |
| Konowalchuk, TW | 1 |
| Elhilali, M | 1 |
| Mackillop, WJ | 1 |
| Chiao, JW | 1 |
| Nagamatsu, GR | 1 |
| Addonizio, JC | 1 |
| Baker, WC | 1 |
| Russo, MA | 1 |
| deVere White, RW | 1 |
| Takada, H | 1 |
| Washizuka, M | 2 |
| Ikegami, S | 2 |
| Igarashi, T | 1 |
| Murakami, S | 1 |
| Higa, T | 1 |
| Ishikawa, T | 1 |
| Zama, S | 1 |
| Kataumi, S | 1 |
| Kataumi, Z | 1 |
| Ohara, S | 1 |
| Hiramatsu, T | 1 |
| Yoshida, K | 3 |
| Yamada, K | 1 |
| Aoyama, H | 1 |
| Hashimoto, M | 1 |
| Watanabe, S | 1 |
| Maru, A | 1 |
| Smith, AY | 1 |
| Vitale, PJ | 1 |
| Lowe, BA | 1 |
| Woodside, JR | 1 |
| Alter, AJ | 1 |
| Malek, GH | 1 |
| Hickey, DP | 1 |
| Tari, K | 1 |
| Satake, I | 1 |
| Negishi, T | 1 |
| Nakame, Y | 1 |
| Kanaoya, F | 1 |
| Horiuchi, S | 1 |
| Saito, T | 1 |
| Owada, F | 1 |
| Heney, NM | 2 |
| Jurincic, CD | 1 |
| Gasch, J | 1 |
| Takiuchi, H | 1 |
| Sugao, H | 1 |
| Yokokawa, K | 1 |
| Takatera, H | 1 |
| Sakurai, T | 1 |
| Ohta, S | 1 |
| Kawano, S | 2 |
| Yano, S | 1 |
| Sakamoto, S | 1 |
| Ogata, J | 1 |
| de Bruyn, EA | 1 |
| Jenkins, BJ | 1 |
| England, HR | 1 |
| Fowler, CG | 1 |
| Tiptaft, RC | 1 |
| Badenoch, DF | 1 |
| Paris, AM | 1 |
| Blandy, JP | 1 |
| Schreinemachers, LM | 1 |
| Geboers, AD | 1 |
| van Leeuwen, MJ | 1 |
| Ruitenberg, EJ | 1 |
| Hardeman, SW | 1 |
| Patterson, JM | 1 |
| Ray, EH | 1 |
| Mendiondo, OA | 1 |
| Medina, WD | 1 |
| Gee, WF | 1 |
| Egghart, G | 1 |
| Steegmüller, O | 1 |
| Wenderoth, U | 1 |
| Hautmann, R | 1 |
| Uscinska, BM | 1 |
| Schwarzman, MI | 1 |
| Johanson, KE | 1 |
| Surya, B | 1 |
| Brown, J | 1 |
| Barton, B | 1 |
| Soloway, M | 1 |
| Trump, DL | 1 |
| Hazra, T | 1 |
| Weinstein, RS | 1 |
| Hatano, T | 1 |
| Miyazato, T | 1 |
| Saito, S | 1 |
| Kashiwabara, N | 1 |
| Koyama, Y | 1 |
| Hayakawa, M | 1 |
| Osawa, A | 1 |
| Fourcade, RO | 1 |
| Giuliano, F | 1 |
| Hu, KN | 1 |
| Kim, A | 1 |
| Khan, AS | 1 |
| Soroff, H | 1 |
| Gonder, M | 1 |
| MacFarlane, JR | 1 |
| Strobel, SL | 1 |
| Tuttle, SE | 1 |
| Wise, HA | 1 |
| Sharma, HM | 1 |
| Keuppens, F | 1 |
| Hendrickx, G | 1 |
| Cooper, EH | 1 |
| Yu, H | 1 |
| Glashan, RW | 1 |
| de Wall, JG | 1 |
| de Jong, EA | 1 |
| Logothetis, CJ | 1 |
| Samuels, ML | 1 |
| Ogden, S | 1 |
| Eksborg, S | 1 |
| Perilä, M | 1 |
| Benson, RC | 1 |
| Hilton, JF | 1 |
| Taylor, WF | 1 |
| Walsh, PC | 1 |
| Whitmore, WF | 1 |
| Somerville, JJ | 1 |
| Kubota, M | 1 |
| Tanaka, K | 1 |
| Holzner, JH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2b, Single-Arm, Multicenter Trial to Evaluate the Efficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients With Low Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC) at Intermediate Risk of Recurrence[NCT03558503] | Phase 2 | 63 participants (Actual) | Interventional | 2018-10-15 | Completed | ||
| Neoadjuvant Short-term Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in NMIBC[NCT03348969] | Phase 4 | 120 participants (Actual) | Interventional | 2017-11-01 | Active, not recruiting | ||
| CALIBER - A Phase II Randomised Feasibility Study of Chemoresection and Surgical Management in Low Risk Non Muscle Invasive Bladder Cancer[NCT02070120] | Phase 2 | 82 participants (Actual) | Interventional | 2014-10-31 | Active, not recruiting | ||
| A Randomized Phase II Study Comparing Single Agent Gemcitabine Intravesical Therapy Versus Mitomycin C in Patients With Intermediate Risk Superficial Bladder Cancer[NCT00192049] | Phase 2 | 90 participants | Interventional | 2003-12-31 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled Phase 3 Multicenter Study of Immediate Postoperative Instillation of Gemcitabine in Patients With Superficial Transitional Cell Carcinoma of the Bladder[NCT00191477] | Phase 3 | 355 participants (Actual) | Interventional | 2004-01-31 | Terminated (stopped due to The study was stopped early for futility reasons.) | ||
| A Prospective, Open-label Randomized Clinical Trial of a Single Bladder Instillation of Mitomycin C vs. Gemcitabine vs. No Additional Treatment Immediately After Transurethral Resection of Bladder Tumor (TURBT)[NCT02695771] | Phase 3 | 101 participants (Actual) | Interventional | 2016-04-19 | Completed | ||
| Effect of Intravesical B.C.G and Gemcitabine on Semen Quality and Testicular Volume in Patients With Non-muscle Invasive Bladder Cancer Patients[NCT05701332] | Phase 4 | 25 participants (Anticipated) | Interventional | 2023-04-01 | Not yet recruiting | ||
| A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) and FGFR Mutations or Fusions[NCT04172675] | Phase 2 | 107 participants (Actual) | Interventional | 2020-02-28 | Active, not recruiting | ||
| HYMN: A Randomized Controlled Phase III Trial Comparing Hyperthermia Plus Mitomycin to a Second Course of Bacillus Calmette-Guerin or Standard Therapy in Patients With Recurrence of Non-Muscle Invasive Bladder Cancer Following Induction or Maintenance Bac[NCT01094964] | Phase 3 | 242 participants (Anticipated) | Interventional | 2009-10-31 | Recruiting | ||
| Pilot Study of External Hyperthermia and Intravesical Mitomycin-C To Treat Recurrent Bladder Cancer After Resection and Standard Adjuvant Therapy[NCT00734994] | Early Phase 1 | 15 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| The Effects of Sequential Mitomycin and Bacillus Calmette-Guérin Treatment Versus Bacillus Calmette-Guérin Monotherapy in Patients With High Risk Non-Muscle Invasive Bladder Cancer[NCT03790384] | Phase 4 | 140 participants (Anticipated) | Interventional | 2019-01-15 | Not yet recruiting | ||
| Intravesical Instillation Therapy With Bacillus Calmette-Guérin (BCG) and Sequential BCG and Electromotive Mitomycin-C (EMDA-MCC) in Patients With High-risk Non-muscle-invasive Bladder Carcinoma[NCT03664869] | Phase 3 | 300 participants (Anticipated) | Interventional | 2018-10-26 | Recruiting | ||
| Prospective Cohort Study of Transurethral Resection of Bladder Tumor (TURBT) Combined With Adjuvant Intravenous GC Chemotherapy to Prevent Moderate-high Recurrence and Progression Risks of Muscle-invasive Bladder Cancer[NCT02716961] | 208 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | |||
| A Randomized Controlled Study Comparing Adjuvant Hyperthermia Treatment in Conjunction With Mitomycin C Versus BCG Immunotherapy (BCG) Adjuvant Treatment in Patients With Superficial Transitional Cell Carcinoma of the Bladder (STCCB)[NCT00384891] | Phase 3 | 190 participants (Actual) | Interventional | 2002-02-28 | Terminated (stopped due to slow accrual) | ||
| The Role of Protopine Associated With Nuciferine (Protoves M1® Syrup) in Controlling Adverse Event During HIVEC® Instillations[NCT04148677] | 100 participants (Anticipated) | Observational | 2019-12-01 | Not yet recruiting | |||
| A Prospective Observational Study to Determine the Negative Predictive Value of UroMark to Rule Out the Presence of Bladder Cancer in Patients With Haematuria.[NCT02676180] | 3,700 participants (Actual) | Observational [Patient Registry] | 2016-03-30 | Completed | |||
| Intravesical Mitomycin-C With Bladder Wall Hyperthermia in Intermediate and High Risk Non-muscle Invasive Bladder Cancer[NCT03694535] | 44 participants (Actual) | Interventional | 2012-01-01 | Completed | |||
| A Randomized Phase II Trial of Sequential Chemo-Immunotherapy Versus Immunotherapy Alone in Carcinoma in Situ of the Urinary Bladder[NCT00023842] | Phase 2 | 97 participants (Actual) | Interventional | 2001-06-30 | Completed | ||
| Intravesically Heated Thermo-chemotherapy With Mitomycin-C Prior to TURBT- Prospective Controlled Study[NCT02471547] | 300 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | |||
| Single Preoperative Intravesical Instillation of Electromotive Mitomycin-c for Primary Non-muscle Invasive Bladder Cancer: a Prospective Randomized Trial.[NCT01149174] | Phase 3 | 352 participants (Actual) | Interventional | 1994-01-31 | Completed | ||
| Intravesical Electromotive Mitomycin for High Risk Urothelial Non-muscle Invasive Bladder Cancer After Intravesical Bacillus Calmette-Guérin Failure[NCT04311580] | Phase 2 | 52 participants (Actual) | Interventional | 2000-01-01 | Completed | ||
| 2X2 Factorial Randomized Phase III Study Comparing Standard Versus Reduced Volume Radiotherapy With and Without Synchronous Chemotherapy in Muscle Invasive Bladder Cancer[NCT00024349] | Phase 3 | 350 participants (Anticipated) | Interventional | 2001-06-30 | Completed | ||
| Efficacy of Atezolizumab Concurrent With Radiotherapy in Patients With Muscle-invasive Bladder cáncer (Study ATEZOBLADDERPRESERVE)[NCT04186013] | Phase 2 | 39 participants (Anticipated) | Interventional | 2019-09-18 | Active, not recruiting | ||
| Sequential Bacillus Calmette-Guérin and Electromotive Mitomycin-C Versus Bacillus Calmette-Guérin Alone for High Risk Superficial Bladder Cancer: a Prospective Randomised Study[NCT01442519] | Phase 3 | 212 participants (Actual) | Interventional | 1994-01-31 | Completed | ||
| Clinical Study of Intravesical Epirubicin Plus BCG to Prevent the Recurrence of Transitional Cell Carcinoma of Bladder After Surgical Management[NCT00343356] | Phase 2 | 138 participants | Interventional | 1996-06-30 | Completed | ||
| Celecoxib for the Treatment of Non-muscle Invasive Bladder Cancer[NCT02343614] | Phase 2 | 58 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| The Effects of Exercise Training on Tumor Vascularity and Response to Neoadjuvant Therapy in Operable Breast Cancer: A Phase I-II Study[NCT00405678] | Phase 1/Phase 2 | 23 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To evaluate the tumor ablative effect of UGN-102 in patients with LG NMIBC. CR rate was defined as the percentage of patients with no detectable disease (NDD) as determined by cystoscopy, for cause biopsy, and urine cytology. (NCT03558503)
Timeframe: 3 months after the first instillation of UGN-102
| Intervention | percentage of patients (Number) |
|---|---|
| UGN-102 | 65.1 |
Mitomycin AUC was assessed in a subset of 6 patients treated with UGN-102 (NCT03558503)
Timeframe: 0 (pre-instillation) to 6 hours after the first instillation of UGN-102
| Intervention | ng*h/mL (Mean) |
|---|---|
| UGN-102 | 5.69 |
Mitomycin Cmax was assessed in a subset of 6 patients treated with UGN-102 (NCT03558503)
Timeframe: 0 (pre-instillation), 0.5, 1, 2, 3, 4, 5, and 6 hours after the first instillation of UGN-102
| Intervention | ng/mL (Mean) |
|---|---|
| UGN-102 | 2.27 |
The number of patients with abnormal, CS physical examination findings post-baseline will be summarized (NCT03558503)
Timeframe: Up to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| UGN-102 | 0 |
The number of patients with abnormal, CS urology-oriented physical examination findings post-baseline will be summarized (NCT03558503)
Timeframe: Up to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| UGN-102 | 2 |
The number of patients who met PCS criteria for vital signs parameters post-baseline will be summarized (NCT03558503)
Timeframe: Up to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| UGN-102 | 8 |
To evaluate the durability of response in patients with LG NMIBC who achieve CR. DCR rate was defined as the percentage of patients who maintained CR at the respective time point. (NCT03558503)
Timeframe: 6, 9, and 12 months after the first instillation of UGN-102
| Intervention | percentage of patients (Number) | ||
|---|---|---|---|
| 6 months (3 months after CR at the 3-month Visit) | 9 months (6 months after CR at the 3-month Visit) | 12 months (9 months after CR at the 3-month Visit) | |
| UGN-102 | 95.1 | 73.2 | 61.0 |
Mitomycin plasma concentrations were assessed in a subset of 6 patients treated with UGN-102 (NCT03558503)
Timeframe: 0 (pre-instillation), 0.5, 1, 2, 3, 4, 5, and 6 hours after the first instillation of UGN-102
| Intervention | ng/mL (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Pre-instillation | 0.5 hours post-instillation | 1 hour post-instillation | 2 hours post-instillation | 3 hours post-instillation | 4 hours post-instillation | 5 hours post-instillation | 6 hours post-instillation | |
| UGN-102 | 0 | 0.75 | 0.60 | 0.34 | 1.88 | 1.93 | 0.57 | 0.32 |
The number of patients who met PCS criteria for chemistry or hematology parameters post-baseline will be summarized (NCT03558503)
Timeframe: Up to 12 months
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Any PCS chemistry value | Any PCS hematology value | |
| UGN-102 | 8 | 4 |
The number of patients with each type of event will be summarized. Adverse event severity was graded according to Common Terminology Criteria for Adverse Events version 5.0 as follows: Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe or medically significant), Grade 4 (life-threatening), Grade 5 (fatal). (NCT03558503)
Timeframe: Up to 12 months
| Intervention | Participants (Count of Participants) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Any TEAEs | Any study drug or procedure related TEAEs | Maximum severity Grade 1 | Maximum severity Grade 2 | Maximum severity Grade 3 | Maximum severity Grade 4 | Maximum severity Grade 5 | Any TEAEs leading to treatment discontinuation | Any serious TEAEs | |
| UGN-102 | 57 | 40 | 26 | 24 | 5 | 1 | 1 | 6 | 5 |
Defined as the time from study enrollment to the date of the first procedure confirming histopathological recurrence or disease progression or death from any cause. Recurrence-free survival (RFS) was censored at the date of the last follow-up visit for participants who were still alive and who had no recurrence/progression. (NCT00191477)
Timeframe: Surgery to recurrence or death (Follow-up assessments were performed at 3 and 6 months after the first TUR-BT, and every 6 months thereafter, until recurrence/progression of disease, or until the end of study, up to 24 months)
| Intervention | Months (Median) |
|---|---|
| Gemcitabine | 37.2 |
| Placebo | 40.2 |
RFS rate was estimated using Kaplan-Meier method. RFS was analyzed in different subgroups based on risk, disease status, and concomitant Bacillus Calmette-Guerin (BCG) instillations. Risk: Grading (G1,G2,G3) was performed according to American Joint Committee on Cancer Staging Criteria for Bladder Cancer. Newly diagnosed disease: Initial diagnosis at study entry. Recurrent disease: history of at least one superficial bladder tumor that was surgically treated and relapsed prior to study entry. With BCG: received at least one instillation of BCG during study. Without BCG: didn't receive BCG. (NCT00191477)
Timeframe: Surgery to recurrence or death (Follow-up assessments were performed at 3 and 6 months after the first TUR-BT, and every 6 months thereafter, until recurrence/progression of disease, or until the end of study, up to 24 months)
| Intervention | percentage of participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Low Risk (G1/G2) - 12 Months (N=106, N=109) | Low Risk (G1/G2) - 24 Months (N=106, N=109) | High Risk (G3) - 12 Months (N=13, N=14) | High Risk (G3) - 24 Months (N=13, N=14) | Newly Diagnosed Disease - 12 Months (N=94, N=98) | Newly Diagnosed Disease - 24 Months (N=94, N=98) | Recurrent Disease - 12 Months (N=30, N=26) | Recurrent Disease - 24 Months (N=30, N=26) | With BCG - 12 Months (N=13, N=21) | With BCG - 24 Months (N=13, N=21) | Without BCG - 12 Months (N=111, N=103) | Without BCG - 24 Months (N=111, N=103) | |
| Gemcitabine | 78.5 | 63.9 | 66.7 | 57.1 | 79.3 | 65.4 | 72.2 | 59.5 | 61.5 | 49.2 | 79.9 | 65.8 |
| Placebo | 78.4 | 64.3 | 42.4 | 31.8 | 79.8 | 63.6 | 58.9 | 50.5 | 79.4 | 63.5 | 74.5 | 60.1 |
Because median time to recurrence was not reached, percentage of participants without event was estimated using Kaplan-Meier method. Time to recurrence was censored on date of death for patients who died, and on date of last visit for patients who were alive, without recurrence. (NCT00191477)
Timeframe: Surgery to recurrence (Follow-up assessments were performed at 3 and 6 months after the first TUR-BT, and every 6 months thereafter, until recurrence/progression of disease, or until the end of study, up to 24 months)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Recurrence-Free at 12 Months | Recurrence-Free at 24 Months | |
| Gemcitabine | 78.4 | 66.3 |
| Placebo | 76.9 | 63.7 |
Tumor recurrence type (superficial, stage pTA or pT1; or muscle-invasive, stage≥pT2) was classified according to American Joint Committee on Cancer Staging Criteria for Bladder Cancer (AJCC Cancer Staging Manual, 6th edition). (NCT00191477)
Timeframe: Surgery to recurrence (Follow-up assessments were performed at 3 and 6 months after the first TUR-BT, and every 6 months thereafter, until recurrence/progression of disease, or until the end of study, up to 24 months)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| No Tumor Recurrence | Superficial Tumor - Stage pTa or pT1 | Muscle-Invasive Tumor - Any Stage ≥pT2 | pTx - Tumor Cannot be Assessed | |
| Gemcitabine | 76 | 44 | 3 | 1 |
| Placebo | 78 | 45 | 1 | 0 |
The secondary endpoint for this study will be the number of subjects who did not experience dystrophic calcification or bladder calculi measured by the number of patients with Grade 3 through Grade 5 Adverse Events that are related to study arm, graded according to NCI CTCAE Version 4.03.Version 4.03 (NCT02695771)
Timeframe: Two years
| Intervention | Participants (Count of Participants) |
|---|---|
| Mitomycin C | 24 |
| Gemcitabine | 23 |
| No Intervention | 25 |
The NCI CTCAE Version 4.03 grades adverse events as follows: grade 3 include severe but non-life-threatening consequences that result in hospitalization and/or interventions, including elective radiologic or operative interventions; grade 4 events include life-threatening consequences, such as those requiring urgent reoperation; and grade 5 events result in treatment-related death. (NCT02695771)
Timeframe: Two years
| Intervention | Participants (Count of Participants) |
|---|---|
| Mitomycin C | 15 |
| Gemcitabine | 14 |
| No Intervention | 20 |
Time to first recurrence of cancer in the bladder. (NCT00734994)
Timeframe: Median follow-up 3.18 years
| Intervention | Months (Median) |
|---|---|
| Hyperthermia System, Mitomycin C | 15.4 |
Number of patient treatments stopped due to safety concerns or treatment intolerability. All events below are grade 1/2 toxicity. No grade 3-5 toxicity was observed. (NCT00734994)
Timeframe: During Treatment Phase average 6 weeks
| Intervention | Grade 1/2 event count (no grade 3+) (Number) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abdominal pain | Fatigue | Myalgia | Heat intolerance | Urethral pain | Chemical cystitis | Hematuria | Bladder spasm | Weak urinary stream | Vaginitis | Nausea | Constipation | Swelling | Pruritis | Rash | Bruising | Flushing | Dizziness | Confusion | Anxiety | Extrapyramidal symptoms | Urinary Tract Infection | Hypertension | |
| Mitomycin C With Hyperthermia | 5 | 2 | 1 | 1 | 6 | 4 | 3 | 2 | 1 | 1 | 2 | 1 | 4 | 3 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 2 | 3 |
113 reviews available for mitomycin and Bladder Cancer
| Article | Year |
|---|---|
Underutilization of Blue Light Cystoscopy for Bladder Cancer in the United States.
Topics: Cystectomy; Cystoscopy; Humans; Mitomycin; United States; Urethra; Urinary Bladder Neoplasms | 2022 |
Immunotherapy for non-muscle-invasive bladder cancer: from the origins of BCG to novel therapies.
Topics: BCG Vaccine; Humans; Immune Checkpoint Inhibitors; Mitomycin; Toll-Like Receptors; Urinary Bladder N | 2022 |
Adjuvant therapies for non-muscle-invasive bladder cancer: advances during BCG shortage.
Topics: Adjuvants, Immunologic; Administration, Intravesical; BCG Vaccine; Female; Humans; Male; Mitomycin; | 2022 |
Drug instillation in the management of urinary tract urothelial carcinoma.
Topics: Carcinoma, Transitional Cell; Humans; Instillation, Drug; Kidney; Mitomycin; Neoplasm Recurrence, Lo | 2022 |
Comparison Between Intravesical Chemotherapy Epirubicin and Mitomycin-C after TURB vs TURB Alone With Recurrence Rate of Non-Muscle Invasive Bladder Cancer: Meta-Analysis.
Topics: Administration, Intravesical; Carcinoma, Transitional Cell; Epirubicin; Female; Humans; Male; Mitomy | 2022 |
The clinical efficacy and safety of equipment-assisted intravesical instillation of mitomycin C after transurethral resection of bladder tumour in patients with nonmuscular invasive bladder cancer: A meta-analysis.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Hematuria; Humans; Mitomycin; Prospective | 2022 |
A systematic review of the efficacy of intravesical electromotive drug administration therapy for non-muscle invasive bladder cancer.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Humans; Mitomycin; Neoplasm | 2023 |
The Emerging Evidence Supporting Integration of Deep Regional Hyperthermia With Chemoradiation in Bladder Cancer.
Topics: Chemoradiotherapy; Combined Modality Therapy; Humans; Hyperthermia, Induced; Mitomycin; Prospective | 2023 |
The Emerging Evidence Supporting Integration of Deep Regional Hyperthermia With Chemoradiation in Bladder Cancer.
Topics: Chemoradiotherapy; Combined Modality Therapy; Humans; Hyperthermia, Induced; Mitomycin; Prospective | 2023 |
The Emerging Evidence Supporting Integration of Deep Regional Hyperthermia With Chemoradiation in Bladder Cancer.
Topics: Chemoradiotherapy; Combined Modality Therapy; Humans; Hyperthermia, Induced; Mitomycin; Prospective | 2023 |
The Emerging Evidence Supporting Integration of Deep Regional Hyperthermia With Chemoradiation in Bladder Cancer.
Topics: Chemoradiotherapy; Combined Modality Therapy; Humans; Hyperthermia, Induced; Mitomycin; Prospective | 2023 |
A Systematic Review and Meta-analysis of Chemoablation for Non-muscle-invasive Bladder Cancer.
Topics: Administration, Intravesical; Aged; Gemcitabine; Humans; Mitomycin; Non-Muscle Invasive Bladder Neop | 2023 |
A Systematic Review and Meta-analysis of Chemoablation for Non-muscle-invasive Bladder Cancer.
Topics: Administration, Intravesical; Aged; Gemcitabine; Humans; Mitomycin; Non-Muscle Invasive Bladder Neop | 2023 |
A Systematic Review and Meta-analysis of Chemoablation for Non-muscle-invasive Bladder Cancer.
Topics: Administration, Intravesical; Aged; Gemcitabine; Humans; Mitomycin; Non-Muscle Invasive Bladder Neop | 2023 |
A Systematic Review and Meta-analysis of Chemoablation for Non-muscle-invasive Bladder Cancer.
Topics: Administration, Intravesical; Aged; Gemcitabine; Humans; Mitomycin; Non-Muscle Invasive Bladder Neop | 2023 |
Effect of intravesical mitomycin compared with gemcitabine on the treatment non-muscle invasive bladder cancer: A meta-analysis.
Topics: Administration, Intravesical; Cystitis; Deoxycytidine; Gemcitabine; Hematuria; Humans; Mitomycin; No | 2023 |
Mitomycin Gel (UGN-101) as a Kidney-sparing Treatment for Upper Tract Urothelial Carcinoma in Patients with Imperative Indications and High-grade Disease.
Topics: Carcinoma, Transitional Cell; Humans; Kidney; Kidney Neoplasms; Mitomycin; Multicenter Studies as To | 2023 |
Heated Intravesical Chemotherapy: Biology and Clinical Utility.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Humans; Hyperthermia, Induced; Mitomycin; | 2020 |
Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma, Transitional Cell | 2020 |
Treatment options and results of adjuvant treatment in nonmuscle-invasive bladder cancer (NMIBC) during the Bacillus Calmette-Guérin shortage.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Chemotherapy, Adjuvant; Huma | 2020 |
Chemoablation in Urothelial Carcinoma: A Systematic Review and Future Perspectives.
Topics: Administration, Intravesical; Antineoplastic Agents; Aziridines; BCG Vaccine; Carcinoma, Transitiona | 2020 |
Intravesical gemcitabine versus mitomycin for non-muscle invasive bladder cancer: a systematic review and meta-analysis of randomized controlled trial.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Deoxycyt | 2020 |
Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer: Abridged summary of the Cochrane Review.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Huma | 2020 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
BCG + Mitomycin trial for high-risk non-muscle-invasive bladder cancer: progress report and lessons learned.
Topics: Administration, Intravesical; Australia; BCG Vaccine; Clinical Trials, Phase III as Topic; Disease-F | 2017 |
Systematic Review and Cumulative Analysis of the Combination of Mitomycin C plus Bacillus Calmette-Guérin (BCG) for Non-Muscle-Invasive Bladder Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Female; Humans; Male; Middle Aged | 2017 |
Intravesical electromotive drug administration for non-muscle invasive bladder cancer.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma in Situ; Carcinoma | 2017 |
[Thermochemotherapy with Mitomycin C: an update on alternative treatment strategies in non-muscleinvasive bladder cancer].
Topics: Antibiotics, Antineoplastic; BCG Vaccine; Disease Progression; Humans; Hyperthermia, Induced; Mitomy | 2018 |
[Radiochemotherapy for invasive bladder cancer : An update].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Biopsy; Carcinoma, Transitional Cell; Chemoradio | 2018 |
Emerging intravesical drugs for the treatment of non muscle-invasive bladder cancer.
Topics: Administration, Intravesical; Animals; Antineoplastic Agents; BCG Vaccine; Disease Progression; Drug | 2018 |
[Chemohyperthermia using MMC in non-muscle-invasive bladder cancer: Current status and future perspectives.]
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Combined Modality Therapy; Forecasting; H | 2018 |
[Immediate post TURBT MMC instillation.]
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Combined Mo | 2018 |
[Mitomycin C HIVEC. Update and results in high risk patients.]
Topics: Antibiotics, Antineoplastic; Combined Modality Therapy; Humans; Hyperthermia, Induced; Mitomycin; Ri | 2018 |
Analysis of tolerance and security of chemo hyperthermia with Mitomycin C for the treatment of non-muscle invasive bladder cancer.
Topics: Antibiotics, Antineoplastic; Combined Modality Therapy; Humans; Hyperthermia, Induced; Mitomycin; Ne | 2018 |
[EMDA with MMC. Critical review.]
Topics: Antibiotics, Antineoplastic; Electrochemotherapy; Humans; Mitomycin; Urinary Bladder Neoplasms | 2018 |
[Sequential treatment with Mitomycin C and BCG in non muscle invasive bladder cancer.]
Topics: Adjuvants, Immunologic; Antibiotics, Antineoplastic; BCG Vaccine; Drug Therapy, Combination; Humans; | 2018 |
[Nonmuscle invasive bladder cancer : Efficacy of electromotive drug administration].
Topics: Administration, Intravesical; Drug Administration Routes; Humans; Iontophoresis; Mitomycin; Neoplasm | 2018 |
Current Clinical Trials in Non-muscle Invasive Bladder Cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibodies, Monoclonal; Antibodies, Monoclonal | 2018 |
Urothelial carcinoma in children, case report with review of literature.
Topics: Administration, Intravesical; Adolescent; Age of Onset; Antibiotics, Antineoplastic; Carcinoma, Tran | 2019 |
[Medical treatment of bladder carcinoma].
Topics: Aminolevulinic Acid; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; BC | 2013 |
Optimizing intravesical mitomycin C therapy in non-muscle-invasive bladder cancer.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Drug Resistance, Neoplasm; Drug Therapy, | 2014 |
Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma
Topics: Administration, Intravesical; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitiona | 2016 |
WITHDRAWN: Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T I bladder cancer.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma in Situ; Carcinoma | 2015 |
The role of hyperthermia as a treatment for non-muscle invasive bladder cancer.
Topics: Administration, Intravesical; Animals; Antibiotics, Antineoplastic; Combined Modality Therapy; Human | 2016 |
Recurrent verrucous carcinoma of the urinary bladder after transurethral resection followed by intravesical mitomycin, and a review of the literature.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma, Verrucous; Humans; Male; | 2016 |
High-Risk Non-Muscle-Invasive Bladder Cancer-Therapy Options During Intravesical BCG Shortage.
Topics: Antineoplastic Agents; BCG Vaccine; Cystectomy; Humans; Hyperthermia, Induced; Immunotherapy; Mitomy | 2016 |
Comparison of the combination therapy of bacillus Calmette-Guérin and mitomycin C with the monotherapy for non-muscle-invasive bladder cancer: a meta-analysis.
Topics: Antibiotics, Antineoplastic; BCG Vaccine; Combined Modality Therapy; Humans; Mitomycin; Urinary Blad | 2016 |
Mitomycin C: new strategies to improve efficacy of a well-known therapy.
Topics: Antibiotics, Antineoplastic; Humans; Mitomycin; Treatment Outcome; Urinary Bladder Neoplasms | 2016 |
Mitomycin C from birth to adulthood.
Topics: Adult; Antibiotics, Antineoplastic; Child; Humans; Mitomycin; Urinary Bladder Neoplasms; Young Adult | 2016 |
Intravesical electro-osmotic administration of mitomycin C.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Electrochemotherapy; Electroosmosis; Huma | 2016 |
Radiofrequency-induced thermo-chemotherapy effect (RITE) for non muscle invasive bladder cancer treatment: current role and perspectives.
Topics: Antibiotics, Antineoplastic; Humans; Hyperthermia, Induced; Mitomycin; Neoplasm Invasiveness; Urinar | 2016 |
Evaluating the efficacy and safety of intravesical chemotherapies for non-muscle invasive bladder cancer: a network meta-analysis.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocol | 2016 |
Assessing the Feasibility of Replacing Standard-Dose Bacillus Calmette-Guérin Immunotherapy with Other Intravesical Instillation Therapies in Bladder Cancer Patients: A Network Meta-Analysis.
Topics: Epirubicin; Female; Humans; Immunotherapy; Male; Mitomycin; Mycobacterium bovis; Urinary Bladder Neo | 2017 |
[Management of Ta, T1, and in situ bladder carcinoma: what is new?].
Topics: Adjuvants, Immunologic; Age Factors; Aged; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma in Si | 2008 |
[Bacillus of Calmette-Guérin immunotherapy: which protocol?].
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Clin | 2008 |
Therapeutic options in the management of intermediate-risk nonmuscle-invasive bladder cancer.
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma in Situ; Disease Progres | 2009 |
Intravesical electromotive drug administration of mitomycin-C for non-muscle invasive bladder cancer.
Topics: Antibiotics, Antineoplastic; Electrochemotherapy; Humans; Mitomycin; Neoplasm Invasiveness; Urinary | 2008 |
An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Huma | 2009 |
An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Huma | 2009 |
An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Huma | 2009 |
An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Huma | 2009 |
Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analyses.
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Combined Modality Therapy; Epirubi | 2010 |
Failure of bacille Calmette-Guérin in patients with high risk non-muscle-invasive bladder cancer unsuitable for radical cystectomy: an update of available treatment options.
Topics: Adjuvants, Immunologic; Administration, Intravesical; BCG Vaccine; Combined Modality Therapy; Cystec | 2010 |
Mitomycin C for the treatment of bladder cancer.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Clinical Trials as Topic; Drug Eruptions; | 2010 |
Update on intravesical agents for non-muscle-invasive bladder cancer.
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Combined Modality Therapy; Cystect | 2010 |
The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Combined Modality Therapy; Humans; Hypert | 2011 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2012 |
Adjuvant methods to improve results of local bladder irrigations by chemotherapy for NMIBC.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Combined Mo | 2013 |
Experience with newer intravesical chemotherapy for high-risk non-muscle-invasive bladder cancer.
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Deox | 2013 |
Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Cyst | 2003 |
Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma in Situ; Carcinoma | 2003 |
[Cyclophosphamide-induced bladder cancer: three case reports].
Topics: Administration, Intravesical; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; | 2003 |
Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Huma | 2004 |
Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Carc | 2004 |
Management of muscle invasive bladder cancer--British approaches to organ conservation.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2005 |
Bladder cancer: current optimal intravesical treatment.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Cystectomy | 2005 |
Intravesical mitomycin C for superficial transitional cell carcinoma.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Clinical Tr | 2006 |
Repeat transurethral resection lowers recurrence rates in T1 bladder tumors, even after intravesical mitomycin C.
Topics: Administration, Intravesical; Carcinoma, Transitional Cell; Humans; Male; Mitomycin; Neoplasm Recurr | 2006 |
Risk of post-operative intravesical mitomycin C instillation following transurethral bladder tumor resection.
Topics: Administration, Intravesical; Animals; Antibiotics, Antineoplastic; Chemotherapy, Adjuvant; Humans; | 2006 |
Electromotive drug administration with mitomycin C for intravesical treatment of non-muscle invasive transitional cell carcinoma.
Topics: Administration, Intravesical; Animals; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Hu | 2008 |
Intravesical chemotherapy in the United States. An overview.
Topics: BCG Vaccine; Bleomycin; Carcinoma in Situ; Clinical Trials as Topic; Doxorubicin; Humans; Mitomycin; | 1983 |
Treatment of superficial carcinoma of the bladder.
Topics: Antineoplastic Agents; BCG Vaccine; Bleomycin; Carcinoma in Situ; Carcinoma, Transitional Cell; Comb | 1984 |
Systemic therapy of bladder cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Transit | 1984 |
The chemotherapy of bladder carcinoma: systemic therapy.
Topics: Alkylating Agents; Antineoplastic Agents; Cisplatin; Doxorubicin; Drug Therapy, Combination; Fluorou | 1983 |
Intravesical chemotherapy of superficial bladder cancer.
Topics: Absorption; Animals; Antineoplastic Agents; BCG Vaccine; Carcinoma in Situ; Doxorubicin; Endoscopy; | 1983 |
Current topics in the pathology of bladder cancer.
Topics: Carcinoma in Situ; Carcinoma, Transitional Cell; Chromosome Aberrations; Chromosomes, Human, 1-3; Cy | 1983 |
The biology and treatment of superficial bladder cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; BCG Vaccine; Carcinoma, Squamous Cell; Carcinoma, Trans | 1984 |
Therapeutic use of mitomycin C in bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Mitomycin; Mitomyc | 1984 |
Intravesical chemotherapy.
Topics: Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Clinical Trials as Topic; Combined | 1984 |
Intravesical and systemic chemotherapy in the management of superficial bladder cancer.
Topics: Administration, Topical; Aged; Antineoplastic Agents; Biopsy; Carcinoma, Transitional Cell; Cisplati | 1984 |
[Clinical application of microencapsulated antineoplastic agents].
Topics: Animals; Antibiotics, Antineoplastic; Capsules; Delayed-Action Preparations; Dogs; Embolization, The | 1982 |
[Bladder retraction, a complication of chemoprophylaxis of superficial bladder cancer using intravesical mitomycin C. Apropos of a case and review of the literature].
Topics: Administration, Intravesical; Aged; Chemoprevention; Cystitis; Humans; Male; Mitomycin; Urinary Blad | 1995 |
BCG in perspective: advances in the treatment of superficial bladder cancer.
Topics: Administration, Intravesical; BCG Vaccine; Doxorubicin; Humans; Mitomycin; Neoplasm Recurrence, Loca | 1995 |
[Our experience with mitomycin C in the prophylaxis of superficial bladder tumors; retrospective study].
Topics: Female; Follow-Up Studies; Humans; Male; Middle Aged; Mitomycin; Neoplasm Recurrence, Local; Retrosp | 1994 |
Papillary-like bladder calcifications following intravescical mitomycin C. A case report.
Topics: Administration, Intravesical; Calcinosis; Carcinoma, Transitional Cell; Combined Modality Therapy; H | 1993 |
[Intravesical instillation in the treatment of superficial tumors of the bladder].
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma; Carcinoma, Transi | 1998 |
Intravesical drug delivery. Pharmacokinetic and clinical considerations.
Topics: Absorption; Administration, Intravesical; Animals; Antibiotics, Antineoplastic; Area Under Curve; Bi | 1999 |
Improved patient outcomes with BCG immunotherapy vs. chemotherapy - Swedish and worldwide experience.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Chemotherapy, Adjuvant; Comb | 2000 |
Intravesical therapy of superficial bladder cancer.
Topics: Administration, Intravesical; Antineoplastic Agents; Doxorubicin; Epirubicin; Humans; Immunotherapy; | 2000 |
An overview of the treatment of superficial bladder cancer. Intravesical chemotherapy.
Topics: Administration, Intravesical; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2000 |
Intravesical therapy for superficial bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Anticarcinogenic | 2000 |
Maintenance therapy for superficial bladder cancer.
Topics: Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma, Transitional Cell; Combined Modality Therapy; H | 2001 |
Chemotherapeutic prophylaxis of superficial bladder tumors.
Topics: Antineoplastic Agents; Doxorubicin; Humans; Mitomycin; Neoplasm Recurrence, Local; Urinary Bladder N | 2001 |
Radiochemotherapy for T1G3 bladder cancer.
Topics: Antineoplastic Agents; Brachytherapy; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Combined | 2002 |
[Intra-arterial chemotherapy in urological cancer].
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capsules; Carcinoma, Re | 2002 |
[Practical impact of pharmacologic and clinical data on early post-operative instillation of mitomycin C].
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Chemotherapy, Adjuvant; Clinical Trials a | 2002 |
BCG in superficial bladder cancer: a review of phase III European trials.
Topics: Administration, Intravesical; BCG Vaccine; Carcinoma in Situ; Carcinoma, Transitional Cell; Clinical | 1992 |
[A case of secondary myelodysplastic syndrome following chemotherapy for lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinoma, Transitio | 1992 |
Managing superficial bladder cancer: an overview.
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Comb | 1992 |
Intravesical chemotherapy. Treatment selection, techniques, and results.
Topics: Administration, Intravesical; Antineoplastic Agents; Carcinoma in Situ; Carcinoma, Transitional Cell | 1992 |
Complications of intravesical chemotherapy.
Topics: Administration, Intravesical; Antineoplastic Agents; Carcinoma, Transitional Cell; Doxorubicin; Epir | 1992 |
Bacillus Calmette-Guérin immunotherapy. Techniques and results.
Topics: Administration, Intravesical; BCG Vaccine; Carcinoma in Situ; Carcinoma, Transitional Cell; Clinical | 1992 |
[Calcified bladder lesions secondary to the instillation of mitomycin C].
Topics: Administration, Intravesical; Calcinosis; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Comb | 1991 |
Current concepts in the management of superficial bladder cancer.
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Combined Modality Therapy; Cystosc | 1990 |
Rationale for intravesical chemotherapy in the treatment and prophylaxis of superficial transitional cell carcinoma.
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma in Situ; Carcinoma, Tran | 1989 |
Complications of Bacillus Calmette-Guerin immunotherapy: review of 2602 patients and comparison of chemotherapy complications.
Topics: Antineoplastic Agents; BCG Vaccine; Doxorubicin; Humans; Mitomycin; Mitomycins; Sepsis; Tuberculosis | 1989 |
Intravesical mitomycin C and superficial bladder tumors.
Topics: Administration, Intravesical; Carcinoma in Situ; Humans; Instillation, Drug; Mitomycin; Mitomycins; | 1989 |
Intravesical chemotherapy: how effective is it?
Topics: Administration, Intravesical; BCG Vaccine; Carcinoma, Transitional Cell; Doxorubicin; Humans; Mitomy | 1988 |
Treatment schedule of intravesical chemotherapy with mitomycin C in superficial bladder cancer: short-term courses or maintenance therapy.
Topics: Administration, Intravesical; Carcinoma, Transitional Cell; Clinical Trials as Topic; Drug Administr | 1988 |
Introduction and overview of intravesical therapy for superficial bladder cancer.
Topics: Administration, Intravesical; BCG Vaccine; Carcinoma in Situ; Carcinoma, Transitional Cell; Doxorubi | 1988 |
Intravesical therapy for bladder cancer.
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Cystoscopy; Doxorubicin; Female; H | 1988 |
Mitomycin C therapy in superficial bladder cancer.
Topics: Drug Evaluation; Humans; Mitomycin; Mitomycins; Neoplasm Recurrence, Local; Urinary Bladder Neoplasm | 1985 |
204 trials available for mitomycin and Bladder Cancer
| Article | Year |
|---|---|
The benefit of a neoadjuvant instillation of chemotherapy in non-muscle invasive bladder cancer: Interim analysis of the PRECAVE randomized clinical trial.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Cystectomy; Humans; Mitomycin; Neoadjuvan | 2021 |
Durability of Response to Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma Using UGN-101, a Mitomycin-Containing Reverse Thermal Gel: OLYMPUS Trial Final Report.
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma; Female; Humans; Hydrogels; Male; Middle Aged; Mitomyci | 2022 |
Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; BCG Vaccine; Humans; Hyperthermia, Induc | 2022 |
Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-yr Follow-up of the Phase 3 Randomised Controlled BC2001 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Fluorouracil; Follow-Up Studies; | 2022 |
Minimal Patient-Reported Side Effects for a Chemoablative Gel (UGN-102) Used as Frontline Treatment in Adults with Nonmuscle-Invasive Bladder Cancer.
Topics: Administration, Intravesical; Adult; Antibiotics, Antineoplastic; Female; Flatulence; Humans; Male; | 2022 |
Phase 1 Study of Chemoradiotherapy Combined with Nivolumab ± Ipilimumab for the Curative Treatment of Muscle-invasive Bladder Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Capecitabine; Chemoradiotherapy; Humans; | 2022 |
Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Chemotherapy, Adj | 2023 |
DaBlaCa-13 Study: Oncological Outcome of Short-Term, Intensive Chemoresection With Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Humans; Mitomycin; Neoplasm Invasiveness; | 2023 |
Clinical Efficacy of Neoadjuvant Intravesical Mitomycin-C Therapy Immediately Before Transurethral Resection of Bladder Tumor in Patients With Nonmuscle-invasive Bladder Cancer: Preliminary Results of a Prospective, Randomized Phase II Study.
Topics: Humans; Mitomycin; Prospective Studies; Transurethral Resection of Bladder; Treatment Outcome; Urina | 2023 |
Reply to Fabio Campodonico, Francesca Mattioli, and Carlo Introini's Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-musc
Topics: Adjuvants, Immunologic; Administration, Intravesical; Humans; Mitomycin; Non-Muscle Invasive Bladder | 2023 |
Re: Wei Shen Tan, Aaron Prendergast, Charlotte Ackermann, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Contro
Topics: Adjuvants, Immunologic; Administration, Intravesical; Humans; Mitomycin; Non-Muscle Invasive Bladder | 2023 |
Re: Wei Shen Tan, Aaron Prendergast, Charlotte Ackerman, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Control
Topics: Adjuvants, Immunologic; Administration, Intravesical; Humans; Mitomycin; Non-Muscle Invasive Bladder | 2023 |
Re: Wei Shen Tan, Aaron Prendergast, Charlotte Ackerman, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Control
Topics: Adjuvants, Immunologic; Administration, Intravesical; Humans; Mitomycin; Non-Muscle Invasive Bladder | 2023 |
Re: Wei Shen Tan, Aaron Prendergast, Charlotte Ackerman, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Control
Topics: Adjuvants, Immunologic; Administration, Intravesical; Humans; Mitomycin; Non-Muscle Invasive Bladder | 2023 |
Re: Wei Shen Tan, Aaron Prendergast, Charlotte Ackerman, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Control
Topics: Adjuvants, Immunologic; Administration, Intravesical; Humans; Mitomycin; Non-Muscle Invasive Bladder | 2023 |
Re: Wei Shen Tan, Aaron Prendergast, Charlotte Ackerman, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Control
Topics: Adjuvants, Immunologic; Administration, Intravesical; Humans; Mitomycin; Non-Muscle Invasive Bladder | 2023 |
Re: Wei Shen Tan, Aaron Prendergast, Charlotte Ackerman, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Control
Topics: Adjuvants, Immunologic; Administration, Intravesical; Humans; Mitomycin; Non-Muscle Invasive Bladder | 2023 |
Re: Wei Shen Tan, Aaron Prendergast, Charlotte Ackerman, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Control
Topics: Adjuvants, Immunologic; Administration, Intravesical; Humans; Mitomycin; Non-Muscle Invasive Bladder | 2023 |
Re: Wei Shen Tan, Aaron Prendergast, Charlotte Ackerman, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Control
Topics: Adjuvants, Immunologic; Administration, Intravesical; Humans; Mitomycin; Non-Muscle Invasive Bladder | 2023 |
Re: Wei Shen Tan, Aaron Prendergast, Charlotte Ackerman, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Control
Topics: Adjuvants, Immunologic; Administration, Intravesical; Humans; Mitomycin; Non-Muscle Invasive Bladder | 2023 |
Hyperthermic Mitomycin C in Intermediate-risk Non-muscle-invasive Bladder Cancer: Results of the HIVEC-1 Trial.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Humans; Male; Mitomycin; Non-Muscle Invasive B | 2023 |
Hyperthermic Mitomycin C in Intermediate-risk Non-muscle-invasive Bladder Cancer: Results of the HIVEC-1 Trial.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Humans; Male; Mitomycin; Non-Muscle Invasive B | 2023 |
Hyperthermic Mitomycin C in Intermediate-risk Non-muscle-invasive Bladder Cancer: Results of the HIVEC-1 Trial.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Humans; Male; Mitomycin; Non-Muscle Invasive B | 2023 |
Hyperthermic Mitomycin C in Intermediate-risk Non-muscle-invasive Bladder Cancer: Results of the HIVEC-1 Trial.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Humans; Male; Mitomycin; Non-Muscle Invasive B | 2023 |
Hyperthermic Mitomycin C in Intermediate-risk Non-muscle-invasive Bladder Cancer: Results of the HIVEC-1 Trial.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Humans; Male; Mitomycin; Non-Muscle Invasive B | 2023 |
Hyperthermic Mitomycin C in Intermediate-risk Non-muscle-invasive Bladder Cancer: Results of the HIVEC-1 Trial.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Humans; Male; Mitomycin; Non-Muscle Invasive B | 2023 |
Hyperthermic Mitomycin C in Intermediate-risk Non-muscle-invasive Bladder Cancer: Results of the HIVEC-1 Trial.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Humans; Male; Mitomycin; Non-Muscle Invasive B | 2023 |
Hyperthermic Mitomycin C in Intermediate-risk Non-muscle-invasive Bladder Cancer: Results of the HIVEC-1 Trial.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Humans; Male; Mitomycin; Non-Muscle Invasive B | 2023 |
Hyperthermic Mitomycin C in Intermediate-risk Non-muscle-invasive Bladder Cancer: Results of the HIVEC-1 Trial.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Humans; Male; Mitomycin; Non-Muscle Invasive B | 2023 |
Reply to Suman Sahoo, Abhishek Pandy, Swarnendu Mandal, Manoj Kumar Das, and Prasant Nayak's Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patient
Topics: Adjuvants, Immunologic; Administration, Intravesical; Humans; Mitomycin; Non-Muscle Invasive Bladder | 2023 |
Reply to Suman Sahoo, Abhishek Pandy, Swarnendu Mandal, Manoj Kumar Das, and Prasant Nayak's Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patient
Topics: Adjuvants, Immunologic; Administration, Intravesical; Humans; Mitomycin; Non-Muscle Invasive Bladder | 2023 |
Reply to Suman Sahoo, Abhishek Pandy, Swarnendu Mandal, Manoj Kumar Das, and Prasant Nayak's Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patient
Topics: Adjuvants, Immunologic; Administration, Intravesical; Humans; Mitomycin; Non-Muscle Invasive Bladder | 2023 |
Reply to Suman Sahoo, Abhishek Pandy, Swarnendu Mandal, Manoj Kumar Das, and Prasant Nayak's Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patient
Topics: Adjuvants, Immunologic; Administration, Intravesical; Humans; Mitomycin; Non-Muscle Invasive Bladder | 2023 |
Reply to Benjamin Pradere, Giuseppe Basile, and Thomas Seisen's Letter to the Editor re: Maria S. Lindgren, Eric Hansen, Nessn Azawi, Anna M. Nielsen, Lars Dyrskjøt, Jørgen B. Jensen. DaBlaCa-13 Study: Oncological Outcome of Short-term, Intensive Chemores
Topics: Humans; Mitomycin; Urinary Bladder Neoplasms | 2023 |
Re: Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial.
Topics: Adjuvants, Immunologic; Administration, Intravesical; BCG Vaccine; Chemotherapy, Adjuvant; Humans; M | 2023 |
Re: Maria S. Lindgren, Eric Hansen, Nessn Azawi, Anna M. Nielsen, Lars Dyrskjøt, Jørgen B. Jensen. DaBlaCa-13 Study: Oncological Outcome of Short-term, Intensive Chemoresection with Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Rand
Topics: Humans; Mitomycin; Urinary Bladder Neoplasms | 2023 |
Clinical Efficacy of Neoadjuvant Intravesical Mitomycin-C Therapy Immediately Before Transurethral Resection of Bladder Tumor in Patients With Nonmuscle-invasive Bladder Cancer: Preliminary Results of a Prospective, Randomized Phase II Study. Letter.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Humans; Mitomycin; Neoadjuvant Therapy; N | 2023 |
Re: Clinical Efficacy of Neoadjuvant Intravesical Mitomycin-C Therapy Immediately Before Transurethral Resection of Bladder Tumor in Patients with Nonmuscle-invasive Bladder Cancer: Preliminary Results of a Prospective, Randomized Phase II Study.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Humans; Mitomycin; Neoadjuvant Therapy; N | 2023 |
Guidance of adjuvant instillation in intermediate-risk non-muscle invasive bladder cancer by drug screens in patient derived organoids: a single center, open-label, phase II trial.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Humans; Mitomycin; Neoplasm Invasiveness; Neop | 2023 |
Acute Toxicity of Hypofractionated and Conventionally Fractionated (Chemo)Radiotherapy Regimens for Bladder Cancer: An Exploratory Analysis from the RAIDER Trial.
Topics: Aged; Brachytherapy; Carcinoma, Transitional Cell; Gemcitabine; Humans; Mitomycin; Radiation Oncolog | 2023 |
Re: DaBlaCa-13 Study: Oncological Outcome of Short-term, Intensive Chemoresection with Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Humans; Mitomycin; Neoplasm Invasiveness; | 2023 |
Treatment of Low-grade Intermediate-risk Nonmuscle-invasive Bladder Cancer With UGN-102 ± Transurethral Resection of Bladder Tumor Compared to Transurethral Resection of Bladder Tumor Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS).
Topics: Administration, Intravesical; Female; Humans; Male; Mitomycin; Neoplasm Invasiveness; Neoplasm Recur | 2023 |
The effect of immediate neoadjuvant electromotive instillation of mitomycin C with Bacillus Calmette-Guérin versus BCG alone in non-muscle-invasive bladder cancer: A randomized controlled trial.
Topics: BCG Vaccine; Humans; Mitomycin; Neoadjuvant Therapy; Non-Muscle Invasive Bladder Neoplasms; Urinary | 2023 |
Chemoablation with Intensive Intravesical Mitomycin C Treatment: A New Approach for Non-muscle-invasive Bladder Cancer.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Chemother | 2019 |
Development of a high-precision bladder hyperthermic intracavitary chemotherapy device for bladder cancer and pharmacokinetic study.
Topics: Adult; Aged; Analysis of Variance; Animals; Antibiotics, Antineoplastic; Cystoscopy; Disease-Free Su | 2019 |
CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin-C vs surgical management in low-risk non-muscle-invasive bladder cancer.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Feasibility Stud | 2020 |
The DaBlaCa-13 Study: Short-term, Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in Non-muscle-invasive Bladder Cancer-A Randomised Controlled Trial.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Chemotherapy, Adjuvant; Cystectomy; | 2020 |
Randomized Study of Postoperative Single Intravesical Instillation With Pirarubicin and Mitomycin C for Low-risk Bladder Cancer.
Topics: Administration, Intravesical; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined | 2020 |
[Single, immediate postoperative intra-vesical instillation (SI) compared to a single preoperative intra-vesical instillation of mitomycin C in non-muscle invasive bladder cancer (NMIBC). Phase II randomized trial].
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Female; Humans; Male; Mitomycin; Neoplasm | 2021 |
The HELENA study: Hexvix
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Antineoplastic Ag | 2021 |
The value of a comprehensive primary outcome - results of a negative randomized control trial in the non-muscle invasive bladder cancer population.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Humans; Mitomycin; Neoplasm Recurrence, L | 2021 |
Intravesical mitomycin C (MMC) and MMC + cytosine arabinoside for non-muscle-invasive bladder cancer: a randomised clinical trial.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Cytarabine; Female; Humans; Male; Mitomyc | 2022 |
Primary Chemoablation of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm Trial.
Topics: Ablation Techniques; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Female; Humans; Hy | 2022 |
Bladder intracavitary hyperthermic perfusion chemotherapy for the prevention of recurrence of non-muscle invasive bladder cancer after transurethral resection.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Combined Modality Therapy; Female; Humans; Hyperthermia, I | 2017 |
Value of an Immediate Intravesical Instillation of Mitomycin C in Patients with Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Randomised Study in 2243 patients.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Chemotherapy, Adjuvant; Cystectomy; | 2018 |
The effect of timing of an immediate instillation of mitomycin C after transurethral resection in 941 patients with non-muscle-invasive bladder cancer.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Cystectomy; Female; Humans; Male; Middle | 2018 |
Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non-muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Th
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antineoplastic Agents; BCG Vaccine; Carcinoma | 2019 |
BOXIT-A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004).
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherap | 2019 |
ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk "BCG failure" non muscle invasive bladder cancer: 3 years follow-up outcomes.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Female; Follow-Up Studies; Humans; | 2018 |
Randomized noninferiority trial of reduced high-dose volume versus standard volume radiation therapy for muscle-invasive bladder cancer: results of the BC2001 trial (CRUK/01/004).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2013 |
Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasi
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Antibiotics, Anti | 2013 |
Intravesical thermo-chemotherapy based on conductive heat: a first pharmacokinetic study with mitomycin C in superficial transitional cell carcinoma patients.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Combi | 2014 |
A pilot clinical trial of intravesical mitomycin-C and external deep pelvic hyperthermia for non-muscle-invasive bladder cancer.
Topics: Aged; Female; Humans; Hyperthermia, Induced; Male; Middle Aged; Mitomycin; Neoplasm Invasiveness; Pe | 2014 |
Contemporary cost-effectiveness analysis comparing sequential bacillus Calmette-Guerin and electromotive mitomycin versus bacillus Calmette-Guerin alone for patients with high-risk non-muscle-invasive bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Canada; Combined Modality Therapy; Cost | 2014 |
Sequential combination of mitomycin C plus bacillus Calmette-Guérin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomiz
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Chem | 2015 |
Sequential combination of mitomycin C plus bacillus Calmette-Guérin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomiz
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Chem | 2015 |
Sequential combination of mitomycin C plus bacillus Calmette-Guérin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomiz
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Chem | 2015 |
Sequential combination of mitomycin C plus bacillus Calmette-Guérin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomiz
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Chem | 2015 |
[Non-muscle invasive bladder cancer: safety of postoperative EMDA-assisted instillation of mitomycin].
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Electrochemother | 2015 |
Sequential intravesical mitomycin plus Bacillus Calmette-Guérin for non-muscle-invasive urothelial bladder carcinoma: translational and phase I clinical trial.
Topics: Administration, Intravesical; Aged; Animals; Carcinoma, Transitional Cell; Combined Modality Therapy | 2015 |
Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Guérin (BCG) or alternating BCG and interferon
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy P | 2015 |
BCG+MMC trial: adding mitomycin C to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer: a randomised phase III trial (ANZUP 1301).
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Clinical Protocols; Combined | 2015 |
Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Antibiotics, Antineoplastic; BCG Vaccine | 2016 |
Randomized controlled study of the efficacy and safety of continuous saline bladder irrigation after transurethral resection for the treatment of non-muscle-invasive bladder cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Combined Modality Therapy; Cystectomy; | 2017 |
Seventeen-year follow-up of the prospective randomized Nordic CIS study: BCG monotherapy versus alternating therapy with mitomycin C and BCG in patients with carcinoma in situ of the urinary bladder.
Topics: Adjuvants, Immunologic; Aged; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma in Situ; Drug Ther | 2016 |
Seventeen-year follow-up of the prospective randomized Nordic CIS study: BCG monotherapy versus alternating therapy with mitomycin C and BCG in patients with carcinoma in situ of the urinary bladder.
Topics: Adjuvants, Immunologic; Aged; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma in Situ; Drug Ther | 2016 |
Seventeen-year follow-up of the prospective randomized Nordic CIS study: BCG monotherapy versus alternating therapy with mitomycin C and BCG in patients with carcinoma in situ of the urinary bladder.
Topics: Adjuvants, Immunologic; Aged; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma in Situ; Drug Ther | 2016 |
Seventeen-year follow-up of the prospective randomized Nordic CIS study: BCG monotherapy versus alternating therapy with mitomycin C and BCG in patients with carcinoma in situ of the urinary bladder.
Topics: Adjuvants, Immunologic; Aged; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma in Situ; Drug Ther | 2016 |
The predictive and prognostic value of tumour necrosis in muscle invasive bladder cancer patients receiving radiotherapy with or without chemotherapy in the BC2001 trial (CRUK/01/004).
Topics: Adult; Aged; Chemoradiotherapy; Female; Fluorouracil; Humans; Male; Middle Aged; Mitomycin; Neoplasm | 2017 |
Quality of transurethral resection of bladder tumor procedure influenced a phase III trial comparing the effect of KLH and mitomycin C.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Immunological; Chemotherapy, Adjuvant; Cl | 2017 |
[Therapeutic effect of mitomycin C in the immediate postoperatory in patients with low-risk non-muscle-invasive bladder tumours].
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Female; Humans; Male; Middle Aged; Mito | 2008 |
Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term follow-up.
Topics: Administration, Intravesical; Antimetabolites, Antineoplastic; Carcinoma, Papillary; Carcinoma, Tran | 2007 |
[Therapeutic effect of mitomycin C in the immediate postoperative period in patients with intermediate-risk non-muscle-invasive bladder tumors].
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Female; Humans; | 2008 |
A randomized prospective study of intravesical prophylaxis in non-musle invasive bladder cancer at intermediate risk of recurrence: mitomycin chemotherapy vs BCG immunotherapy.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, A | 2008 |
Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance.
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; De | 2010 |
Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC).
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Chemotherapy, Adjuvant; Epidemiolog | 2011 |
Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 trial (
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; BCG Vacci | 2011 |
Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 trial (
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; BCG Vacci | 2011 |
Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 trial (
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; BCG Vacci | 2011 |
Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 trial (
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; BCG Vacci | 2011 |
Long-term experience with early single mitomycin C instillations in patients with low-risk non-muscle-invasive bladder cancer: prospective, single-centre randomised trial.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Combined Modality Therapy; Female; | 2011 |
Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial).
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma; Female; Humans; Kidney Neopl | 2011 |
Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; | 2011 |
Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; | 2011 |
Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; | 2011 |
Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; | 2011 |
Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; | 2011 |
Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; | 2011 |
Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; | 2011 |
Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; | 2011 |
Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; | 2011 |
[Evaluation of the efficacy and safety of intravesical instillation with gemcitabine after first-line intravesical chemotherapy failure in the treatment of non-muscle-invasive bladder cancer].
Topics: Administration, Intravesical; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplas | 2011 |
A phase II study of mitomycin, fluorouracil, folinic acid, and irinotecan (MFI) for the treatment of transitional cell carcinoma of the bladder.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Carcinoma, Transitional | 2013 |
Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free Surviv | 2012 |
Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free Surviv | 2012 |
Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free Surviv | 2012 |
Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free Surviv | 2012 |
Intracutaneous and intravesical immunotherapy with keyhole limpet hemocyanin compared with intravesical mitomycin in patients with non-muscle-invasive bladder cancer: results from a prospective randomized phase III trial.
Topics: Administration, Cutaneous; Administration, Intravesical; Aged; Disease-Free Survival; Female; Hemocy | 2012 |
Neoadjuvant short-term intensive intravesical mitomycin C regimen compared with weekly schedule for low-grade recurrent non-muscle-invasive bladder cancer: preliminary results of a randomised phase 2 study.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Cell Prol | 2012 |
Long-term results of maintenance treatment of mitomycin C or alternating mitomycin C and bacillus Calmette-Guérin instillation therapy of patients with carcinoma in situ of the bladder: a subgroup analysis of the prospective FinnBladder 2 study with a 17-
Topics: Adjuvants, Immunologic; Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, A | 2012 |
Single early instillation of mitomycin C and urinary alkalinization in low-risk non-muscle-invasive bladder cancer: a preliminary study.
Topics: Administration, Intravesical; Adult; Aged; Antibiotics, Antineoplastic; Cystoscopy; Disease-Free Sur | 2013 |
Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma.
Topics: Adjuvants, Immunologic; Aged; Antibiotics, Antineoplastic; BCG Vaccine; Drug Administration Schedule | 2002 |
Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a nordic study.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Antibiotics, Antineoplastic; BCG Vaccine | 2003 |
[Prevention of postoperative recurrence of human bladder carcinoma by intravesical instillation of immunotoxin, a clinical study].
Topics: Administration, Intravesical; Aged; BCG Vaccine; Carcinoma, Transitional Cell; Female; Humans; Immun | 2003 |
[Prevention and treatment of bladder tumors recurrence with furtulon].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2000 |
Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study.
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma in Situ; Carcinoma, Transitional Cell; Disease Progress | 2003 |
Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study.
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma in Situ; Carcinoma, Transitional Cell; Disease Progress | 2003 |
Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study.
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma in Situ; Carcinoma, Transitional Cell; Disease Progress | 2003 |
Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study.
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma in Situ; Carcinoma, Transitional Cell; Disease Progress | 2003 |
[Oral tegafur plus mitomycin versus intravesical mitomycin alone in the prevention of recurrence in stage Ta bladder tumors].
Topics: Administration, Intravesical; Administration, Oral; Antibiotics, Antineoplastic; Antineoplastic Agen | 2003 |
Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma.
Topics: Administration, Intravesical; Aged; Antibiotic Prophylaxis; Antibiotics, Antineoplastic; Carcinoma, | 2003 |
The immunomodulating effect of interferon-gamma intravesical instillations in preventing bladder cancer recurrence.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Female; Humans; Instillation, Drug; Int | 2003 |
A mixed-method study into quality of life for bladder cancer patients.
Topics: Administration, Intravesical; Aged; Alkylating Agents; Antineoplastic Combined Chemotherapy Protocol | 2004 |
Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Carcinoma | 2004 |
Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Combined Modalit | 2004 |
Thermo-chemotherapy for intermediate or high-risk recurrent superficial bladder cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Female; Follow-Up Studies; Humans; Hyperthermia, Induced; Male; Midd | 2005 |
A phase-1 study of sequential mitomycin C and 5-aminolaevulinic acid-mediated photodynamic therapy in recurrent superficial bladder carcinoma.
Topics: Aged; Aminolevulinic Acid; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional C | 2005 |
Photodynamic therapy for bladder cancer.
Topics: Aminolevulinic Acid; Antineoplastic Combined Chemotherapy Protocols; Humans; Mitomycin; Neoplasm Rec | 2005 |
Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carc | 2006 |
Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carc | 2006 |
Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carc | 2006 |
Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carc | 2006 |
Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carc | 2006 |
Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carc | 2006 |
Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carc | 2006 |
Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carc | 2006 |
Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carc | 2006 |
Intravesical adjuvant therapy using mitomycin C.
Topics: Administration, Intravesical; Adult; Aged; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell | 2006 |
The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma | 2006 |
Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin-C and bacillus Calmette-Guérin in patients with high-risk bladder cancer.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineopl | 2007 |
Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; BCG Vaccine; Ca | 2007 |
A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomyci
Topics: Administration, Intravesical; Aged; BCG Vaccine; Biopsy; Chemotherapy, Adjuvant; Cystectomy; Cystosc | 2007 |
The influence of thermo-chemotherapy on bladder tumours: an immunohistochemical analysis.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Cell | 2007 |
Intravesical chemotherapy of high-grade bladder cancer with HTI-286, a synthetic analogue of the marine sponge product hemiasterlin.
Topics: Administration, Intravesical; Animals; Antibiotics, Antineoplastic; Apoptosis; Cell Cycle; Cell Prol | 2008 |
[Comparison of the effectiveness between long-term instillation of mitomycin C and short-term prophylaxis with MMC or bacille Calmette-Guérin. Study of patients with non-muscle-invasive urothelial cancer of the urinary bladder].
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; BCG Vacci | 2008 |
Are prostate biopsies mandatory in patients with prostate-specific antigen increase during intravesical immuno- or chemotherapy for superficial bladder cancer?
Topics: Aged; Antibiotics, Antineoplastic; BCG Vaccine; Biopsy; Drug Monitoring; Epirubicin; Humans; Immunot | 2008 |
Intravesical chemotherapy in the United States. An overview.
Topics: BCG Vaccine; Bleomycin; Carcinoma in Situ; Clinical Trials as Topic; Doxorubicin; Humans; Mitomycin; | 1983 |
Bladder cancer chemotherapy studies supported by the National Bladder Cancer Project.
Topics: Adult; Aminoacridines; Amsacrine; Antineoplastic Agents; Carcinoma in Situ; Carcinoma, Papillary; Ci | 1983 |
Cooperative studies of systemic chemotherapy. A review of the work of the EORTC Urological Group and of the Yorkshire Urological Cancer Research Group (YUCRG).
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as | 1983 |
Randomized clinical trial on chemoprophylaxis of recurrence in cases of superficial bladder cancer.
Topics: Clinical Trials as Topic; Cystitis; Doxorubicin; Humans; Japan; Mitomycin; Mitomycins; Neoplasm Recu | 1983 |
Intravesical chemotherapy for superficial bladder cancer.
Topics: BCG Vaccine; Carcinoma, Transitional Cell; Clinical Trials as Topic; Doxorubicin; Ethoglucid; Follow | 1984 |
Long-term mitomycin C instillation after transurethral resection of superficial bladder carcinoma: influence on recurrence, progression and survival.
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Combined Modality Therapy; Female; | 1984 |
Therapeutic use of mitomycin C in bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Mitomycin; Mitomyc | 1984 |
Intravesical chemotherapy.
Topics: Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Clinical Trials as Topic; Combined | 1984 |
Resume of selected studies of the National Bladder Cancer Collaborative Group A and new protocols.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Cisplatin; Clini | 1984 |
Clinical trials in superficial and invasive bladder cancer.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Clinical Trials as Topic; Combined Modalit | 1984 |
[Clinical trials with localized mitomycin instillation therapy for superficial urothelial bladder carcinoma].
Topics: Adult; Aged; Carcinoma in Situ; Carcinoma, Transitional Cell; Clinical Trials as Topic; Follow-Up St | 1982 |
Systemic mitomycin C as second-line treatment for metastatic urothelial cancer.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisp | 1995 |
Alternating mitomycin C and bacillus Calmette-Guerin instillation therapy for carcinoma in situ of the bladder. The Finnbladder Group.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Antibiotics, Antineoplastic; BCG Vaccine | 1995 |
Local mitomycin-C therapy in relapse-prevention of superficial bladder neoplasms treated by means of laser.
Topics: Adult; Aged; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Female; Humans; Injections, Intra | 1994 |
[Long-term results of intravesical prevention of recurrence with mitomycin C and adriamycin in patients with superficial bladder cancer].
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy P | 1994 |
Long-term monitoring of 486P 3/12 antigen pattern (quantitative immunocytology) before, during, and after mitomycin C prophylaxis in patients with superficial bladder cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antigens, Neoplasm; Biomarkers, Tumor; Carci | 1995 |
A randomized study of intravesical mitomycin C, bacillus Calmette-Guerin Tice and bacillus Calmette-Guerin RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder.
Topics: Administration, Intravesical; BCG Vaccine; Carcinoma in Situ; Carcinoma, Papillary; Follow-Up Studie | 1995 |
Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Carcinoma, Transitional Cell; Chemotherapy, A | 1995 |
[Prospective and randomized study comparing mitomycin C and interferon alpha 2b in the prevention of superficial tumors of the bladder].
Topics: Adolescent; Adult; Aged; Carcinoma, Transitional Cell; Female; Humans; Interferon alpha-2; Interfero | 1994 |
Prognostic factors in pTa-pT1 superficial bladder tumours treated with intravesical instillations. The Dutch South-Eastern Urological Collaborative Group.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; BCG Vaccine; Carcinoma in Situ; Carcin | 1994 |
Prophylaxis of superficial bladder cancer with mitomycin or interferon alfa-2b: results of a multicentric Italian study.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Carcinoma in Situ; Carcinoma, Papillar | 1994 |
[Prophylaxis of transitional cell carcinoma of the bladder G1-G2; pTa-pT1 with mitomycin C or interferon alpha-2a. Preliminary data].
Topics: Carcinoma, Transitional Cell; Combined Modality Therapy; Follow-Up Studies; Humans; Interferon alpha | 1993 |
Superficial urinary bladder cancer. Results from the Finnbladder studies and a review on instillation treatments.
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma in Situ; Carcinoma, Tran | 1993 |
[Response of superficial bladder carcinoma to prophylacit treatment with mitomycin-C versus interferon. Preliminary study].
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Female; Humans; Interferon-alpha; Male | 1993 |
[A prospective and randomized study of the complete response, index of recurrences and progression in superficial bladder carcinoma treated with mitomycin C alone versus mitomycin C and BCG alternatively].
Topics: BCG Vaccine; Carcinoma, Transitional Cell; Chi-Square Distribution; Drug Therapy, Combination; Femal | 1993 |
A randomised prospective study comparing intravesical instillations of mitomycin-C, BCG-Tice, and BCG-RIVM in pTa-pT1 tumours and primary carcinoma in situ of the urinary bladder. Dutch South-East Cooperative Urological Group.
Topics: Administration, Intravesical; Aged; BCG Vaccine; Carcinoma in Situ; Carcinoma, Transitional Cell; Cy | 1993 |
Neoadjuvant combined microwave induced local hyperthermia and topical chemotherapy versus chemotherapy alone for superficial bladder cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Combined | 1996 |
The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma | 1996 |
Marker tumour responses to the sequential combination of intravesical therapy with mitomycin-C and BCG-RIVM in multiple superficial bladder tumours. Report from the European Organisation for Research and Treatment on Cancer-Genitourinary Group (EORTC 3089
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Aged, 80 and over; Antibiotics, Antineop | 1996 |
A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, A | 1996 |
[Mitomycin C for the treatment of superficial tumors of the bladder (Tis-Ta-T1) with one or more risk factors. Argentinian Cooperative Group of Oncourology (GCAO)].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Female; Follow-Up Studies; H | 1996 |
A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating Clinics.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Antibiotics, Antineoplastic; BCG Vaccine | 1996 |
Recurrences and progression of superficial bladder cancer following long-term intravesical prophylactic therapy with mitomycin C: 48-month follow-up.
Topics: Administration, Intravesical; Analysis of Variance; Antibiotic Prophylaxis; Antibiotics, Antineoplas | 1996 |
Chemoresection in Ta-T1 bladder cancer. Members of the EORTC Genito-Urinary Group.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Drug | 1996 |
[Mitomycin-C 30 mg for 12 months versus Mitomycin-C 40 mg for 6 months in the prevention of superficial bladder carcinoma G1-G2].
Topics: Administration, Intravesical; Adult; Aged; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell | 1996 |
[Results of a prospective study of chemoprophylaxis with alternating mitomycin-C and BCG: complete response and recurrence and progression index].
Topics: Adjuvants, Immunologic; Antibiotics, Antineoplastic; BCG Vaccine; Combined Modality Therapy; Disease | 1996 |
[Prevention of superficial bladder cancer with mitomycin C or interferon: final results of a prospective study].
Topics: Adult; Aged; Aged, 80 and over; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Mitomycin | 1996 |
Long-term follow-up of cytostatic intravesical instillation in patients with superficial bladder carcinoma. Is short-term, intensive instillation better than maintenance therapy?
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma | 1997 |
[Therapy with mitomycin C, folic acid and 5-fluorouracil in treatment of metastatic, refractory urinary bladder carcinoma--phase II study].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Drug Resistance, | 1997 |
Intravesical electromotive administration of drugs for treatment of superficial bladder cancer: a comparative Phase II study.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Elect | 1998 |
Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille Calmette-Guérin-RIVM and mitomycin C in superficial bladder cancer. EORTC GU Group and the Dutch South East Cooperative Urological Group. European Organisation for
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Aged, 80 and over; Antibiotics, Antineop | 1998 |
Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Carc | 1998 |
Microstaging of pT1 transitional cell carcinoma of the bladder: identification of subgroups with distinct risks of progression.
Topics: Adjuvants, Immunologic; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma, Transitional Cell; Dise | 1998 |
Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Female; Follow-Up Studies; Humans; Male; | 1999 |
5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group.
Topics: Adjuvants, Immunologic; Antibiotics, Antineoplastic; BCG Vaccine; Disease Progression; Follow-Up Stu | 1999 |
The effect of intravesical mitomycin C on the recurrence of superficial (Ta-T1) bladder cancer. A Hungarian Multicenter Study.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Humans; Hun | 1999 |
Weekly mitomycin C followed by monthly bacillus Calmette-Guerin or alternating monthly interferon-alpha2B and bacillus Calmette-Guerin for prophylaxis of recurrent papillary superficial bladder carcinoma.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Antineoplas | 2000 |
[Long-term results of intravesical N-CWS instillation to prevent recurrence after surgery for bladder cancer].
Topics: Adjuvants, Immunologic; Administration, Intravesical; Adult; Aged; Antibiotics, Antineoplastic; Carc | 1997 |
Thermo-chemotherapy and electromotive drug administration of mitomycin C in superficial bladder cancer eradication. a pilot study on marker lesion.
Topics: Antibiotics, Antineoplastic; Combined Modality Therapy; Feasibility Studies; Humans; Hyperthermia, I | 2001 |
Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma | 2001 |
Prophylactic intravesical instillation of mitomycin C and cytosine arabinoside for prevention of recurrent bladder tumors following surgery for upper urinary tract tumors: a prospective randomized study.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, | 2001 |
A phase I-II study of synchronous chemoradiotherapy for poor prognosis locally advanced bladder cancer.
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 2001 |
Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma | 2001 |
Equivalent efficacy of mitomycin C plus doxorubicin instillation to bacillus Calmette-Guerin therapy for carcinoma in situ of the bladder.
Topics: Adjuvants, Immunologic; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carcinoma | 2001 |
Clinical aspects of drug delivery to tumors.
Topics: Administration, Intravesical; Animals; Antineoplastic Agents; Clinical Trials as Topic; Drug Deliver | 2002 |
[Prevention of postoperative recurrence of bladder cancer: a clinical study].
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; BCG | 1999 |
A randomized comparative dose-ranging study of interferon-alpha and mitomycin-C as an internal control in primary or recurrent superficial transitional cell carcinoma of the bladder.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Transitional Cell; Dose-Response Relationship, Drug; | 2002 |
[Prophylactic effect of UFT in combination with intravesical chemotherapy on the recurrence of superficial bladder tumor].
Topics: Administration, Intravesical; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic C | 1992 |
BCG-RIVM versus BCG-Tice versus mitomycin-C in superficial bladder cancer. Rationale, design, and interim analysis of the trial of the South-East Cooperative Urological Group, The Netherlands.
Topics: Administration, Intravesical; BCG Vaccine; Carcinoma in Situ; Carcinoma, Transitional Cell; Humans; | 1992 |
Long-term results of intravesical chemoprophylaxis of superficial bladder cancer: experience of the Japanese Urological Cancer Research Group for Adriamycin.
Topics: Actuarial Analysis; Administration, Intravesical; Aged; Combined Modality Therapy; Doxorubicin; Drug | 1992 |
Intravesical combination chemotherapy with mitomycin C and doxorubicin for superficial bladder cancer: a randomized trial of maintenance versus no maintenance following a complete response.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocol | 1992 |
Sequential instillation therapy with mitomycin C and adriamycin for superficial bladder cancer.
Topics: Administration, Intravesical; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cystitis; | 1992 |
Results of adjuvant chemotherapy for invasive uroepithelial cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cis | 1992 |
BCG in superficial bladder cancer: a review of phase III European trials.
Topics: Administration, Intravesical; BCG Vaccine; Carcinoma in Situ; Carcinoma, Transitional Cell; Clinical | 1992 |
[Prophylactic intravesical instillation therapy in patients with superficial bladder cancer--results of a randomized prospective study].
Topics: Administration, Intravesical; Carcinoma, Transitional Cell; Doxorubicin; Drug Administration Schedul | 1992 |
Pharmacodynamics and pharmacokinetics of intravesical mitomycin C upon different dwelling times.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Female; Follow-Up Studies; Humans; Mal | 1992 |
4'-epidoxorubicin versus mitomycin C intravesical chemoprophylaxis of superficial bladder cancer.
Topics: Administration, Intravesical; Aged; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Epirubicin | 1992 |
Interferon-alpha 2b instillation prophylaxis in superficial bladder cancer--a prospective, controlled three-armed trial. Project Group Bochum--Interferon and Superficial Bladder Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Humans; Interferon alpha-2; Interferon-alpha; | 1992 |
Intravesical chemotherapy (mitomycin C) versus immunotherapy (bacillus Calmette-Guérin) in superficial bladder cancer.
Topics: Administration, Intravesical; Aged; BCG Vaccine; Carcinoma, Transitional Cell; Female; Humans; Immun | 1991 |
Instillation therapy in superficial urinary bladder cancer. Finnbladder Group.
Topics: Administration, Intravesical; BCG Vaccine; Carcinoma in Situ; Carcinoma, Transitional Cell; Combined | 1991 |
Prophylactic instillation therapy of superficial bladder cancer. A randomized study comparing mitomycin C and adriamycin with special reference to DNA ploidy.
Topics: Administration, Intravesical; Combined Modality Therapy; DNA, Neoplasm; Doxorubicin; Female; Humans; | 1991 |
Recurrence of superficial bladder tumors in prostatic urethra.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma in Si | 1991 |
Carcinoma in situ associated with superficial bladder tumor.
Topics: Actuarial Analysis; Administration, Intravesical; Adult; Aged; Antineoplastic Agents; Carcinoma in S | 1991 |
[Intravesical instillation of bacillus Calmette-Guerin for superficial bladder carcinoma: study on significance of additional maintenance instillations of bacillus Calmette-Guerin].
Topics: Administration, Intravesical; Adult; Aged; BCG Vaccine; Carcinoma, Transitional Cell; Drug Administr | 1991 |
Combination chemotherapy with cis-platinum, adriamycin, mitomycin-C (PAM) in patients with advanced bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Female; Humans; Male; | 1990 |
Comparison of different schedules of cytostatic intravesical instillations in patients with superficial bladder carcinoma: final evaluation of a prospective multicenter study with 419 patients.
Topics: Administration, Intravesical; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modalit | 1990 |
[Intravesical instillation chemotherapy of anticancer agents including cylocide: studies of prophylactic effects on the recurrence].
Topics: Actuarial Analysis; Administration, Intravesical; Antineoplastic Combined Chemotherapy Protocols; Ch | 1990 |
Immunocytology as a possible marker to identify patients who require prophylaxis.
Topics: Administration, Intravesical; Aged; Antibodies, Monoclonal; Antigens, Neoplasm; Biomarkers, Tumor; C | 1990 |
Evaluation of principles in intravesical chemo- and immunotherapy for superficial bladder cancer.
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma in Situ; Carcinoma, Papi | 1990 |
Approaches to the treatment of bladder cancer at Stanford.
Topics: Administration, Intravesical; Antineoplastic Agents; Carcinoma in Situ; Carcinoma, Papillary; Carcin | 1987 |
Metaphylactic effect of mitomycin C with and without hyaluronidase after transurethral resection of bladder cancer: randomized trial.
Topics: Adult; Aged; Carcinoma, Transitional Cell; Clinical Trials as Topic; Combined Modality Therapy; Doub | 1989 |
Recurrence of superficial bladder carcinoma after intravesical instillation of mitomycin-C. Comparison of exposure times.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Carcinoma in Situ; Carcinoma, Transiti | 1989 |
Efficacy of intravesical mitomycin C in the treatment of superficial transitional cell carcinoma of the urinary bladder.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Carcinoma, Transitional Cell; Clinical | 1989 |
Intravesical mitomycin C instillation as a prophylactic treatment of superficial bladder tumor.
Topics: Administration, Intravesical; Female; Follow-Up Studies; Humans; Male; Middle Aged; Mitomycin; Mitom | 1989 |
Prognostic factors for recurrence and followup policies in the treatment of superficial bladder cancer: report from the British Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party).
Topics: Administration, Intravesical; Carcinoma, Transitional Cell; Cystoscopy; Follow-Up Studies; Humans; M | 1989 |
Mitomycin-C and BCG in intravesical chemotherapy and immunotherapy of superficial bladder cancer. Finnbladder Research Group.
Topics: Administration, Intravesical; BCG Vaccine; Carcinoma in Situ; Drug Administration Schedule; Follow-U | 1989 |
BCG-RIVM versus BCG-Tice versus mitomycin-C in superficial bladder cancer. Rationale and design of the trial of the Southeast Co-operative Urological Group, The Netherlands.
Topics: Administration, Intravesical; BCG Vaccine; Carcinoma in Situ; Carcinoma, Papillary; Cystitis; Humans | 1989 |
BCG-(RIVM) versus mitomycin intravesical therapy in patients with superficial bladder cancer. EORTC GU Group and the Dutch South-East Collaborative Group.
Topics: Administration, Intravesical; BCG Vaccine; Carcinoma, Papillary; Carcinoma, Transitional Cell; Clini | 1989 |
[Mitomycin C in the topical treatment of superficial neoplasms of the bladder].
Topics: Administration, Intravesical; Carcinoma in Situ; Carcinoma, Papillary; Clinical Trials as Topic; Dru | 1989 |
A trial of prophylactic thiotepa or mitomycin C intravesical therapy in patients with recurrent or multiple superficial bladder cancers.
Topics: Carcinoma, Transitional Cell; Clinical Trials as Topic; Humans; Mitomycin; Mitomycins; Neoplasm Recu | 1986 |
[Prophylactic intravesical instillation therapy with adriamycin (ADM) and mitomycin C (MMC) in patients with superficial bladder cancer].
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Combined Mod | 1986 |
Sequential instillation therapy with mitomycin C and adriamycin for superficial bladder tumors.
Topics: Administration, Intravesical; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma | 1987 |
Prophylactic intravesical instillation therapy with adriamycin and mitomycin C in patients with superficial bladder cancer.
Topics: Administration, Intravesical; Carcinoma, Papillary; Clinical Trials as Topic; Combined Modality Ther | 1987 |
Prophylaxis of superficial bladder cancer with instillation of adriamycin or mitomycin C.
Topics: Administration, Intravesical; Aged; Carcinoma, Transitional Cell; Clinical Trials as Topic; Combined | 1987 |
Prophylactic treatment for superficial bladder cancer following transurethral resection.
Topics: Administration, Intravesical; Aged; Antineoplastic Agents; Carcinoma, Transitional Cell; Combined Mo | 1987 |
Comparative analysis of short-term and long-term prophylactic intravesical chemotherapy of superficial bladder cancer. Prospective, randomized, controlled studies of the Japanese Urological Cancer Research Group.
Topics: Administration, Intravesical; Aged; Clinical Trials as Topic; Combined Modality Therapy; Doxorubicin | 1987 |
Treatment schedule of intravesical chemotherapy with mitomycin C in superficial bladder cancer: short-term courses or maintenance therapy.
Topics: Administration, Intravesical; Carcinoma, Transitional Cell; Clinical Trials as Topic; Drug Administr | 1988 |
Immunotherapy in bladder cancer with keyhole-limpet hemocyanin: a randomized study.
Topics: Administration, Intravesical; Antigens; Clinical Trials as Topic; Female; Follow-Up Studies; Hemocya | 1988 |
Mitomycin C resorption following repeated intravesical instillations using different instillation times.
Topics: Administration, Intravesical; Aged; Carcinoma in Situ; Carcinoma, Transitional Cell; Clinical Trials | 1988 |
Cytostatic intravesical instillation in patients with superficial bladder carcinoma for the prevention of recurrent tumors.
Topics: Administration, Intravesical; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Clini | 1988 |
BCG-RIVM intravesical immunoprophylaxis for superficial bladder cancer.
Topics: Administration, Intravesical; Animals; BCG Vaccine; Carcinoma in Situ; Carcinoma, Transitional Cell; | 1988 |
Is there an optimal treatment scheme for adjuvant intravesical therapy? Preliminary analysis of an EORTC protocol comparing early and delayed instillation with and without maintenance of either adriamycin or mitomycin-C in patients with superficial transi
Topics: Administration, Intravesical; Carcinoma, Transitional Cell; Clinical Trials as Topic; Combined Modal | 1988 |
[Can topical chemoprevention modify the rate of recurrence and progression of superficial bladder cancer?].
Topics: Administration, Intravesical; Clinical Trials as Topic; Combined Modality Therapy; Doxorubicin; Foll | 1988 |
Effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: interim report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party).
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Carcinoma, Transitional Cell; Clinical | 1988 |
Intravesical thiotepa versus mitomycin C in patients with Ta, T1 and TIS transitional cell carcinoma of the bladder: a phase III prospective randomized study.
Topics: Administration, Intravesical; Carcinoma, Transitional Cell; Clinical Trials as Topic; Humans; Mitomy | 1988 |
Proteinuria after intravesical chemotherapy.
Topics: Carcinoembryonic Antigen; Carcinoma in Situ; Clinical Trials as Topic; Doxorubicin; Humans; Mitomyci | 1985 |
Intravesical thiotepa and mitomycin C treatment immediately after transurethral resection and later for superficial (stages Ta and Tis) bladder cancer: a prospective, randomized, stratified study with crossover design.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Carcinoma in Situ; Carcinoma, Transitional Cell; Clinical | 1985 |
[Significance of urothelial dysplasia in macroscopically normal mucosa in patients with bladder tumors. Results of a randomized study with and without intravesical mitomycin C in the prevention of recurrence].
Topics: Aged; Biopsy; Clinical Trials as Topic; Female; Humans; Hyperplasia; Male; Middle Aged; Mitomycin; M | 1985 |
611 other studies available for mitomycin and Bladder Cancer
| Article | Year |
|---|---|
Urine DNA for monitoring chemoradiotherapy response in muscle-invasive bladder cancer: a pilot study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cetuximab; Chemoradiotherapy; Cli | 2022 |
Comparison of intravesical adjuvant therapy in bladder cancer with two different maintenance regimens of mitomycin and BCG.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Humans; Mitomycin; Neoplasm | 2022 |
Loco-regional deep hyperthermia combined with intravesical Mitomycin instillation reduces the recurrence of non-muscle invasive papillary bladder cancer.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Humans; Hyperthermia, Induced; Mitomycin; | 2021 |
Electromotive Drug Administration of Mitomycin C (EMDA/MMC) versus Intravesical Immunotherapy with Bacillus Calmette-Guérin (BCG) in Intermediate and High Risk Non Muscle Invasive Bladder Cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; BCG Vaccine; Humans; Immunotherapy; Mitomycin; | 2023 |
In vitro assessment of intra-operative and post-operative environment in reducing bladder cancer recurrence.
Topics: Apoptosis; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Humans; Hyperthermia, Induced | 2022 |
Chidamide and mitomycin C exert synergistic cytotoxic effects against bladder cancer cells in vitro and suppress tumor growth in a rat bladder cancer model.
Topics: Administration, Intravesical; Aminopyridines; Animals; Antineoplastic Agents; Apoptosis; BCG Vaccine | 2022 |
Continuous Saline Bladder Irrigation in Reducing Recurrence and Progression When Compared to Immediate Mitomycin- C Instillation Post- Resection of Bladder Tumor: A Short Communication.
Topics: Administration, Intravesical; Cystectomy; Female; Humans; Male; Middle Aged; Mitomycin; Neoplasm Rec | 2022 |
Re: Long-term Experience with Radiofrequency-induced Hyperthermia Combined with Intravesical Chemotherapy for Non-muscle Invasive Bladder Cancer.
Topics: Administration, Intravesical; Combined Modality Therapy; Female; Humans; Hyperthermia, Induced; Male | 2022 |
Antegrade Instillation of UGN-101 (Mitomycin for Pyelocalyceal Solution) for Low-Grade Upper Tract Urothelial Carcinoma: Initial Clinical Experience.
Topics: Carcinoma, Transitional Cell; Female; Humans; Hydrogels; Kidney Neoplasms; Male; Mitomycin; Ureteral | 2022 |
[Intravesical adjuvant regimen of epitubicin for intermediate risk NMIBC: Feasability study from CC-AFU vessie].
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Antibiotics, Antineoplastic; BCG Vaccine | 2022 |
[Guidelines from the cancer committee of the French Association of Urology (CC-AFU) for adequate intravesical instillations of Mitomycin C, Epirubicin, and BCG for non-muscle invasive bladder cancer].
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Epirubicin; Female; Humans; | 2022 |
[Adjuvant instillation therapy for non-muscle invasive bladder cancer - beyond BCG and mitomycin C].
Topics: Administration, Intravesical; BCG Vaccine; Humans; Hyperthermia, Induced; Mitomycin; Neoplasm Invasi | 2022 |
Comment on "Durability of response to primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel: OLYMPUS trial final report".
Topics: Carcinoma, Transitional Cell; Female; Humans; Male; Mitomycin; Urinary Bladder Neoplasms; Urothelium | 2022 |
Mitomycin C allergy after passive and device-assisted hyperthermia for non-muscle invasive bladder cancer treatment: A retrospective cohort from a high-volume center.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Humans; Hypersensitivity; Hyperthermia, I | 2022 |
Characterizing molecular subtypes of high-risk non-muscle-invasive bladder cancer in African American patients.
Topics: BCG Vaccine; Black or African American; Extracellular Matrix Proteins; Humans; Mitomycin; Neoplasm I | 2022 |
Impact of Urinary pH on the Efficacy of a Postoperative Single Instillation of Mitomycin-C.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Humans; Hydrogen-Ion Concentration; Mitom | 2022 |
A new catheter-integrated drug-delivery system for controlled intravesical mitomycin C release.
Topics: Administration, Intravesical; Animals; Antibiotics, Antineoplastic; Catheters; Drug Delivery Systems | 2022 |
In silico development and experimental validation of a novel 7-gene signature based on PI3K pathway-related genes in bladder cancer.
Topics: Cisplatin; Deoxyuridine; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Immunoglobu | 2022 |
Enhancement of human bladder carcinoma cell chemosensitivity to Mitomycin C through quasi-monochromatic blue light (λ = 453 ± 10 nm).
Topics: Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Humans; Mitomycin; Reactive Oxygen Specie | 2022 |
Antegrade administration of mitomycin gel for upper tract urothelial carcinoma via percutaneous nephrostomy tube: a multi-institutional retrospective cohort study.
Topics: Carcinoma, Transitional Cell; Constriction, Pathologic; Humans; Mitomycin; Nephrostomy, Percutaneous | 2023 |
Conductive hyperthermic chemotherapy versus electromotive drug administration of mitomycin C as intravesical adjuvant treatment of patients with intermediate or high-risk non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Huma | 2023 |
Conductive hyperthermic chemotherapy versus electromotive drug administration of mitomycin C as intravesical adjuvant treatment of patients with intermediate or high-risk non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Huma | 2023 |
Conductive hyperthermic chemotherapy versus electromotive drug administration of mitomycin C as intravesical adjuvant treatment of patients with intermediate or high-risk non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Huma | 2023 |
Conductive hyperthermic chemotherapy versus electromotive drug administration of mitomycin C as intravesical adjuvant treatment of patients with intermediate or high-risk non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Huma | 2023 |
Conductive hyperthermic chemotherapy versus electromotive drug administration of mitomycin C as intravesical adjuvant treatment of patients with intermediate or high-risk non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Huma | 2023 |
Conductive hyperthermic chemotherapy versus electromotive drug administration of mitomycin C as intravesical adjuvant treatment of patients with intermediate or high-risk non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Huma | 2023 |
Conductive hyperthermic chemotherapy versus electromotive drug administration of mitomycin C as intravesical adjuvant treatment of patients with intermediate or high-risk non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Huma | 2023 |
Conductive hyperthermic chemotherapy versus electromotive drug administration of mitomycin C as intravesical adjuvant treatment of patients with intermediate or high-risk non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Huma | 2023 |
Conductive hyperthermic chemotherapy versus electromotive drug administration of mitomycin C as intravesical adjuvant treatment of patients with intermediate or high-risk non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Huma | 2023 |
Early experience with UGN-101 for the treatment of upper tract urothelial cancer - A multicenter evaluation of practice patterns and outcomes.
Topics: Adjuvants, Immunologic; Carcinoma, Transitional Cell; Humans; Kidney Neoplasms; Mitomycin; Ureteral | 2023 |
Early experience with UGN-101 for the treatment of upper tract urothelial cancer - A multicenter evaluation of practice patterns and outcomes.
Topics: Adjuvants, Immunologic; Carcinoma, Transitional Cell; Humans; Kidney Neoplasms; Mitomycin; Ureteral | 2023 |
Early experience with UGN-101 for the treatment of upper tract urothelial cancer - A multicenter evaluation of practice patterns and outcomes.
Topics: Adjuvants, Immunologic; Carcinoma, Transitional Cell; Humans; Kidney Neoplasms; Mitomycin; Ureteral | 2023 |
Early experience with UGN-101 for the treatment of upper tract urothelial cancer - A multicenter evaluation of practice patterns and outcomes.
Topics: Adjuvants, Immunologic; Carcinoma, Transitional Cell; Humans; Kidney Neoplasms; Mitomycin; Ureteral | 2023 |
Early experience with UGN-101 for the treatment of upper tract urothelial cancer - A multicenter evaluation of practice patterns and outcomes.
Topics: Adjuvants, Immunologic; Carcinoma, Transitional Cell; Humans; Kidney Neoplasms; Mitomycin; Ureteral | 2023 |
Early experience with UGN-101 for the treatment of upper tract urothelial cancer - A multicenter evaluation of practice patterns and outcomes.
Topics: Adjuvants, Immunologic; Carcinoma, Transitional Cell; Humans; Kidney Neoplasms; Mitomycin; Ureteral | 2023 |
Early experience with UGN-101 for the treatment of upper tract urothelial cancer - A multicenter evaluation of practice patterns and outcomes.
Topics: Adjuvants, Immunologic; Carcinoma, Transitional Cell; Humans; Kidney Neoplasms; Mitomycin; Ureteral | 2023 |
Early experience with UGN-101 for the treatment of upper tract urothelial cancer - A multicenter evaluation of practice patterns and outcomes.
Topics: Adjuvants, Immunologic; Carcinoma, Transitional Cell; Humans; Kidney Neoplasms; Mitomycin; Ureteral | 2023 |
Early experience with UGN-101 for the treatment of upper tract urothelial cancer - A multicenter evaluation of practice patterns and outcomes.
Topics: Adjuvants, Immunologic; Carcinoma, Transitional Cell; Humans; Kidney Neoplasms; Mitomycin; Ureteral | 2023 |
Quality Control Indicators for Transurethral Resection of Bladder Tumor: Results from an Embedded Belgian Multicenter Prospective Registry.
Topics: Administration, Intravesical; BCG Vaccine; Belgium; Humans; Mitomycin; Quality Control; Retrospectiv | 2023 |
Thiolated Mesoporous Silica Nanoparticles as an Immunoadjuvant to Enhance Efficacy of Intravesical Chemotherapy for Bladder Cancer.
Topics: Adjuvants, Immunologic; Animals; Antibiotics, Antineoplastic; Mitomycin; Nanoparticles; Silicon Diox | 2023 |
Efficacy and Safety of Mitomycin Gel (UGN-101) as an Adjuvant Therapy After Complete Endoscopic Management of Upper Tract Urothelial Carcinoma.
Topics: Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Constriction, Pathologic; Humans; Kidney Neopl | 2023 |
ARHGAP6 inhibits bladder cancer cell viability, migration, and invasion via β-catenin signaling and enhances mitomycin C sensitivity.
Topics: beta Catenin; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Gene Expression Re | 2023 |
Evaluation of thermal dose effect in radiofrequency-induced hyperthermia with intravesical chemotherapy for nonmuscle invasive bladder cancer.
Topics: Combined Modality Therapy; Epirubicin; Humans; Hyperthermia, Induced; Mitomycin; Neoplasm Invasivene | 2023 |
A 6-month maintenance schedule of mitomycin C after radical nephroureterectomy for upper tract urothelial carcinoma for the prevention of intravesical recurrence: a retrospective, single center study.
Topics: Carcinoma, Transitional Cell; Humans; Mitomycin; Neoplasm Recurrence, Local; Nephroureterectomy; Ret | 2023 |
Long-term prevention of bladder cancer progression by alpha1-oleate alone or in combination with chemotherapy.
Topics: Animals; Antibiotics, Antineoplastic; Epirubicin; Mice; Mitomycin; Neoplasm Recurrence, Local; Oleic | 2023 |
Complete Remission of BCG-Refractory High-grade Bladder CIS with Pharmacologic Ascorbate and Mistletoe.
Topics: Adult; Aged; Antineoplastic Agents; BCG Vaccine; Carcinogens; Carcinoma in Situ; Female; Humans; Mal | 2023 |
Adjuvant intravesical treatment in patients with intermediate and high-risk non-muscle-invasive bladder cancer with BCG versus MMC applied with COMBAT or EMDA. Results of a prospective study.
Topics: Adjuvants, Immunologic; Administration, Intravesical; BCG Vaccine; Humans; Mitomycin; Neoplasm Invas | 2023 |
Results from HIVEC-II for Intermediate-risk Non-muscle-invasive Bladder Cancer: Is This a Dead End for Mitomycin C Hyperthermia?
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Humans; Hyperthermia, Induced; Mitomycin; | 2023 |
Conservative treatment for high-risk NMIBC failing BCG treatment: who benefits from adding electromotive drug administration (EMDA) of mitomycin C (MMC) to a second BCG induction cycle?
Topics: Adjuvants, Immunologic; Administration, Intravesical; BCG Vaccine; Combined Modality Therapy; Conser | 2023 |
Variation in Statewide Intravesical Treatment Rates for Non-Muscle Invasive Bladder Cancer During the Bacillus Calmette-Guerin Drug Shortage.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; BCG Vaccine; Humans; Medicare; Mitomycin | 2023 |
Animal model assessment of a new design for a coated mitomycin-eluting biodegradable ureteral stent for intracavitary instillation as an adjuvant therapy in upper urothelial carcinoma.
Topics: Animals; Carcinoma, Transitional Cell; Drug-Eluting Stents; Female; Fibroins; Mitomycin; Models, Ani | 2023 |
Sequential Treatment With Bacillus Calmette-Güerin (BCG) and Mitomycin C Administered With Electromotive Drug Administration (EMDA) in Patients With High-Risk Nonmuscle Invasive Bladder Cancer After BCG Failure.
Topics: Administration, Intravesical; Aged; BCG Vaccine; Humans; Immunotherapy; Mitomycin; Neoplasm Invasive | 2023 |
Single-Dose Post-Office Fulguration Mitomycin C Instillation Appears to Improve Recurrence-Free Survival in Patients With Low-Grade Noninvasive Bladder Cancer.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Female; Hum | 2023 |
The patient experience with localized upper tract urothelial cancer.
Topics: Aged; Carcinoma, Transitional Cell; Female; Humans; Kidney Neoplasms; Male; Mitomycin; Patient Outco | 2023 |
Comment on: "Animal model assessment of a new design for a coated mitomycin-eluting biodegradable ureteral stent for intracavitary instillation as an adjuvant therapy in upper urothelial carcinoma".
Topics: Animals; Carcinoma, Transitional Cell; Combined Modality Therapy; Mitomycin; Urinary Bladder Neoplas | 2023 |
The ablative effect of mitomycin reverse thermal gel: Expanding the role for nephron preservation therapy in low grade upper tract urothelial carcinoma.
Topics: Carcinoma, Transitional Cell; Humans; Kidney Neoplasms; Mitomycin; Nephrons; Retrospective Studies; | 2023 |
The efficacy of hyperthermic intravesical chemotherapy in high-risk non-muscle-invasive bladder cancer patients with BCG intolerance.
Topics: Adjuvants, Immunologic; Administration, Intravesical; BCG Vaccine; Carcinoma, Transitional Cell; Hum | 2023 |
Adhesion-regulating molecule 1 (ADRM1) can be a potential biomarker and target for bladder cancer.
Topics: Biomarkers; CD8-Positive T-Lymphocytes; Cisplatin; Humans; Intracellular Signaling Peptides and Prot | 2023 |
Primary Chemoablation for Intermediate-risk Low-grade Bladder Cancer: New Paradigm or Added Uncertainty?
Topics: Humans; Mitomycin; Uncertainty; Urinary Bladder; Urinary Bladder Neoplasms | 2023 |
Primary Chemoablation for Intermediate-Risk Low-Grade Bladder Cancer: New Paradigm or Added Uncertainty? Letter.
Topics: Humans; Mitomycin; Uncertainty; Urinary Bladder; Urinary Bladder Neoplasms | 2023 |
Demographics, pathological characteristics and survival in urothelial bladder cancer in a cohort of Sri Lankan patients.
Topics: Aged; Carcinoma, Transitional Cell; Demography; Female; Humans; Male; Mitomycin; Neoplasm Recurrence | 2022 |
Intravesical Treatment with Electro-Mediated Administration of Mytomicin C as Prophylaxis for Intermediate and High-Risk Nonmuscle-Invasive Bladder Cancer: A Retrospective Multicenter Study.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Electrochemotherapy; Female; Humans | 2019 |
Single-dose perioperative mitomycin-C versus thiotepa for low-grade noninvasive bladder cancer.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic A | 2019 |
[Safety of Hyperthermic IntraVEsical Chemotherapy (HIVEC) for BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients].
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; BCG Vacci | 2020 |
Factors affecting guideline adherence in the initial treatment of non-muscle invasive bladder cancer: Retrospective study in a French peripheral hospital.
Topics: Aged; Antibiotics, Antineoplastic; BCG Vaccine; Female; France; Guideline Adherence; Humans; Male; M | 2020 |
Reasons for intravesical instillation postponement during adjuvant treatment of non-muscle-invasive bladder cancer: A prospective study.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Antibiotics, Antineoplastic; BCG Vaccine | 2020 |
Re: Robert A. Huddart, Emma Hall, Rebecca Lewis, et al. Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy ± Chemotherapy in the BC2001 Phase III Randomised Controlled Trial. Eur Urol 2020;77
Topics: Administration, Intravesical; Humans; Mitomycin; Patient Reported Outcome Measures; Quality of Life; | 2020 |
Mitomycin C-induced cell cycle arrest enhances 5-aminolevulinic acid-based photodynamic therapy for bladder cancer.
Topics: Aminolevulinic Acid; Cell Cycle Checkpoints; Cell Line, Tumor; Humans; Mitomycin; Photochemotherapy; | 2020 |
Intraoperative prophylactic intravesical chemotherapy to reduce bladder recurrence following radical nephroureterectomy.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Femal | 2020 |
Safety and efficacy of intravesical chemotherapy and hyperthermia in the bladder: results of a porcine study.
Topics: Administration, Intravesical; Animals; Antibiotics, Antineoplastic; Female; Hyperthermia; Hypertherm | 2020 |
Enhanced Quality and Effectiveness of Transurethral Resection of Bladder Tumour in Non-muscle-invasive Bladder Cancer: A Multicentre Real-world Experience from Scotland's Quality Performance Indicators Programme.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Cystectom | 2020 |
Sequential administration of Bacillus Calmette-Guerin (BCG) and Electromotive Drug Administration (EMDA) of mitomycin C (MMC) for the treatment of high-grade nonmuscle invasive bladder cancer after BCG failure.
Topics: Adjuvants, Immunologic; Aged; Antibiotics, Antineoplastic; BCG Vaccine; Female; Humans; Iontophoresi | 2020 |
Quality of life and adverse events in patients with nonmuscle invasive bladder cancer receiving adjuvant treatment with BCG, MMC, or chemohyperthermia.
Topics: Adjuvants, Immunologic; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; BCG Vaccine; Chemother | 2021 |
Radiation with concurrent radiosensitizing capecitabine tablets and single-dose mitomycin-C for muscle-invasive bladder cancer: A convenient alternative to 5-fluorouracil.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Fluorouracil; Humans; Mitomycin; | 2020 |
The combination cytology/epichek test in non muscle invasive bladder carcinoma follow-up: Effective tool or useless expence?
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Aged, 80 and over; Antibiotics, Antineop | 2021 |
CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin-C vs surgical management in low-risk non-muscle-invasive bladder cancer.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Feasibility Studies; Humans; Mitomycin; U | 2020 |
Re: Chemoablation with Intensive Intravesical Mitomycin C Treatment: A New Approach for Non-Muscle-Invasive Bladder Cancer.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Humans; Mitomycin; Urinary Bladder Neopla | 2020 |
Efficacy of BCG vaccine and Mitomycin C for the treatment of ocular squamous cell carcinoma in bovines.
Topics: Administration, Intravesical; Animals; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma, Squamous | 2020 |
Cystectomy outcomes in patients who have failed Radiofrequency-induced Thermo-chemotherapeutic Effect Mitomycin-C (RITE-MMC) treatment for high-risk non-muscle invasive bladder cancer (HRNMIBC)-Does it complicate surgery and adversely impact oncological o
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Combined Modality Therapy; Cystectomy; | 2021 |
E2F1 Promotes Progression of Bladder Cancer by Modulating RAD54L Involved in Homologous Recombination Repair.
Topics: Base Sequence; Cell Line, Tumor; Disease Progression; DNA Breaks, Double-Stranded; DNA Helicases; DN | 2020 |
Treatment of Large Non-Muscle-Invasive Bladder Cancer: The Potential Role of Neoadjuvant Intravesical Chemotherapy.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Chemotherapy, Ad | 2021 |
[Treatment of Ta and T1 intermediate or high risk bladder cancer with intravesical Bacillus Calmette-Guérin or mitomycin C].
Topics: Adjuvants, Immunologic; Administration, Intravesical; BCG Vaccine; Humans; Mitomycin; Neoplasm Recur | 2021 |
Clinical trial of high dose hyperthermic intravesical mitomycin C for intermediate and high-risk non-muscle invasive bladder cancer during BCG shortage.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; BCG Vaccine; Female; Follow-Up Stud | 2021 |
[Intravesical Gemcitabine instillations following BCG failure and allergy to Mitomycin: A unique case of a patient with an inverted papilloma of the bladder].
Topics: Administration, Intravesical; BCG Vaccine; Deoxycytidine; Gemcitabine; Humans; Hypersensitivity; Mit | 2021 |
Reply to Claudia Signorini and Massimo Maffezzini's Letter to the Editor re: Maria S. Lindgren, Peter Bue, Nessn Azawi, et al. The DaBlaCa-13 Study: Short-term, Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in Non-muscle-inv
Topics: Adjuvants, Immunologic; Administration, Intravesical; Environment; Humans; Mitomycin; Urinary Bladde | 2021 |
Re: Maria S. Lindgren, Peter Bue, Nessn Azawi, et al. The DaBlaCa-13 Study: Short-term, Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in Non-muscle-invasive Bladder Cancer-A Randomized Controlled Trial. Eur Urol 2020;78:856-
Topics: Adjuvants, Immunologic; Administration, Intravesical; Environment; Humans; Mitomycin; Urinary Bladde | 2021 |
Anti-Cancer Effects and Tumor Marker Role of Glutathione
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Buthionine Sulfoximine; Ce | 2021 |
Prognostic Implications of Treatment Delays for Patients with Non-muscle-invasive Bladder Cancer.
Topics: BCG Vaccine; Humans; Mitomycin; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Prognosis; Retros | 2022 |
Spinal Anesthesia Provides Longer Administration Time for Postoperative Intravesical Chemotherapy after TUR-B Operation.
Topics: Administration, Intravesical; Anesthesia, Spinal; Humans; Mitomycin; Pain; Urinary Bladder Neoplasms | 2022 |
Topical and systemic immunoreaction triggered by intravesical chemotherapy in an N-butyl-N-(4-hydroxybutyl) nitorosamine induced bladder cancer mouse model.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Animals; Antineoplastic Combined Chemotherapy | 2017 |
Toward Better Predictions of Chemosensitivity: Comparative Study of Conventional and Simulated Chemosensitivity Tests for Bladder Cancer Cell Lines.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Docetaxel; Epirubicin; G | 2017 |
Effectivity of intravescical thermo-chemotherapy prophylaxis for patients with high recurrence and progression risk for non-muscle invasive bladder cancer.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Combined | 2017 |
American Urological Association (AUA) - 112th Annual Meeting (May 12-16, 2017 - Boston, Massachusetts, USA).
Topics: Acetanilides; Administration, Intranasal; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carc | 2017 |
Cytological and histological changes in the urothelium produced by electromotive drug administration (EMDA) and by the combination of intravescical hyperthermia and chemotherapy (thermochemotherapy).
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Transitiona | 2017 |
Tissue-engineered human 3D model of bladder cancer for invasion study and drug discovery.
Topics: Cell Line, Tumor; Drug Discovery; Drug Evaluation, Preclinical; Human Umbilical Vein Endothelial Cel | 2017 |
Fewer Recurrences with Immediate versus Delayed Intravesical Mitomycin C: A Prospective Randomized European Trial.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma, Transitional Cell | 2018 |
Update on the role of endovesical chemotherapy in nonmuscle-invasive bladder cancer.
Topics: Administration, Intravesical; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitiona | 2018 |
Intravesical radiofrequency induced hyperthermia enhances mitomycin C accumulation in tumour tissue.
Topics: Aged; Female; Humans; Hyperthermia, Induced; Male; Middle Aged; Mitomycin; Urinary Bladder Neoplasms | 2018 |
Impact of age on outcomes of patients with non-muscle-invasive bladder cancer treated with immediate postoperative instillation of mitomycin C.
Topics: Administration, Intravesical; Age Factors; Aged; Antibiotics, Antineoplastic; Carcinoma, Transitiona | 2018 |
Ganoderma microsporum immunomodulatory protein induces apoptosis and potentiates mitomycin C-induced apoptosis in urinary bladder urothelial carcinoma cells.
Topics: Apoptosis; Cell Line, Tumor; Fungal Proteins; Ganoderma; Gene Expression Regulation, Neoplastic; Hum | 2018 |
Lidocaine enhances the effects of chemotherapeutic drugs against bladder cancer.
Topics: Administration, Intravesical; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; | 2018 |
Ultrasound beam steering of oxygen nanobubbles for enhanced bladder cancer therapy.
Topics: Animals; Antibiotics, Antineoplastic; Cell Line, Tumor; Cellulose; Disease Models, Animal; Drug Deli | 2018 |
Single ablative intravesical electromotive mitomycin C administration for small non-muscle-invasive bladder cancer: a prospective study.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Female; H | 2018 |
[Development and treatment of localized/systemic BCGitis : Retrospective studies in direct comparison to mitomycin C].
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Huma | 2018 |
CXCL5 promotes mitomycin C resistance in non-muscle invasive bladder cancer by activating EMT and NF-κB pathway.
Topics: Cell Line, Tumor; Chemokine CXCL5; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gen | 2018 |
A care bundle to improve perioperative mitomycin use in non-muscle-invasive bladder cancer.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Female; Guidelin | 2018 |
Re: Value of an Immediate Intravesical Instillation of Mitomycin C in Patients with Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Randomised Study in 2243 patients.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Humans; Mitomycin; Neoplasm Recurrence, L | 2018 |
Neoadjuvant chemohyperthermia: Our experience after 10 years.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Case-Control Studies; Female; Humans; Hyperthe | 2018 |
Patient Compliance With Maintenance Intravesical Therapy for Nonmuscle Invasive Bladder Cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Antibiotics, Antineoplastic; BCG Vaccine | 2018 |
An immediate, single intravesical instillation of mitomycin C is of benefit in patients with non-muscle-invasive bladder cancer irrespective of prognostic risk groups.
Topics: Aged; Antibiotics, Antineoplastic; Female; Humans; Middle Aged; Mitomycin; Prognosis; Risk Factors; | 2018 |
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Antitubercular Agents; BCG Vaccine; Equi | 2018 |
FOXM1 overexpression is associated with adverse outcome and predicts response to intravesical instillation therapy in stage pT1 non-muscle-invasive bladder cancer.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Disease-Free Survival; Female; Fork | 2019 |
Re: Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C versus bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-Risk Non-Muscle-Invasive Bladder Cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; BCG Vaccine; Humans; Mitomycin; Urinary Bladde | 2018 |
Re: Tom J.H. Arends, Ofer Nativ, Massimo Maffezzini, et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guerin for Adjuvant Treatment of Patients with Intermediate- and High-r
Topics: Adjuvants, Immunologic; Administration, Intravesical; BCG Vaccine; Humans; Mitomycin; Urinary Bladde | 2019 |
Postoperative intravesical chemotherapy has an important role in reducing subsequent bladder tumours - why is it not routine?
Topics: Administration, Intravesical; Humans; Mitomycin; Neoplasm Recurrence, Local; Postoperative Period; U | 2018 |
Reply to Harshit Garg, Brusabhanu Nayak and Prabhjot Singh's Letter to the Editor Re: Tom J.H. Arends, Ofer Nativ, Massimo Maffezzini, et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillu
Topics: Adjuvants, Immunologic; Administration, Intravesical; BCG Vaccine; Humans; Mitomycin; Urinary Bladde | 2019 |
Health-related quality of life after BCG or MMC induction for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Adult; Age Factors; Aged; Aged, 80 and over; A | 2018 |
The effect of air pockets in the urinary bladder on the temperature distribution during loco-regional hyperthermia treatment of bladder cancer patients.
Topics: Combined Modality Therapy; Female; Humans; Hyperthermia, Induced; Male; Mitomycin; Temperature; Urin | 2018 |
Comparison of Different Treatment Schedules of Mitomycin C Intravesical Instillation in High-Risk Superficial Bladder Cancer Patients.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Cohort Studies | 2019 |
Continuous saline bladder irrigation for two hours following transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer does not prevent recurrence or progression compared with intravesical Mitomycin-C.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Combined Modalit | 2018 |
Drug resistance restricts the efficacy of short term low dose Mitomycin-C treatment in UMUC-3 bladder cancer cells.
Topics: Antibiotics, Antineoplastic; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Mitomycin; Time | 2018 |
Managing Toxicity of Intravesical Therapy.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Drug-Relat | 2018 |
Ex vivo assays to predict enhanced chemosensitization by hyperthermia in urothelial cancer of the bladder.
Topics: Cell Line, Tumor; Cisplatin; Cytochromes c; Humans; Hyperthermia, Induced; Mitomycin; Urinary Bladde | 2018 |
Intravesical treatment of chemotherapeutic agents sensitizes bacillus Calmette‑Guerin by the modulation of the tumor immune environment.
Topics: Administration, Intravesical; Animals; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; | 2019 |
Cancer-associated fibroblasts induce epithelial-mesenchymal transition of bladder cancer cells through paracrine IL-6 signalling.
Topics: Biomarkers; Cancer-Associated Fibroblasts; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell | 2019 |
Pro-GA, a Novel Inhibitor of γ-Glutamylcyclotransferase, Suppresses Human Bladder Cancer Cell Growth.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2019 |
A Comparison of Different Prophylactic Intravesical Chemotherapy Regimens for Bladder Cancer Recurrence After Nephroureterectomy for Primary Upper Tract Urothelial Carcinomas: A Retrospective 2-center Study.
Topics: Administration, Intravesical; Aged; Combined Modality Therapy; Cystoscopy; Disease-Free Survival; Do | 2019 |
ASC-J9® increases the bladder cancer chemotherapy efficacy via altering the androgen receptor (AR) and NF-κB survival signals.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Prolifera | 2019 |
The investigation of a traditional Chinese medicine, Guizhi Fuling Wan (GFW) as an intravesical therapeutic agent for urothelial carcinoma of the bladder.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma; Cell Cycle; Cell Lin | 2013 |
Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non-muscle invasive bladder cancer.
Topics: Academic Medical Centers; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Proto | 2014 |
UPEC biomimickry at the urothelial barrier: lectin-functionalized PLGA microparticles for improved intravesical chemotherapy.
Topics: Administration, Intravesical; Antineoplastic Agents; Biomimetic Materials; Cell Adhesion; Cell Line, | 2013 |
The interaction of celecoxib with MDR transporters enhances the activity of mitomycin C in a bladder cancer cell line.
Topics: Animals; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP B | 2013 |
Complications associated with single-dose, perioperative mitomycin-C for patients undergoing bladder tumor resection.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Case-Control Studies; Chi-Square Distri | 2014 |
Systemic absorption and pharmacokinetics of single-dose early intravesical mitomycin C after transurethral resection of non-muscle-invasive bladder cancer.
Topics: Absorption; Aged; Antibiotics, Antineoplastic; Female; Humans; Male; Middle Aged; Mitomycin; Sex Fac | 2013 |
Delayed healing at transurethral resection of bladder tumour sites after immediate postoperative mitomycin C instillation.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Cystectomy; Huma | 2014 |
Comet assay measures of DNA damage are predictive of bladder cancer cell treatment sensitivity in vitro and outcome in vivo.
Topics: Cell Line, Tumor; Cisplatin; Comet Assay; DNA Damage; Humans; Mitomycin; Treatment Outcome; Urinary | 2014 |
Bladder cancer in Spain 2011: population based study.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Comorbidi | 2014 |
Destruction of the bladder by single dose Mitomycin C for low-stage transitional cell carcinoma (TCC)--avoidance, recognition, management and consent.
Topics: Adult; Aged; Carcinoma, Transitional Cell; Female; Humans; Informed Consent; Male; Middle Aged; Mito | 2014 |
Novel multisensor probe for monitoring bladder temperature during locoregional chemohyperthermia for nonmuscle-invasive bladder cancer: technical feasibility study.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Body Temperature; Equipment Design; Feasi | 2013 |
The effect of photochemical internalization of bleomycin in the treatment of urothelial carcinoma of the bladder: an in vitro study.
Topics: Animals; Antibiotics, Antineoplastic; Bleomycin; Carcinoma, Transitional Cell; Cell Line, Tumor; Cel | 2014 |
Intravesical mitomycin therapy for stage T1 and tis high-grade squamous cell carcinoma of the bladder.
Topics: Administration, Intravesical; Aged, 80 and over; Carcinoma, Squamous Cell; Humans; Induction Chemoth | 2014 |
Epigallocatechin-3-gallate prevents tumor cell implantation/growth in an experimental rat bladder tumor model.
Topics: Animals; Catechin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Female; | 2014 |
Would the benefits of hexaminolevulinate fluorescence cystoscopy be eliminated if every patient received postoperative installation of intravesical chemotherapy?
Topics: Aminolevulinic Acid; Antibiotics, Antineoplastic; Cystoscopy; Female; Humans; Male; Mitomycin; Neopl | 2013 |
Intravesical mitomycin C combined with local microwave hyperthermia in non-muscle-invasive bladder cancer with increased European Organization for Research and Treatment of Cancer (EORTC) score risk of recurrence and progression.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Disease P | 2014 |
Toll-like receptor 6 and connective tissue growth factor are significantly upregulated in mitomycin-C-treated urothelial carcinoma cells under hydrostatic pressure stimulation.
Topics: Apoptosis; Cell Line, Tumor; Connective Tissue Growth Factor; Gene Expression; Humans; Hydrostatic P | 2014 |
Combined chemohyperthermia: 10-year single center experience in 160 patients with nonmuscle invasive bladder cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Combined Modality Therapy; Disease-Free | 2014 |
Anthocyans as tertiary chemopreventive agents in bladder cancer: anti-oxidant mechanisms and interaction with mitomycin C.
Topics: Anthocyanins; Antineoplastic Agents; Antioxidants; Cell Count; Cell Cycle; Cell Line, Tumor; Cell Pr | 2014 |
Cationic core-shell nanoparticles for intravesical chemotherapy in tumor-induced rat model: safety and efficacy.
Topics: Administration, Intravesical; Animals; Antibiotics, Antineoplastic; Butylhydroxybutylnitrosamine; Ca | 2014 |
Predicting factors for recurrence in low-grade Ta primary bladder tumours.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma, Transitional Ce | 2014 |
Toward online adaptive hyperthermia treatment planning: correlation between measured and simulated specific absorption rate changes caused by phase steering in patients.
Topics: Algorithms; Antibiotics, Antineoplastic; Humans; Hyperthermia, Induced; Male; Mitomycin; Radiography | 2014 |
[Efficacy of prophylactic intravesical mitomycin C in patients with non-muscle-invasive bladder cancer].
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Female; Humans; Male; Middle Aged; Mitomycin; | 2014 |
In vitro and in vivo experiments on electrochemotherapy for bladder cancer.
Topics: Animals; Antineoplastic Agents; Cisplatin; Electrochemotherapy; Humans; Mice; Mitomycin; Tumor Cells | 2015 |
Is thermochemotherapy with the Synergo system a viable treatment option in patients with recurrent non-muscle-invasive bladder cancer?
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Biopsy; F | 2015 |
High-dose chemotherapeutics of intravesical chemotherapy rapidly induce mitochondrial dysfunction in bladder cancer-derived spheroids.
Topics: Administration, Intravesical; Animals; Antineoplastic Agents; DNA Fragmentation; Epirubicin; Humans; | 2015 |
Commentary on "economic and humanistic consequences of preventable bladder tumor recurrences in nonmuscle invasive bladder cancer cases." Lee CT, Barocas D, Globe DR, Oefelein MG, Colayco DC, Bruno A, O׳Day K, Bramley T, Department of Urology, University
Topics: Antibiotics, Antineoplastic; Cost of Illness; Humans; Mitomycin; Neoplasm Recurrence, Local; Urinary | 2014 |
The correct sequence of intravesical chemotherapy and bacillus Calmette-Guérin for non-muscle-invasive bladder cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Female; Hu | 2015 |
Urinary cytokines in patients treated with intravesical mitomycin-C with and without hyperthermia.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Biomarkers, Tumo | 2015 |
XRCC1 polymorphisms associated with survival among Chinese bladder cancer patients receiving epirubicin and mitomycin C.
Topics: Aged; Alleles; Biomarkers, Pharmacological; China; Disease-Free Survival; DNA-Binding Proteins; Epir | 2015 |
[Intravesical instillation for bladder tumors].
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Drug | 2014 |
Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocol | 2016 |
Reducing recurrence in non-muscle-invasive bladder cancer using photodynamic diagnosis and immediate post-transurethral resection of the bladder chemoprophylaxis.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Chemoprevention; Cystoscopy; Female; Fo | 2015 |
Ablative Intravesical Chemotherapy for Small Recurrent Non-Muscle-Invasive Bladder Cancer: A Prospective Study.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic A | 2016 |
Long-term outcomes of the FinnBladder-4 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Female; Humans; Interferon-alpha; Male; | 2015 |
Results of Intravesical Chemo-Hyperthermia in High-risk Non-muscle Invasive Bladder Cancer.
Topics: ABO Blood-Group System; Administration, Intravesical; Aged; Aged, 80 and over; Antibiotics, Antineop | 2015 |
Reply from authors re: Robert S. Svatek. Long-term outcomes of the FinnBladder-4 study. Eur Urol 2015;68:618-9: which type of maintenance matters?
Topics: Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Female; Humans; Interferon-alpha; Male; | 2015 |
Combining Mitomycin C and Regional 70 MHz Hyperthermia in Patients with Nonmuscle Invasive Bladder Cancer: A Pilot Study.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Combined | 2015 |
European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Chemotherap | 2015 |
Editorial Comment.
Topics: Female; Humans; Hyperthermia, Induced; Male; Mitomycin; Urinary Bladder Neoplasms | 2015 |
Single instillation of mitomycin C plus bacillus Calmette-Guérin (BCG) versus BCG alone in high grade non-muscle invasive bladder cancer.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy P | 2015 |
Predictive Factors for Time to Progression after Hyperthermic Mitomycin C Treatment for High-Risk Non-Muscle Invasive Urothelial Carcinoma of the Bladder: An Observational Cohort Study of 97 Patients.
Topics: Aged; Antibiotics, Antineoplastic; Biopsy; Carcinoma in Situ; Cohort Studies; Cystectomy; Cystoscopy | 2016 |
Re: Contemporary Cost-Effectiveness Analysis Comparing Sequential bacillus Calmette-Guerin and Electromotive Mitomycin versus bacillus Calmette-Guerin Alone for Patients with High-Risk Non-Muscle-Invasive Bladder Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Humans; Mitomycin; Models, Economic; Ur | 2015 |
Evaluation of Su Fu'ning Lotion's Inhibitory Effects on Bladder Cancer Cells In Vitro and In Vivo by Intravesical Instillation.
Topics: Administration, Intravesical; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; | 2016 |
GSTP1 and GSTO1 single nucleotide polymorphisms and the response of bladder cancer patients to intravesical chemotherapy.
Topics: Administration, Intravesical; Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Epirubi | 2015 |
Reply to Yan Shibing and Wei Qiang's Letter to the Editor re: Morgan Rouprêt, Marko Babjuk, Eva Compérat, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update. Eur Urol 2015;68:868-79.
Topics: Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Humans; Kidney Neoplasms; Mitomycin; Neop | 2016 |
Re: Morgan Rouprêt, Marko Babjuk, Eva Compérat, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update. Eur Urol 2015;68:868-79.
Topics: Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Humans; Kidney Neoplasms; Mitomycin; Neop | 2016 |
[Assessment of the optimization of the conditions of mitomycin C intravesical instillation completion in the setting of non-muscle invasive bladder cancer treatment].
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Drinking Water; Humans; Mitomycin; Neopla | 2016 |
Gemcitabine and mitomycin induced autophagy regulates cancer stem cell pool in urothelial carcinoma cells.
Topics: Adult; Aged; Antineoplastic Agents; Autophagy; Autophagy-Related Protein 7; Blotting, Western; Carci | 2016 |
Appendicovesical Fistula Following Transurethral Resection of Bladder Tumor With Mitomycin C.
Topics: Antibiotics, Antineoplastic; Appendix; Cecal Diseases; Cystectomy; Humans; Intestinal Fistula; Male; | 2016 |
[Observational survey of the French Urological Association Oncology Committee (CCAFU) evaluating the practice of immediate postoperative instillation (IPOP) using mitomycin C for non-muscle invasive bladder cancer (NMIBC) treatment].
Topics: Administration, Intravesical; Combined Modality Therapy; France; Health Care Surveys; Humans; Mitomy | 2016 |
Sequential bacillus Calmette-Guérin/Electromotive Drug Administration of Mitomycin C as the Standard Intravesical Regimen in High Risk Nonmuscle Invasive Bladder Cancer: 2-Year Outcomes.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Alkylating Agents; Cystoscopy; Drug Ther | 2016 |
Chemohyperthermia with Mitomycin-C Compared with Bacillus Calmette-Guérin: A "Hot" Topic.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Bacillus; BCG Vaccine; Humans; Mitomycin; Urin | 2016 |
Recirculant hyperthermic IntraVEsical chemotherapy (HIVEC) in intermediate-high-risk non-muscle-invasive bladder cancer.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Chemotherapy, Ad | 2016 |
Dermatological side effects of intravesical Mitomycin C: Delayed hypersensitivity.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Humans; Hypersensitivity, Delayed; Mitomy | 2016 |
MicroRNA-31 functions as a tumor suppressor and increases sensitivity to mitomycin-C in urothelial bladder cancer by targeting integrin α5.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Female; Genes, Tumor Suppressor; Humans; Integrin alp | 2016 |
Capsaicin triggers autophagic cell survival which drives epithelial mesenchymal transition and chemoresistance in bladder cancer cells in an Hedgehog-dependent manner.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Autophagy; Beclin-1; Capsaicin; Cell Line, Tumor; Cel | 2016 |
Re: Tom J.H. Arends, Ofer Nativ, Massimo Maffezzini, et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-r
Topics: Adjuvants, Immunologic; Administration, Intravesical; Bacillus; BCG Vaccine; Humans; Mitomycin; Urin | 2017 |
Reply to Sławomir Poletajew, Piotr Radziszewski, Juan Palou's Letter to the Editor re: Tom J.H. Arends, Ofer Nativ, Massimo Maffezzini, et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacill
Topics: Adjuvants, Immunologic; Administration, Intravesical; Bacillus; BCG Vaccine; Humans; Mitomycin; Urin | 2017 |
Clostridium perfringens enterotoxin as a potential drug for intravesical treatment of bladder cancer.
Topics: Administration, Intravesical; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Claudin-4; Clostri | 2016 |
Re: Sequential Intravesical Mitomycin plus Bacillus Calmette-Guérin for Non-Muscle-Invasive Urothelial Bladder Carcinoma: Translational and Phase I Clinical Trial.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Bacillus; BCG Vaccine; Carcinoma, Transitional | 2016 |
Editorial comments on: Seventeen-year follow-up of the prospective randomized Nordic CIS study: BCG monotherapy versus alternating therapy with mitomycin C and BCG in patients with carcinoma in situ of the urinary bladder, by E. Kaasinen et al. (in this i
Topics: Adjuvants, Immunologic; Administration, Intravesical; BCG Vaccine; Carcinoma in Situ; Follow-Up Stud | 2016 |
Prognostic significance of markers of systemic inflammatory response in patients with non-muscle-invasive bladder cancer.
Topics: Adjuvants, Immunologic; Aged; Antineoplastic Agents; BCG Vaccine; Biomarkers; C-Reactive Protein; Ca | 2016 |
Sustained-release Formulation of Mitomycin C to the Upper Urinary Tract Using a Thermosensitive Polymer: A Preclinical Study.
Topics: Administration, Intravesical; Animals; Carcinoma, Transitional Cell; Cross-Linking Reagents; Delayed | 2017 |
Ellagic Acid Inhibits Bladder Cancer Invasiveness and In Vivo Tumor Growth.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; B7-H1 A | 2016 |
Intravesical chemotherapy use after radical nephroureterectomy: A national survey of urologic oncologists.
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Chem | 2017 |
Re: Sequential bacillus Calmette-Guérin/Electromotive Drug Administration of Mitomycin C as the Standard Intravesical Regimen in High Risk Nonmuscle Invasive Bladder Cancer: 2-Year Outcomes: C. Gan, S. Amery, K. Chatterton, M. S. Khan, K. Thomas and T. O'
Topics: Administration, Intravesical; BCG Vaccine; Humans; Mitomycin; Mycobacterium bovis; Urinary Bladder N | 2017 |
Reply by Authors.
Topics: BCG Vaccine; Clinical Protocols; Humans; Mitomycin; Mycobacterium bovis; Urinary Bladder Neoplasms | 2017 |
Re: Long-Term Outcome of Patients with Frequently Recurrent Non-Muscle-Invasive Bladder Carcinoma Treated with One Perioperative plus Four Weekly Instillations of Mitomycin C followed by Monthly bacillus Calmette-Guérin (BCG) or Alternating BCG and Interf
Topics: BCG Vaccine; Humans; Interferon alpha-2; Interferon-alpha; Mitomycin; Neoplasm Recurrence, Local; Pr | 2017 |
[ BCG-immunotherapy and bladder cancer].
Topics: Adjuvants, Immunologic; Administration, Intravesical; Anti-Bacterial Agents; Antibiotics, Antineopla | 2008 |
Increasing patient comfort by optimized postoperative administration of intravesical mitomycin C.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Chemother | 2008 |
Anticarcinogenic and antimitotic effects of Turkish propolis and mitomycin-C on tissue cultures of bladder cancer.
Topics: Anticarcinogenic Agents; Female; Humans; Male; Mitomycin; Mitosis; Propolis; Urinary Bladder Neoplas | 2008 |
Vesicoenteric, vesicovaginal, vesicocutaneous fistula -an unusual complication with intravesical mitomycin.
Topics: Administration, Intravesical; Adult; Aged; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell | 2008 |
[Case 4. Perspectives in 2007 for bladder pathology. Giant cell urothelial carcinoma in situ].
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma in Situ; Diagnosis, Differential; Humans; Immunohistoch | 2008 |
Intravesical cationic nanoparticles of chitosan and polycaprolactone for the delivery of Mitomycin C to bladder tumors.
Topics: Administration, Intravesical; Animals; Antibiotics, Antineoplastic; Cations; Cell Survival; Chitosan | 2009 |
A multicolour fluorescence in situ hybridization test predicts recurrence in patients with high-risk superficial bladder tumours undergoing intravesical therapy.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy P | 2009 |
Updates in intravesical electromotive drug administration of mitomycin-C for non-muscle invasive bladder cancer.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Electrochemotherapy; Humans; Mitomycin; N | 2009 |
Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo working party.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma in Situ; Combined Modality Therapy; | 2009 |
Re: Ocular side-effects of urological pharmacy.
Topics: Antineoplastic Agents; BCG Vaccine; Dimethyl Sulfoxide; Eye Diseases; Humans; Mitomycin; Urinary Bla | 2009 |
[Treatment of non-muscle infiltrating tumours of the bladder].
Topics: Administration, Intravesical; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cystoscopy; Hu | 2009 |
Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20
Topics: Adjuvants, Immunologic; Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, A | 2009 |
[A simple and efficient method for establishing a mouse model of orthotopic MB49 bladder cancer].
Topics: Animals; Cell Line, Tumor; Cell Transformation, Neoplastic; Disease Models, Animal; Female; Mice; Mi | 2009 |
Is intravesical bacillus Calmette-Guérin better than mitomycin for intermediate-risk bladder cancer?
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Huma | 2009 |
Bacillus Calmette-Guérin versus mitomycin C for the treatment of intermediate-risk non-muscle-invasive bladder cancer: the debate continues.
Topics: Adjuvants, Immunologic; Antibiotics, Antineoplastic; BCG Vaccine; Humans; Mitomycin; Risk Factors; U | 2009 |
The MRC superficial bladder cancer trial of intravesical mytomicin-c after complete surgical resection. Sequential statistical methods applied to survival data from a randomised clinical trial.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Cystectomy; Data Interpretation, Statisti | 2009 |
Drug eruption due to intravesical instillations of both epirubicin and mitomycin C.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Drug Eruptions; Epirubicin; Humans; Male; | 2009 |
Cell adhesion to fibronectin induces mitomycin C resistance in bladder cancer cells.
Topics: Antibiotics, Antineoplastic; Apoptosis; Apoptosis Inducing Factor; Blotting, Western; Caspase Inhibi | 2009 |
[Postoperative and adjuvant intravesical therapy of superficial bladder tumours. Clinical practice and applied therapeutic agents].
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Chem | 2009 |
Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, A | 2009 |
Editorial comment.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Comb | 2009 |
[Urinary tuberculosis caused by Mycobacterium bovis BCG variety, following intravesical instillation].
Topics: Administration, Intravesical; Aged; Antitubercular Agents; BCG Vaccine; Carcinoma, Transitional Cell | 2010 |
Multidrug resistance in a urothelial cancer cell line after 1-hour mitomycin C exposure.
Topics: Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Cell Line, Tumor; Drug Resistance, Neopla | 2009 |
Intravesical alpha-radioimmunotherapy with 213Bi-anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude mice.
Topics: Administration, Intravesical; Alpha Particles; Animals; Antibodies, Monoclonal; Bismuth; Cell Line, | 2009 |
[Treatment of non-muscle invasive bladder tumours by instillations of mitomycin C and BCG: a survey on French urologists by the French Urological Association].
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Fran | 2009 |
Photodynamic diagnosis (5-aminolevulinic acid) of transitional cell carcinoma after bacillus Calmette-Guérin immunotherapy and mitomycin C intravesical therapy.
Topics: Administration, Intravesical; Aminolevulinic Acid; Antibiotics, Antineoplastic; BCG Vaccine; Biopsy; | 2010 |
Delayed hypersensitivity to Mitomycin C.
Topics: Antibiotics, Antineoplastic; Humans; Hypersensitivity, Delayed; Male; Middle Aged; Mitomycin; Skin T | 2009 |
Perivesical inflammation and necrosis due to mitomycin C instillation after transurethral resection of bladder tumor: we must be vigilant!
Topics: Administration, Intravesical; Aged; Anti-Bacterial Agents; Cystectomy; Cystitis; Humans; Male; Mitom | 2009 |
Re: Per-Uno Malmström, Richard J. Sylvester, David E. Crawford, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladd
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Huma | 2010 |
Bladder cancer: meta-analysis of BCG versus mitomycin C--a deeper insight?
Topics: Administration, Intravesical; BCG Vaccine; Humans; Meta-Analysis as Topic; Mitomycin; Randomized Con | 2010 |
Intravesical mitomycin-C-induced interstitial pneumonia.
Topics: Administration, Intravesical; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma in Situ; Fat | 2010 |
Contemporary cost analysis of single instillation of mitomycin after transurethral resection of bladder tumor in a universal health care system.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Combined Modality Therapy; Costs and Cost | 2010 |
An improved orthotopic rat bladder tumor model using Dil-loaded fluorescent AY-27 cells.
Topics: Animals; Antibiotics, Antineoplastic; Carbocyanines; Cell Line, Tumor; Disease Models, Animal; Femal | 2010 |
[Management of non invasive bladder cancers. T1Ga urothelial cell carcinoma: benefit of immediate post operative instillation?].
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Antineoplastic Agents; Carcinoma, Transit | 2010 |
Increasing medical staff safety by using a closed system for intravesical instillation of mitomycin C.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Combined Modality Therapy; Equipment Desi | 2010 |
Intensive intravesical mitomycin C therapy in non-muscle-invasive bladder cancer: a dose intensity approach.
Topics: Administration, Intravesical; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; | 2010 |
Re: Per-Uno Malmström, Richard J. Sylvester, David E. Crawford, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladd
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Huma | 2010 |
Prognostic value of p53 and Ki-67 expression in intermediate-risk patients with nonmuscle-invasive bladder cancer receiving adjuvant intravesical mitomycin C therapy.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Chemother | 2010 |
Effect of mitomycin C on concentrations of vascular endothelial growth factor and its receptors in bladder cancer cells and in bladders of rats intravesically instilled with mitomycin C.
Topics: Administration, Intravesical; Animals; Antibiotics, Antineoplastic; Carcinoma in Situ; Carcinoma, Tr | 2011 |
Bacillus Calmette-Guerin immunotherapy of bladder cancer induces selection of human leukocyte antigen class I-deficient tumor cells.
Topics: Adjuvants, Immunologic; Adult; Aged; Antibiotics, Antineoplastic; BCG Vaccine; Histocompatibility An | 2011 |
Pseudoscleroderma possibly induced by intravesical instillation of mitomycin C.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Drug Eruptions; Humans; Male; Mitom | 2010 |
Combination intravesical hyperthermia and chemotherapy for bladder cancer.
Topics: Administration, Intravesical; Combined Modality Therapy; Humans; Hyperthermia, Induced; Mitomycin; U | 2010 |
Hyperthermia and intravesical therapy: emerging one-two punch for bladder cancer?
Topics: Administration, Intravesical; BCG Vaccine; Humans; Hyperthermia, Induced; Mitomycin; Urinary Bladder | 2010 |
Urinary pH is highly associated with tumor recurrence during intravesical mitomycin C therapy for nonmuscle invasive bladder tumor.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Female; H | 2011 |
Superficial bladder tumours: recurrence and progression.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Biopsy; Carcinoma, Transitional Cell; C | 2011 |
Re: Willem Oosterlinck, Ziya Kirkali,Richard Sylvester, et al. Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: resu
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Carc | 2011 |
Instillation of mitomycin C after transurethral resection of bladder cancer impairs wound healing: an animal model.
Topics: Administration, Intravesical; Animals; Disease Models, Animal; Female; Mitomycin; Rats; Rats, Spragu | 2011 |
Continuous saline bladder irrigation after transurethral resection is a prophylactic treatment choice for non-muscle invasive bladder tumor.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Femal | 2011 |
Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC).
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Humans; Hyperthermia, Induced; Mitomycin; | 2011 |
A comparative study of the inhibiting effects of mitomycin C and polyphenolic catechins on tumor cell implantation/growth in a rat bladder tumor model.
Topics: Animals; Antibiotics, Antineoplastic; Anticarcinogenic Agents; Catechin; Cell Line, Tumor; Cell Prol | 2011 |
Postoperative intravesical therapy to prevent bladder tumor recurrence: are we ready to listen yet?
Topics: Antibiotics, Antineoplastic; Carcinoma; Female; Humans; Kidney Neoplasms; Male; Mitomycin; Nephrecto | 2011 |
Bladder cancer: neoadjuvant is new again.
Topics: Antibiotics, Antineoplastic; Carcinoma; Cystectomy; Female; Humans; Male; Mitomycin; Urinary Bladder | 2011 |
Re: Urinary pH is highly associated with tumor recurrence during intravesical mitomycin C therapy for nonmuscle invasive bladder tumor. T. Maeda, E. Kikuchi, K. Matsumoto, A. Miyajima and M. Oya. J Urol 2011; 185: 802-806.
Topics: Antibiotics, Antineoplastic; Female; Humans; Male; Mitomycin; Neoplasm Recurrence, Local; Urinary Bl | 2011 |
RNA interference-mediated vascular endothelial growth factor-C reduction suppresses malignant progression and enhances mitomycin C sensitivity of bladder cancer T24 cells.
Topics: Antibiotics, Antineoplastic; Apoptosis; Cell Growth Processes; Cell Line, Tumor; Disease Progression | 2012 |
Chemotherapy: Electromotive mitomycin in superficial bladder cancer.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Electrochem | 2011 |
Maximizing intravesical therapy options: is there an advantage to the administration of perioperative mitomycin C prior to an induction course of BCG?
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; BCG Vaccine; Car | 2011 |
Potentiation of mitomycin C tumoricidal activity for transitional cell carcinoma by histone deacetylase inhibitors in vitro.
Topics: Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Drug Synergism; Drug Therapy, Combination | 2011 |
Chondroitin sulphate enhances the antitumor activity of gemcitabine and mitomycin-C in bladder cancer cells with different mechanisms.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspases; Cell Line, Tumor; Cell Prolifer | 2012 |
Identification of a methylation hotspot in the death receptor Fas/CD95 in bladder cancer.
Topics: Aged; Apoptosis; Caco-2 Cells; Carcinoma, Transitional Cell; Cell Line, Tumor; CpG Islands; DNA Meth | 2012 |
Electromotive administration of mitomycin.
Topics: Antibiotics, Antineoplastic; Carcinoma; Cystectomy; Female; Humans; Male; Mitomycin; Urinary Bladder | 2011 |
Re: Tim O'Brien, Eleanor Ray, Rajinder Singh, Bola Coker, Ralph Beard, British Association of Urological Surgeons Section of Oncology. Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospecti
Topics: Antibiotics, Antineoplastic; Carcinoma; Female; Humans; Kidney Neoplasms; Male; Mitomycin; Nephrecto | 2012 |
Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for patients with peritoneal carcinomatosis secondary to urachal adenocarcinoma.
Topics: Adenocarcinoma; Adolescent; Adult; Antibiotics, Antineoplastic; Chemotherapy, Adjuvant; Chemotherapy | 2012 |
Engagement of integrinβ1 induces resistance of bladder cancer cells to mitomycin-C.
Topics: Antibiotics, Antineoplastic; Apoptosis; Blotting, Western; Carcinoma, Transitional Cell; Caspase 10; | 2012 |
Cost-effectiveness of fluorescent cystoscopy for noninvasive papillary tumors: pro.
Topics: Antibiotics, Antineoplastic; Carcinoma, Papillary; Cost-Benefit Analysis; Cystoscopy; Humans; Mitomy | 2012 |
Prolonged retention and in vivo evaluation of cationic nanoparticles loaded with Mitomycin C designed for intravesical chemotherapy of bladder tumours.
Topics: Animals; Antibiotics, Antineoplastic; Chitosan; Drug Delivery Systems; Drug Screening Assays, Antitu | 2012 |
Reported use of intravesical therapy for non-muscle-invasive bladder cancer (NMIBC): results from the Bladder Cancer Advocacy Network (BCAN) survey.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antineoplastic Ag | 2012 |
Adjuvant intravesical instillation for primary T1G3 bladder cancer: BCG versus MMC in Korea.
Topics: Antibiotics, Antineoplastic; BCG Vaccine; Mitomycin; Neoplasm Recurrence, Local; Republic of Korea; | 2012 |
Optimising existing therapeutic strategies for the treatment of non-muscle-invasive bladder cancer: the role of intensive neoadjuvant intravesical mitomycin C.
Topics: Antibiotics, Antineoplastic; Female; Humans; Male; Mitomycin; Neoadjuvant Therapy; Neoplasm Recurren | 2012 |
Histological changes due to intravesical instillation of mitomycin C.
Topics: Administration, Intravesical; Aged; Antineoplastic Agents; Carcinoma, Transitional Cell; Chemotherap | 2012 |
Chemotherapy sorting can be used to identify cancer stem cell populations.
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Cell Cycle; Cell Line, Tumor; Drug Therapy; Gen | 2012 |
FAVL impairment of the Fanconi anemia pathway promotes the development of human bladder cancer.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; DNA Damage; DNA Repair; Fanconi Anemia; Fanconi Anemi | 2012 |
10-year single-center experience of combined intravesical chemohyperthermia for nonmuscle invasive bladder cancer.
Topics: Administration, Intravesical; Antineoplastic Agents; Cohort Studies; Combined Modality Therapy; Foll | 2012 |
Electroporation enhances mitomycin C cytotoxicity on T24 bladder cancer cell line: a potential improvement of intravesical chemotherapy in bladder cancer.
Topics: Administration, Intravesical; Animals; Antineoplastic Agents; Biological Transport; Bleomycin; Cell | 2012 |
Intravesical mitomycin C-induced generalized pustular folliculitis.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Drug Eruptions; Folliculitis; Humans; Mal | 2012 |
Re: Renzo Colombo, Lorenzo Rocchini, Nazareno Suardi, et al. Neoadjuvant short-term intensive intravesical mitomycin C regimen compared with weekly schedule for low-grade recurrent non-muscle-invasive bladder cancer: preliminary results of a randomised ph
Topics: Antibiotics, Antineoplastic; Female; Humans; Male; Mitomycin; Neoadjuvant Therapy; Neoplasm Recurren | 2013 |
siRNA-mediated inhibition of antiapoptotic genes enhances chemotherapy efficacy in bladder cancer cells.
Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Cell Line, Tumor; Cisplatin; Gene Silencing; Humans | 2012 |
Economic and humanistic consequences of preventable bladder tumor recurrences in nonmuscle invasive bladder cancer cases.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Cost of Illness; Humans; Mitomycin; Neopl | 2012 |
Reply to Manish Garg, Apul Goel and Jai Prakash's letter to the editor re: Renzo Colombo, Lorenzo Rocchini, Nazareno Suardi, et al. Neoadjuvant short-term intensive intravesical mitomycin C regimen compared with weekly schedule for low-grade recurrent non
Topics: Antibiotics, Antineoplastic; Female; Humans; Male; Mitomycin; Neoadjuvant Therapy; Neoplasm Recurren | 2013 |
[Guidelines for good practice of intravesical instillations of BCG and mitomycin C from the French national cancer committee (CC-AFU) for non-muscle invasive bladder cancer].
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Huma | 2012 |
Comparison of the cellular molecular stress responses after treatments used in bladder cancer.
Topics: Animals; Antibiotics, Antineoplastic; Blotting, Western; Collagen; Heat-Shock Proteins; HSP47 Heat-S | 2002 |
Clinical outcome of conservative therapy for stage T1, grade 3 transitional cell carcinoma of the bladder.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, A | 2003 |
Over expression of metallothionein predicts resistance of transitional cell carcinoma of bladder to intravesical mitomycin therapy.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma | 2003 |
Distal ureteral stenosis after early adjuvant intravesical mitomycin C application for superficial bladder cancer.
Topics: Administration, Intravesical; Aged; Biopsy, Needle; Chemotherapy, Adjuvant; Cystectomy; Female; Foll | 2003 |
Apoptosis of bladder cancer cells induced by short-term and low-dose Mitomycin-C: potential molecular mechanism and clinical implication.
Topics: Antibiotics, Antineoplastic; Apoptosis; Carcinoma, Transitional Cell; Caspase 3; Caspases; Cell Line | 2003 |
Unusual complication after immediate postoperative intravesical mitomycin C instillation.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Extravasation of Diagnostic and Therapeut | 2003 |
Effect of intravesical treatment of transitional cell carcinoma with bacillus Calmette-Guerin and mitomycin C on urinary survivin levels and outcome.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Aged, 80 and over; Antibiotics, Antineop | 2003 |
Urinary interleukin-8 levels are elevated in subjects with transitional cell carcinoma.
Topics: Adenocarcinoma; Administration, Intravesical; Aged; Antineoplastic Agents, Alkylating; BCG Vaccine; | 2003 |
A novel device for reconstituting and delivering intravesical chemotherapy.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Drug Delivery Systems; Equipment Design; | 2003 |
Combined intravesical hyperthermia and mitomycin chemotherapy: a preliminary in vivo study.
Topics: Adipose Tissue; Administration, Intravesical; Animals; Antibiotics, Antineoplastic; Biopsy; Carcinom | 2003 |
TREATMENT OF MALIGNANT TUMOURS WITH 5-FLUOROURACIL IN 80 PATIENTS.
Topics: Biomedical Research; Breast Neoplasms; Colonic Neoplasms; Drug Therapy; Esophageal Neoplasms; Female | 1964 |
Intravesical therapy for superficial bladder cancer: slow but steady progress.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Combined Mo | 2003 |
T1G3 transitional cell carcinoma of the bladder: recurrence, progression and survival.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antineoplastic | 2004 |
Investigation of sequential mitomycin C and photodynamic therapy in a mitomycin-resistant bladder cancer cell-line model.
Topics: Aminolevulinic Acid; Antibiotics, Antineoplastic; Cell Line, Tumor; Cell Survival; Drug Interactions | 2004 |
[An experimental study on high intensity focused ultrasound combined with mitomycin treatment of bladder tumor].
Topics: Animals; Apoptosis; Combined Modality Therapy; Female; Male; Mice; Mitomycin; Ultrasonic Therapy; Ur | 2003 |
Immunohistochemical analysis of NAD(P)H:quinone oxidoreductase and NADPH cytochrome P450 reductase in human superficial bladder tumours: relationship between tumour enzymology and clinical outcome following intravesical mitomycin C therapy.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Disease-Free Survival; Gene Expression Re | 2004 |
[Sepsis and multiple organ failure after BCG-instillation for bladder cancer].
Topics: Adjuvants, Immunologic; Administration, Intravesical; Bacteriuria; BCG Vaccine; Biopsy; Bone Marrow; | 2004 |
Percutaneous nephroscopic management of upper urinary tract transitional cell carcinoma: recurrence and long-term followup.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Endo | 2004 |
[Early postoperative mitomycin C instillation: when and how?].
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Combined Modality Therapy; Equipment Desi | 2004 |
Polymorphism within the cyclin D1 gene is associated with an increased risk of carcinoma in situ in patients with superficial bladder cancer.
Topics: Aged; Alternative Splicing; Antineoplastic Agents, Alkylating; BCG Vaccine; Carcinoma in Situ; Carci | 2004 |
NAD(P)H:Quinone oxidoreductase-1 C609T polymorphism analysis in human superficial bladder cancers: relationship of genotype status to NQO1 phenotype and clinical response to Mitomycin C.
Topics: Carcinoma, Transitional Cell; Genotype; Humans; Mitomycin; NAD(P)H Dehydrogenase (Quinone); Neoplasm | 2004 |
The effect of hyperthermia on mitomycin-C induced cytotoxicity in four human bladder cancer cell lines.
Topics: Antibiotics, Antineoplastic; Combined Modality Therapy; Humans; Hyperthermia, Induced; Mitomycin; Tu | 2004 |
[The heat shock protein 70 antisense oligomers enhance the sensitivity of bladder cancer cell EJ to mitomycin C].
Topics: Cell Division; Cell Line, Tumor; HSP70 Heat-Shock Proteins; Humans; Mitomycin; Oligonucleotides, Ant | 2004 |
Bioadhesive drug carriers for postoperative chemotherapy in bladder cancer.
Topics: Administration, Intravesical; Alginates; Animals; Antibiotics, Antineoplastic; Chitosan; Cross-Linki | 2004 |
A novel multidrug resistance phenotype of bladder tumor cells grown on Matrigel or SIS gel.
Topics: Cell Culture Techniques; Cell Line, Tumor; Collagen; Doxorubicin; Drug Combinations; Drug Resistance | 2005 |
Allergic contact sensitization from intravesical mitomycin C, without dermatitis.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Drug | 2004 |
Effect of hyperthermia on the cytotoxicity of 4 chemotherapeutic agents currently used for the treatment of transitional cell carcinoma of the bladder: an in vitro study.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2005 |
Re: A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Antineoplastic Agents; Humans; Mitomycin; | 2005 |
Effects of intravesical chemotherapy and immunotherapy on semen analysis.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Adult; Antibiotics, Antineoplastic; BCG Vaccin | 2005 |
[Toxicity attenuation and efficacy potentiation effects of sijunzi decoction on bladder carcinoma treated by chemotherapy in mice].
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Carcinoma, Transitional Cel | 2005 |
Low dose suramin as a chemosensitizer of bladder cancer to mitomycin C.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neo | 2005 |
Vascular endothelial growth factor antisense pretreatment of bladder cancer cells significantly enhances the cytotoxicity of mitomycin C, gemcitabine and Cisplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Transitional Cell; Cell Line, | 2005 |
Herpes simplex virus based gene therapy enhances the efficacy of mitomycin C for the treatment of human bladder transitional cell carcinoma.
Topics: Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Cell Line, Tumor; Cell Survival; Dose-Res | 2005 |
Bladder perforation: a potential risk of early endovesical chemotherapy with mitomycin C.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Cystectomy; | 2005 |
Enhanced sensitivity to mitomycin C by abating heat shock protein 70 expression in human bladder cancer cell line of BIU-87.
Topics: Apoptosis; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; HSP70 Heat-Shock Proteins; Huma | 2005 |
Electromotive drug delivery and bladder cancer.
Topics: Antibiotics, Antineoplastic; Clinical Trials as Topic; Disease Progression; Electric Stimulation The | 2006 |
Conservative treatment of high grade superficial bladder tumours.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Antineoplas | 2005 |
Immediate administration of intravesical mitomycin C after tumour resection for superficial bladder cancer.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Feasibility Studies; Humans; Male; Mitomy | 2006 |
Chemo-prevention in superficial bladder cancer using mitomycin C: a survey of the practice patterns of British urologists.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Combined Modality Therapy; Humans; Mitomy | 2006 |
Reducing recurrence and costs in superficial bladder cancer: preclinical evaluation of osmotic cytolysis by distilled water vs. mitomycin.
Topics: Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Cell Proliferation; Cell Survival; Cost S | 2006 |
[5 years intravesical instillation with mitomycin-C and pirarubicin as a prophylactic treatment for superficial bladder cancer].
Topics: Administration, Intravesical; Adult; Aged; Antibiotic Prophylaxis; Doxorubicin; Drug Administration | 2006 |
Immediate administration of intravesical mitomycin C after tumour resection for superficial bladder cancer.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Combined Modality Therapy; Feasibility St | 2006 |
Cutaneous complications of intravesical treatments for bladder cancer: granulomatous inflammation of the penis following BCG therapy and penile gangrene following mitomycin therapy.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma, Transitiona | 2006 |
Meglumine Eicosapentaenoic acid (MeEPA) a new soluble omega-3 fatty acid formulation: in vitro bladder cancer cytotoxicity tests in combination with epirubicin and mitomycin.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug | 2006 |
Intravesical bacillus Calmette-Guérin combined with electromotive mitomycin for high-risk superficial bladder cancer.
Topics: Adjuvants, Immunologic; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma, Transitional Cell; Clin | 2006 |
Smac/DIABLO promotes mitomycin C-induced apoptosis of bladder cancer T24 cells.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Transitional Cell; Cell Line, Tumor; Cell Proli | 2006 |
[Bladder cancer with skin metastasis: a case report].
Topics: Administration, Intravesical; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Trans | 2006 |
[Adriamycin and mitomycin dose-dependently downregulate X-kinked inhibitor of apoptosis protein in human bladder cancer cells].
Topics: Antibiotics, Antineoplastic; Apoptosis; Cell Line, Tumor; Dose-Response Relationship, Drug; Epirubic | 2006 |
A chemosensitivity test for superficial bladder cancer based on three-dimensional culture of tumour spheroids.
Topics: Antineoplastic Agents; Ciprofloxacin; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, | 2007 |
[Cytotoxic effect of oncolytic virus combined with mitomycin against human bladder cancer cells in vitro and in vivo].
Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival | 2006 |
Interview with Dr Richard Sylvester: transition cell carcinoma of the bladder. Interview by Christine McKillop.
Topics: Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Humans; Mitomycin; Neoplasm Recurr | 2007 |
Editorial comment on: Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder c
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Huma | 2007 |
[Establishment and application of an orthotopic murine bladder cancer model].
Topics: Animals; Cell Line, Tumor; Contrast Media; Disease Models, Animal; Down-Regulation; Female; Gadolini | 2007 |
[Fixed points and open questions in the treatment of superficial bladder carcinoma].
Topics: Adjuvants, Immunologic; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma, Papillary; Humans; Mito | 2006 |
[New therapeutics in the suppression of superficial bladder carcinoma].
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antineoplastic Combined Chemotherapy Protocols | 2006 |
[The not-infrequent story of a superficial bladder carcinoma...Discussion of clinical case no.2].
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Agmatine; Antimetabolites, Antineoplasti | 2006 |
Re: Hamid Mazdak, Iraj Meshki and Fatemeh Ghassami. Effect of mitomycin C on anterior urethral stricture recurrence after internal urethrotomy. Eur Urol 2007;51:1089-92.
Topics: Animals; Antibiotics, Antineoplastic; Disease Models, Animal; Humans; Mitomycin; Rats; Secondary Pre | 2007 |
Re: Hamid Mazdak, Iraj Meshki and Fatemeh Ghassami. Effect of mitomycin C on anterior urethral stricture recurrence after internal urethrotomy. Eur Urol 2007;51:1089-92.
Topics: Antibiotics, Antineoplastic; Follow-Up Studies; Humans; Mitomycin; Secondary Prevention; Treatment O | 2007 |
Expression of X-linked inhibitor of apoptosis protein and its effect on chemotherapeutic sensitivity of bladder carcinoma.
Topics: Antibiotics, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Gene Expression Regula | 2007 |
FANCD2 depletion sensitizes cancer cells repopulation ability in vitro.
Topics: Antibiotics, Antineoplastic; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA Damage; Dos | 2007 |
[Overexpression of PTEN gene inhibits proliferation of bladder transitional carcinoma cell line EJ].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Transit | 2007 |
Multidrug resistance in a urothelial cancer cell line after 3, 1-hour exposures to mitomycin C.
Topics: Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Cell Line, Tumor; Dose-Response Relations | 2007 |
Bacillus Calmette-Guerin inhibits apoptosis in human urothelial carcinoma cell lines in response to cytotoxic injury.
Topics: Adjuvants, Immunologic; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; B | 2007 |
Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; BCG Vaccine; Carcinoma, Transitio | 2007 |
Holmium laser treatment for low grade, low stage, noninvasive bladder cancer with local anesthesia and early instillation of mitomycin C.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Anesthesia, Local; Carcinoma, Transitional Ce | 2007 |
Late onset of bladder urothelial carcinoma after kidney transplantation for end-stage aristolochic acid nephropathy: a case series with 15-year follow-up.
Topics: Administration, Intravesical; Adult; Antibiotics, Antineoplastic; Aristolochic Acids; Carcinogens; D | 2008 |
Pneumoperitoneum with carbon dioxide inhibits macrophage tumor necrosis factor-alpha secretion: source of transitional-cell carcinoma port-site metastasis, with prophylactic irrigation strategies to decrease laparoscopic oncologic risks.
Topics: Animals; Anti-Infective Agents, Local; Antibiotics, Antineoplastic; Carbon Dioxide; Carcinoma, Trans | 2008 |
Two hour exposure to sodium butyrate sensitizes bladder cancer to anticancer drugs.
Topics: Animals; Antineoplastic Agents; Butyrates; Cell Line, Tumor; Cisplatin; Doxorubicin; Drug Synergism; | 2008 |
In vitro chemosensitivity of human bladder cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Carcinoma, Transitional Cell; Cell Survival; Cel | 1983 |
New preoperative chemotherapy for bladder cancer using combination hemodialysis and direct hemoperfusion: preliminary report.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Bleomycin; Combined Modality Therapy; Dogs; Doxorubicin | 1984 |
Chemotherapy in advanced urinary bladder cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 1984 |
[Chemotherapy of urothelial cancer with vincristine, mitomycin C, bleomycin, tegafur and OK-432].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Female; | 1984 |
[Chemosensitivity in established human bladder carcinoma and HELA cell lines in vitro].
Topics: Antineoplastic Agents; Bleomycin; Carbazilquinone; Carcinoma, Transitional Cell; Cell Division; Cell | 1983 |
[Intravesical chemotherapy for superficial bladder tumors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carbazilquinone; Cytarabine; Doxorubicin; | 1984 |
Microcapsule chemoembolization therapy: a new approach to bladder cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; | 1984 |
[Study of combination chemotherapy with cytosine arabinoside in the intravesical treatment of superficial bladder tumors].
Topics: Adult; Aged; Carbazilquinone; Cytarabine; Drug Evaluation; Drug Therapy, Combination; Female; Humans | 1983 |
Dermatitis due to mitomycin bladder instillations.
Topics: Aged; Carcinoma, Transitional Cell; Drug Eruptions; Humans; Male; Mitomycin; Mitomycins; Urinary Bla | 1984 |
[Inhibitory effects of aromatic retinoic acid analog, administered alone or in combination with mitomycin C, on the in vitro growth of rat bladder carcinoma cells].
Topics: Acitretin; Animals; Cell Division; Cell Line; Cells, Cultured; Dose-Response Relationship, Drug; Dru | 1984 |
Therapeutic effect of an aromatic retinoic acid analog on rats with bladder carcinoma upon administration alone or in combination with mitomycin C.
Topics: Animals; Antineoplastic Agents; Carrier Proteins; Drug Therapy, Combination; Etretinate; Male; Mitom | 1982 |
Chemoimmunotherapy of implanted murine bladder cancer.
Topics: Animals; Carcinoma, Transitional Cell; Drug Therapy, Combination; Female; Levamisole; Mice; Mice, In | 1983 |
Intravesical chemotherapy of urinary bladder tumor in rabbit by ferromagnetic mitomycin C.
Topics: Absorption; Animals; Ferric Compounds; Iron; Magnetics; Mitomycin; Mitomycins; Neoplasms, Experiment | 1983 |
Optimising mitomycin C activity during intravesical instillation.
Topics: Animals; Buffers; Carcinoma 256, Walker; Cell Line; Drug Stability; Hydrogen-Ion Concentration; Mito | 1983 |
Prostatic recurrences in the management of superficial bladder tumors.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Humans; Male; Middle Aged; M | 1983 |
Severely contracted bladder following intravesical mitomycin C therapy.
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Contracture; Humans; Male; Mitomyci | 1983 |
Intravesical instillation of mitomycin C in the prophylactic treatment of recurring superficial transitional cell carcinoma of the bladder.
Topics: Aged; Carcinoma, Transitional Cell; Female; Humans; Male; Middle Aged; Mitomycin; Mitomycins; Neopla | 1983 |
Mixed adenocarcinoma and anaplastic transitional cell carcinoma of the urinary bladder.
Topics: Adenocarcinoma; Aged; Carcinoma, Transitional Cell; Humans; Male; Mitomycin; Mitomycins; Urinary Bla | 1983 |
[Intracavitary instillation for bladder tumor with antitumor agent. 5th Report: Difference of the action of mitomycin C on normal bladder and tumor of the bladder (experimental and clinical study)].
Topics: Animals; Antibiotics, Antineoplastic; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Humans | 1983 |
[Combination of intra-arterial administration of anticancer agent and hemocarboperfusion in treatment of advanced cancer].
Topics: Antibiotics, Antineoplastic; Female; Hemoperfusion; Humans; Infusions, Intra-Arterial; Injections, I | 1983 |
[Combination chemotherapy of mitomycin C and cytosine arabinoside in superficial bladder tumors. 1. Evaluation of intravesical infusion therapy].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Cytarabine; Drug Therapy, Combination; Female; Humans; Mal | 1983 |
Effects of intravesical instillation of antitumor drugs on the induction of preneoplastic bladder lesions in rats.
Topics: Animals; Butylhydroxybutylnitrosamine; Doxorubicin; Female; Hyperplasia; Mitomycin; Mitomycins; Prec | 1983 |
A phase II study of intravesical mitomycin C in the treatment of superficial bladder cancer.
Topics: Carcinoma in Situ; Carcinoma, Transitional Cell; Cystitis; Drug Evaluation; Drug Implants; Erythema; | 1983 |
Comparison of the efficacy of intravesical Bacillus Calmette-Guérin with thiotepa, mitomycin C, poly I:C/poly-L-lysine and cis platinum in murine bladder cancer.
Topics: Administration, Topical; Animals; Antineoplastic Agents; BCG Vaccine; Cisplatin; Female; Mice; Mice, | 1984 |
Bladder cancer induced by noncarcinogenic substances.
Topics: Administration, Topical; Animals; Carcinoma, Papillary; Cisplatin; Female; Hyperplasia; Mitomycin; M | 1984 |
Local chemotherapeutic effects in bladder cancer demonstrated by selective sampling and flow cytometry.
Topics: Administration, Topical; Antineoplastic Agents; DNA, Neoplasm; Doxorubicin; Flow Cytometry; Humans; | 1984 |
[Blood and tissue levels of mitomycin C after intravesical instillation].
Topics: Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Humans; Mitomycin; Mitomycins; Urinary Bl | 1983 |
Therapeutic effect of a retinoid (Ro 10-9359) on rats with bladder tumours induced by N-butyl-N-(4-hydroxybutyl)-nitrosamine upon administration alone or in combination with mitomycin C.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Butylhydroxybutylnitrosamine; Drug Administ | 1983 |
Mitomycin C intravesical therapy in noninvasive bladder cancer after failure on thiotepa.
Topics: Adult; Aged; Drug Evaluation; Humans; Inflammation; Middle Aged; Mitomycin; Mitomycins; Skin Disease | 1984 |
The stability and antitumor activity of recycled (intravesical) mitomycin C.
Topics: Animals; Carcinoma, Transitional Cell; Chromatography, High Pressure Liquid; Drug Stability; FANFT; | 1984 |
[Stage P-1 primary neoplasia of the bladder. Critical evaluation of results obtained with the use of adriamycin and mitomycin C in the prevention of recurrences].
Topics: Administration, Topical; Antibiotics, Antineoplastic; Doxorubicin; Follow-Up Studies; Humans; Mitomy | 1984 |
[Combination chemotherapy of mitomycin C and cytosine arabinoside in the intravesical treatment for superficial bladder tumors: report 2. Evaluation of prophylactic intravesical infusion therapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedul | 1984 |
Studies of mitomycin C absorption after intravesical treatment of superficial bladder tumors.
Topics: Antibiotics, Antineoplastic; Bone Marrow; Carcinoma, Transitional Cell; Combined Modality Therapy; D | 1984 |
Superficial bladder cancer: comments on evaluation and management.
Topics: Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Combined Modality Therapy; Humans; Mitomy | 1984 |
[Experimental and clinical studies on intravesical instillation therapy for bladder cancer].
Topics: Adolescent; Adult; Aged; Carbazilquinone; Carcinoma, Transitional Cell; Cytodiagnosis; Doxorubicin; | 1983 |
Mitomycin C reused: an in vitro cost-effectiveness study.
Topics: Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Cell Survival; Costs and Cost Analysis; D | 1984 |
Effects of intravesical instillation of antitumor chemotherapeutic agents on bladder carcinogenesis in rats treated with N-butyl-N-(4-hydroxybutyl)nitrosamine.
Topics: Animals; Antineoplastic Agents; Butylhydroxybutylnitrosamine; Doxorubicin; Drug Synergism; Female; H | 1984 |
[Local mitomycin-C therapy of infiltrating bladder cancer].
Topics: Administration, Topical; Combined Modality Therapy; Cystitis; Humans; Mitomycin; Mitomycins; Neoplas | 1984 |
Intravesical chemotherapy for carcinoma in situ of the urinary bladder: 5 years later.
Topics: Adult; Aged; Carcinoma in Situ; Doxorubicin; Female; Follow-Up Studies; Humans; Male; Middle Aged; M | 1984 |
[Anti-tumor effect of intravesical instillation of mitomycin C combined with cytosine arabinoside].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine | 1984 |
Magnetic microcapsules for targeted delivery of anticancer drugs.
Topics: Animals; Antineoplastic Agents; Aorta; Capsules; Cellulose; Dogs; Ferric Compounds; Magnetics; Mitom | 1984 |
Choosing the right intravesical chemotherapeutic agent. Results of an in vitro monolayer cell culture assay.
Topics: Antibiotics, Antineoplastic; Cell Survival; Cells, Cultured; Doxorubicin; Humans; Mitomycin; Mitomyc | 1984 |
Side effects associated with intravesical mitomycin.
Topics: Aged; Carcinoma, Transitional Cell; Drug Eruptions; Female; Humans; Male; Middle Aged; Mitomycin; Mi | 1981 |
The effect of mitomycin C on superficial bladder cancer.
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma in Situ; Carcinoma, Transitional Cell; Female; Humans; | 1981 |
Transcatheter intraarterial infusion of chemotherapy in advanced bladder cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Transitional Cell; Cisplatin; Doxorubicin; Drug Thera | 1982 |
Single and sequential combination intravesical chemotherapy of murine bladder cancer.
Topics: Animals; Antineoplastic Agents; Cisplatin; Disease Models, Animal; Doxorubicin; Drug Therapy, Combin | 1982 |
[Local chemotherapy of bladder carcinoma with mitomycin (author's transl)].
Topics: Adult; Aged; Carcinoma in Situ; Humans; Middle Aged; Mitomycin; Mitomycins; Neoplasm Staging; Urinar | 1982 |
Intravesical therapy of low stage bladder carcinoma with mitomycin C: comparison of results in untreated and previously treated patients.
Topics: Adult; Aged; Carcinoma in Situ; Carcinoma, Transitional Cell; Drug Resistance; Female; Humans; Male; | 1982 |
Systemic mitomycin C versus cisplatin: comparison of antitumor activity in primary murine bladder cancer.
Topics: Animals; Antibiotics, Antineoplastic; Cisplatin; Drug Synergism; FANFT; Female; Mice; Mitomycin; Mit | 1982 |
[Intravesical chemical prevention of recurrence of superficial urothelial bladder cancer. Progress report of the Urology Clinic of Mainz University 1975-1981].
Topics: Administration, Topical; Doxorubicin; Humans; Mitomycin; Mitomycins; Neoplasm Recurrence, Local; Uri | 1982 |
[Recurrence rate in adjuvant local chemotherapy of bladder cancer with mitomycin C].
Topics: Administration, Topical; Carcinoma in Situ; Carcinoma, Transitional Cell; Humans; Mitomycin; Mitomyc | 1982 |
[Intravesical chemical prevention of recurrence. A randomized animal experimental study].
Topics: Administration, Topical; Animals; Cisplatin; Doxorubicin; Epithelium; Female; Mitomycin; Mitomycins; | 1982 |
[Study of in vitro sensitivity of human bladder cancer cell lines to sex steroid hormones. Combined effects of adriamycin or mitomycin-C and estradiol-17 beta on T24 cells].
Topics: Cell Line; Cell Survival; Doxorubicin; Drug Synergism; Estradiol; Humans; Mitomycin; Mitomycins; Neo | 1982 |
Postoperative prophylactic intravesical instillation of cytosine arabinoside and mitomycin C in superficial bladder tumor. A follow-up study.
Topics: Adult; Aged; Cystoscopy; Cytarabine; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; M | 1982 |
[Possibilities and value of intracavitary and systemic chemotherapy of bladder cancer].
Topics: Antineoplastic Agents; Carcinoma in Situ; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Therapy, Co | 1982 |
[Effect of cis-diamminedichloroplatinum (II) (CDDP) on bladder cancer on rats induced by N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN)].
Topics: Animals; Butylhydroxybutylnitrosamine; Cisplatin; Cyclophosphamide; Female; Mitomycin; Mitomycins; N | 1982 |
[Periodic prophylactic bladder instillation (PPI) of mitomycin C].
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Female; Humans; Intraoperative Care; Male; Mid | 1982 |
[Bladder cancer: chemotherapy of advanced bladder cancer].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Cells, Cultured; Cisplatin; Cyclophosphamide; Do | 1982 |
Long-term follow-up of patients with superficial transitional cell carcinoma of the urinary bladder treated by intravesical mitomycin C.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Carcinoma, Transitional Cell; Cystosco | 1995 |
Bladder carcinoma--the good, the bad and the ugly.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Prot | 1996 |
Histological grading of carcinoma in situ of the bladder: its clinical significance in patients who underwent intravesical mitomycin C and doxorubicin sequential therapy.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherap | 1996 |
Up-front intravesical chemotherapy for low stage, low grade recurrent bladder cancer.
Topics: Administration, Intravesical; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Trans | 1996 |
Characterization of a human bladder cancer cell line selected for resistance to BMY 25067, a novel analogue of mitomycin C.
Topics: Antineoplastic Agents; Cell Cycle; Drug Resistance; Glutathione; Glutathione Transferase; Humans; In | 1995 |
Mechanism of cross-resistance to cisplatin in a mitomycin C-resistant human bladder cancer cell line.
Topics: Antimetabolites, Antineoplastic; Biological Transport; Buthionine Sulfoximine; Cadmium; Cadmium Chlo | 1995 |
Use of intracavitary interferon-alpha-2b in the prophylactic treatment of patients with superficial bladder cancer.
Topics: Administration, Intravesical; Aged; Carcinoma, Transitional Cell; Female; Humans; Immunotherapy; Int | 1995 |
Enhancement of sensitivity of urinary bladder tumor cells to cisplatin by c-myc antisense oligonucleotide.
Topics: Antineoplastic Agents; Base Sequence; Blotting, Northern; Carcinoma, Transitional Cell; Cisplatin; D | 1994 |
Correlation of human bladder tumor histoculture proliferation and sensitivity to mitomycin C with tumor pathobiology.
Topics: Autoradiography; Carcinoma, Transitional Cell; Culture Techniques; Drug Resistance; Humans; Immunohi | 1994 |
Loss of heterozygosity at the NAD(P)H: quinone oxidoreductase locus associated with increased resistance against mitomycin C in a human bladder carcinoma cell line.
Topics: Base Sequence; Cell Division; Chromosome Deletion; DNA Primers; Drug Resistance; Heterozygote; Human | 1994 |
Studies of effects of anticancer agents in combination with/without hyperthermia on metastasized human bladder cancer cells in chick embryos using the polymerase chain reaction technique.
Topics: Animals; Antineoplastic Agents; Base Sequence; Carboplatin; Cell Division; Cell Transplantation; Chi | 1994 |
Treatment of bladder carcinoma in situ with mitomycin C: long-term follow-up.
Topics: Administration, Intravesical; Carcinoma in Situ; Carcinoma, Transitional Cell; Female; Follow-Up Stu | 1994 |
Characterization of a human bladder cancer cell line selected for resistance to mitomycin C.
Topics: Antineoplastic Agents; Carcinoma; Catalase; Cell Cycle; Cell Survival; DNA Damage; Drug Resistance; | 1994 |
[Fibrino-necrotic ulcers in endovesical chemoprophylaxis in superficial bladder carcinoma: our case histories].
Topics: Administration, Intravesical; Aged; Carcinoma; Combined Modality Therapy; Female; Fibrosis; Follow-U | 1994 |
[Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer].
Topics: Administration, Intravesical; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; | 1994 |
Intravesical mitomycin C for the treatment of carcinoma in situ of the bladder: 36 months follow-up.
Topics: Administration, Intravesical; Aged; Carcinoma in Situ; Cystectomy; Female; Humans; Male; Middle Aged | 1994 |
Intravesical mitomycin C and doxorubicin sequential therapy for carcinoma in situ of the bladder: a longer followup result.
Topics: Administration, Intravesical; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Car | 1994 |
Incrusted cystitis after intravesical mitomycin C treatment.
Topics: Administration, Intravesical; Calcinosis; Carcinoma, Transitional Cell; Combined Modality Therapy; C | 1993 |
The combined effects of high-energy shock waves and cytostatic drugs or cytokines on human bladder cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Cisplatin; Combined Modality Therapy; Cytokines | 1994 |
Mechanism of differential sensitivity of human bladder cancer cells to mitomycin C and its analogue.
Topics: DNA, Neoplasm; Drug Resistance; Humans; Lipid Peroxidation; Mitomycin; Mitomycins; Tumor Cells, Cult | 1994 |
Mitomycin C sensitivity in human bladder cancer cells: possible role of glutathione and glutathione transferase in resistance.
Topics: Antimetabolites, Antineoplastic; Buthionine Sulfoximine; Cell Line; Cell Survival; Dose-Response Rel | 1994 |
Penetration of mitomycin C in human bladder.
Topics: Administration, Intravesical; Aged; Animals; Combined Modality Therapy; Cryopreservation; Cystectomy | 1993 |
Use of pharmacologic data and computer simulations to design an efficacy trial of intravesical mitomycin C therapy for superficial bladder cancer.
Topics: Administration, Intravesical; Adult; Cell Division; Computer Simulation; Dose-Response Relationship, | 1993 |
[Mitomycin C caused contact allergy].
Topics: Administration, Intravesical; Aged; Dermatitis, Allergic Contact; Humans; Male; Mitomycin; Urinary B | 1993 |
Effect of different local and systemic therapy upon urinary bladder cytology.
Topics: Administration, Intravesical; Aged; Carcinoma, Transitional Cell; Combined Modality Therapy; DNA, Ne | 1993 |
Mitomycin-C in superficial bladder cancer. Is long-term maintenance therapy worthwhile after initial treatment?
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Transitional Cell; Drug Administration Schedule; Female; | 1993 |
Non-P-glycoprotein-mediated atypical multidrug resistance in a human bladder cancer cell line.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette | 1995 |
Penetration of intravesical doxorubicin in human bladders.
Topics: Administration, Intravesical; Adult; Aged; Antibiotics, Antineoplastic; Doxorubicin; Humans; Middle | 1996 |
Biochemical characterization of a mitomycin C-resistant human bladder cancer cell line.
Topics: Antibiotics, Antineoplastic; Biotransformation; Cell Survival; DNA Polymerase I; Drug Resistance, Ne | 1996 |
New data from abroad about intravesical therapy of bladder cancer--how does it play in Peoria?
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Huma | 1996 |
[pT1G3 tumor of the bladder].
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Biopsy; Carcinoma, Transitio | 1996 |
[pT1G3 bladder carcinoma: our experience].
Topics: Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma, Transitional Cell; Combined Modality Therapy; C | 1996 |
Free radicals in toxicology: redox cycling and NAD(P)H:quinone oxidoreductase.
Topics: Antibiotics, Antineoplastic; Carcinoma, Renal Cell; Drug Resistance, Microbial; Free Radicals; Gene | 1996 |
[Efficacy of the chemosensitivity test using collagen gel matrix-supported culture system for urogenital tumors].
Topics: Animals; Antineoplastic Agents; Bleomycin; Carcinoma, Renal Cell; Cisplatin; Collagen; Culture Media | 1996 |
[Mechanism of resistance to mitomycin C in a human bladder cancer cell line].
Topics: Antibiotics, Antineoplastic; DNA, Neoplasm; Drug Resistance, Neoplasm; Humans; Mitomycin; NAD(P)H De | 1995 |
[A comparative study of BCG and mitomycin C in superficial carcinomas of the bladder].
Topics: Adjuvants, Immunologic; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma in Situ; Evaluation Stud | 1996 |
Lack of a role of glutathione in cellular nonenzymatic activation of BMS-181174, a novel analogue of mitomycin C.
Topics: Antineoplastic Agents, Alkylating; Biotransformation; Buthionine Sulfoximine; Cysteine; Enzyme Inhib | 1996 |
Cytophotometry in the monitoring of bladder cancer under intravesical chemotherapy.
Topics: Administration, Intravesical; Aged; Aneuploidy; Antibiotics, Antineoplastic; Carcinoma, Transitional | 1996 |
Interferons modify in vitro proliferation of human bladder transitional cell carcinoma in the presence of doxorubicin and mitomycin C.
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Cell Division; Doxorubicin; Humans; Interferon- | 1996 |
Sensitivity of cell lines to mitomycin C.
Topics: Adenocarcinoma; Animals; Antibiotics, Antineoplastic; Dose-Response Relationship, Drug; Humans; Hydr | 1996 |
Management of invasive squamous cell carcinoma of the bulbomembranous male urethra with co-ordinated chemo-radiotherapy and genital preservation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Squamous Cell; Comb | 1996 |
Abrogation of apoptosis induced by DNA-damaging agents in human bladder-cancer cell lines with p21/WAF1/CIP1 and/or p53 gene alterations.
Topics: Apoptosis; Cisplatin; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; DNA; DNA Damage; Genes, p53; G | 1996 |
Different pH dependency of mitomycin C activity in monolayer and three-dimensional cultures.
Topics: Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Cell Division; Humans; Hydrogen-Ion Conce | 1996 |
[The efficacy of ATP sensitivity assay on intravesical prophylactic instillation for superficial bladder cancer].
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineopl | 1996 |
Mechanism of increased sensitivity to etoposide in a mitomycin C-resistant human bladder cancer cell line.
Topics: Antineoplastic Agents, Phytogenic; DNA Topoisomerases, Type II; Drug Resistance, Neoplasm; Etoposide | 1997 |
Eosinophilic cystitis induced by mitomycin-C.
Topics: Administration, Intravesical; Biopsy; Carcinoma, Transitional Cell; Cystitis; Eosinophilia; Female; | 1996 |
Pharmacodynamic evaluation of mitomycin C analog BMS-181174 for potential use in intravesical bladder cancer therapy.
Topics: Administration, Intravesical; Antineoplastic Agents, Alkylating; Carcinoma, Squamous Cell; Carcinoma | 1997 |
Plasma mitomycin C concentrations determined by HPLC coupled to solid-phase extraction.
Topics: Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Chromatography, High Pressure Liquid; Hum | 1997 |
Allergic contact dermatitis from mitomycin C.
Topics: Administration, Intravesical; Carcinoma; Dermatitis, Allergic Contact; Female; Humans; Middle Aged; | 1997 |
Effect of photodynamic therapy in combination with mitomycin C on a mitomycin-resistant bladder cancer cell line.
Topics: Aminolevulinic Acid; Carcinoma, Transitional Cell; Cell Survival; Dose-Response Relationship, Drug; | 1997 |
Characterization of a BMS-181174-resistant human bladder cancer cell line.
Topics: Antineoplastic Agents, Alkylating; Cell Survival; Drug Resistance; Humans; Mitomycin; Mitomycins; Tu | 1997 |
[Neoadjuvant intra-arterial chemotherapy based on chemosensitivity tests for locally invasive bladder cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Doxorubicin | 1997 |
Does topical instillation therapy influence chromosomal aberrations in superficial bladder cancer?
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; BCG Vacci | 1998 |
Bladder tissue uptake of mitomycin C during intravesical therapy is linear with drug concentration in urine.
Topics: Administration, Intravesical; Animals; Antibiotics, Antineoplastic; Dogs; Dose-Response Relationship | 1998 |
[Results of BCG in the treatment of pTa and pT1 bladder tumors. Evaluation of a long protocol using 75 mg of Pasteur strain BCG].
Topics: Actuarial Analysis; Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antin | 1998 |
Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II).
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic | 1998 |
Bladder cancer recurrence by implantation of exfoliated cells: is gamma-linolenic acid an effective tumoricidal agent?
Topics: Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Cell Adhesion; Drug Resistance, Neoplasm; | 1998 |
7-N-(2-([2-(gamma-L-glutamylamino)-ethyl]-dithio)-ethyl)-mitomycin C (KW-2149) is more active than mitomycin C on chemonaive and drug-resistant urothelial carcinoma cells.
Topics: Anti-Bacterial Agents; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Drug Interactions; | 1998 |
Inhibition of tumor cell growth by RTP/rit42 and its responsiveness to p53 and DNA damage.
Topics: Animals; Breast Neoplasms; Cell Cycle; Cell Cycle Proteins; Cell Division; Cells, Cultured; Chromoso | 1998 |
[The results of a long-term follow-up for patients with stage Ta bladder cancer, especially regarding those with multiple recurrences].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 1998 |
Bilateral ureteric strictures after intravesical mitomycin C.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Female; Humans; Mitomycin; Radiogra | 1993 |
Re: Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antineoplastic Co | 1999 |
Perivesical fat necrosis after adjuvant intravesical chemotherapy.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Chemo | 1999 |
[Study of the synergy of microwave hyperthermia/intravesical chemotherapy in the prevention of recurrences of superficial tumors of the bladder].
Topics: Administration, Intravesical; Animals; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Co | 1999 |
p21Waf1/Cip1/Sdi1 induces permanent growth arrest with markers of replicative senescence in human tumor cells lacking functional p53.
Topics: Apoptosis; beta-Galactosidase; Biomarkers; Carcinoma; CDC2-CDC28 Kinases; Cell Division; Cellular Se | 1999 |
[Long-term effects on recurrence and mortality in superficial urothelioma of the bladder treated with endovesical chemotherapy].
Topics: Administration, Intravesical; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitiona | 1999 |
Regional heterogeneity and pharmacodynamics in human solid tumor histoculture.
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Cell Division; Culture Techniques; Drug Screeni | 1999 |
Perivesical inflammation after early mitomycin C instillation.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Cystitis; Humans; Male; Middle Aged; Mito | 2000 |
Type III and type IV hypersensitivity reactions due to mitomycin C.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma; Dermatitis, Exfoliative; | 2000 |
Biochemical mechanism of cross-resistance to paclitaxel in a mitomycin c-resistant human bladder cancer cell line.
Topics: Antineoplastic Agents; Apoptosis; DNA Damage; Drug Resistance, Neoplasm; Humans; Mitomycin; Paclitax | 2000 |
Induction of apoptosis by mitomycin-C in an ex vivo model of bladder cancer.
Topics: Antibiotics, Antineoplastic; Apoptosis; Carcinoma, Transitional Cell; Dose-Response Relationship, Dr | 2000 |
Re: bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 AND TIS)
Topics: Antibiotics, Antineoplastic; BCG Vaccine; Disease Progression; Humans; Mitomycin; Neoplasm Staging; | 2000 |
Efficacy of prophylactic Immucothel in patients pretreated with conventional drugs to prevent recurrence of superficial bladder carcinoma.
Topics: Adjuvants, Immunologic; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; BCG Vaccine; Female; H | 2000 |
Microwave thermochemotherapy in the treatment of the bladder carcinoma--electromagnetic and dielectric studies--clinical protocol.
Topics: Animals; Antibiotics, Antineoplastic; Combined Modality Therapy; Disease Models, Animal; Dogs; Elect | 2000 |
[Arterial infusion chemotherapy for patients with advanced and moderately advanced cancer of urinary bladder].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 1998 |
Necrosis of the glans penis: a rare complication of intravesical therapy with mitomycin c.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Human | 2000 |
The effect of fasting or desmopressin before treatment on the concentration of mitomycin C during intravesical administration.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Deami | 2000 |
[Intravesical chemotherapy with mitomycin C after TUR for superficial bladder carcinoma].
Topics: Administration, Intravesical; Aged; Carcinoma; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Hu | 1999 |
Advanced adenocarcinoma of the urinary bladder successfully treated by the combination of cisplatinum, mitomycin-C, etoposide and tegafur-uracil chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Humans | 2001 |
Intravesical therapy for bladder cancer: empiricism at the helm.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma in Situ; Humans; I | 2001 |
Expression of DT-diaphorase and cytochrome P450 reductase correlates with mitomycin C activity in human bladder tumors.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antibiotics, Antineoplastic; DNA, Neoplasm; Dr | 2001 |
Blockage of IGF-1R signaling sensitizes urinary bladder cancer cells to mitomycin-mediated cytotoxicity.
Topics: Antibiotics, Antineoplastic; Apoptosis; Autocrine Communication; Carcinoma, Transitional Cell; Cell | 2001 |
The effect of antisense Bcl-2 oligonucleotides on Bcl-2 protein expression and apoptosis in human bladder transitional cell carcinoma.
Topics: Apoptosis; Carcinoma, Transitional Cell; Down-Regulation; Genes, bcl-2; Humans; Mitomycin; Oligonucl | 2001 |
Bladder wall calcification after intravesical chemotherapy with mitomycin C--a case report.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Calcinosis; Humans; Male; Middle Aged; Mi | 2001 |
Re: methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial.
Topics: Administration, Intravesical; Antineoplastic Agents; Black or African American; Carcinoma, Transitio | 2001 |
Effect of intravesical instillations on the human complement factor H related protein (BTA stat) test.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antigens, Neop | 2001 |
Knockdown of IGF-IR by Antisense Oligodeoxynucleotide auguments the sensitivity of bladder cancer cells to mitomycin.
Topics: Antibiotics, Antineoplastic; Apoptosis; Drug Resistance, Neoplasm; Humans; Insulin-Like Growth Facto | 2001 |
Frequency of positive biopsies after visual disappearance of superficial bladder cancer marker lesions.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Biopsy; Carcinoma, Transitio | 2001 |
Intravesical immunotoxin as adjuvant therapy to prevent the recurrence of bladder cancer.
Topics: Administration, Intravesical; Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Ca | 2000 |
[Lung sarcoidosis following instillation of mitomycin C in the urinary bladder].
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Humans; Male; Mitomycin; Sarcoidosi | 2001 |
[Treatment of bladder tumors].
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Combined Modality Therapy; C | 2002 |
Design and evaluation of a mucoadhesive therapeutic agent delivery system for postoperative chemotherapy in superficial bladder cancer.
Topics: Adhesives; Animals; Antibiotics, Antineoplastic; Biocompatible Materials; Chitin; Chitosan; Drug Car | 2002 |
Eosinophilic cystitis presenting as a recurrent symptomatic bladder mass following intravesical mitomycin C therapy.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Cystitis; Eosinophilia; Humans; Male; Mid | 2002 |
[Retrospective survey of pharmacologic tolerance in the prevention of neoplastic recurrence of superficial urothelioma].
Topics: Administration, Intravesical; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Humans; In | 1992 |
Recurrence of superficial bladder tumours after transurethral resection.
Topics: Administration, Intravesical; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Doxorubicin; Fem | 1992 |
[Intravesical BCG, mitomycin-C and thiotepa in the prevention of bladder tumor recurrence after operation].
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Chem | 1992 |
[A case of metastatic urinary bladder tumor from gastric carcinoma].
Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Fluorouracil; | 1992 |
Three cases of allergic dermatitis due to intravesical mitomycin C.
Topics: Administration, Intravesical; Aged; Drug Eruptions; Humans; Male; Mitomycin; Urinary Bladder Neoplas | 1992 |
Long-term immunobiological effects of intravesical bacillus Calmette-Guérin against bladder carcinoma recurrences.
Topics: Administration, Intravesical; BCG Vaccine; Biomarkers, Tumor; Carcinoma, Transitional Cell; Chemothe | 1992 |
Superficial bladder disease: case studies and therapeutic advances.
Topics: Administration, Intravesical; Adult; Aged; Antineoplastic Agents; BCG Vaccine; Carcinoma in Situ; Ca | 1992 |
[Study on chemosensitivity test of urogenital tumors by ATP assay].
Topics: Adenosine Triphosphate; Antineoplastic Agents; Doxorubicin; Drug Screening Assays, Antitumor; HeLa C | 1992 |
Topical chemoprophylaxis of superficial bladder cancer with mitomycin C and adjuvant hyaluronidase.
Topics: Administration, Intravesical; Aged; Carcinoma, Transitional Cell; Combined Modality Therapy; Female; | 1992 |
Some aspects in treatment of superficial bladder cancer.
Topics: Administration, Intravesical; BCG Vaccine; Carcinoma in Situ; Carcinoma, Transitional Cell; Female; | 1992 |
Endovesical instillation of mitomycin-C in preventing recurrence of superficial bladder carcinoma.
Topics: Administration, Intravesical; Adult; Aged; Carcinoma, Transitional Cell; Female; Humans; Male; Middl | 1992 |
Effects of photodynamic therapy in combination with intravesical drugs in a murine bladder tumor model.
Topics: Administration, Intravesical; Animals; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; | 1992 |
Mitomycin C in multiple superficial bladder tumors: short-term therapy, long-term results.
Topics: Administration, Intravesical; Carcinoma in Situ; Carcinoma, Transitional Cell; Drug Administration S | 1992 |
Cytostatic effect of different strains of Bacillus Calmette-Guérin on human bladder cancer cells in vitro alone and in combination with mitomycin C and interferon-alpha.
Topics: BCG Vaccine; Carcinoma, Transitional Cell; Combined Modality Therapy; Humans; Interferon-alpha; Mito | 1992 |
[Clinical study of intravesical instillation therapy of superficial bladder tumor--combination therapy of mitomycin C, adriamycin, peplomycin and cytosine arabinoside].
Topics: Administration, Intravesical; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cytar | 1990 |
Bladder cancer chemotherapy: is response of squamous tumours different to that of transitional cell tumours?
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 1991 |
[Superficial bladder cancer: prophylaxis of recurrence and progression].
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Bleomycin; Cisplatin; Doxorubicin; | 1991 |
Modulation by cis-diamminedichloroplatinum (II) of the susceptibilities of human T24 lined and freshly separated autologous urinary bladder transitional carcinoma cells to peripheral blood lymphocytes and lymphokine activated killer cells.
Topics: Aged; Aged, 80 and over; Carcinoma, Transitional Cell; Cell Line; Chloroquine; Cisplatin; Cytotoxici | 1992 |
The effect of pH on the in vitro colony forming ability of transitional cell carcinoma cells treated with various chemotherapeutic agents: implications for in vivo therapy.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Transitional Cell; Doxorubicin; Humans; Hydrogen-Ion | 1992 |
Value of bladder wash cytology in the follow-up of patients with bladder carcinoma receiving intravesical chemoprophylaxis with mitomycin C.
Topics: Administration, Intravesical; Carcinoma, Transitional Cell; Humans; Mitomycin; Neoplasm Recurrence, | 1991 |
Intravesical chemotherapy for superficial carcinoma of the bladder.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Carcinoma, Transitional Cell; Female; | 1991 |
[Eosinophilic cystitis as a special form of response to mitomycin C. Analysis and comments on our cases].
Topics: Administration, Intravesical; Antigen-Antibody Complex; Carcinoma; Combined Modality Therapy; Cystit | 1991 |
Combined intravesical chemotherapy with mitomycin C and local bladder microwave-induced hyperthermia as a preoperative therapy for superficial bladder tumors. A preliminary clinical study.
Topics: Administration, Intravesical; Aged; Carcinoma, Transitional Cell; Cystectomy; Female; Humans; Hypert | 1991 |
Dermatitis due to mitomycin C bladder instillations: study of 2 cases.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Transitiona | 1991 |
Cultured human bladder tumors for pharmacodynamic studies.
Topics: Antineoplastic Agents; Autoradiography; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Dose | 1991 |
In vitro study of the interaction of doxorubicin, thiotepa, and mitomycin-C, agents used for intravesical chemotherapy of superficial bladder cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; | 1991 |
Long-term observation after intravesical metaphylaxis with mitomycin C in patients with superficial bladder tumors.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Ther | 1991 |
Re: Bladder wall calcification after intravesical mitomycin C treatment of superficial bladder cancer.
Topics: Administration, Intravesical; Calcinosis; Cystitis; Humans; Mitomycin; Mitomycins; Urinary Bladder N | 1991 |
[Chemosensitivity test on superficial urinary bladder cancer using the dye exclusion assay--model of intravesical chemotherapy].
Topics: Administration, Intravesical; Animals; Antineoplastic Agents; Carcinoma, Transitional Cell; Doxorubi | 1991 |
Pharmacodynamics of mitomycin C in cultured human bladder tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cell Division; Female; Humans; Kinetics; Male | 1991 |
Pharmacokinetics of intravesical mitomycin C in superficial bladder cancer patients.
Topics: Administration, Intravesical; Analysis of Variance; Antineoplastic Agents; Chromatography, High Pres | 1991 |
Organ conservation in bladder cancer.
Topics: Administration, Intravesical; Combined Modality Therapy; Drug Administration Schedule; Epirubicin; H | 1991 |
Intravesical bacillus Calmette-Guerin or mitomycin C in the treatment of carcinoma in situ of the bladder following prior pelvic radiation therapy.
Topics: Administration, Intravesical; Aged; BCG Vaccine; Carcinoma in Situ; Carcinoma, Transitional Cell; Co | 1991 |
Secondary hematologic neoplasm after intravesical chemotherapy for superficial bladder carcinoma.
Topics: Aged; Antineoplastic Agents; Doxorubicin; Ethoglucid; Female; Humans; Leukemia, Myeloid, Acute; Lymp | 1990 |
Topical mitomycin C therapy for carcinoma in situ of the bladder: a followup.
Topics: Administration, Intravesical; Carcinoma in Situ; Cystectomy; Humans; Mitomycin; Mitomycins; Neoplasm | 1990 |
Intravesical mitomycin C for carcinoma in situ of the urinary bladder.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Carcinoma in Situ; Carcinoma, Papillary; Comb | 1990 |
[Effect of etoposide orally administered every other day for the prevention of recurrence of bladder tumor].
Topics: Administration, Intravesical; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined | 1990 |
Follow up of patients receiving treatment for superficial bladder cancer with mitomycin C and BCG.
Topics: Administration, Intravesical; BCG Vaccine; Carcinoma, Transitional Cell; Combined Modality Therapy; | 1990 |
[Balloon-occluded arterial infusion as chemotherapy in bladder cancer--long-term results].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cel | 1990 |
Reduced bladder capacity in patients receiving intravesical chemoprophylaxis with mitomycin C.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cystectomy; Dru | 1990 |
Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy.
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma in Situ; Epirubicin; Hum | 1990 |
Dermatitis due to intravesical mitomycin C: a delayed-type hypersensitivity reaction?
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Alkylating Agents; Antigen-Presenting Cells; | 1990 |
[Topical application of mitomycin C conjugated with dextran (MMC-D): a high molecular weight derivative of mitomycin C].
Topics: Aged; Animals; Antibiotics, Antineoplastic; Dextrans; Female; Humans; Mitomycin; Mitomycins; Neoplas | 1985 |
[Comparative study of chemosensitivity tests of human urogenital tumors between a clonogenic assay and a novel dye exclusion test].
Topics: Antineoplastic Agents; Cell Survival; Cells, Cultured; Cisplatin; Colony-Forming Units Assay; Cyclop | 1985 |
[Prophylaxis of recurrence of superficial bladder tumor by diluted postoperative continuous intravesical instillation of anti-tumor solutions].
Topics: Adult; Aged; Antineoplastic Agents; Bleomycin; Carcinoma, Transitional Cell; Doxorubicin; Female; Hu | 1985 |
Superficial bladder cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carcinoma, Papillary; Doxorubici | 1985 |
DNA/RNA ratio in bladder cancer: a factor indicating the recurrence rate?
Topics: Antibiotics, Antineoplastic; DNA; Female; Flow Cytometry; Follow-Up Studies; Humans; Male; Mitomycin | 1985 |
Effects of interferon in combination with cytotoxic drugs on mouse bladder tumor (MBT-2) growth in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Dose-Response Relationship, Drug; Doxorubicin; Drug Therapy, Combina | 1988 |
[Multivariate evaluation of survival factors and postoperative adjuvant chemotherapy in patients with bladder cancer treated by radical cystectomy].
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cispla | 1988 |
Combined intracavitary and external beam irradiation for superficial transitional cell carcinoma of the bladder: an alternative to cystectomy for patients with recurrence after intravesical chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Transitional Cell; C | 1989 |
Intravesical combination chemotherapy with mitomycin C and doxorubicin for carcinoma in situ of the bladder.
Topics: Administration, Intravesical; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma in Sit | 1989 |
Treatment modalities in superficial bladder cancer.
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Doxo | 1989 |
Preoperative intra-arterial infusion chemotherapy for patients with bladder cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; | 1989 |
Combination of hyperthermia and cytostatics in the treatment of bladder cancer.
Topics: Carcinoma, Transitional Cell; Combined Modality Therapy; Humans; Hyperthermia, Induced; Infusions, I | 1989 |
Conservative treatment of diffuse carcinoma in situ of the bladder with repeated courses of intravesical therapy.
Topics: Administration, Intravesical; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Car | 1989 |
[Adjuvant chemotherapy after cystectomy of bladder tumor].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 1989 |
Bladder wall calcification after intravesical mitomycin C treatment of superficial bladder cancer.
Topics: Administration, Intravesical; Calcinosis; Carcinoma, Transitional Cell; Humans; Male; Middle Aged; M | 1989 |
Renal failure after intravesical mitomycin C.
Topics: Acute Kidney Injury; Administration, Intravesical; Carcinoma in Situ; Carcinoma, Transitional Cell; | 1989 |
[A case report of retrovesical tumor effectively responsive to chemotherapy].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Mal | 1989 |
Enhancement by X-ray irradiation of target cell susceptibility to natural killer cells.
Topics: Cytotoxicity Tests, Immunologic; Humans; Interferon Type I; Killer Cells, Natural; Kinetics; Lymphoc | 1989 |
Re: Recurrence of superficial bladder carcinoma after intravesical instillation of Mitomycin-C.
Topics: Administration, Intravesical; Data Interpretation, Statistical; Humans; Mitomycin; Mitomycins; Neopl | 1989 |
[Effects of mitomycin C perfusion after bladder tumor surgery].
Topics: Administration, Intravesical; Adult; Aged; Carcinoma, Transitional Cell; Chemotherapy, Cancer, Regio | 1989 |
Effect of concentration and time of drug exposure on clonal growth of murine bladder cancer.
Topics: Animals; Antineoplastic Agents; Bleomycin; Cell Line; Cisplatin; Colony-Forming Units Assay; Disease | 1985 |
Transcatheter arterial embolization of vesical artery in the treatment of invasive bladder cancer.
Topics: Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Embolization, Therapeutic; Female; Gelati | 1988 |
Benign ulcers after bladder instillation of mitomycin C.
Topics: Administration, Topical; Humans; Mitomycin; Mitomycins; Postoperative Complications; Ulcer; Urinary | 1986 |
Persistent ulcers after bladder instillation of mitomycin C.
Topics: Chronic Disease; Humans; Mitomycin; Mitomycins; Neoplasm Recurrence, Local; Neoplasms, Multiple Prim | 1986 |
[Toxicoallergic exanthema caused by intravesical instillation of mitomycin C].
Topics: Administration, Intravesical; Aged; Drug Eruptions; Exanthema; Humans; Male; Mitomycin; Mitomycins; | 1987 |
Mutual neoplastic promotion by instillation of mitomycin C and cauterization on rat bladder urothelium.
Topics: Animals; Cautery; Cocarcinogenesis; Female; Hyperplasia; Microscopy, Electron, Scanning; Mitomycin; | 1986 |
Transitional explant reduction assay--a new in vitro testing system for intravesical chemotherapy.
Topics: Carcinoma, Transitional Cell; Cisplatin; Colony-Forming Units Assay; Doxorubicin; Drug Evaluation; D | 1986 |
Effect of mitomycin C and doxorubicin instillation on carcinoma in situ of the urinary bladder. A Finnish multicenter study.
Topics: Administration, Topical; Adult; Aged; Buffers; Carcinoma in Situ; Cystitis; Doxorubicin; Female; Hum | 1986 |
[Mitomycin C-induced palmar exanthema].
Topics: Aged; Exanthema; Female; Hand Dermatoses; Humans; Mitomycin; Mitomycins; Urinary Bladder Neoplasms | 1986 |
Carcinogenesis in mammalian urothelium: changes induced by non-carcinogenic substances and chronic indwelling catheters.
Topics: Animals; Carcinoma in Situ; Carcinoma, Papillary; Carcinoma, Transitional Cell; Catheters, Indwellin | 1986 |
Mitomycin C plasma levels after intravesical instillation with and without hyaluronidase.
Topics: Combined Modality Therapy; Drug Combinations; Humans; Hyaluronoglucosaminidase; Mitomycin; Mitomycin | 1986 |
Use of intravesical cisplatin and mitomycin-C for recurrent transitional cell carcinoma of bladder refractory to thiotepa.
Topics: Biopsy; Carcinoma in Situ; Carcinoma, Transitional Cell; Cisplatin; Cystoscopy; Drug Evaluation; Dru | 1986 |
Prognostic significance of urine cytology on initial follow-up after intravesical mitomycin C for superficial bladder cancer.
Topics: Aged; Carcinoma, Transitional Cell; Cytodiagnosis; Follow-Up Studies; Humans; Middle Aged; Mitomycin | 1986 |
Bone marrow suppression after intravesical mitomycin C treatment.
Topics: Aged; Anemia, Aplastic; Female; Humans; Mitomycin; Mitomycins; Postoperative Care; Urinary Bladder N | 1986 |
Intravesical chemotherapy: studies on the relationship between osmolality and cytotoxicity.
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Cell Line; Cisplatin; Colony-Forming Units Assa | 1986 |
Treatment of urothelial carcinoma of the upper urinary tract following prostatocystectomy with mitomycin C instillation in the ileal loop.
Topics: Aged; Carcinoma, Transitional Cell; Combined Modality Therapy; Humans; Ileum; Kidney Neoplasms; Male | 1986 |
Intravesical chemotherapy. Studies on the relationship between pH and cytotoxicity.
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Cell Line; Cisplatin; Doxorubicin; Epirubicin; | 1986 |
Intravesical chemotherapy: in vitro studies on the relationship between dose and cytotoxicity.
Topics: Antineoplastic Agents; Cell Line; Cell Survival; Dose-Response Relationship, Drug; Doxorubicin; Etho | 1986 |
[Lung parenchyma disease following instillation of mitomycin C in the bladder].
Topics: Administration, Intravesical; Adult; Carcinoma, Transitional Cell; Humans; Lung Diseases; Male; Mito | 1986 |
Cytomorphological lesions induced by chemotherapeutic agents in transitional cell carcinoma in vitro.
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Cells, Cultured; Cisplatin; Doxorubicin; Humans | 1986 |
[Effect of intravesical instillation of the antitumor chemotherapeutic agents mitomycin C and cytosine arabinoside on rat bladder carcinogenesis initiated by N-butyl-N-(4-hydroxybutyl) nitrosamine].
Topics: Administration, Intravesical; Animals; Antineoplastic Combined Chemotherapy Protocols; Butylhydroxyb | 1987 |
Superficial bladder cancer: intravesical chemotherapy and tumour progression to muscle invasion or metastases.
Topics: Administration, Intravesical; Carcinoma, Transitional Cell; Ethoglucid; Humans; Methotrexate; Mitomy | 1986 |
Distilled water versus chemotherapeutic agents for transitional bladder carcinoma.
Topics: Carcinoma, Transitional Cell; Cell Survival; Humans; In Vitro Techniques; Mitomycin; Mitomycins; Neo | 1986 |
[Intra-arterial infusion chemotherapy for poor-risk patients with locally advanced bladder cancer--clinical assessment of five cases].
Topics: Aged; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Doxorubicin; Female; Humans; Injection | 1987 |
Antineoplastic drug cytotoxicity in a human bladder cancer cell line: implications for intravesical chemotherapy.
Topics: Administration, Intravesical; Antineoplastic Agents; Cell Survival; Cisplatin; Doxorubicin; Fluorour | 1987 |
Intravesical chemotherapy: combination with Tween 80 increases cytotoxicity in vitro.
Topics: Administration, Intravesical; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Colony- | 1987 |
Intravesical mitomycin C for the treatment of recurrent superficial bladder tumours.
Topics: Administration, Intravesical; Humans; Mitomycin; Mitomycins; Neoplasm Recurrence, Local; Neoplasm St | 1987 |
Bacillus Calmette-Guerin for treatment of superficial transitional cell carcinoma of the bladder in patients who have failed thiotepa and/or mitomycin C.
Topics: Administration, Intravesical; BCG Vaccine; Carcinoma in Situ; Carcinoma, Transitional Cell; Female; | 1987 |
[Pulmonary fibrosis following instillation of mitomycin C in the urinary bladder].
Topics: Administration, Intravesical; Adult; Carcinoma, Transitional Cell; Humans; Male; Mitomycin; Mitomyci | 1987 |
In vitro drug sensitivity studies in human transitional cell carcinoma of the bladder.
Topics: Carcinoma, Transitional Cell; Clone Cells; Colony-Forming Units Assay; Culture Techniques; Dimethyl | 1987 |
Selecting initial therapy for bladder cancer.
Topics: Administration, Intravesical; BCG Vaccine; Combined Modality Therapy; Cystoscopy; Doxorubicin; Human | 1987 |
[The role of transurethral cauterization and instillation of mitomycin-C on carcinogenesis of the urinary bladder].
Topics: Administration, Intravesical; Animals; Electrocoagulation; Female; Mitomycin; Mitomycins; Rats; Rats | 1987 |
Instillation of mitomycin C and doxorubicin in the prevention of recurrent superficial (Ta-T1) bladder cancer.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Carcinoma, Papillary; Doxorubicin; Fem | 1987 |
Monocyte cytolytic factor in promoting monocyte-mediated lysis of bladder cancer cells by bacillus Calmette-Guerin.
Topics: Cell Line; Cytotoxicity, Immunologic; Cytotoxins; Dactinomycin; Humans; Mitomycin; Mitomycins; Monoc | 1987 |
Severe bladder contracture in patient receiving intravesical mitomycin C for superficial bladder cancer.
Topics: Administration, Intravesical; Carcinoma, Transitional Cell; Contracture; Female; Humans; Middle Aged | 1987 |
Adjuvant chemotherapy for invasive bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Transitional Cell; Cispl | 1987 |
Size and location of tumors influencing the effect of bladder instillation therapy.
Topics: Administration, Intravesical; Cytarabine; Doxorubicin; Humans; Mitomycin; Mitomycins; Neoplasm Stagi | 1987 |
Topical mitomycin C therapy for carcinoma of the bladder.
Topics: Administration, Intravesical; Aged; Carcinoma in Situ; Drug Evaluation; Female; Follow-Up Studies; H | 1987 |
Treatment of superficial papillary transitional cell carcinoma of the ureter by vesicoureteral reflux of mitomycin C.
Topics: Administration, Intravesical; Aged; Carcinoma in Situ; Carcinoma, Transitional Cell; Humans; Male; M | 1987 |
Bladder wall calcification after topical mitomycin C.
Topics: Administration, Intravesical; Aged; Calcinosis; Carcinoma, Transitional Cell; Combined Modality Ther | 1987 |
Comparison of single agent cisplatin and cisplatin containing combinations in treatment of murine bladder cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Do | 1987 |
[Prophylactic intravesical chemotherapy in bladder tumors after surgery of upper tract urothelial carcinoma].
Topics: Administration, Intravesical; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carbazilq | 1987 |
Allergy to mitomycin C complicating topical administration for urothelial cancer.
Topics: Administration, Intravesical; Aged; Carcinoma, Transitional Cell; Cystitis; Drug Hypersensitivity; E | 1987 |
[Sequential instillation therapy with mitomycin-C and adriamycin in superficial bladder tumor with special reference to fate of 43 patients achieving complete response].
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy P | 1987 |
[A case of invasive squamous carcinoma of the urinary bladder perforated intraperitoneally after intra-arterial chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Female; H | 1987 |
[Effect of a calcium influx blocker, verapamil, on the sensitivity of human bladder cancer cells to adriamycin and mitomycin C].
Topics: Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Humans; In Vitro Techniques; Mitomyci | 1988 |
Effect of continuous intravesical infusion of low-concentrated mitomycin-C on bladder carcinogenesis in rats treated with N-butyl-N-4-hydroxybutyl-nitrosamine.
Topics: Administration, Intravesical; Animals; Butylhydroxybutylnitrosamine; Carcinoma, Papillary; Carcinoma | 1988 |
Chemotherapy for carcinoma in situ of the bladder.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Carcinoma in Situ; Combined Modality T | 1988 |
Transitional cell carcinoma of the prostate following intravesical therapy for transitional cell carcinoma of the bladder.
Topics: Administration, Intravesical; Aged; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell | 1988 |
A new treatment for invasive squamous cell bladder cancer: the Nigro regimen: preoperative chemotherapy and radiation therapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 1988 |
Doxorubicin plus mitomycin C regimen in the prophylactic treatment of superficial bladder tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Papillary | 1988 |
Study of intravesical mitomycin C in patients with multiple prior occurrences of superficial bladder cancer.
Topics: Administration, Intravesical; Aged; Humans; Middle Aged; Mitomycin; Mitomycins; Neoplasm Recurrence, | 1988 |
[Clinical studies of the treatment of bladder tumor and its effects--experience in 86 cases].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinoma, Tr | 1988 |
[Intravesical mitomycin for superficial tumors of the bladder: difficulties of cystoscopic monitoring].
Topics: Administration, Intravesical; Catheterization; Cystoscopy; Follow-Up Studies; Humans; Mitomycin; Mit | 1988 |
[Effect of intrabladder instillation of various anticancer agents on carcinogenesis in rat bladder].
Topics: Administration, Intravesical; Animals; Antineoplastic Agents; Butylhydroxybutylnitrosamine; Doxorubi | 1988 |
Combined thiotepa and mitomycin C instillation therapy for low-grade superficial bladder tumor.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Transitional Cell; Cystosco | 1985 |
Intravesical mitomycin C therapy for superficial bladder cancer. Report of a multicentre phase II study.
Topics: Carcinoma, Transitional Cell; Cystitis; Drug Evaluation; Humans; Mitomycin; Mitomycins; Skin Disease | 1985 |
Mitomycin-C induced improvement in superficial bladder tumors: a morphologic and immunohistochemical evaluation.
Topics: Biopsy; Carcinoma, Transitional Cell; Humans; Isoantigens; Mitomycin; Mitomycins; Urinary Bladder; U | 1985 |
Intravesical chemotherapy--frequency of instillation.
Topics: Antineoplastic Agents; Doxorubicin; Drug Administration Schedule; Ethoglucid; Humans; Mitomycin; Mit | 1985 |
Plasma levels during intravesical instillation of mitomycin-C.
Topics: Carcinoma, Transitional Cell; Humans; Mitomycin; Mitomycins; Neoplasm Recurrence, Local; Urinary Bla | 1985 |
Chemotherapy for adenocarcinomas of bladder and urachal origin: 5-fluorouracil, doxorubicin, and mitomycin-C.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antige | 1985 |
[Sequential intravesical chemotherapy with mitomycin C and adriamycin for superficial bladder tumor (preliminary report)].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cystitis; Doxorubicin; Female; Humans; | 1985 |
The absorption of doxorubicin and mitomycin C in perioperative instillation. An experimental and clinical study.
Topics: Absorption; Aged; Animals; Antibiotics, Antineoplastic; Doxorubicin; Female; Humans; Intraoperative | 1985 |
Treatment of superficial bladder cancer with intravesical mitomycin C: analysis of immediate and long-term response in 70 patients.
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma in Situ; Carcinoma, Transitional Cell; Female; Follow-U | 1985 |
Intensive intravesical chemotherapy in the treatment of flat carcinoma in situ: is it safe?
Topics: Antibiotics, Antineoplastic; Carcinoma in Situ; Carcinoma, Transitional Cell; Follow-Up Studies; Hum | 1985 |
Chemotherapy for bladder cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional | 1985 |
[Fundamental study on intra-arterial chemotherapy with direct hemoperfusion].
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Cisplatin; Doxorubicin; Hemoperfusion; | 1985 |
Mitomycin C in superficial bladder cancer: 24-month follow-up.
Topics: Antibiotics, Antineoplastic; Carcinoma in Situ; Follow-Up Studies; Humans; Mitomycin; Mitomycins; Ne | 1985 |
Detecting mitomycin C in human plasma during intravesical therapy.
Topics: Administration, Topical; Aged; Female; Humans; Male; Middle Aged; Mitomycin; Mitomycins; Urinary Bla | 1985 |
[Experience of intra-arterial chemotherapy for advanced bladder cancer with antitumor agents].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carbazilquinone; Cisplatin; Female; Flu | 1985 |